<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:georss='http://www.georss.org/georss' xmlns:gd='http://schemas.google.com/g/2005' xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-6604160603980694949</id><updated>2011-07-26T14:43:15.412-07:00</updated><category term='sporadic CJD'/><category term='CWRU'/><category term='atypical CWD'/><category term='protease-sensitive'/><category term='prionpathy'/><category term='Prion Unit CWRU'/><category term='UNKNOWN CJD'/><category term='PSPr'/><category term='nvCJD'/><category term='38 year old'/><category term='USA'/><category term='TME'/><category term='CANADA'/><category term='Texas'/><category term='NATIONAL PRION UNIT USA'/><category term='PRION BSE TESTING PROJECTS FUNDING NORTH AMERICA 2011'/><category term='CJD FOUNDATION'/><category term='R-CALF'/><category term='BSE'/><category term='SCRAPIE'/><category term='2010 CJD Foundation Family Conference'/><category term='CJD'/><category term='FFI'/><category term='GSS'/><category term='CWD'/><category term='TSE'/><category term='atypical Nor-98 Scrapie'/><category term='PRION'/><category term='atypical BSE'/><category term='MAD COW'/><category term='CJD VOICE'/><title type='text'>Progress Report from the USA PRION UNIT April 2008</title><subtitle type='html'></subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://prionunitusaupdate2008.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default?max-results=100'/><link rel='alternate' type='text/html' href='http://prionunitusaupdate2008.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Terry S. Singeltary Sr.</name><uri>http://www.blogger.com/profile/06986622967539963260</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='22' src='http://bp2.blogger.com/_gwMAfd8g9xo/SHuerfBUR1I/AAAAAAAAAAM/nNI1xcLm_Z4/S220/scan0002.jpg'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>11</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>100</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-6604160603980694949.post-2229878203715357033</id><published>2011-04-15T19:47:00.000-07:00</published><updated>2011-04-23T13:28:35.103-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='PRION BSE TESTING PROJECTS FUNDING NORTH AMERICA 2011'/><title type='text'>PRION TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY PROJECTS, RESEARCH FUNDING, BSE VOLUNTARY TESTING UPDATE IN NORTH AMERICA 2011</title><content type='html'>PRION TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY PROJECTS, RESEARCH FUNDING, BSE VOLUNTARY TESTING UPDATE IN NORTH AMERICA 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Projects&lt;br /&gt;&lt;br /&gt;Research Lead:&lt;br /&gt;&lt;br /&gt;Dr. Aubrey Mendonca, ChemRoutes Corporation Academic Lead:&lt;br /&gt;&lt;br /&gt;Dr. Michael Woodside, University of Alberta Project:&lt;br /&gt;&lt;br /&gt;“Testing potential chemical chaperones for prions with single-molecule spectroscopies”&lt;br /&gt;&lt;br /&gt;The proposal outlines screening and development of new and novel small molecule compounds that will act as “chaperones” for native prion proteins whose function is to prevent misfolding into the pathogenic PrPSc form. This will provide clues and insight into understanding prion protein structure, and as the definitive goal, provide compounds that will be able to protect or treat prion associated diseases. Screening is multi step and complex. Initial screen of developed small molecules will be done by fluorescene correlation sprectroscopy (FCS) in order to discern compounds that will bind to prion proteins. Screening moves through cross-correlation spectroscopy and fluorescence resonance energy transfer (FRET) analysis. Finally, using single molecule force spectroscopy (SMFS) the effect of identified hits on individual prion proteins will be resolved.&lt;br /&gt;&lt;br /&gt;Funding: $1,125,000 Alberta Prion Research Institute&lt;br /&gt;&lt;br /&gt;$350,000 PrioNet Canada (academic researcher support)&lt;br /&gt;&lt;br /&gt;$6,000,000 ChemRoutes Corporation Cash and in-kind&lt;br /&gt;&lt;br /&gt;$2,500,000 The National Institute for Nanotechnology (NINT) contribution&lt;br /&gt;&lt;br /&gt;$3,000,000 nanoWorks, Technology Futures (formerly Alberta Ingenuity Fund)&lt;br /&gt;&lt;br /&gt;$12,975,000 TOTAL&lt;br /&gt;&lt;br /&gt;Research Lead: Industries Sanimax Corporation &amp;amp; JOFE Services Group Academic Lead: Dr. David Bressler, University of Alberta Project: “Development of Value-Added Applications derived from Rendering By-product Streams including Specified Risk Materials (SRMs)”&lt;br /&gt;&lt;br /&gt;This aim of this is to add value to the rendering stream by developing and commercializing applications for protein rich rendering byproducts,some of which represent a burden to the industry as they are destined for the landfill due to regulations surrounding the use of SRM. The scientific approach to this research involves first hydrolyzing the rendered material using two approved hydrolysis methods. Results show that for both blood meal and meat and bone meal, the alkaline method hydrolyzed the protein to a greater extent than the thermal method. Despite such increased destruction, both methods yielded hydrolysis products that were successfully incorporated into the second step: crosslinking. Initial cross-linking resulted in the formation of polymeric compounds that could potentially be used in bioapplications. Screening of additional cross-linking agents and end product characterization is ongoing, and results are communicated to the industrial partner, Sanimax, to align the scientific progress with marketing and communication strategies and efforts. This program originated as an industry driven applied research project with the goal of commercializing technologies to provide an additional market revenue stream for the rendering industry.&lt;br /&gt;&lt;br /&gt;Funding: $ 255,000 Alberta Prion Research Institute&lt;br /&gt;&lt;br /&gt;$ 255,000 APRI SRM-CAP Program&lt;br /&gt;&lt;br /&gt;$ 300,000 PrioNet Canada (academic researcher support)&lt;br /&gt;&lt;br /&gt;$ 170,000 cash Sanimax Corporation&lt;br /&gt;&lt;br /&gt;$ 170,000 In-kind Sanimax Corporation&lt;br /&gt;&lt;br /&gt;$ 1,125,000 In-kind University of Alberta&lt;br /&gt;&lt;br /&gt;$ 2,275,000 TOTAL&lt;br /&gt;&lt;br /&gt;Research Lead: Dr. Norman Neumann, University of Alberta Project: “Defining the Fate of BSE and CWD in Specified Risk Materials Treated by Composting, Biodigestion, Thermal hydrolysis and/or Advanced Oxidation”&lt;br /&gt;&lt;br /&gt;See Targeted Areas Program for project description&lt;br /&gt;&lt;br /&gt;Funding: $498,536&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prioninstitute.ca/index.php?page=webpages&amp;amp;id=118&amp;amp;action=displaypage"&gt;http://prioninstitute.ca/index.php?page=webpages&amp;amp;id=118&amp;amp;action=displaypage&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;A Cost-Benefit Analysis of Voluntary BSE Testing of Cattle&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Al Mussell, Kevin Grier, Claudia Schmidt, Wayne Martin, Darryl Robinson, John Cranfield, Kurt Klein, Ted Schroeder, and Ron Doering&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;January, 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Executive Summary&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The purpose of this study was to evaluate the costs and benefits of voluntary testing for BSE in cattle at, or before, slaughter. To that end, the following were undertaken:&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The veterinary epidemiology literature on BSE was reviewed&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Selected agricultural economics literature on BSE was reviewed&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;A survey of industry participants was conducted to evaluate demand for a BSE tested product&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The cost of implementing BSE testing using post mortem and ante mortem testing procedures was estimated&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Consumer research was conducted in Canada to evaluate the demand for BSE tested product&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The policy and regulatory context for a BSE test was reviewed&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;An overview of the strategic context for a BSE test was developed&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Results&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The results showed the following:&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Given the scope of Canadian SRM removal (which is the key approach to safeguarding the human food supply) and the age at which fed cattle are slaughtered, post mortem BSE testing of them is extraordinarily unlikely to identify infected animals or indicate progress toward BSE eradication. Its value is essentially determined by the preferences of customers for, and value assigned to, tested product. An ante mortem test has less certain prospects, as only one of the approaches appears to be close to commercial reality, and practically speaking this could easily take five or more years for it to reach the Canadian market if validated. It is similarly unclear whether live BSE tests in development could detect positive BSE cases in younger cattle than the existing post mortem tests.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The US and Canadian consumers appear only weakly inclined to pay for BSE testing, compared with certain other countries like Japan. BSE testing is not a panacea- it is not a market access opener by itself, and it is not the only way of enhancing perceived safety in the system as there are other approaches such as tracking and tracing. As noted, the major ways of protecting human foods from BSE are through implementation of the Enhanced feed ban, removal of specified risk materials (SRM), and traceability.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The essential economic basis upon which to evaluate testing is the following:&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;* What benefit can be expected from testing due to increased market access and/or price premiums, relative to&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;* Adverse market impacts resulting from testing, such as lower prices or decreased market access for non-tested product, and&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;* The direct cost of implementing testing.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Canadian processors and exporters are not seeing requests for BSE-tested product. However, one major Japanese importer has directly requested it, and a senior meat trader knowledgeable with the Japanese market saw BSE testing as a potentially effective strategy to exploit Canada‘s niche in Asian markets. On balance, there appears to be customer interest in a tested product, but it will require marketing effort and development as importers are unlikely to take the lead.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Given the current estimates about the low prevalence of BSE in our national herd and the even lower likelihood of detecting infection in animals under 24 months of age, BSE testing under a voluntary test is expected to be relatively inexpensive.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;For the post mortem test, the anticipated cost is just over $40/head, comprised almost entirely of the cost of the test kit and sample analysis. For the prospective ante mortem test, the expected cost is $15/head with the dominant proportion of the cost associated with veterinary oversight of sample collection.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Canadian consumers indicated some willingness to purchase a beef product that had been tested for BSE, but BSE testing is not viewed as 'trumping' other aspects of a beef product; there remains a clear tradeoff between BSE testing and other product attributes, notably freshness and price. Labeling of beef products that had been tested for BSE did appear to confuse more broadly held perceptions regarding the safety of Canadian beef, as about 20% of consumers appeared to have a more negative attitude regarding the safety of Canadian beef when product labeled tested was available. Conversely when exported product was tested but domestic product was not, only about 13% perceived untested domestic product as less safe than tested exports.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The Canadian Food Inspection Agency (CFIA) has extensive approval authority in regards to a BSE test, as well as extensive discretion regarding how that authority is used. Current CFIA policy and perspective is not supportive of a test; it is quite conservative in nature. CFIA approval for the test would not be readily forthcoming. The Alberta government appears also to have a view on the merits of BSE testing consistent with that of CFIA.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Canada is among the smallest of the significant beef exporting countries. Among the major exporters, none currently test for BSE beyond surveillance measures. Australia and New Zealand have livestock identification systems in place, but the other major exporters do not. It is not expected that the other major exporters will begin testing for BSE apart from surveillance because they are either negligible risk for BSE, or lack a livestock identification system to manage the process. In most Asian markets, Canada‘s effective competitors are Australia and New Zealand supplying mostly grass-fed product, and the US supplying grain-fed product; South American competitors are faced with access issues relating to foot and mouth disease (FMD). Meanwhile, the Canadian cow herd is in structural decline, but the Canadian cattle slaughter has remained relatively constant. This has occurred as the segments of the cattle industry have been reeling from losses due to a structurally stronger Canadian currency and feed costs that are structurally stronger than that in the US.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The economic results observed in this study are supportive of a latent export market for tested product. The evidence supporting this includes written testament by would-be Japanese buyers to an Alberta processor, as well as presentations and appeals made by Japanese meat importers. This market potential would be as a niche, and the nature of these markets is such that its potential would need to be developed proactively. A range of considerations arise in terms of potential adverse market impacts with voluntary BSE testing and would need to be appropriately addressed. Testing works against Canada’s position that trade rules be science based. However, if it is viewed as marketing based on customer preference rather than abandoning a scientific perspective, it is unclear that this is a significant issue nor that it sets an ominous precedent. Prior examples include a willingness on behalf of Canada to adopt hormone-free protocols for beef exported to the European Union (EU), and a willingness to segregate certain genetic modification (GM)-free grains.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Some consumers perceive non-tested product as unsafe. This possibility was tested in consumer research in this study, and it was observed that only a core committed subset of Canadians would adopt this view. However, the risk of potential domestic consumer pushback of allowing testing for export marketing purposes suggests caution and would require close monitoring and management. There are no price premiums for tested product. The detailed analysis done by Rancher‘s Beef in 2005 suggested that, for a range of cuts preferred in Japan, prices are higher than in Canada. The anticipation here is that Canadian tested beef could be well positioned to take market share from grass-fed beef in the Japanese market. According to the USDA Foreign Agricultural Service, Japanese beef consumption in 2010 was about 1.2 million metric tonnes; with Canadian exports to Japan currently at about 10,000 tonnes, even if Canadian exports sharply increased it should not be expected to materially affect prices in Japan.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CFIA is not supportive of testing. CFIA has taken a very conservative position relative to testing, and Canadian proponents of voluntary BSE testing would need to engage the CFIA on this. If it is indeed the case that testing could create significant benefit at low risk and low cost, this analysis should be presented to CFIA and advocated as being in the public interest; at a minimum, it must be acknowledged by the CFIA that the current situation itself constitutes risk in terms of lost market opportunity and associated revenue impacts. Trade risks from testing. The principal risk associated with voluntary testing from a trade perspective is that it results in more positive cases being observed. This risk is understood to be very low in cattle aged Under Thirty Months (UTM). However, if this occurred it could diminish Canada‘s reputation and prolong its 'controlled risk' status.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;At the same time, there is a trade risk associated with not testing, arising from not expanding exports to the Japanese market, and perhaps other export markets. The costs associated with implementing a BSE test are relatively low. Based on actual budgeted costs for a plant in Alberta and on required changes in plant engineering/operations, the quantifiable costs of a post mortem test is expected to be just over $40/head. A prospective ante mortem test is expected to cost about $15/head. These results suggest that the economic potential is likely to exist to successfully market a BSE-tested product in Asian export markets, with Japan the focus here. This market potential would be as a niche, and the nature of these markets is such that the potential that may exist for tested product will need to be developed proactively; it will not be motivated nor developed by importers themselves with a request then coming to exporters. Thus, a latent market benefit to a BSE-tested product is envisioned, but clearly more work is required to understand its nature and measure its potential size. Implications and Conclusions The results of this study are consistent with an economic benefit from allowing a voluntary test for BSE, with some qualifications. The target market for the tested product is Japan, it is by nature a market niche, and developing a market for tested product will require initiative and effort on behalf of Canadian beef marketers; based on analysis relating to Japan, Asian importers are unlikely to provide the initiative. As with the roll out of any new product, due diligence is required and, as such, more formal market research is warranted in Asian target markets prior to proceeding. The positioning of such an initiative domestically requires some sensitivity, as the results show that the prospect of a BSE tested product in export markets could negatively affect the perception of beef on behalf of a small proportion (13%) of Canadian consumers surveyed.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The Japanese market has long been seen as a premium market for beef. It supplies well under half of its domestic market, and has been testing cattle for BSE since 2001. Beef in Japan was labeled as tested until about 2007 but this has fallen away. Domestic product remains a premium product in Japan, but there is some preference in favour of grain-fed import products. The benefits of allowing testing foreseen here relate to better satisfying market demand and increasing sales, leading to improved market access, in export markets where BSE testing is a valued attribute. In this study Japan was the focus, and it was clear that a latent interest exists in accessing Canadian BSE tested product. Under post mortem testing technology, the costs of implementing testing in fed cattle appear surprisingly low, contingent on a low prevalence of positive cases. It is also evident that the presence of a BSE tested export product would not significantly cannibalize the domestic market for non-tested product, as 70% of respondents perceived untested beef in Canada as no less safe and perceived that tested exports are either safer or no less safe; 13% perceived non-tested product available in Canada as less safe and tested exports to be safer. Ante mortem testing presents less certain prospects (EFSA, 2006, 2007), but is expected to be less costly to implement.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The drawbacks of allowing testing relate to the potential to negatively impact consumer attitudes toward untested beef, lack of support from regulators, and the prospect that testing, especially under a future ante mortem test, might identify positive cases and adversely impact Canada‘s BSE risk status.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;SNIP...SEE FULL TEXT ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prioninstitute.ca/forms/BSE%20Testing%20Final-revised%20%20Plus%20App%20C%20AM%20Mar%2029.pdf"&gt;http://prioninstitute.ca/forms/BSE%20Testing%20Final-revised%20%20Plus%20App%20C%20AM%20Mar%2029.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, August 29, 2008 &lt;br /&gt;&lt;br /&gt;CREEKSTONE VS USDA COURT OF APPEALS, BUSH SAYS, NO WAY, NO HOW &lt;br /&gt;&lt;br /&gt;United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT Argued May 9, 2008 Decided August 29, 2008 No. 07-5173 CREEKSTONE FARMS PREMIUM BEEF, L.L.C., APPELLEE/CROSS-APPELLANT v. DEPARTMENT OF AGRICULTURE AND EDWARD T. SCHAFER, SECRETARY OF AGRICULTURE, APPELLANTS/CROSS-APPELLEES Consolidated with NO. 07-5199 Appeals from the United States District Court for the District of Columbia (No. 06cv00544) Eric Fleisig-Greene, Attorney, United States Department of Justice, argued the cause for the appellants/cross-appellees. Jeffrey S. Bucholtz, Acting Assistant Attorney General, Jeffrey A. Taylor, United States Attorney, and Mark B. Stern and Michael S. Raab, Attorneys, United States Department of Justice, were on brief. James J. Gilligan, Attorney, United States Department of Justice, and R. Craig Lawrence, Assistant United States Attorney, entered appearances.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://pacer.cadc.uscourts.gov/docs/common/opinions/200808/07-5173-1135720.pdf"&gt;http://pacer.cadc.uscourts.gov/docs/common/opinions/200808/07-5173-1135720.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;SNIP...SEE MORE HERE ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowtesting.blogspot.com/2008/08/creekstone-vs-usda-court-of-appeals.html"&gt;http://madcowtesting.blogspot.com/2008/08/creekstone-vs-usda-court-of-appeals.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;PRION TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY RESEARCH FUNDING U.S.A.&lt;br /&gt;&lt;br /&gt;COMPARE TO USA PRION FUNDING 2011&lt;br /&gt;&lt;br /&gt;"which includes the ___elimination___ of Prion activities ($5,473,000),"&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;All Other Emerging and Zoonotic Infectious Diseases CDC‘s FY 2012 request of $52,658,000 for all other emerging and zoonotic infectious disease activities is a decrease of $13,607,000 below the FY 2010 level, which includes the elimination of Prion activities ($5,473,000), a reduction for other cross-cutting infectious disease activities, and administrative savings. These funds support a range of critical emerging and zoonotic infectious disease programs such Lyme Disease, Chronic Fatigue Syndrome, and Special Pathogens, as well as other activities described below.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cdc.gov/fmo/topic/Budget%20Information/appropriations_budget_form_pdf/FY2012_CDC_CJ_Final.pdf"&gt;http://www.cdc.gov/fmo/topic/Budget%20Information/appropriations_budget_form_pdf/FY2012_CDC_CJ_Final.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;PRION MAD COW UDPATE NORTH AMERICA 2011&lt;br /&gt;&lt;br /&gt;Sunday, April 3, 2011&lt;br /&gt;&lt;br /&gt;PRION 2011 NEWWORLD MONTREAL CANADA MAY 16 - 19&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2011/04/prion-2011-newworld-montreal-canada-may.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2011/04/prion-2011-newworld-montreal-canada-may.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, April 5, 2011&lt;br /&gt;&lt;br /&gt;Action Plan National Program 103 Animal Health 2012-2017 PRIONS AND TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY&lt;br /&gt;&lt;br /&gt;Action Plan National Program 103 Animal Health 2012-2017&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2011/04/action-plan-national-program-103-animal.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2011/04/action-plan-national-program-103-animal.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Greetings,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;WITH more and more atypical Transmissible Spongiform Encephalopathy cases showing up in more and more species here in North America, and the enormous monumental amount of banned mad cow protein in commerce since the infamous partial and voluntary mad cow feed ban inked on paper, with tons and tons crossing back and forth between the USA, Canada, and Mexico, it just does not surprise me of all these "PENDING CLASSIFICATIONS" of human TSE in Canada, and the USA. UK c-BSE transmitted to humans became nvCJD. WE now have atypical strains of BSE in cattle. Mission Texas experiments long ago showed that transmitted USA sheep scrapie to USA bovine, produced a TSE much different than the UK typical c-BSE. SO why would human TSE in the USA look like UK human TSE ? The corruption is mind boggling. The UK saw a suspicious TSE in humans, and science linked it to cattle. North America is awash with human and animal TSE, CJD is rising in young and old, with the same pathology and same symptoms, and none of it is related to the other. isn't that nice. who, what, bestowed such miracles upon North America $&lt;br /&gt;&lt;br /&gt;Archive Number 20100405.1091 Published Date 05-APR-2010&lt;br /&gt;&lt;br /&gt;Subject PRO/AH/EDR&amp;gt; Prion disease update 1010 (04)&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;[Terry S. Singeltary Sr. has added the following comment:&lt;br /&gt;&lt;br /&gt;"According to the World Health Organisation, the future public health threat of vCJD in the UK and Europe and potentially the rest of the world is of concern and currently unquantifiable. However, the possibility of a significant and geographically diverse vCJD epidemic occurring over the next few decades cannot be dismissed&lt;br /&gt;&lt;br /&gt;&lt;http: 2003="" 9241545887.pdf="" publications="" whqlibdoc.who.int=""&gt;.&lt;br /&gt;&lt;br /&gt;The key word here is diverse. What does diverse mean? If USA scrapie transmitted to USA bovine does not produce pathology as the UK c-BSE, then why would CJD from there look like UK vCJD?"&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.promedmail.org/pls/apex/f?p=2400:1001:568933508083034::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,82101"&gt;http://www.promedmail.org/pls/apex/f?p=2400:1001:568933508083034::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,82101&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, April 17, 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Transmission of Prion Strains in a Transgenic Mouse Model Overexpressing Human A53T Mutated [alpha]-Synuclein&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2011/04/transmission-of-prion-strains-in.html"&gt;http://bse-atypical.blogspot.com/2011/04/transmission-of-prion-strains-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CANADA CJD UPDATE 2011&lt;br /&gt;&lt;br /&gt;CJD Deaths Reported by CJDSS1, 1994-20112 As of January 31, 2011&lt;br /&gt;&lt;br /&gt;3. Final classification of 49 cases from 2009, 2010, 2011 is pending.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.phac-aspc.gc.ca/hcai-iamss/cjd-mcj/cjdss-ssmcj/pdf/stats_0111-eng.pdf"&gt;http://www.phac-aspc.gc.ca/hcai-iamss/cjd-mcj/cjdss-ssmcj/pdf/stats_0111-eng.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;USA 2011&lt;br /&gt;&lt;br /&gt;USA&lt;br /&gt;&lt;br /&gt;National Prion Disease Pathology Surveillance Center&lt;br /&gt;&lt;br /&gt;Cases Examined1&lt;br /&gt;&lt;br /&gt;(November 1, 2010)&lt;br /&gt;&lt;br /&gt;Year Total Referrals2 Prion Disease Sporadic Familial Iatrogenic vCJD&lt;br /&gt;&lt;br /&gt;1996 &amp;amp; earlier 51 33 28 5 0 0&lt;br /&gt;&lt;br /&gt;1997 114 68 59 9 0 0&lt;br /&gt;&lt;br /&gt;1998 87 51 43 7 1 0&lt;br /&gt;&lt;br /&gt;1999 121 73 65 8 0 0&lt;br /&gt;&lt;br /&gt;2000 146 103 89 14 0 0&lt;br /&gt;&lt;br /&gt;2001 209 119 109 10 0 0&lt;br /&gt;&lt;br /&gt;2002 248 149 125 22 2 0&lt;br /&gt;&lt;br /&gt;2003 274 176 137 39 0 0&lt;br /&gt;&lt;br /&gt;2004 325 186 164 21 0 13&lt;br /&gt;&lt;br /&gt;2005 344 194 157 36 1 0&lt;br /&gt;&lt;br /&gt;2006 383 197 166 29 0 24&lt;br /&gt;&lt;br /&gt;2007 377 214 187 27 0 0&lt;br /&gt;&lt;br /&gt;2008 394 231 205 25 0 0&lt;br /&gt;&lt;br /&gt;2009 425 258 215 43 0 0&lt;br /&gt;&lt;br /&gt;2010 333 213 158 33 0 0&lt;br /&gt;&lt;br /&gt;TOTAL 38315 22656 1907 328 4 3&lt;br /&gt;&lt;br /&gt;1 Listed based on the year of death or, if not available, on year of referral;&lt;br /&gt;&lt;br /&gt;2 Cases with suspected prion disease for which brain tissue and/or blood (in familial cases) were submitted;&lt;br /&gt;&lt;br /&gt;3 Disease acquired in the United Kingdom;&lt;br /&gt;&lt;br /&gt;4 Disease was acquired in the United Kingdom in one case and in Saudi Arabia in the other case;&lt;br /&gt;&lt;br /&gt;5 Includes 18 cases in which the diagnosis is pending, and 18 inconclusive cases;&lt;br /&gt;&lt;br /&gt;6 Includes 23 (22 from 2010) cases with type determination pending in which the diagnosis of vCJD has been excluded.&lt;br /&gt;&lt;br /&gt;http://www.cjdsurveillance.com/pdf/case-table.pdf&lt;br /&gt;&lt;br /&gt;Please notice where sporadic CJD cases in 1996 went from 28 cases, to 215 cases in 2009, the highest recorded year to date. sporadic CJD is on a steady rise, and has been since 1996.&lt;br /&gt;&lt;br /&gt;I also urge you to again notice these disturbing factors in lines 5 and 6 ;&lt;br /&gt;&lt;br /&gt;5 Includes 18 cases in which the diagnosis is pending, and 18 inconclusive cases;&lt;br /&gt;&lt;br /&gt;6 Includes 23 (22 from 2010) cases with type determination pending in which the diagnosis of vCJD has been excluded.&lt;br /&gt;&lt;br /&gt;========end=====tss=====2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, August 9, 2010&lt;br /&gt;&lt;br /&gt;National Prion Disease Pathology Surveillance Center Cases Examined (July 31, 2010)&lt;br /&gt;&lt;br /&gt;(please watch and listen to the video and the scientist speaking about atypical BSE and sporadic CJD and listen to Professor Aguzzi)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/08/national-prion-disease-pathology.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/08/national-prion-disease-pathology.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Atypical BSE (BASE) Transmitted from Asymptomatic Aging Cattle to a Primate&lt;br /&gt;&lt;br /&gt;Emmanuel E. Comoy1*, Cristina Casalone2, Nathalie Lescoutra-Etchegaray1, Gianluigi Zanusso3, Sophie Freire1, Dominique Marcé1, Frédéric Auvré1, Marie-Magdeleine Ruchoux1, Sergio Ferrari3, Salvatore Monaco3, Nicole Salès4, Maria Caramelli2, Philippe Leboulch1,5, Paul Brown1, Corinne I. Lasmézas4, Jean-Philippe Deslys1&lt;br /&gt;&lt;br /&gt;1 Institute of Emerging Diseases and Innovative Therapies, CEA, Fontenay-aux-Roses, France, 2 Istituto Zooprofilattico Sperimentale del Piemonte, Turin, Italy, 3 Policlinico G.B. Rossi, Verona, Italy, 4 Scripps Florida, Jupiter, Florida, United States of America, 5 Genetics Division, Brigham &amp;amp; Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America&lt;br /&gt;&lt;br /&gt;Abstract Top Background Human variant Creutzfeldt-Jakob Disease (vCJD) results from foodborne transmission of prions from slaughtered cattle with classical Bovine Spongiform Encephalopathy (cBSE). Atypical forms of BSE, which remain mostly asymptomatic in aging cattle, were recently identified at slaughterhouses throughout Europe and North America, raising a question about human susceptibility to these new prion strains.&lt;br /&gt;&lt;br /&gt;Methodology/Principal Findings Brain homogenates from cattle with classical BSE and atypical (BASE) infections were inoculated intracerebrally into cynomolgus monkeys (Macacca fascicularis), a non-human primate model previously demonstrated to be susceptible to the original strain of cBSE. The resulting diseases were compared in terms of clinical signs, histology and biochemistry of the abnormal prion protein (PrPres). The single monkey infected with BASE had a shorter survival, and a different clinical evolution, histopathology, and prion protein (PrPres) pattern than was observed for either classical BSE or vCJD-inoculated animals. Also, the biochemical signature of PrPres in the BASE-inoculated animal was found to have a higher proteinase K sensitivity of the octa-repeat region. We found the same biochemical signature in three of four human patients with sporadic CJD and an MM type 2 PrP genotype who lived in the same country as the infected bovine.&lt;br /&gt;&lt;br /&gt;Conclusion/Significance Our results point to a possibly higher degree of pathogenicity of BASE than classical BSE in primates and also raise a question about a possible link to one uncommon subset of cases of apparently sporadic CJD. Thus, despite the waning epidemic of classical BSE, the occurrence of atypical strains should temper the urge to relax measures currently in place to protect public health from accidental contamination by BSE-contaminated products.&lt;br /&gt;&lt;br /&gt;Citation: Comoy EE, Casalone C, Lescoutra-Etchegaray N, Zanusso G, Freire S, et al. (2008) Atypical BSE (BASE) Transmitted from Asymptomatic Aging Cattle to a Primate. PLoS ONE 3(8): e3017. doi:10.1371/journal.pone.0003017&lt;br /&gt;&lt;br /&gt;Editor: Neil Mabbott, University of Edinburgh, United Kingdom&lt;br /&gt;&lt;br /&gt;Received: April 24, 2008; Accepted: August 1, 2008; Published: August 20, 2008&lt;br /&gt;&lt;br /&gt;Copyright: © 2008 Comoy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.&lt;br /&gt;&lt;br /&gt;Funding: This work has been supported by the Network of Excellence NeuroPrion.&lt;br /&gt;&lt;br /&gt;Competing interests: CEA owns a patent covering the BSE diagnostic tests commercialized by the company Bio-Rad.&lt;br /&gt;&lt;br /&gt;* E-mail: mhtml:%7B33B38F65-8D2E-434D-8F9B-8BDCD77D3066%7Dmid://00000110/!x-usc:mailto:emmanuel.comoy@cea.fr&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003017"&gt;http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003017&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;FC5.5.1&lt;br /&gt;&lt;br /&gt;BASE Transmitted to Primates and MV2 sCJD Subtype Share PrP27-30 and PrPSc C-terminal Truncated Fragments&lt;br /&gt;&lt;br /&gt;Zanusso, G1; Commoy, E2; Fasoli, E3; Fiorini, M3; Lescoutra, N4; Ruchoux, MM4; Casalone, C5; Caramelli, M5; Ferrari, S3; Lasmezas, C6; Deslys, J-P4; Monaco, S3 1University of Verona, of Neurological and Visual Sciences, Italy; 2CEA, IMETI/SEPIA, France; 3University of Verona, Neurological and Visual Sciences, Italy; 4IMETI/SEPIA, France; 5IZSPLVA, Italy; 6The Scripps Research Insitute, USA&lt;br /&gt;&lt;br /&gt;The etiology of sporadic Creutzfeldt-Jakob disease (sCJD), the most frequent human prion disease, remains still unknown. The marked disease phenotype heterogeneity observed in sCJD is thought to be influenced by the type of proteinase K-resistant prion protein, or PrPSc (type 1 or type 2 according to the electrophoretic mobility of the unglycosylated backbone), and by the host polymorphic Methionine/Valine (M/V) codon 129 of the PRNP. By using a two-dimensional gel electrophoresis (2D-PAGE) and imunoblotting we previously showed that in sCJD, in addition to the PrPSc type, distinct PrPSc C-terminal truncated fragments (CTFs) correlated with different sCJD subtypes. Based on the combination of CTFs and PrPSc type, we distinguished three PrPSc patterns: (i) the first was observed in sCJD with PrPSc type 1 of all genotypes,; (ii) the second was found in M/M-2 (cortical form); (iii) the third in amyloidogenic M/V- 2 and V/V-2 subtypes (Zanusso et al., JBC 2004) . Recently, we showed that sCJD subtype M/V-2 shared molecular and pathological features with an atypical form of BSE, named BASE, thus suggesting a potential link between the two conditions. This connection was further confirmed after 2D-PAGE analysis, which showed an identical PrPSc signature, including the biochemical pattern of CTFs. To pursue this issue, we obtained brain homogenates from Cynomolgus macaques intracerebrally inoculated with brain homogenates from BASE. Samples were separated by using a twodimensional electrophoresis (2D-PAGE) followed by immunoblotting. ***We here show that the PrPSc pattern obtained in infected primates is identical to BASE and sCJD MV-2 subtype. These data strongly support the link, or at least a common ancestry, between a sCJD subtype and BASE. This work was supported by Neuroprion (FOOD-CT-2004-506579)&lt;br /&gt;&lt;br /&gt;FC5.5.2&lt;br /&gt;&lt;br /&gt;Transmission of Italian BSE and BASE Isolates in Cattle Results into a Typical BSE Phenotype and a Muscle Wasting Disease&lt;br /&gt;&lt;br /&gt;Zanusso, G1; Lombardi, G2; Casalone, C3; D’Angelo, A4; Gelmetti, D2; Torcoli, G2; Barbieri, I2; Corona, C3; Fasoli, E1; Farinazzo, A1; Fiorini, M1; Gelati, M1; Iulini, B3; Tagliavini, F5; Ferrari, S1; Monaco, S1; Caramelli, M3; Capucci, L2 1University of Verona, Neurological and Visual Sciences, Italy; 2IZSLER, Italy; 3IZSPLVA, Italy; 4University of Turin, Animal Pathology, Italy; 5Isituto Carlo Besta, Italy&lt;br /&gt;&lt;br /&gt;The clinical phenotype of bovine spongiform encephalopathy has been extensively reported in early accounts of the disorder. Following the introduction of statutory active surveillance, almost all BSE cases have been diagnosed on a pathological/molecular basis, in a pre-symptomatic clinical stage. In recent years, the active surveillance system has uncovered atypical BSE cases, which are characterized by distinct conformers of the PrPSc, named high-type (BSE-H) and low-type (BSE-L), whose clinicopathological phenotypes remain unknown. We recently reported two Italian atypical cases with a PrPSc type similar to BSE-L, pathologically characterized by PrP amyloid plaques. Experimental transmission to TgBov mice has recently disclosed that BASE is caused by a distinct prion strain which is extremely virulent. A major limitation of transmission studies to mice is the lack of reliable information on clinical phenotype of BASE in its natural host. In the present study, we experimentally infected Fresian/Holstein and Alpine/Brown cattle with Italian BSE and BASE isolates by i.c. route. BASE infected cattle showed survival times significantly shorter than BSE, a finding more readily evident in Fresian/Holstein, and in keeping with previous observations in TgBov mice. Clinically, BSE-infected cattle developed a disease phenotype highly comparable with that described in field BSE cases and in experimentally challenged cattle. On the contrary, BASE-inoculated cattle developed an amyotrophic disorder accompanied by mental dullness. The molecular and neuropathological profiles, including PrP deposition pattern, closely matched those observed in the original cases. ***This study further confirms that BASE is caused by a distinct prion isolate and discloses a novel disease phenotype in cattle, closely resembling the phenotype previous reported in scrapie-inoculated cattle and in some subtypes of inherited and sporadic Creutzfeldt-Jakob disease.&lt;br /&gt;&lt;br /&gt;P02.35&lt;br /&gt;&lt;br /&gt;Molecular Features of the Protease-resistant Prion Protein (PrPres) in H-type BSE&lt;br /&gt;&lt;br /&gt;Biacabe, A-G1; Jacobs, JG2; Gavier-Widén, D3; Vulin, J1; Langeveld, JPM2; Baron, TGM1 1AFSSA, France; 2CIDC-Lelystad, Netherlands; 3SVA, Sweden&lt;br /&gt;&lt;br /&gt;Western blot analyses of PrPres accumulating in the brain of BSE-infected cattle have demonstrated 3 different molecular phenotypes regarding to the apparent molecular masses and glycoform ratios of PrPres bands. We initially described isolates (H-type BSE) essentially characterized by higher PrPres molecular mass and decreased levels of the diglycosylated PrPres band, in contrast to the classical type of BSE. This type is also distinct from another BSE phenotype named L-type BSE, or also BASE (for Bovine Amyloid Spongiform Encephalopathy), mainly characterized by a low representation of the diglycosylated PrPres band as well as a lower PrPres molecular mass. Retrospective molecular studies in France of all available BSE cases older than 8 years old and of part of the other cases identified since the beginning of the exhaustive surveillance of the disease in 20001 allowed to identify 7 H-type BSE cases, among 594 BSE cases that could be classified as classical, L- or H-type BSE. By Western blot analysis of H-type PrPres, we described a remarkable specific feature with antibodies raised against the C-terminal region of PrP that demonstrated the existence of a more C-terminal cleaved form of PrPres (named PrPres#2 ), in addition to the usual PrPres form (PrPres #1). In the unglycosylated form, PrPres #2 migrates at about 14 kDa, compared to 20 kDa for PrPres #1. The proportion of the PrPres#2 in cattle seems to by higher compared to the PrPres#1. Furthermore another PK–resistant fragment at about 7 kDa was detected by some more N-terminal antibodies and presumed to be the result of cleavages of both N- and C-terminal parts of PrP. These singular features were maintained after transmission of the disease to C57Bl/6 mice. ***The identification of these two additional PrPres fragments (PrPres #2 and 7kDa band) reminds features reported respectively in sporadic Creutzfeldt-Jakob disease and in Gerstmann-Sträussler-Scheinker (GSS) syndrome in humans.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neuroprion.com/pdf_docs/conferences/prion2007/abstract_book.pdf"&gt;http://www.neuroprion.com/pdf_docs/conferences/prion2007/abstract_book.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;And last but not least, similarities of PrPres between Htype BSE and human prion diseases like CJD or GSS have been put forward [10], as well as between L-type BSE and CJD [17]. These findings raise questions about the origin and inter species transmission of these prion diseases that were discovered through the BSE active surveillance.&lt;br /&gt;&lt;br /&gt;full text 18 pages ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.vetres.org/index.php?option=article&amp;amp;access=standard&amp;amp;Itemid=129&amp;amp;url=/articles/vetres/pdf/2008/04/v07232.pdf"&gt;http://www.vetres.org/index.php?option=article&amp;amp;access=standard&amp;amp;Itemid=129&amp;amp;url=/articles/vetres/pdf/2008/04/v07232.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please see full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2008/06/review-on-epidemiology-and-dynamics-of.html"&gt;http://bse-atypical.blogspot.com/2008/06/review-on-epidemiology-and-dynamics-of.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P.4.23&lt;br /&gt;&lt;br /&gt;Transmission of atypical BSE in humanized mouse models&lt;br /&gt;&lt;br /&gt;Liuting Qing1, Wenquan Zou1, Cristina Casalone2, Martin Groschup3, Miroslaw Polak4, Maria Caramelli2, Pierluigi Gambetti1, Juergen Richt5, Qingzhong Kong1 1Case Western Reserve University, USA; 2Instituto Zooprofilattico Sperimentale, Italy; 3Friedrich-Loeffler-Institut, Germany; 4National Veterinary Research Institute, Poland; 5Kansas State University (Previously at USDA National Animal Disease Center), USA&lt;br /&gt;&lt;br /&gt;Background: Classical BSE is a world-wide prion disease in cattle, and the classical BSE strain (BSE-C) has led to over 200 cases of clinical human infection (variant CJD). Atypical BSE cases have been discovered in three continents since 2004; they include the L-type (also named BASE), the H-type, and the first reported case of naturally occurring BSE with mutated bovine PRNP (termed BSE-M). The public health risks posed by atypical BSE were largely undefined.&lt;br /&gt;&lt;br /&gt;Objectives: To investigate these atypical BSE types in terms of their transmissibility and phenotypes in humanized mice. Methods: Transgenic mice expressing human PrP were inoculated with several classical (C-type) and atypical (L-, H-, or Mtype) BSE isolates, and the transmission rate, incubation time, characteristics and distribution of PrPSc, symptoms, and histopathology were or will be examined and compared.&lt;br /&gt;&lt;br /&gt;Results: Sixty percent of BASE-inoculated humanized mice became infected with minimal spongiosis and an average incubation time of 20-22 months, whereas only one of the C-type BSE-inoculated mice developed prion disease after more than 2 years. Protease-resistant PrPSc in BASE-infected humanized Tg mouse brains was biochemically different from bovine BASE or sCJD. PrPSc was also detected in the spleen of 22% of BASE-infected humanized mice, but not in those infected with sCJD. Secondary transmission of BASE in the humanized mice led to a small reduction in incubation time.*** The atypical BSE-H strain is also transmissible with distinct phenotypes in the humanized mice, but no BSE-M transmission has been observed so far.&lt;br /&gt;&lt;br /&gt;Discussion: Our results demonstrate that BASE is more virulent than classical BSE, has a lymphotropic phenotype, and displays a modest transmission barrier in our humanized mice. BSE-H is also transmissible in our humanized Tg mice. The possibility of more than two atypical BSE strains will be discussed.&lt;br /&gt;&lt;br /&gt;Supported by NINDS NS052319, NIA AG14359, and NIH AI 77774.&lt;br /&gt;&lt;br /&gt;P02.16&lt;br /&gt;&lt;br /&gt;Analysis of Bovine Prion Protein Gene Sequence Variation in Animals with Classical and Atypical BSE&lt;br /&gt;&lt;br /&gt;Polak, MP; Larska, M; Rola, J; Zmudzinski, JF National Veterinary Research Institute, Department of Virology, Poland B.&lt;br /&gt;&lt;br /&gt;Variation within prion protein gene sequence have major impact on the susceptibility to prion diseases in humans and sheep. However no major differences between healthy cattle and bovine spongiform encephalopathy (BSE) affected individuals were identified. Recent studies indicate that susceptibility to bovine spongiform encephalopathy is associated with 23-base pair (bp) and 12-bp indel sequences. Identification of atypical BSE in older cattle in several countries pointed at the possibility of spontaneous origin of this new form of prion disease due to possible mutations within prion gene (PRNP) sequence. A./O. Therefore the aim of the study was to analyze and to compare prion protein gene sequences in animals showing classical and atypical BSE for any genetic traits differentating both forms of the disease. M. Analysis included: octapeptide-repeat polymorphism; sequence analysis of exon 3 region; deletion/insertion polymorphism within the promoter sequence (23-bp), intron 1 (12-bp) and 3’untranslated region - UTR (14-bp) of PRNP gene. R. No major differences were found as for the octapeptide-repeats. Most dominant genotype in both classical and atypical BSE involved 6/6 homozygous animals. Sequence comparison within exon 3 region also showed no differences. Results from indel sequence analysis within three regions of PRNP gene were also quite uniform between both forms of BSE. D. Therefore no genetic traits explaining the appearance of atypical BSE could be found. However, it is too early to reject the hypothesis that genetic makeup is not involved in atypical BSE. Further and more detailed studies including more cases of atypical BSE would be more reliable to draw such a conclusion.&lt;br /&gt;&lt;br /&gt;O.10.6&lt;br /&gt;&lt;br /&gt;Biological typing of sporadic Creutzfeldt- Jakob disease isolates and comparison with animal prion isolates&lt;br /&gt;&lt;br /&gt;Romolo Nonno1, Michele Di Bari1, Laura Pirisinu1, Stefano Marcon1, Claudia D’Agostino1, Elena Esposito1, Paola Fazzi1, Shimon Simson1, Paolo Frassanito1, Cristina Casalone3, Franco Cardone2, Maurizio Pocchiari2, Gabriele Vaccari1, Umberto Agrimi1 1Dept. SPVSA, Istituto Superiore di Sanità, Italy; 2Dept. BCN, Istituto Superiore di Sanità, Italy; 3Istituto Zooprofilattico del Piemonte, Liguria e Valle D’Aosta, Italy&lt;br /&gt;&lt;br /&gt;Background: Our incomplete understanding of the nature of TSE agents, along with the current technical limitations in the analysis of PrPSc structure, prevent the direct typing of prion isolates. The characterization of prion strains still relies upon bioassay in rodents. Bank vole (Myodes glareolus), being susceptible to a wide range of prion sources, offers the opportunity to investigate the biological properties of prion isolates from different species in a single model.&lt;br /&gt;&lt;br /&gt;Objectives: To study the biological properties of sCJD subtypes and compare them with animal TSEs. Methods: We analysed the phenotype of transmission of MM1, MV1, MM2, MV2, and VV2 sCJD subtypes to voles, in comparison with BSE, BASE and classical scrapie isolates from different EU countries. Molecular analysis of PrPSc from the original isolates preceded voles inoculation. Survival time and attack rate were calculated upon primary transmissions and subsequent passages. The brain of voles were analysed by WB for PrPSc type, by Gnd- HCl denaturation for PrPSc conformational stability, by immunohistochemistry and PET-blot for PrPSc deposition pattern and by E&amp;amp;E for lesion profile.&lt;br /&gt;&lt;br /&gt;Results: This study demonstrated that prion diseases induce in voles a variety of molecular and pathological phenotypes. CJD isolates were grouped into 4 categories: i) MM1/MV1 (n=3), ii) MM2 (n=1), iii) MV2 (n=2) and iv) VV2 (n=1). Scrapie isolates were categorised in at least 4 groups, with no overlapping with sCJD isolates. BSE was distinct from scrapie and sCJD phenotypes. Finally, BASE gave a phenotype distinct from BSE and scrapie but indistinguishable from VV2 sCJD.&lt;br /&gt;&lt;br /&gt;Discussion: Overall, the biological classification of sCJD subtypes concurs with their clinico-pathological classification.*** Similarities in the transmission pattern of prion isolates from different host species were very rare, with the notable exception of BASE and VV2 sCJD. Herein, the meaning of such similarities is discussed in the context of current knowledge on strains and of available tools for their typing.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf"&gt;http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P26 TRANSMISSION OF ATYPICAL BOVINE SPONGIFORM ENCEPHALOPATHY (BSE) IN HUMANIZED MOUSE MODELS&lt;br /&gt;&lt;br /&gt;Liuting Qing1, Fusong Chen1, Michael Payne1, Wenquan Zou1, Cristina Casalone2, Martin Groschup3, Miroslaw Polak4, Maria Caramelli2, Pierluigi Gambetti1, Juergen Richt5*, and Qingzhong Kong1 1Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA; 2CEA, Istituto Zooprofilattico Sperimentale, Italy; 3Friedrich-Loeffler-Institut, Germany; 4National Veterinary Research Institute, Poland; 5Kansas State University, Diagnostic Medicine/Pathobiology Department, Manhattan, KS 66506, USA. *Previous address: USDA National Animal Disease Center, Ames, IA 50010, USA&lt;br /&gt;&lt;br /&gt;Classical BSE is a world-wide prion disease in cattle, and the classical BSE strain (BSE-C) has led to over 200 cases of clinical human infection (variant CJD). Two atypical BSE strains, BSE-L (also named BASE) and BSE-H, have been discovered in three continents since 2004. The first case of naturally occurring BSE with mutated bovine PrP gene (termed BSE-M) was also found in 2006 in the USA. The transmissibility and phenotypes of these atypical BSE strains/isolates in humans were unknown. We have inoculated humanized transgenic mice with classical and atypical BSE strains (BSE-C, BSE-L, BSE-H) and the BSE-M isolate. We have found that the atypical BSE-L strain is much more virulent than the classical BSE-C.*** The atypical BSE-H strain is also transmissible in the humanized transgenic mice with distinct phenotype, but no transmission has been observed for the BSE-M isolate so far.&lt;br /&gt;&lt;br /&gt;III International Symposium on THE NEW PRION BIOLOGY: BASIC SCIENCE, DIAGNOSIS AND THERAPY 2 - 4 APRIL 2009, VENEZIA (ITALY)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.istitutoveneto.it/prion_09/Abstracts_09.pdf"&gt;http://www.istitutoveneto.it/prion_09/Abstracts_09.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;I ask Professor Kong ;&lt;br /&gt;&lt;br /&gt;Thursday, December 04, 2008 3:37 PM Subject: RE: re--Chronic Wating Disease (CWD) and Bovine Spongiform Encephalopathies (BSE): Public Health Risk Assessment&lt;br /&gt;&lt;br /&gt;''IS the h-BSE more virulent than typical BSE as well, or the same as cBSE, or less virulent than cBSE? just curious.....''&lt;br /&gt;&lt;br /&gt;Professor Kong reply ;&lt;br /&gt;&lt;br /&gt;.....snip&lt;br /&gt;&lt;br /&gt;''As to the H-BSE, we do not have sufficient data to say one way or another, but we have found that H-BSE can infect humans. I hope we could publish these data once the study is complete. Thanks for your interest.''&lt;br /&gt;&lt;br /&gt;Best regards, Qingzhong Kong, PhD Associate Professor Department of Pathology Case Western Reserve University Cleveland, OH 44106 USA&lt;br /&gt;&lt;br /&gt;END...TSS&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein&lt;br /&gt;&lt;br /&gt;Emmanuel A. Asante, Jacqueline M. Linehan, Melanie Desbruslais, Susan Joiner, Ian Gowland, Andrew L. Wood, Julie Welch, Andrew F. Hill, Sarah E. Lloyd, Jonathan D.F. Wadsworth, and John Collinge1 MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College, Queen Square, London WC1N 3BG, UK 1Corresponding author e-mail: j.collinge@prion.ucl.ac.ukReceived August 1, 2002; Revised September 24, 2002; Accepted October 17, 2002.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC136957/?tool=pubmed"&gt;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC136957/?tool=pubmed&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The EMBO Journal (2002) 21, 6358 - 6366 doi:10.1093/emboj/cdf653&lt;br /&gt;&lt;br /&gt;BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein&lt;br /&gt;&lt;br /&gt;Emmanuel A. Asante1, Jacqueline M. Linehan1, Melanie Desbruslais1, Susan Joiner1, Ian Gowland1, Andrew L. Wood1, Julie Welch1, Andrew F. Hill1, Sarah E. Lloyd1, Jonathan D.F. Wadsworth1 and John Collinge1&lt;br /&gt;&lt;br /&gt;1.MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College, Queen Square, London WC1N 3BG, UK Correspondence to:&lt;br /&gt;&lt;br /&gt;John Collinge, E-mail: j.collinge@prion.ucl.ac.uk&lt;br /&gt;&lt;br /&gt;Received 1 August 2002; Accepted 17 October 2002; Revised 24 September 2002&lt;br /&gt;&lt;br /&gt;--------------------------------------------------------------------------------&lt;br /&gt;&lt;br /&gt;Abstract&lt;br /&gt;&lt;br /&gt;Variant Creutzfeldt–Jakob disease (vCJD) has been recognized to date only in individuals homozygous for methionine at PRNP codon 129. Here we show that transgenic mice expressing human PrP methionine 129, inoculated with either bovine spongiform encephalopathy (BSE) or variant CJD prions, may develop the neuropathological and molecular phenotype of vCJD, consistent with these diseases being caused by the same prion strain. Surprisingly, however, BSE transmission to these transgenic mice, in addition to producing a vCJD-like phenotype, can also result in a distinct molecular phenotype that is indistinguishable from that of sporadic CJD with PrPSc type 2. These data suggest that more than one BSE-derived prion strain might infect humans; it is therefore possible that some patients with a phenotype consistent with sporadic CJD may have a disease arising from BSE exposure.&lt;br /&gt;&lt;br /&gt;Keywords:BSE, Creutzfeldt–Jakob disease, prion, transgenic&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nature.com/emboj/journal/v21/n23/abs/7594869a.html"&gt;http://www.nature.com/emboj/journal/v21/n23/abs/7594869a.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The most recent assessments (and reassessments) were published in June 2005 (Table I; 18), and included the categorisation of Canada, the USA, and Mexico as GBR III. Although only Canada and the USA have reported cases, the historically open system of trade in North America suggests that it is likely that BSE is present also in Mexico.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.oie.int/boutique/extrait/06heim937950.pdf"&gt;http://www.oie.int/boutique/extrait/06heim937950.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, March 4, 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Alberta dairy cow found with mad cow disease&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/alberta-dairy-cow-found-with-mad-cow.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/alberta-dairy-cow-found-with-mad-cow.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle&lt;br /&gt;&lt;br /&gt;To date the OIE/WAHO assumes that the human and animal health standards set out in the BSE chapter for classical BSE (C-Type) applies to all forms of BSE which include the H-type and L-type atypical forms. This assumption is scientifically not completely justified and accumulating evidence suggests that this may in fact not be the case. Molecular characterization and the spatial distribution pattern of histopathologic lesions and immunohistochemistry (IHC) signals are used to identify and characterize atypical BSE. Both the L-type and H-type atypical cases display significant differences in the conformation and spatial accumulation of the disease associated prion protein (PrPSc) in brains of afflicted cattle. Transmission studies in bovine transgenic and wild type mouse models support that the atypical BSE types might be unique strains because they have different incubation times and lesion profiles when compared to C-type BSE. When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures.&lt;br /&gt;&lt;br /&gt;This study will contribute to a correct definition of specified risk material (SRM) in atypical BSE. The incumbent of this position will develop new and transfer existing, ultra-sensitive methods for the detection of atypical BSE in tissue of experimentally infected cattle.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2"&gt;http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please see all seven threats listed in the USA, and more...FULL TEXT ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, August 12, 2010&lt;br /&gt;&lt;br /&gt;Seven main threats for the future linked to prions&lt;br /&gt;&lt;br /&gt;First threat&lt;br /&gt;&lt;br /&gt;The TSE road map defining the evolution of European policy for protection against prion diseases is based on a certain numbers of hypotheses some of which may turn out to be erroneous. In particular, a form of BSE (called atypical Bovine Spongiform Encephalopathy), recently identified by systematic testing in aged cattle without clinical signs, may be the origin of classical BSE and thus potentially constitute a reservoir, which may be impossible to eradicate if a sporadic origin is confirmed. ***Also, a link is suspected between atypical BSE and some apparently sporadic cases of Creutzfeldt-Jakob disease in humans. These atypical BSE cases constitute an unforeseen first threat that could sharply modify the European approach to prion diseases.&lt;br /&gt;&lt;br /&gt;Second threat&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neuroprion.org/en/np-neuroprion.html"&gt;http://www.neuroprion.org/en/np-neuroprion.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionpathy.blogspot.com/2010/08/seven-main-threats-for-future-linked-to.html"&gt;http://prionpathy.blogspot.com/2010/08/seven-main-threats-for-future-linked-to.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionpathy.blogspot.com/"&gt;http://prionpathy.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;14th ICID International Scientific Exchange Brochure -&lt;br /&gt;&lt;br /&gt;Final Abstract Number: ISE.114&lt;br /&gt;&lt;br /&gt;Session: International Scientific Exchange&lt;br /&gt;&lt;br /&gt;Transmissible Spongiform encephalopathy (TSE) animal and human TSE in North America&lt;br /&gt;&lt;br /&gt;update October 2009&lt;br /&gt;&lt;br /&gt;T. Singeltary&lt;br /&gt;&lt;br /&gt;Bacliff, TX, USA&lt;br /&gt;&lt;br /&gt;Background:&lt;br /&gt;&lt;br /&gt;An update on atypical BSE and other TSE in North America. Please remember, the typical U.K. c-BSE, the atypical l-BSE (BASE), and h-BSE have all been documented in North America, along with the typical scrapie's, and atypical Nor-98 Scrapie, and to date, 2 different strains of CWD, and also TME. All these TSE in different species have been rendered and fed to food producing animals for humans and animals in North America (TSE in cats and dogs ?), and that the trading of these TSEs via animals and products via the USA and Canada has been immense over the years, decades.&lt;br /&gt;&lt;br /&gt;Methods:&lt;br /&gt;&lt;br /&gt;12 years independent research of available data&lt;br /&gt;&lt;br /&gt;Results:&lt;br /&gt;&lt;br /&gt;I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2009. With all the science to date refuting it, to continue to validate this old myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, medical i.e., surgical, blood, dental, endoscopy, optical, nutritional supplements, cosmetics etc.&lt;br /&gt;&lt;br /&gt;Conclusion:&lt;br /&gt;&lt;br /&gt;I would like to submit a review of past CJD surveillance in the USA, and the urgent need to make all human TSE in the USA a reportable disease, in every state, of every age group, and to make this mandatory immediately without further delay. The ramifications of not doing so will only allow this agent to spread further in the medical, dental, surgical arena's. Restricting the reporting of CJD and or any human TSE is NOT scientific. Iatrogenic CJD knows NO age group, TSE knows no boundaries. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Gajdusek, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Transmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf"&gt;http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P26 TRANSMISSION OF ATYPICAL BOVINE SPONGIFORM ENCEPHALOPATHY (BSE) IN HUMANIZED MOUSE MODELS&lt;br /&gt;&lt;br /&gt;Liuting Qing1, Fusong Chen1, Michael Payne1, Wenquan Zou1, Cristina Casalone2, Martin Groschup3, Miroslaw Polak4, Maria Caramelli2, Pierluigi Gambetti1, Juergen Richt5*, and Qingzhong Kong1 1Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA; 2CEA, Istituto Zooprofilattico Sperimentale, Italy; 3Friedrich-Loeffler-Institut, Germany; 4National Veterinary Research Institute, Poland; 5Kansas State University, Diagnostic Medicine/Pathobiology Department, Manhattan, KS 66506, USA. *Previous address: USDA National Animal Disease Center, Ames, IA 50010, USA&lt;br /&gt;&lt;br /&gt;Classical BSE is a world-wide prion disease in cattle, and the classical BSE strain (BSE-C) has led to over 200 cases of clinical human infection (variant CJD). Two atypical BSE strains, BSE-L (also named BASE) and BSE-H, have been discovered in three continents since 2004. The first case of naturally occurring BSE with mutated bovine PrP gene (termed BSE-M) was also found in 2006 in the USA. The transmissibility and phenotypes of these atypical BSE strains/isolates in humans were unknown. We have inoculated humanized transgenic mice with classical and atypical BSE strains (BSE-C, BSE-L, BSE-H) and the BSE-M isolate. We have found that the atypical BSE-L strain is much more virulent than the classical BSE-C. The atypical BSE-H strain is also transmissible in the humanized transgenic mice with distinct phenotype, but no transmission has been observed for the BSE-M isolate so far.&lt;br /&gt;&lt;br /&gt;III International Symposium on THE NEW PRION BIOLOGY: BASIC SCIENCE, DIAGNOSIS AND THERAPY 2 - 4 APRIL 2009, VENEZIA (ITALY)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.istitutoveneto.it/prion_09/Abstracts_09.pdf"&gt;http://www.istitutoveneto.it/prion_09/Abstracts_09.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, January 29, 2011&lt;br /&gt;&lt;br /&gt;Atypical L-Type Bovine Spongiform Encephalopathy (L-BSE) Transmission to Cynomolgus Macaques, a Non-Human Primate&lt;br /&gt;&lt;br /&gt;Jpn. J. Infect. Dis., 64 (1), 81-84, 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2011/01/atypical-l-type-bovine-spongiform.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2011/01/atypical-l-type-bovine-spongiform.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, November 02, 2010&lt;br /&gt;&lt;br /&gt;BSE - ATYPICAL LESION DISTRIBUTION (RBSE 92-21367) statutory (obex only) diagnostic criteria CVL 1992&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/11/bse-atypical-lesion-distribution-rbse.html"&gt;http://bse-atypical.blogspot.com/2010/11/bse-atypical-lesion-distribution-rbse.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, July 14, 2009&lt;br /&gt;&lt;br /&gt;U.S. Emergency Bovine Spongiform Encephalopathy Response Plan Summary and BSE Red Book Date: February 14, 2000 at 8:56 am PST&lt;br /&gt;&lt;br /&gt;WHERE did we go wrong $$$&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowtesting.blogspot.com/2009/07/us-emergency-bovine-spongiform.html"&gt;http://madcowtesting.blogspot.com/2009/07/us-emergency-bovine-spongiform.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P.9.21&lt;br /&gt;&lt;br /&gt;Molecular characterization of BSE in Canada&lt;br /&gt;&lt;br /&gt;Jianmin Yang1, Sandor Dudas2, Catherine Graham2, Markus Czub3, Tim McAllister1, Stefanie Czub1 1Agriculture and Agri-Food Canada Research Centre, Canada; 2National and OIE BSE Reference Laboratory, Canada; 3University of Calgary, Canada&lt;br /&gt;&lt;br /&gt;Background: Three BSE types (classical and two atypical) have been identified on the basis of molecular characteristics of the misfolded protein associated with the disease. To date, each of these three types have been detected in Canadian cattle.&lt;br /&gt;&lt;br /&gt;Objectives: This study was conducted to further characterize the 16 Canadian BSE cases based on the biochemical properties of there associated PrPres. Methods: Immuno-reactivity, molecular weight, glycoform profiles and relative proteinase K sensitivity of the PrPres from each of the 16 confirmed Canadian BSE cases was determined using modified Western blot analysis.&lt;br /&gt;&lt;br /&gt;Results: Fourteen of the 16 Canadian BSE cases were C type, 1 was H type and 1 was L type. The Canadian H and L-type BSE cases exhibited size shifts and changes in glycosylation similar to other atypical BSE cases. PK digestion under mild and stringent conditions revealed a reduced protease resistance of the atypical cases compared to the C-type cases. N terminal- specific antibodies bound to PrPres from H type but not from C or L type. The C-terminal-specific antibodies resulted in a shift in the glycoform profile and detected a fourth band in the Canadian H-type BSE.&lt;br /&gt;&lt;br /&gt;Discussion: The C, L and H type BSE cases in Canada exhibit molecular characteristics similar to those described for classical and atypical BSE cases from Europe and Japan. This supports the theory that the importation of BSE contaminated feedstuff is the source of C-type BSE in Canada. *It also suggests a similar cause or source for atypical BSE in these countries.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf"&gt;http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, January 17, 2011&lt;br /&gt;&lt;br /&gt;MAD COW Update on Feed Enforcement Activities to Limit the Spread of BSE January 13, 2011&lt;br /&gt;&lt;br /&gt;January 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2011/01/mad-cow-update-on-feed-enforcement.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2011/01/mad-cow-update-on-feed-enforcement.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, November 6, 2010&lt;br /&gt;&lt;br /&gt;TAFS1 Position Paper on Position Paper on Relaxation of the Feed Ban in the EU Berne, 2010 TAFS&lt;br /&gt;&lt;br /&gt;INTERNATIONAL FORUM FOR TRANSMISSIBLE ANIMAL DISEASES AND FOOD SAFETY a non-profit Swiss Foundation&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/11/tafs1-position-paper-on-position-paper.html"&gt;http://madcowfeed.blogspot.com/2010/11/tafs1-position-paper-on-position-paper.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, June 12, 2010&lt;br /&gt;&lt;br /&gt;PUBLICATION REQUEST AND FOIA REQUEST Project Number: 3625-32000-086-05 Study of Atypical Bse&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/06/publication-request-and-foia-request.html"&gt;http://bse-atypical.blogspot.com/2010/06/publication-request-and-foia-request.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, July 28, 2010&lt;br /&gt;&lt;br /&gt;re-Freedom of Information Act Project Number 3625-32000-086-05, Study of Atypical BSE UPDATE July 28, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/07/re-freedom-of-information-act-project.html"&gt;http://bse-atypical.blogspot.com/2010/07/re-freedom-of-information-act-project.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;LET'S take a closer look at this new prionpathy or prionopathy, and then let's look at the g-h-BSEalabama mad cow.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;ALABAMA MAD COW g-h-BSEalabama&lt;br /&gt;&lt;br /&gt;In this study, we identified a novel mutation in the bovine prion protein gene (Prnp), called E211K, of a confirmed BSE positive cow from Alabama, United States of America. This mutation is identical to the E200K pathogenic mutation found in humans with a genetic form of CJD. This finding represents the first report of a confirmed case of BSE with a potential pathogenic mutation within the bovine Prnp gene. We hypothesize that the bovine Prnp E211K mutation most likely has caused BSE in "the approximately 10-year-old cow" carrying the E221K mutation.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000156"&gt;http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000156&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plospathogens.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.ppat.1000156&amp;amp;representation=PDF"&gt;http://www.plospathogens.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.ppat.1000156&amp;amp;representation=PDF&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, August 14, 2010&lt;br /&gt;&lt;br /&gt;BSE Case Associated with Prion Protein Gene Mutation (g-h-BSEalabama) and VPSPr PRIONPATHY&lt;br /&gt;&lt;br /&gt;(see mad cow feed in COMMERCE IN ALABAMA...TSS)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionpathy.blogspot.com/2010/08/bse-case-associated-with-prion-protein.html"&gt;http://prionpathy.blogspot.com/2010/08/bse-case-associated-with-prion-protein.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2009 UPDATE ON ALABAMA AND TEXAS MAD COWS 2005 and 2006&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html"&gt;http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;her healthy calf also carried the mutation (J. A. Richt and S. M. Hall PLoS Pathog. 4, e1000156; 2008).&lt;br /&gt;&lt;br /&gt;This raises the possibility that the disease could occasionally be genetic in origin. Indeed, the report of the UK BSE Inquiry in 2000 suggested that the UK epidemic had most likely originated from such a mutation and argued against the scrapierelated assumption. Such rare potential pathogenic PRNP mutations could occur in countries at present considered to be free of BSE, such as Australia and New Zealand. So it is important to maintain strict surveillance for BSE in cattle, with rigorous enforcement of the ruminant feed ban (many countries still feed ruminant proteins to pigs). Removal of specified risk material, such as brain and spinal cord, from cattle at slaughter prevents infected material from entering the human food chain. Routine genetic screening of cattle for PRNP mutations, which is now available, could provide additional data on the risk to the public. Because the point mutation identified in the Alabama animals is identical to that responsible for the commonest type of familial (genetic) CJD in humans, it is possible that the resulting infective prion protein might cross the bovine–human species barrier more easily. Patients with vCJD continue to be identified. The fact that this is happening less often should not lead to relaxation of the controls necessary to prevent future outbreaks.&lt;br /&gt;&lt;br /&gt;Malcolm A. Ferguson-Smith Cambridge University Department of Veterinary Medicine, Madingley Road, Cambridge CB3 0ES, UK e-mail: maf12@cam.ac.uk Jürgen A. Richt College of Veterinary Medicine, Kansas State University, K224B Mosier Hall, Manhattan, Kansas 66506-5601, USA&lt;br /&gt;&lt;br /&gt;NATURE|Vol 457|26 February 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nature.com/nature/journal/v457/n7233/full/4571079b.html"&gt;http://www.nature.com/nature/journal/v457/n7233/full/4571079b.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1st, let's look at the recent science on risk factors of CWD in deer and elk, and the potential for human transmission, is real ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, April 06, 2011&lt;br /&gt;&lt;br /&gt;Presence and Seeding Activity of Pathological Prion Protein (PrPTSE) in Skeletal Muscles of White-Tailed Deer Infected with Chronic Wasting Disease&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Thank you Professor Beekes et al, and again to PLos for open access !&lt;br /&gt;&lt;br /&gt;This is another important study showing risk factors that should be taken seriously for human health via CWD, and risk factors there from iatrogenically i.e. via friendly fire or the pass it forward mode of human and animal Transmissible Spongiform Encephalopathy. in my opinion, we have floundered too long. IN 2001 i brought this up to the O.I.E., and they said they too were concerned, but yet a decade later, they too are still floundering, thus, humans and animals are still being exposed, and more and more science shows that CWD can transmit to humans. ...&lt;br /&gt;&lt;br /&gt;kind regards, terry&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;for anyone interested, please see my comments and source data here ;&lt;br /&gt;&lt;br /&gt;IMPORTANT IMPLICATIONS FOR HUMAN HEALTH !&lt;br /&gt;&lt;br /&gt;Wednesday, April 06, 2011&lt;br /&gt;&lt;br /&gt;Presence and Seeding Activity of Pathological Prion Protein (PrPTSE) in Skeletal Muscles of White-Tailed Deer Infected with Chronic Wasting Disease&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2011/04/presence-and-seeding-activity-of.html"&gt;http://chronic-wasting-disease.blogspot.com/2011/04/presence-and-seeding-activity-of.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;let's take a closer look shall we ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;PLEASE NOTE CWD TO CATTLE TRANSMISSION, AND THE REAL RISK FACTORS OF CWD TO HUMANS ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;A kind greetings from Bacliff, Texas !&lt;br /&gt;&lt;br /&gt;please use this information with how ever many grains of salt you wish, i don't care what you eat.&lt;br /&gt;&lt;br /&gt;cutting out the high risk cns portions will not do away with all the risk, even if you don't cut yourselves by butcher. they have now found in CWD the prion TSE agent in muscle and fat tissue, now they say with smaller amounts of infectivity, but i personally believe in the accumaltion as a factor of risk as well. seems these prion strains as they mutate, the get more virulent. you accumulate enough of the prions and you become clinical. what the threshold from sub-clinical to clinical would be, would depend on the route, the source, titre of infectivity, and ones genetic make up, and whom you expose and or infect while being sub-clinically exposed via the medical and surgical arena's i.e. friendly fire, is a frightening thought now, and a real risk factor. for them to keep saying that there is no _known_ risk factor to humans, with the cjd surveillance system and diagnostic criteria, they would never know. you are correct about the officials being misinformed and misleading. that's why i post the science behind any reports they publish on CWD, hoping someone will read it. personally i think the deer and elk hunting industry were a pawn in a big game of chess. the king was the cattle industry. they have brain washed every one into believing scrapie will not transmit to man, when all science shows that it will. the deer and elk industry were sacrificed. USDA et al tried to cover up mad cow disease, because the evidence was already out (without using a human guinea pig, which i promote over primates i.e. death row inmates, that's another story though), so they just kept saying cwd would not transmit to humans. when the evidence was the same for BSE to humans as it was for CWD to humans, as with Scrapie, and they knew this in 2000, or earlier. the evidence was the same in that study i.e. raymand et al, no matter how low, or high the risk factor is, the risk was the same for BSE, Scrapie, and CWD to humans ;&lt;br /&gt;&lt;br /&gt;Clearly, it is premature to draw firm conclusions about CWD passing naturally into humans, cattle and sheep, but the present results suggest that CWD transmissions to humans would be as limited by PrP incompatibility as transmissions of BSE or sheep scrapie to humans. Although there is no evidence that sheep scrapie has affected humans, it is likely that BSE has caused variant CJD in 74 people (definite and probable variant CJD cases to date according to the UK CJD Surveillance Unit). Given the presumably large number of people exposed to BSE infectivity, the susceptibility of humans may still be very low compared with cattle, which would be consistent with the relatively inefficient conversion of human PrP-sen by PrPBSE. Nonetheless, since humans have apparently been infected by BSE, it would seem prudent to take reasonable measures to limit exposure of humans (as well as sheep and cattle) to CWD infectivity as has been recommended for other animal TSEs.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nature.com/emboj/journal/v19/n17/full/7593259a.html"&gt;http://www.nature.com/emboj/journal/v19/n17/full/7593259a.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;THEN, 11 years later you get this 2011 ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.jbc.org/content/early/2011/01/04/jbc.M110.198465.long"&gt;http://www.jbc.org/content/early/2011/01/04/jbc.M110.198465.long&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Our findings demonstrate that cervid PrPSc, upon strain adaptation by serial passages in vitro or in cervid transgenic mice, is capable of converting human PrPC to produce PrPSc with unique biochemical properties, likely representing a new human prion strain. The newly generated CWD-huPrPSc material has been inoculated into transgenic mice expressing human PrP to study infectivity and disease phenotype and this data will be published elsewhere. ...end&lt;br /&gt;&lt;br /&gt;PLEASE SEE FULL TEXT ;&lt;br /&gt;&lt;br /&gt;Generation of a new form of human PrPSc in vitro by inter-species transmission from cervids prions&lt;br /&gt;&lt;br /&gt;Marcelo A. Barria1, Glenn C. Telling2, Pierluigi Gambetti3, James A. Mastrianni4 and Claudio Soto5,* + Author Affiliations&lt;br /&gt;&lt;br /&gt;1 University of Texas Medical School at Houston, United States; 2 University of Kentucky, United States; 3 Case Western Reserve University, United States; 4 University of Chicago, United States; 5 University of Texas Medical School, United States * Corresponding author; email: claudio.soto@uth.tmc.edu&lt;br /&gt;&lt;br /&gt;Received October 28, 2010. Accepted January 4, 2011. Copyright © 2011, The American Society for Biochemistry and Molecular Biology&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.jbc.org/content/early/2011/01/04/jbc.M110.198465.long"&gt;http://www.jbc.org/content/early/2011/01/04/jbc.M110.198465.long&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;then you had this data ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD9/10022&lt;br /&gt;&lt;br /&gt;October 1994&lt;br /&gt;&lt;br /&gt;Mr R.N. Elmhirst Chairman British Deer Farmers Association Holly Lodge Spencers Lane BerksWell Coventry CV7 7BZ&lt;br /&gt;&lt;br /&gt;Dear Mr Elmhirst,&lt;br /&gt;&lt;br /&gt;CREUTZFELDT-JAKOB DISEASE (CJD) SURVEILLANCE UNIT REPORT&lt;br /&gt;&lt;br /&gt;Thank you for your recent letter concerning the publication of the third annual report from the CJD Surveillance Unit. I am sorry that you are dissatisfied with the way in which this report was published.&lt;br /&gt;&lt;br /&gt;The Surveillance Unit is a completely independant outside body and the Department of Health is committed to publishing their reports as soon as they become available. In the circumstances it is not the practice to circulate the report for comment since the findings of the report would not be amended. In future we can ensure that the British Deer Farmers Association receives a copy of the report in advance of publication.&lt;br /&gt;&lt;br /&gt;The Chief Medical Officer has undertaken to keep the public fully informed of the results of any research in respect of CJD. This report was entirely the work of the unit and was produced completely independantly of the the Department.&lt;br /&gt;&lt;br /&gt;The statistical results reqarding the consumption of venison was put into perspective in the body of the report and was not mentioned at all in the press release. Media attention regarding this report was low key but gave a realistic presentation of the statistical findings of the Unit. This approach to publication was successful in that consumption of venison was highlighted only once by the media ie. in the News at one television proqramme.&lt;br /&gt;&lt;br /&gt;I believe that a further statement about the report, or indeed statistical links between CJD and consumption of venison, would increase, and quite possibly give damaging credence, to the whole issue. From the low key media reports of which I am aware it seems unlikely that venison consumption will suffer adversely, if at all.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20030511010117/http://www.bseinquiry.gov.uk/files/yb/1994/10/00003001.pdf"&gt;http://web.archive.org/web/20030511010117/http://www.bseinquiry.gov.uk/files/yb/1994/10/00003001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;and why do we not want to do TSE transmission studies on chimpanzees $&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;5. A positive result from a chimpanzee challenged severly would likely create alarm in some circles even if the result could not be interpreted for man. I have a view that all these agents could be transmitted provided a large enough dose by appropriate routes was given and the animals kept long enough. Until the mechanisms of the species barrier are more clearly understood it might be best to retain that hypothesis.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;R. BRADLEY&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://collections.europarchive.org/tna/20080102222950/http://www.bseinquiry.gov.uk/files/yb/1990/09/23001001.pdf"&gt;http://collections.europarchive.org/tna/20080102222950/http://www.bseinquiry.gov.uk/files/yb/1990/09/23001001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;From: TSS (216-119-163-189.ipset45.wt.net)&lt;br /&gt;&lt;br /&gt;Subject: CWD aka MAD DEER/ELK TO HUMANS ???&lt;br /&gt;&lt;br /&gt;Date: September 30, 2002 at 7:06 am PST&lt;br /&gt;&lt;br /&gt;From: "Belay, Ermias"&lt;br /&gt;&lt;br /&gt;To:&lt;br /&gt;&lt;br /&gt;Cc: "Race, Richard (NIH)" ; ; "Belay, Ermias"&lt;br /&gt;&lt;br /&gt;Sent: Monday, September 30, 2002 9:22 AM&lt;br /&gt;&lt;br /&gt;Subject: RE: TO CDC AND NIH - PUB MED- 3 MORE DEATHS - CWD - YOUNG HUNTERS&lt;br /&gt;&lt;br /&gt;Dear Sir/Madam, In the Archives of Neurology you quoted (the abstract of which was attached to your email), we did not say CWD in humans will present like variant CJD.&lt;br /&gt;&lt;br /&gt;That assumption would be wrong. I encourage you to read the whole article and call me if you have questions or need more clarification (phone: 404-639-3091). Also, we do not claim that "no-one has ever been infected with prion disease from eating venison." Our conclusion stating that we found no strong evidence of CWD transmission to humans in the article you quoted or in any other forum is limited to the patients we investigated.&lt;br /&gt;&lt;br /&gt;Ermias Belay, M.D. Centers for Disease Control and Prevention&lt;br /&gt;&lt;br /&gt;-----Original Message-----&lt;br /&gt;&lt;br /&gt;From:&lt;br /&gt;&lt;br /&gt;Sent: Sunday, September 29, 2002 10:15 AM&lt;br /&gt;&lt;br /&gt;To: [log in to unmask]"&amp;gt;[log in to unmask]; [log in to unmask]"&amp;gt;[log in to unmask]; [log in to unmask]"&amp;gt;[log in to unmask]&lt;br /&gt;&lt;br /&gt;Subject: TO CDC AND NIH - PUB MED- 3 MORE DEATHS - CWD - YOUNG HUNTERS&lt;br /&gt;&lt;br /&gt;Sunday, November 10, 2002 6:26 PM ......snip........end..............TSS&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2009/02/exotic-meats-usa-announces-urgent.html"&gt;http://chronic-wasting-disease.blogspot.com/2009/02/exotic-meats-usa-announces-urgent.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;FDA is not recalling this CWD positive elk meat for the well being of the dead elk ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 18, 2009&lt;br /&gt;&lt;br /&gt;Noah's Ark Holding, LLC, Dawson, MN RECALL Elk products contain meat derived from an elk confirmed to have CWD NV, CA, TX, CO, NY, UT, FL, OK RECALLS AND FIELD CORRECTIONS: FOODS CLASS II&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2009/03/noahs-ark-holding-llc-dawson-mn-recall.html"&gt;http://chronic-wasting-disease.blogspot.com/2009/03/noahs-ark-holding-llc-dawson-mn-recall.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;see full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2009/04/cwd-update-infection-studies-in-two.html"&gt;http://chronic-wasting-disease.blogspot.com/2009/04/cwd-update-infection-studies-in-two.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Chronic Wasting Disease Susceptibility of Four North American Rodents&lt;br /&gt;&lt;br /&gt;Chad J. Johnson1*, Jay R. Schneider2, Christopher J. Johnson2, Natalie A. Mickelsen2, Julia A. Langenberg3, Philip N. Bochsler4, Delwyn P. Keane4, Daniel J. Barr4, and Dennis M. Heisey2 1University of Wisconsin School of Veterinary Medicine, Department of Comparative Biosciences, 1656 Linden Drive, Madison WI 53706, USA 2US Geological Survey, National Wildlife Health Center, 6006 Schroeder Road, Madison WI 53711, USA 3Wisconsin Department of Natural Resources, 101 South Webster Street, Madison WI 53703, USA 4Wisconsin Veterinary Diagnostic Lab, 445 Easterday Lane, Madison WI 53706, USA *Corresponding author email: cjohnson@svm.vetmed.wisc.edu&lt;br /&gt;&lt;br /&gt;We intracerebrally challenged four species of native North American rodents that inhabit locations undergoing cervid chronic wasting disease (CWD) epidemics. The species were: deer mice (Peromyscus maniculatus), white-footed mice (P. leucopus), meadow voles (Microtus pennsylvanicus), and red-backed voles (Myodes gapperi). The inocula were prepared from the brains of hunter-harvested white-tailed deer from Wisconsin that tested positive for CWD. Meadow voles proved to be most susceptible, with a median incubation period of 272 days. Immunoblotting and immunohistochemistry confirmed the presence of PrPd in the brains of all challenged meadow voles. Subsequent passages in meadow voles lead to a significant reduction in incubation period. The disease progression in red-backed voles, which are very closely related to the European bank vole (M. glareolus) which have been demonstrated to be sensitive to a number of TSEs, was slower than in meadow voles with a median incubation period of 351 days. We sequenced the meadow vole and red-backed vole Prnp genes and found three amino acid (AA) differences outside of the signal and GPI anchor sequences. Of these differences (T56-, G90S, S170N; read-backed vole:meadow vole), S170N is particularly intriguing due its postulated involvement in "rigid loop" structure and CWD susceptibility. Deer mice did not exhibit disease signs until nearly 1.5 years post-inoculation, but appear to be exhibiting a high degree of disease penetrance. White-footed mice have an even longer incubation period but are also showing high penetrance. Second passage experiments show significant shortening of incubation periods. Meadow voles in particular appear to be interesting lab models for CWD. These rodents scavenge carrion, and are an important food source for many predator species. Furthermore, these rodents enter human and domestic livestock food chains by accidental inclusion in grain and forage. Further investigation of these species as potential hosts, bridge species, and reservoirs of CWD is required.&lt;br /&gt;&lt;br /&gt;Potential Venison Exposure Among FoodNet Population Survey Respondents, 2006-2007&lt;br /&gt;&lt;br /&gt;Ryan A. Maddox1*, Joseph Y. Abrams1, Robert C. Holman1, Lawrence B. Schonberger1, Ermias D. Belay1 Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA *Corresponding author e-mail: rmaddox@cdc.gov&lt;br /&gt;&lt;br /&gt;The foodborne transmission of bovine spongiform encephalopathy to humans, resulting in variant Creutzfeldt-Jakob disease, indicates that humans can be susceptible to animal prion diseases. However, it is not known whether foodborne exposure to the agent causing chronic wasting disease (CWD) in cervids can cause human disease. The United States Foodborne Diseases Active Surveillance Network (FoodNet) conducts surveillance for foodborne diseases through an extensive survey administered to respondents in selected states. To describe the frequency of deer and elk hunting and venison consumption, five questions were included in the 2006-2007 FoodNet survey. This survey included 17,372 respondents in ten states: California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee. Of these respondents, 3,220 (18.5%) reported ever hunting deer or elk, with 217 (1.3%) reporting hunting in a CWD-endemic area (northeastern Colorado, southeastern Wyoming, and southwestern Nebraska). Of the 217 CWD-endemic area hunters, 74 (34.1%) were residents of Colorado. Respondents reporting hunting were significantly more likely to be male than female (prevalence ratio: 3.3, 95% confidence interval: 3.1-3.6) and, in general, older respondents were significantly more likely to report hunting than younger respondents. Venison consumption was reported by more than half (67.4%) of the study population, and most venison consumers (94.1%) reported that at least half of their venison came from the wild. However, more than half (59.1%) of the consumers reported eating venison only one to five times in their life or only once or twice a year. These findings indicate that a high percentage of the United States population engages in hunting and/or venison consumption. If CWD continues to spread to more areas across the country, a substantial number of people could potentially be exposed to the infectious agent.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cwd-info.org/pdf/3rd_CWD_Symposium_utah.pdf"&gt;http://www.cwd-info.org/pdf/3rd_CWD_Symposium_utah.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;UPDATED DATA ON 2ND CWD STRAIN&lt;br /&gt;&lt;br /&gt;Wednesday, September 08, 2010&lt;br /&gt;&lt;br /&gt;CWD PRION CONGRESS SEPTEMBER 8-11 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2010/09/cwd-prion-2010.html"&gt;http://chronic-wasting-disease.blogspot.com/2010/09/cwd-prion-2010.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;PPo2-27:&lt;br /&gt;&lt;br /&gt;Generation of a Novel form of Human PrPSc by Inter-species Transmission of Cervid Prions&lt;br /&gt;&lt;br /&gt;Marcelo A. Barria,1 Glenn C. Telling,2 Pierluigi Gambetti,3 James A. Mastrianni4 and Claudio Soto1 1Mitchell Center for Alzheimer’s disease and related Brain disorders; Dept of Neurology; University of Texas Houston Medical School; Houston, TX USA; 2Dept of Microbiology, Immunology &amp;amp; Molecular Genetics and Neurology; Sanders Brown Center on Aging; University of Kentucky Medical Center; Lexington, KY USA; 3Institute of Pathology; Case western Reserve University; Cleveland, OH USA; 4Dept of Neurology; University of Chicago; Chicago, IL USA&lt;br /&gt;&lt;br /&gt;Prion diseases are infectious neurodegenerative disorders affecting humans and animals that result from the conversion of normal prion protein (PrPC) into the misfolded and infectious prion (PrPSc). Chronic wasting disease (CWD) of cervids is a prion disorder of increasing prevalence within the United States that affects a large population of wild and captive deer and elk. CWD is highly contagious and its origin, mechanism of transmission and exact prevalence are currently unclear. The risk of transmission of CWD to humans is unknown. Defining that risk is of utmost importance, considering that people have been infected by animal prions, resulting in new fatal diseases. To study the possibility that human PrPC can be converted into the infectious form by CWD PrPSc we performed experiments using the Protein Misfolding Cyclic Amplification (PMCA) technique, which mimic in vitro the process of prion replication. Our results show that cervid PrPSc can induce the pathological conversion of human PrPC, but only after the CWD prion strain has been stabilized by successive passages in vitro or in vivo. Interestingly, this newly generated human PrPSc exhibits a distinct biochemical pattern that differs from any of the currently known forms of human PrPSc, indicating that it corresponds to a novel human prion strain. Our findings suggest that CWD prions have the capability to infect humans, and that this ability depends on CWD strain adaptation, implying that the risk for human health progressively increases with the spread of CWD among cervids.&lt;br /&gt;&lt;br /&gt;PPo3-7:&lt;br /&gt;&lt;br /&gt;Prion Transmission from Cervids to Humans is Strain-dependent&lt;br /&gt;&lt;br /&gt;Qingzhong Kong, Shenghai Huang,*Fusong Chen, Michael Payne, Pierluigi Gambetti and Liuting Qing Department of Pathology; Case western Reserve University; Cleveland, OH USA *Current address: Nursing Informatics; Memorial Sloan-Kettering Cancer Center; New York, NY USA&lt;br /&gt;&lt;br /&gt;Key words: CWD, strain, human transmission&lt;br /&gt;&lt;br /&gt;Chronic wasting disease (CWD) is a widespread prion disease in cervids (deer and elk) in North America where significant human exposure to CWD is likely and zoonotic transmission of CWD is a concern. Current evidence indicates a strong barrier for transmission of the classical CWD strain to humans with the PrP-129MM genotype. A few recent reports suggest the presence of two or more CWD strains. What remain unknown is whether individuals with the PrP-129VV/MV genotypes are also resistant to the classical CWD strain and whether humans are resistant to all natural or adapted cervid prion strains. Here we report that a human prion strain that had adopted the cervid prion protein (PrP) sequence through passage in cervidized transgenic mice efficiently infected transgenic mice expressing human PrP, indicating that the species barrier from cervid to humans is prion strain-dependent and humans can be vulnerable to novel cervid prion strains. Preliminary results on CWD transmission in transgenic mice expressing human PrP-129V will also be discussed.&lt;br /&gt;&lt;br /&gt;Acknowledgement Supported by NINDS NS052319 and NIA AG14359.&lt;br /&gt;&lt;br /&gt;PPo2-7:&lt;br /&gt;&lt;br /&gt;Biochemical and Biophysical Characterization of Different CWD Isolates&lt;br /&gt;&lt;br /&gt;Martin L. Daus and Michael Beekes Robert Koch Institute; Berlin, Germany&lt;br /&gt;&lt;br /&gt;Key words: CWD, strains, FT-IR, AFM&lt;br /&gt;&lt;br /&gt;Chronic wasting disease (CWD) is one of three naturally occurring forms of prion disease. The other two are Creutzfeldt-Jakob disease in humans and scrapie in sheep. CWD is contagious and affects captive as well as free ranging cervids. As long as there is no definite answer of whether CWD can breach the species barrier to humans precautionary measures especially for the protection of consumers need to be considered. In principle, different strains of CWD may be associated with different risks of transmission to humans. Sophisticated strain differentiation as accomplished for other prion diseases has not yet been established for CWD. However, several different findings indicate that there exists more than one strain of CWD agent in cervids. We have analysed a set of CWD isolates from white-tailed deer and could detect at least two biochemically different forms of disease-associated prion protein PrPTSE. Limited proteolysis with different concentrations of proteinase K and/or after exposure of PrPTSE to different pH-values or concentrations of Guanidinium hydrochloride resulted in distinct isolate-specific digestion patterns. Our CWD isolates were also examined in protein misfolding cyclic amplification studies. This showed different conversion activities for those isolates that had displayed significantly different sensitivities to limited proteolysis by PK in the biochemical experiments described above. We further applied Fourier transform infrared spectroscopy in combination with atomic force microscopy. This confirmed structural differences in the PrPTSE of at least two disinct CWD isolates. The data presented here substantiate and expand previous reports on the existence of different CWD strains.&lt;br /&gt;&lt;br /&gt;PPo2-22:&lt;br /&gt;&lt;br /&gt;CWD Strain Emergence in Orally Inoculated White-tailed Deer (Odocoileus virginianus) with Different PRNP Genotypes&lt;br /&gt;&lt;br /&gt;Camilo Duque-Velasquez,1 Chad Johnson,2 Allen Herbst,1 Judd Aiken1 and Debbie McKenzie1 1Centre for Prions and Protein Folding Diseases; University of Alberta; Edmonton, Alberta Canada; 2Department of Soil Science; University of Wisconsin; Madison, Wisconsin USA&lt;br /&gt;&lt;br /&gt;Key words: CWD, strains, emergence&lt;br /&gt;&lt;br /&gt;Chronic wasting disease (CWD) is a prion disease affecting captive and free-ranging cervids in North America. We have previously demonstrated that specific Prnp polymorphisms are linked to susceptibility/resistance to CWD infection in free-ranging white-tailed deer populations. The “wild-type” alleles (with glutamine at aa 95 and a Glycine at aa 96) were over-represented in the infected deer while the polymorphisms at aa 95 (Q95H) and 96 (G96S) were under-represented in the CWD-positive animals. Experimental oral infection of white-tailed deer with known Prnp genotypes (with inocula from CWD-positive wt/wt deer) confirmed this link between Prnp primary sequence and incubation period. All orally infected animals became clinically positive for CWD. The wt/wt had the shortest incubation period (693 dpi) and the Q95H/G96S the longest (1596 dpi). Brain homogenates prepared from clinically affected deer of each genotype were treated with proteinase K and resolved by western blot; differences in the glycosylation pattern and PK resistance were observed and are suggestive of different PrPSc isoforms. Subsequent experiments regarding biochemical properties like detergent solubility, structural stability, host range and the stability of these characteristics upon serial passages will allow us to further define potential CWD strain emergence in white-tailed deer.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2010/09/cwd-prion-2010.html"&gt;http://chronic-wasting-disease.blogspot.com/2010/09/cwd-prion-2010.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;NOW FOR RISK FACTORS FOR CWD TRANSMISSION TO CATTLE ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;----- Original Message -----&lt;br /&gt;&lt;br /&gt;From: David Colby&lt;br /&gt;&lt;br /&gt;To: flounder9@verizon.net&lt;br /&gt;&lt;br /&gt;Cc: stanley@XXXXXXXX&lt;br /&gt;&lt;br /&gt;Sent: Tuesday, March 01, 2011 8:25 AM&lt;br /&gt;&lt;br /&gt;Subject: Re: FW: re-Prions David W. Colby1,* and Stanley B. Prusiner1,2 + Author Affiliations&lt;br /&gt;&lt;br /&gt;Dear Terry Singeltary,&lt;br /&gt;&lt;br /&gt;Thank you for your correspondence regarding the review article Stanley Prusiner and I recently wrote for Cold Spring Harbor Perspectives. Dr. Prusiner asked that I reply to your message due to his busy schedule. We agree that the transmission of CWD prions to beef livestock would be a troubling development and assessing that risk is important. In our article, we cite a peer-reviewed publication reporting confirmed cases of laboratory transmission based on stringent criteria. The less stringent criteria for transmission described in the abstract you refer to lead to the discrepancy between your numbers and ours and thus the interpretation of the transmission rate. We stand by our assessment of the literature--namely that the transmission rate of CWD to bovines appears relatively low, but we recognize that even a low transmission rate could have important implications for public health and we thank you for bringing attention to this matter.&lt;br /&gt;&lt;br /&gt;Warm Regards, David Colby&lt;br /&gt;&lt;br /&gt;--&lt;br /&gt;&lt;br /&gt;David Colby, PhDAssistant ProfessorDepartment of Chemical EngineeringUniversity of Delaware&lt;br /&gt;&lt;br /&gt;PLEASE SEE FULL TEXT ;&lt;br /&gt;&lt;br /&gt;Wednesday, January 5, 2011&lt;br /&gt;&lt;br /&gt;ENLARGING SPECTRUM OF PRION-LIKE DISEASES Prusiner Colby et al 2011&lt;br /&gt;&lt;br /&gt;Prions&lt;br /&gt;&lt;br /&gt;David W. Colby1,* and Stanley B. Prusiner1,2&lt;br /&gt;&lt;br /&gt;http://cshperspectives.cshlp.org/content/3/1/a006833.full.pdf+html&lt;br /&gt;&lt;br /&gt;re-ENLARGING SPECTRUM OF PRION-LIKE DISEASES Prusiner Colby et al 2011 Prions&lt;br /&gt;&lt;br /&gt;CWD to cattle figures CORRECTION&lt;br /&gt;&lt;br /&gt;Greetings,&lt;br /&gt;&lt;br /&gt;I believe the statement and quote below is incorrect ;&lt;br /&gt;&lt;br /&gt;"CWD has been transmitted to cattle after intracerebral inoculation, although the infection rate was low (4 of 13 animals [Hamir et al. 2001]). This finding raised concerns that CWD prions might be transmitted to cattle grazing in contaminated pastures."&lt;br /&gt;&lt;br /&gt;Please see ;&lt;br /&gt;&lt;br /&gt;Within 26 months post inoculation, 12 inoculated animals had lost weight, revealed abnormal clinical signs, and were euthanatized. Laboratory tests revealed the presence of a unique pattern of the disease agent in tissues of these animals. These findings demonstrate that when CWD is directly inoculated into the brain of cattle, 86% of inoculated cattle develop clinical signs of the disease.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.ars.usda.gov/research/publications/publications.htm?seq_no_115=194089"&gt;http://www.ars.usda.gov/research/publications/publications.htm?seq_no_115=194089&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;" although the infection rate was low (4 of 13 animals [Hamir et al. 2001]). "&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;shouldn't this be corrected, 86% is NOT a low rate. ...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;kindest regards,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA 77518&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thank you!&lt;br /&gt;&lt;br /&gt;Thanks so much for your updates/comments. We intend to publish as rapidly as possible all updates/comments that contribute substantially to the topic under discussion.&lt;br /&gt;&lt;br /&gt;http://cshperspectives.cshlp.org/letters/submit&lt;br /&gt;&lt;br /&gt;please see full text of my submission here ;&lt;br /&gt;&lt;br /&gt;Wednesday, January 5, 2011&lt;br /&gt;&lt;br /&gt;ENLARGING SPECTRUM OF PRION-LIKE DISEASES Prusiner Colby et al 2011&lt;br /&gt;&lt;br /&gt;Prions&lt;br /&gt;&lt;br /&gt;David W. Colby1,* and Stanley B. Prusiner1,2&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://betaamyloidcjd.blogspot.com/2011/01/enlarging-spectrum-of-prion-like.html"&gt;http://betaamyloidcjd.blogspot.com/2011/01/enlarging-spectrum-of-prion-like.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/"&gt;http://chronic-wasting-disease.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, March 27, 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;SCRAPIE USA UPDATE FEBRUARY 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/scrapie-usa-update-february-2011.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/scrapie-usa-update-february-2011.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, February 16, 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;IN CONFIDENCE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;SCRAPIE TRANSMISSION TO CHIMPANZEES&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;IN CONFIDENCE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://scrapie-usa.blogspot.com/2011/02/in-confidence-scrapie-transmission-to.html"&gt;http://scrapie-usa.blogspot.com/2011/02/in-confidence-scrapie-transmission-to.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Increased Atypical Scrapie Detections&lt;br /&gt;&lt;br /&gt;Press reports indicate that increased surveillance is catching what otherwise would have been unreported findings of atypical scrapie in sheep. In 2009, five new cases have been reported in Quebec, Ontario, Alberta, and Saskatchewan. With the exception of Quebec, all cases have been diagnosed as being the atypical form found in older animals. Canada encourages producers to join its voluntary surveillance program in order to gain scrapie-free status. The World Animal Health will not classify Canada as scrapie-free until no new cases are reported for seven years. The Canadian Sheep Federation is calling on the government to fund a wider surveillance program in order to establish the level of prevalence prior to setting an eradication date. Besides long-term testing, industry is calling for a compensation program for farmers who report unusual deaths in their flocks.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://gain.fas.usda.gov/Recent%20GAIN%20Publications/This%20Week%20in%20Canadian%20Agriculture%20%20%20%20%20Issue%2028_Ottawa_Canada_11-6-2009.pdf"&gt;http://gain.fas.usda.gov/Recent%20GAIN%20Publications/This%20Week%20in%20Canadian%20Agriculture%20%20%20%20%20Issue%2028_Ottawa_Canada_11-6-2009.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, February 11, 2011&lt;br /&gt;&lt;br /&gt;Atypical/Nor98 Scrapie Infectivity in Sheep Peripheral Tissues&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;The presence of infectivity in peripheral tissues that enter the food chain clearly indicates that the risk of dietary exposure to Atypical/Nor98 scrapie cannot be disregarded. However, according to our observations, in comparison to the brain, the infectious titres in the peripheral tissues were five log10 lower in Atypical/Nor98 scrapie than in classical scrapie. Therefore, the reduction of the relative exposure risk following SRM removal (CNS, head, spleen and ileum) is probably significantly higher in Atypical/Nor98 scrapie cases than in classical scrapie cases. However, considering the currently estimated prevalence of Atypical/Nor98 scrapie in healthy slaughtered EU population [10], it is probable that atypical scrapie infectivity enters in the food chain despite the prevention measures in force.&lt;br /&gt;&lt;br /&gt;Finally, the capacity of Atypical/Nor98 scrapie agent (and more generally of small ruminants TSE agents) to cross species barrier that naturally limits the transmission risk is insufficiently documented. Recently, the transmission of an Atypical/Nor98 scrapie isolate was reported into transgenic mice over-expressing the porcine PrP [47]. Such results cannot directly be extrapolated to natural exposure conditions and natural hosts. However, they underline the urgent need for further investigations on the potential capacity of Atypical/Nor98 scrapie to propagate in other species than small ruminants.&lt;br /&gt;&lt;br /&gt;snip...please see full text thanks to the Authors and plospathogens.org/&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1001285;jsessionid=CECDA9978AB8F920FB2ED52F4EB71071.ambra01"&gt;http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1001285;jsessionid=CECDA9978AB8F920FB2ED52F4EB71071.ambra01&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Background ----------- "Retrospective studies have identified cases predating the initial identification of this form of scrapie, and epidemiological studies have indicated that it does not conform to the behaviour of an infectious disease, giving rise to the hypothesis that it represents spontaneous disease. However, atypical scrapie isolates have been shown to be infectious experimentally, through intracerebral inoculation in transgenic mice and sheep. [Many of the neurological diseases can be transmitted by intracerebral inoculation, which causes this moderator to approach intracerebral studies as a tool for study, but not necessarily as a direct indication of transmissibility of natural diseases. - Mod.TG]&lt;br /&gt;&lt;br /&gt;"The 1st successful challenge of a sheep with 'field' atypical scrapie from an homologous donor sheep was reported in 2007.&lt;br /&gt;&lt;br /&gt;"Results -------- "This study demonstrates that atypical scrapie has distinct clinical, pathological, and biochemical characteristics which are maintained on transmission and sub-passage, and which are distinct from other strains of transmissible spongiform encephalopathies in the same host genotype.&lt;br /&gt;&lt;br /&gt;"Conclusions ------------ Atypical scrapie is consistently transmissible within AHQ homozygous sheep, and the disease phenotype is preserved on sub-passage."&lt;br /&gt;&lt;br /&gt;Lastly, this moderator wishes to thank Terry Singletary for some of his behind the scenes work of providing citations and references for this posting. - Mod.TG]&lt;br /&gt;&lt;br /&gt;The HealthMap/ProMED-mail interactive map of Australia is available at &lt;http: 00co="" healthmap.org="" r=""&gt;. - Sr.Tech.Ed.MJ]&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.promedmail.org/pls/otn/f?p=2400:1001:962575216785367::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,81729"&gt;http://www.promedmail.org/pls/otn/f?p=2400:1001:962575216785367::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,81729&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Scrapie&lt;br /&gt;&lt;br /&gt;The two Commissions discussed the issue of ‘atypical’ scrapie in terms of notification requirements and the issue of the host genetic resistance. In response to questions of Members, the Code Commission clarified that ‘classical’ scrapie is reportable to the OIE but that ‘atypical’ scrapie is not reportable (in accordance with the recommendations made by the ad hoc Group on Atypical Scrapie and Atypical BSE, which met in November 2007). However, the sharing of scientific information on ‘atypical’ scrapie is encouraged. At this time, the Code Commission considered that more scientific information would be needed to fully address the issues associated with host genotype.&lt;br /&gt;&lt;br /&gt;EU comment&lt;br /&gt;&lt;br /&gt;4&lt;br /&gt;&lt;br /&gt;OIE Terrestrial Animal Health Standards Commission / September 2010&lt;br /&gt;&lt;br /&gt;The EU takes note of the fact that atypical scrapie is not an OIE listed disease. Nevertheless, it will remain notifiable in the EU. Moreover it must be stressed that any emergence of this disease should be notified to the OIE by Members and that scientific data should continue to be gathered.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Zoonotic Potential&lt;br /&gt;&lt;br /&gt;Has transmission to humans been proven? (with the exception of artificial&lt;br /&gt;&lt;br /&gt;circumstances) AND&lt;br /&gt;&lt;br /&gt;Is human infection associated with severe consequences? (death or prolonged illness)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ec.europa.eu/food/international/organisations/docs/EU_comments_OIE_terrestrial_animal_health_code_en.pdf"&gt;http://ec.europa.eu/food/international/organisations/docs/EU_comments_OIE_terrestrial_animal_health_code_en.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2011/02/atypicalnor98-scrapie-infectivity-in.html"&gt;http://nor-98.blogspot.com/2011/02/atypicalnor98-scrapie-infectivity-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, December 12, 2010&lt;br /&gt;&lt;br /&gt;EFSA reviews BSE/TSE infectivity in small ruminant tissues News Story 2 December 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2010/12/efsa-reviews-bsetse-infectivity-in.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2010/12/efsa-reviews-bsetse-infectivity-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, November 22, 2010&lt;br /&gt;&lt;br /&gt;Atypical transmissible spongiform encephalopathies in ruminants: a challenge for disease surveillance and control&lt;br /&gt;&lt;br /&gt;REVIEW ARTICLES&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2010/11/atypical-transmissible-spongiform.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2010/11/atypical-transmissible-spongiform.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, April 18, 2010&lt;br /&gt;&lt;br /&gt;SCRAPIE AND ATYPICAL SCRAPIE TRANSMISSION STUDIES A REVIEW 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://scrapie-usa.blogspot.com/2010/04/scrapie-and-atypical-scrapie.html"&gt;http://scrapie-usa.blogspot.com/2010/04/scrapie-and-atypical-scrapie.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, December 18, 2010&lt;br /&gt;&lt;br /&gt;OIE Global Conference on Wildlife Animal Health and Biodiversity - Preparing for the Future (TSE AND PRIONS) Paris (France), 23-25 February 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2010/12/oie-global-conference-on-wildlife.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2010/12/oie-global-conference-on-wildlife.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowtesting.blogspot.com/"&gt;http://madcowtesting.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CANADA GREENS CALL FOR 100% BSE MAD COW TESTING&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Greens call for ban on federal GMO research Apr 10, 2011 11:45 PM&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;The party said it would also aim to tighten Canada's testing net for bovine spongiform encephalopathy (BSE) in slaughter cattle by implementing "100 per cent" testing of all slaughtered animals, but only "as soon as the process of detecting BSE in blood samples is perfected." The party also calls for ensuring no "animal byproducts" are used in ruminant animal feed....&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.albertafarmexpress.ca/issues/story.aspx?aid=1000407400"&gt;http://www.albertafarmexpress.ca/issues/story.aspx?aid=1000407400&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Green Party MPs will develop a National Agricultural and Food Policy which:&lt;br /&gt;&lt;br /&gt;Improves Food Safety by:&lt;br /&gt;&lt;br /&gt;• Amending the Canadian Food Inspection Agency mandate to remove any obligation to promote Canadian agri-business, ensuring the focus is on food safety and food safety only, with enhanced resources for inspection and monitoring.&lt;br /&gt;&lt;br /&gt;• Ensuring the quality and wholesomeness of food by strengthening the monitoring of pesticides, herbicides, fungicides, growth hormones, non-therapeutic antibiotics and insecticides in food production, processing and storage, with the goal of an orderly reduction in detectable residues of these substances until they reach undetectable limits.&lt;br /&gt;&lt;br /&gt;• Establishing federally funded, community-guided school lunch programs across Canada to ensure that our children have daily access to healthy local food and can learn about sustainable food production and healthy eating.&lt;br /&gt;&lt;br /&gt;• Strengthening Plant Protection and Health of Animals Programs with measures to ensure the integrity of farm food products.&lt;br /&gt;&lt;br /&gt;• Improving and strengthening the Canadian Organic Standard.&lt;br /&gt;&lt;br /&gt;• Providing transitional assistance for those switching to certified organic farming practices.&lt;br /&gt;&lt;br /&gt;• Ensuring that no animal by-products are used in ruminant animal feed.&lt;br /&gt;&lt;br /&gt;• Strengthen testing for BSE by implementing 100% testing (testing of every slaughtered animal) as soon as the process of detecting BSE in blood samples is perfected.&lt;br /&gt;&lt;br /&gt;Vision Green April 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://greenparty.ca/files/attachments/april_2011_vision_green.pdf"&gt;http://greenparty.ca/files/attachments/april_2011_vision_green.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, April 13, 2011&lt;br /&gt;&lt;br /&gt;Joint consultation by the FSA, Defra and Welsh Assembly Government on proposed changes to BSE testing of cattle slaughtered for human consumption&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowtesting.blogspot.com/2011/04/joint-consultation-by-fsa-defra-and.html"&gt;http://madcowtesting.blogspot.com/2011/04/joint-consultation-by-fsa-defra-and.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 9, 2011&lt;br /&gt;&lt;br /&gt;27 U.S. Senators want to force feed Japan Highly Potential North America Mad Cow Beef TSE PRION CJD March 8, 2011&lt;br /&gt;&lt;br /&gt;President Barack Obama The White House&lt;br /&gt;&lt;br /&gt;1600 Pennsylvania Avenue, W Washington, DC 20500&lt;br /&gt;&lt;br /&gt;Dear President Obama:&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/27-us-senators-want-to-force-feed-japan.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/27-us-senators-want-to-force-feed-japan.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, May 11, 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Rare BSE mutation raises concerns over risks to public health&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2009/05/rare-bse-mutation-raises-concerns-over.html"&gt;http://bse-atypical.blogspot.com/2009/05/rare-bse-mutation-raises-concerns-over.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, March 5, 2011&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;MAD COW ATYPICAL CJD PRION TSE CASES WITH CLASSIFICATIONS PENDING ON THE RISE IN NORTH AMERICA&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/mad-cow-atypical-cjd-prion-tse-cases.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2011/03/mad-cow-atypical-cjd-prion-tse-cases.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TSS&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6604160603980694949-2229878203715357033?l=prionunitusaupdate2008.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://prionunitusaupdate2008.blogspot.com/feeds/2229878203715357033/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=6604160603980694949&amp;postID=2229878203715357033' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/2229878203715357033'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/2229878203715357033'/><link rel='alternate' type='text/html' href='http://prionunitusaupdate2008.blogspot.com/2011/04/prion-transmissible-spongiform.html' title='PRION TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY PROJECTS, RESEARCH FUNDING, BSE VOLUNTARY TESTING UPDATE IN NORTH AMERICA 2011'/><author><name>Terry S. Singeltary Sr.</name><uri>http://www.blogger.com/profile/06986622967539963260</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='22' src='http://bp2.blogger.com/_gwMAfd8g9xo/SHuerfBUR1I/AAAAAAAAAAM/nNI1xcLm_Z4/S220/scan0002.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6604160603980694949.post-1668868578486478818</id><published>2010-08-09T19:27:00.000-07:00</published><updated>2010-08-10T09:16:57.248-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='GSS'/><category scheme='http://www.blogger.com/atom/ns#' term='sporadic CJD'/><category scheme='http://www.blogger.com/atom/ns#' term='NATIONAL PRION UNIT USA'/><category scheme='http://www.blogger.com/atom/ns#' term='prionpathy'/><category scheme='http://www.blogger.com/atom/ns#' term='atypical BSE'/><title type='text'>National Prion Disease Pathology Surveillance Center Cases Examined (July 31, 2010)</title><content type='html'>National Prion Disease Pathology Surveillance Center Cases Examined1 (July 31, 2010)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Year Total Referrals2 Prion Disease Sporadic Familial Iatrogenic vCJD&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1996 &amp;amp; earlier 51 33 28 5 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1997 114 68 59 9 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1998 88 52 44 7 1 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1999 120 72 64 8 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2000 146 103 89 14 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2001 209 119 109 10 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2002 248 149 125 22 2 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2003 274 176 137 39 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2004 325 186 164 21 0 1(3)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2005 344 194 157 36 1 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2006 383 197 166 29 0 2(4)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2007 377 214 187 27 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2008 394 231 204 25 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2009 425 259 216 43 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2010 204 124 85 20 0 0&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TOTAL 3702(5) 2177(6) 1834 315 4 3&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1 Listed based on the year of death or, if not available, on year of referral;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2 Cases with suspected prion disease for which brain tissue and/or blood (in familial cases) were submitted;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;3 Disease acquired in the United Kingdom;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;4 Disease was acquired in the United Kingdom in one case and in Saudi Arabia in the other case;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;5 Includes 16 cases in which the diagnosis is pending, and 18 inconclusive cases;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;6 Includes 21 (19 from 2010) cases with type determination pending in which the diagnosis of vCJD has been excluded.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cjdsurveillance.com/pdf/case-table.pdf"&gt;http://www.cjdsurveillance.com/pdf/case-table.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;14th ICID International Scientific Exchange Brochure -&lt;br /&gt;&lt;br /&gt;Final Abstract Number: ISE.114&lt;br /&gt;&lt;br /&gt;Session: International Scientific Exchange&lt;br /&gt;&lt;br /&gt;Transmissible Spongiform encephalopathy (TSE) animal and human TSE in North America&lt;br /&gt;&lt;br /&gt;update October 2009&lt;br /&gt;&lt;br /&gt;T. Singeltary&lt;br /&gt;&lt;br /&gt;Bacliff, TX, USA&lt;br /&gt;&lt;br /&gt;Background:&lt;br /&gt;&lt;br /&gt;An update on atypical BSE and other TSE in North America. Please remember, the typical U.K. c-BSE, the atypical l-BSE (BASE), and h-BSE have all been documented in North America, along with the typical scrapie's, and atypical Nor-98 Scrapie, and to date, 2 different strains of CWD, and also TME. All these TSE in different species have been rendered and fed to food producing animals for humans and animals in North America (TSE in cats and dogs ?), and that the trading of these TSEs via animals and products via the USA and Canada has been immense over the years, decades.&lt;br /&gt;&lt;br /&gt;Methods:&lt;br /&gt;&lt;br /&gt;12 years independent research of available data&lt;br /&gt;&lt;br /&gt;Results:&lt;br /&gt;&lt;br /&gt;I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2009. With all the science to date refuting it, to continue to validate this old myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, medical i.e., surgical, blood, dental, endoscopy, optical, nutritional supplements, cosmetics etc.&lt;br /&gt;&lt;br /&gt;Conclusion:&lt;br /&gt;&lt;br /&gt;I would like to submit a review of past CJD surveillance in the USA, and the urgent need to make all human TSE in the USA a reportable disease, in every state, of every age group, and to make this mandatory immediately without further delay. The ramifications of not doing so will only allow this agent to spread further in the medical, dental, surgical arena's. Restricting the reporting of CJD and or any human TSE is NOT scientific. Iatrogenic CJD knows NO age group, TSE knows no boundaries. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Gajdusek, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Transmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route.&lt;br /&gt;&lt;br /&gt;see page 114 ;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf"&gt;http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;I ask Professor Kong ;&lt;br /&gt;&lt;br /&gt;Thursday, December 04, 2008 3:37 PM Subject: RE: re--Chronic Wating Disease (CWD) and Bovine Spongiform Encephalopathies (BSE): Public Health Risk Assessment&lt;br /&gt;&lt;br /&gt;''IS the h-BSE more virulent than typical BSE as well, or the same as cBSE, or less virulent than cBSE? just curious.....''&lt;br /&gt;&lt;br /&gt;Professor Kong reply ;&lt;br /&gt;&lt;br /&gt;.....snip&lt;br /&gt;&lt;br /&gt;''As to the H-BSE, we do not have sufficient data to say one way or another, but we have found that H-BSE can infect humans. I hope we could publish these data once the study is complete.&lt;br /&gt;&lt;br /&gt;Thanks for your interest.''&lt;br /&gt;&lt;br /&gt;Best regards,&lt;br /&gt;&lt;br /&gt;Qingzhong Kong, PhD Associate Professor Department of Pathology Case Western Reserve University Cleveland, OH 44106 USA&lt;br /&gt;&lt;br /&gt;END...TSS&lt;br /&gt;&lt;br /&gt;P.4.23&lt;br /&gt;&lt;br /&gt;Transmission of atypical BSE in humanized mouse models&lt;br /&gt;&lt;br /&gt;Liuting Qing1, Wenquan Zou1, Cristina Casalone2, Martin Groschup3, Miroslaw Polak4, Maria Caramelli2, Pierluigi Gambetti1, Juergen Richt5, Qingzhong Kong1 1Case Western Reserve University, USA; 2Instituto Zooprofilattico Sperimentale, Italy; 3Friedrich-Loeffler-Institut, Germany; 4National Veterinary Research Institute, Poland; 5Kansas State University (Previously at USDA National Animal Disease Center), USA&lt;br /&gt;&lt;br /&gt;Background: Classical BSE is a world-wide prion disease in cattle, and the classical BSE strain (BSE-C) has led to over 200 cases of clinical human infection (variant CJD). Atypical BSE cases have been discovered in three continents since 2004; they include the L-type (also named BASE), the H-type, and the first reported case of naturally occurring BSE with mutated bovine PRNP (termed BSE-M). The public health risks posed by atypical BSE were largely undefined.&lt;br /&gt;&lt;br /&gt;Objectives: To investigate these atypical BSE types in terms of their transmissibility and phenotypes in humanized mice. Methods: Transgenic mice expressing human PrP were inoculated with several classical (C-type) and atypical (L-, H-, or Mtype) BSE isolates, and the transmission rate, incubation time, characteristics and distribution of PrPSc, symptoms, and histopathology were or will be examined and compared.&lt;br /&gt;&lt;br /&gt;Results: Sixty percent of BASE-inoculated humanized mice became infected with minimal spongiosis and an average incubation time of 20-22 months, whereas only one of the C-type BSE-inoculated mice developed prion disease after more than 2 years. Protease-resistant PrPSc in BASE-infected humanized Tg mouse brains was biochemically different from bovine BASE or sCJD. PrPSc was also detected in the spleen of 22% of BASE-infected humanized mice, but not in those infected with sCJD. Secondary transmission of BASE in the humanized mice led to a small reduction in incubation time.&lt;br /&gt;&lt;br /&gt;The atypical BSE-H strain is also transmissible with distinct phenotypes in the humanized mice, but no BSE-M transmission has been observed so far.&lt;br /&gt;&lt;br /&gt;Discussion: Our results demonstrate that BASE is more virulent than classical BSE, has a lymphotropic phenotype, and displays a modest transmission barrier in our humanized mice.&lt;br /&gt;&lt;br /&gt;BSE-H is also transmissible in our humanized Tg mice.&lt;br /&gt;&lt;br /&gt;The possibility of more than two atypical BSE strains will be discussed.&lt;br /&gt;&lt;br /&gt;Supported by NINDS NS052319, NIA AG14359, and NIH AI 77774.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf"&gt;http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle&lt;br /&gt;&lt;br /&gt;To date the OIE/WAHO assumes that the human and animal health standards set out in the BSE chapter for classical BSE (C-Type) applies to all forms of BSE which include the H-type and L-type atypical forms. This assumption is scientifically not completely justified and accumulating evidence suggests that this may in fact not be the case. Molecular characterization and the spatial distribution pattern of histopathologic lesions and immunohistochemistry (IHC) signals are used to identify and characterize atypical BSE. Both the L-type and H-type atypical cases display significant differences in the conformation and spatial accumulation of the disease associated prion protein (PrPSc) in brains of afflicted cattle. Transmission studies in bovine transgenic and wild type mouse models support that the atypical BSE types might be unique strains because they have different incubation times and lesion profiles when compared to C-type BSE. When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures.&lt;br /&gt;&lt;br /&gt;This study will contribute to a correct definition of specified risk material (SRM) in atypical BSE. The incumbent of this position will develop new and transfer existing, ultra-sensitive methods for the detection of atypical BSE in tissue of experimentally infected cattle.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2"&gt;http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;SEE FULL TEXT ;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html"&gt;http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, August 9, 2010&lt;br /&gt;&lt;br /&gt;Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein or just more Prionbaloney ?&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2010&lt;br /&gt;&lt;br /&gt;Original Article&lt;br /&gt;&lt;br /&gt;Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; Because 8 out of 10 patients had a positive family history of dementia in the original study, a genetic cause was suspected. Although all cases were homozygous for valine at codon 129 of the PrP gene, NO mutations were detected. &lt;&lt;&lt; &lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;IN CONFIDENCE AS implied in the Inset 25 we must not _ASSUME_ that transmission of BSE to other species will invariably present pathology typical of a scrapie-like disease.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://collections.europarchive.org/tna/20080102185948/http://www.bseinquiry.gov.uk/files/yb/1991/01/04004001.pdf"&gt;http://collections.europarchive.org/tna/20080102185948/http://www.bseinquiry.gov.uk/files/yb/1991/01/04004001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;and ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;In Confidence Perceptions of unconventional slow virus diseases of animals in the USA - APRIL-MAY 1989 - G A H Wells&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;3. Prof. A Robertson gave a brief account of BSE. The US approach was to accord it a very low profile indeed. Dr. A Thiermann showed the picture in the ''Independent'' with cattle being incinerated and thought this was a fanatical incident to be avoided in the US at all costs. BSE was not reported in the USA.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://collections.europarchive.org/tna/20080102193705/http://www.bseinquiry.gov.uk/files/mb/m11b/tab01.pdf"&gt;http://collections.europarchive.org/tna/20080102193705/http://www.bseinquiry.gov.uk/files/mb/m11b/tab01.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, October 19, 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Atypical BSE, BSE, and other human and animal TSE in North America Update October 19, 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2009/10/atypical-bse-bse-and-other-human-and.html"&gt;http://bse-atypical.blogspot.com/2009/10/atypical-bse-bse-and-other-human-and.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, September 6, 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;MAD COW USA 1997 [SECRET VIDEO]&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowusda.blogspot.com/2009/09/mad-cow-usa-1997-video.html"&gt;http://madcowusda.blogspot.com/2009/09/mad-cow-usa-1997-video.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;U.S.A. HIDING MAD COW DISEASE VICTIMS AS SPORADIC CJD ? [SEE VIDEO at bottom]&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2009/07/usa-hiding-mad-cow-disease-victims-as.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2009/07/usa-hiding-mad-cow-disease-victims-as.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;DAMNING TESTIMONY FROM STANLEY PRUSINER THE NOBEL PEACE PRIZE WINNER ON PRIONS SPEAKING ABOUT ANN VENEMAN [SEE VIDEO]&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://maddeer.org/video/embedded/prusinerclip.html"&gt;http://maddeer.org/video/embedded/prusinerclip.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, April 12, 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;r-calf and the USA mad cow problem, don't look, don't find, and then blame Canada&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2009/04/r-calf-and-usa-mad-cow-problem-dont.html"&gt;http://prionunitusaupdate2008.blogspot.com/2009/04/r-calf-and-usa-mad-cow-problem-dont.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, June 24, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Accumulation of L-type Bovine Prions in Peripheral Nerve Tissues Volume 16, Number 7–July 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/06/accumulation-of-l-type-bovine-prions-in.html"&gt;http://bse-atypical.blogspot.com/2010/06/accumulation-of-l-type-bovine-prions-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, June 12, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;PUBLICATION REQUEST AND FOIA REQUEST&lt;br /&gt;&lt;br /&gt;Project Number: 3625-32000-086-05 Study of Atypical Bse&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/06/publication-request-and-foia-request.html"&gt;http://bse-atypical.blogspot.com/2010/06/publication-request-and-foia-request.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Archive Number 20100405.1091 Published Date 05-APR-2010 Subject PRO/AH/EDR&gt; Prion disease update 1010 (04)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;[Terry S. Singeltary Sr. has added the following comment:&lt;br /&gt;&lt;br /&gt;"According to the World Health Organisation, the future public health threat of vCJD in the UK and Europe and potentially the rest of the world is of concern and currently unquantifiable. However, the possibility of a significant and geographically diverse vCJD epidemic occurring over the next few decades cannot be dismissed.&lt;br /&gt;&lt;br /&gt;The key word here is diverse. What does diverse mean? If USA scrapie transmitted to USA bovine does not produce pathology as the UK c-BSE, then why would CJD from there look like UK vCJD?"&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.promedmail.org/pls/apex/f?p=2400:1001:568933508083034::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,82101"&gt;http://www.promedmail.org/pls/apex/f?p=2400:1001:568933508083034::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,82101&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; Up until about 6 years ago, the pt worked at Tyson foods where she&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; worked on the assembly line, slaughtering cattle and preparing them for&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; packaging. She was exposed to brain and spinal cord matter when she&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; would euthanize the cattle.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8"&gt;http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html"&gt;http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, April 5, 2010&lt;br /&gt;&lt;br /&gt;UPDATE - CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/04/update-cjd-texas-38-year-old-female.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/04/update-cjd-texas-38-year-old-female.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, June 1, 2010&lt;br /&gt;&lt;br /&gt;USA cases of dpCJD rising with 24 cases so far in 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2010/06/usa-cases-of-dpcjd-rising-with-24-cases.html"&gt;http://cjdtexas.blogspot.com/2010/06/usa-cases-of-dpcjd-rising-with-24-cases.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, July 11, 2010&lt;br /&gt;&lt;br /&gt;CJD or prion disease 2 CASES McLennan County Texas population 230,213 both cases in their 40s&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/07/cjd-2-cases-mclennan-county-texas.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/07/cjd-2-cases-mclennan-county-texas.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, February 05, 2010&lt;br /&gt;&lt;br /&gt;New Variant Creutzfelt Jakob Disease case reports United States 2010 A Review&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html"&gt;http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Manuscript Draft Manuscript Number: Title: HUMAN and ANIMAL TSE Classifications i.e. mad cow disease and the UKBSEnvCJD only theory Article Type: Personal View Corresponding Author: Mr. Terry S. Singeltary, Corresponding Author's Institution: na First Author: Terry S Singeltary, none Order of Authors: Terry S Singeltary, none; Terry S. Singeltary&lt;br /&gt;&lt;br /&gt;Abstract: TSEs have been rampant in the USA for decades in many species, and they all have been rendered and fed back to animals for human/animal consumption. I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2007.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.regulations.gov/fdmspublic/ContentViewer?objectId=090000648027c28e&amp;amp;disposition=attachment&amp;amp;contentType=pdf"&gt;http://www.regulations.gov/fdmspublic/ContentViewer?objectId=090000648027c28e&amp;amp;disposition=attachment&amp;amp;contentType=pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, June 13, 2009&lt;br /&gt;&lt;br /&gt;Monitoring the occurrence of emerging forms of Creutzfeldt-Jakob disease in the United States 2003 revisited 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdusa.blogspot.com/2009/06/monitoring-occurrence-of-emerging-forms.html"&gt;http://cjdusa.blogspot.com/2009/06/monitoring-occurrence-of-emerging-forms.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, January 2, 2010&lt;br /&gt;&lt;br /&gt;Human Prion Diseases in the United States January 1, 2010 ***FINAL***&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;my comments to PLosone here ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd"&gt;http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;HOW many of you recieved a written CJD Questionnaire asking real questions pertaining to route and source (and there are many here in North America) ?&lt;br /&gt;&lt;br /&gt;IS every case getting a cjd questionnaire asking real questions ???&lt;br /&gt;&lt;br /&gt;Friday, November 30, 2007&lt;br /&gt;&lt;br /&gt;CJD QUESTIONNAIRE USA CWRU AND CJD FOUNDATION USA PRION UNIT&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdquestionnaire.blogspot.com/"&gt;http://cjdquestionnaire.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;BSE MAD COW FIREWALL IN THE USA, THE MAD COW FEED BAN, WHAT BAN ?&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;10,000,000+ LBS. of PROHIBITED BANNED MAD COW FEED I.E. BLOOD LACED MBM IN COMMERCE USA 2007&lt;br /&gt;&lt;br /&gt;Date: March 21, 2007 at 2:27 pm PST&lt;br /&gt;&lt;br /&gt;RECALLS AND FIELD CORRECTIONS: VETERINARY MEDICINES -- CLASS II&lt;br /&gt;&lt;br /&gt;___________________________________&lt;br /&gt;&lt;br /&gt;PRODUCT&lt;br /&gt;&lt;br /&gt;Bulk cattle feed made with recalled Darling's 85% Blood Meal, Flash Dried, Recall # V-024-2007&lt;br /&gt;&lt;br /&gt;CODE&lt;br /&gt;&lt;br /&gt;Cattle feed delivered between 01/12/2007 and 01/26/2007&lt;br /&gt;&lt;br /&gt;RECALLING FIRM/MANUFACTURER&lt;br /&gt;&lt;br /&gt;Pfeiffer, Arno, Inc, Greenbush, WI. by conversation on February 5, 2007.&lt;br /&gt;&lt;br /&gt;Firm initiated recall is ongoing.&lt;br /&gt;&lt;br /&gt;REASON&lt;br /&gt;&lt;br /&gt;Blood meal used to make cattle feed was recalled because it was cross- contaminated with prohibited bovine meat and bone meal that had been manufactured on common equipment and labeling did not bear cautionary BSE statement.&lt;br /&gt;&lt;br /&gt;VOLUME OF PRODUCT IN COMMERCE&lt;br /&gt;&lt;br /&gt;42,090 lbs.&lt;br /&gt;&lt;br /&gt;DISTRIBUTION&lt;br /&gt;&lt;br /&gt;WI&lt;br /&gt;&lt;br /&gt;___________________________________&lt;br /&gt;&lt;br /&gt;PRODUCT&lt;br /&gt;&lt;br /&gt;Custom dairy premix products: MNM ALL PURPOSE Pellet, HILLSIDE/CDL Prot- Buffer Meal, LEE, M.-CLOSE UP PX Pellet, HIGH DESERT/ GHC LACT Meal, TATARKA, M CUST PROT Meal, SUNRIDGE/CDL PROTEIN Blend, LOURENZO, K PVM DAIRY Meal, DOUBLE B DAIRY/GHC LAC Mineral, WEST PIONT/GHC CLOSEUP Mineral, WEST POINT/GHC LACT Meal, JENKS, J/COMPASS PROTEIN Meal, COPPINI - 8# SPECIAL DAIRY Mix, GULICK, L-LACT Meal (Bulk), TRIPLE J - PROTEIN/LACTATION, ROCK CREEK/GHC MILK Mineral, BETTENCOURT/GHC S.SIDE MK-MN, BETTENCOURT #1/GHC MILK MINR, V&amp;amp;C DAIRY/GHC LACT Meal, VEENSTRA, F/GHC LACT Meal, SMUTNY, A- BYPASS ML W/SMARTA, Recall # V-025-2007&lt;br /&gt;&lt;br /&gt;CODE&lt;br /&gt;&lt;br /&gt;The firm does not utilize a code - only shipping documentation with commodity and weights identified.&lt;br /&gt;&lt;br /&gt;RECALLING FIRM/MANUFACTURER&lt;br /&gt;&lt;br /&gt;Rangen, Inc, Buhl, ID, by letters on February 13 and 14, 2007. Firm initiated recall is complete.&lt;br /&gt;&lt;br /&gt;REASON&lt;br /&gt;&lt;br /&gt;Products manufactured from bulk feed containing blood meal that was cross contaminated with prohibited meat and bone meal and the labeling did not bear cautionary BSE statement.&lt;br /&gt;&lt;br /&gt;VOLUME OF PRODUCT IN COMMERCE&lt;br /&gt;&lt;br /&gt;9,997,976 lbs.&lt;br /&gt;&lt;br /&gt;DISTRIBUTION&lt;br /&gt;&lt;br /&gt;ID and NV&lt;br /&gt;&lt;br /&gt;END OF ENFORCEMENT REPORT FOR MARCH 21, 2007&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.fda.gov/Safety/Recalls/EnforcementReports/2007/ucm120446.htm"&gt;http://www.fda.gov/Safety/Recalls/EnforcementReports/2007/ucm120446.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, March 2, 2010&lt;br /&gt;&lt;br /&gt;Animal Proteins Prohibited in Ruminant Feed/Adulterated/Misbranded Rangen Inc 2/11/10 USA&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/03/animal-proteins-prohibited-in-ruminant.html"&gt;http://madcowfeed.blogspot.com/2010/03/animal-proteins-prohibited-in-ruminant.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, March 1, 2010&lt;br /&gt;&lt;br /&gt;ANIMAL PROTEIN I.E. MAD COW FEED IN COMMERCE A REVIEW 2010&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/03/animal-protien-ie-mad-cow-feed-in.html"&gt;http://madcowfeed.blogspot.com/2010/03/animal-protien-ie-mad-cow-feed-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr. (Submitted question): Monday, April 5, 2010&lt;br /&gt;&lt;br /&gt;Update on Feed Enforcement Activities to Limit the Spread of BSE April 5, 2010&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/04/update-on-feed-enforcement-activities.html"&gt;http://madcowfeed.blogspot.com/2010/04/update-on-feed-enforcement-activities.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, March 19, 2009&lt;br /&gt;&lt;br /&gt;MILLIONS AND MILLIONS OF POUNDS OF MAD COW FEED IN COMMERCE USA WITH ONGOING 12 YEARS OF DENIAL&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/03/millions-and-millions-of-pounds-of-mad.html"&gt;http://madcowfeed.blogspot.com/2009/03/millions-and-millions-of-pounds-of-mad.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TSS&lt;br /&gt;&lt;object width="320" height="266" class="BLOG_video_class" id="BLOG_video-2449637735185c72" classid="clsid:D27CDB6E-AE6D-11cf-96B8-444553540000" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"&gt;&lt;param name="movie" value="http://www.youtube.com/get_player"&gt;&lt;param name="bgcolor" value="#FFFFFF"&gt;&lt;param name="allowfullscreen" value="true"&gt;&lt;param name="flashvars" value="flvurl=http://v11.nonxt1.googlevideo.com/videoplayback?id%3D2449637735185c72%26itag%3D5%26app%3Dblogger%26ip%3D0.0.0.0%26ipbits%3D0%26expire%3D1329885020%26sparams%3Did,itag,ip,ipbits,expire%26signature%3D5D28A0EFEC156535DF9BFAD7998FBBC3C33864C.3450E454BE97AB468ECF2E2BE606682400394C77%26key%3Dck1&amp;amp;iurl=http://video.google.com/ThumbnailServer2?app%3Dblogger%26contentid%3D2449637735185c72%26offsetms%3D5000%26itag%3Dw160%26sigh%3D4FDdW2FVdWD8kF4ftlGU_pSo82o&amp;amp;autoplay=0&amp;amp;ps=blogger"&gt;&lt;embed src="http://www.youtube.com/get_player" type="application/x-shockwave-flash"width="320" height="266" bgcolor="#FFFFFF"flashvars="flvurl=http://v11.nonxt1.googlevideo.com/videoplayback?id%3D2449637735185c72%26itag%3D5%26app%3Dblogger%26ip%3D0.0.0.0%26ipbits%3D0%26expire%3D1329885020%26sparams%3Did,itag,ip,ipbits,expire%26signature%3D5D28A0EFEC156535DF9BFAD7998FBBC3C33864C.3450E454BE97AB468ECF2E2BE606682400394C77%26key%3Dck1&amp;iurl=http://video.google.com/ThumbnailServer2?app%3Dblogger%26contentid%3D2449637735185c72%26offsetms%3D5000%26itag%3Dw160%26sigh%3D4FDdW2FVdWD8kF4ftlGU_pSo82o&amp;autoplay=0&amp;ps=blogger"allowFullScreen="true" /&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6604160603980694949-1668868578486478818?l=prionunitusaupdate2008.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://prionunitusaupdate2008.blogspot.com/feeds/1668868578486478818/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=6604160603980694949&amp;postID=1668868578486478818' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/1668868578486478818'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/1668868578486478818'/><link rel='alternate' type='text/html' href='http://prionunitusaupdate2008.blogspot.com/2010/08/national-prion-disease-pathology.html' title='National Prion Disease Pathology Surveillance Center Cases Examined (July 31, 2010)'/><author><name>Terry S. Singeltary Sr.</name><uri>http://www.blogger.com/profile/06986622967539963260</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='22' src='http://bp2.blogger.com/_gwMAfd8g9xo/SHuerfBUR1I/AAAAAAAAAAM/nNI1xcLm_Z4/S220/scan0002.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6604160603980694949.post-8698570306834045150</id><published>2010-08-09T10:41:00.000-07:00</published><updated>2010-08-10T10:53:32.417-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='TSE'/><category scheme='http://www.blogger.com/atom/ns#' term='protease-sensitive'/><category scheme='http://www.blogger.com/atom/ns#' term='GSS'/><category scheme='http://www.blogger.com/atom/ns#' term='sporadic CJD'/><category scheme='http://www.blogger.com/atom/ns#' term='PSPr'/><category scheme='http://www.blogger.com/atom/ns#' term='prionpathy'/><title type='text'>Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein or just more Prionbaloney ?</title><content type='html'>Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein or just more Prionbaloney ?&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Greetings,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;I think something is terribly wrong here with this prionpathy debate vs prion debate i.e. Ironside first 10 nvCJD in 1996, compared to Gambetti's first 10+ prionpathy here in the USA in 2010.&lt;br /&gt;&lt;br /&gt;what does this tell us ???&lt;br /&gt;&lt;br /&gt;let's compare Gambetti's first 10 in 2010, to Ironside's first 10 in 1996, to a few other cases of this prionpathy in other countries. let' compare clinical and pathological features.&lt;br /&gt;&lt;br /&gt;we know that the UKBSEnvCJD theory was born from the theory of sheep scrapie, to BSE in cows via feed, to nvCJD to humans via the infectious mad cows that were fed this tainted feed. but we now know that these different strains, cause different symptoms, length of illness from onset of symptoms to death, psychotic vs dementia, kuru type plaques vs no kuru plaques. but yet in 2010, this does not matter.&lt;br /&gt;&lt;br /&gt;so why did it matter with the first 10 of Ironside?&lt;br /&gt;&lt;br /&gt;How can we overlook some of the exact same clinical and pathological features from nvCJD (Ironside's first 10) to (Gambetti's first 10), and how can they conclude that in 1996 they meant one thing, but yet in 2010 they mean something else?&lt;br /&gt;&lt;br /&gt;so how can there be so much change in science from then to now?&lt;br /&gt;&lt;br /&gt;how can the big pond be such a factor in prion science $&lt;br /&gt;&lt;br /&gt;why is it that only the UK and other EU countries can have mad cows, and have humans with mad cow disease there from, but here in the USA, where we have the most documented prion disease in different species on the planet, it's all spontaneous, or generic, with no related gene mutation, but a sporadic genetic prion disease, now called prionpathy ?&lt;br /&gt;&lt;br /&gt;I don't believe it. I believe that it's just more of the same, just different strains.&lt;br /&gt;&lt;br /&gt;I now call this new prionpathy, 'Prionbaloney'.&lt;br /&gt;&lt;br /&gt;they cannot have their cake, and eat it too. which is it ? who is right ? Ironside or Gambetti ?&lt;br /&gt;&lt;br /&gt;Does the USA really have a prion cloaking devise that protects us no matter how much banned mad cow protein is in commerce?&lt;br /&gt;&lt;br /&gt;WHY is it so hard to believe that these atypical BSE strains were a cause of feed, same as with the c-BSE?&lt;br /&gt;&lt;br /&gt;This theory was proven by the EU mad cow feed ban and the dramatic drop in mad cow cases across the EU, there from.&lt;br /&gt;&lt;br /&gt;WHY is it that no one will assess this scientifically with transmission studies $ i.e. will atypical BSE transmit via feed as does/did c-BSE?&lt;br /&gt;&lt;br /&gt;The only cow documented in the world to date with a Genetic mutation g-h-BSEalabama, the same as Gambetti's first 10+ in humans, and this cow had access to TONS of banned mad cow protein in Alabama during that same time period, and there is no link there, it's all just generic, spontaneous, but there is no related mutation to the humans, only to the cow in Alabama ???&lt;br /&gt;&lt;br /&gt;something just does not compute here $&lt;br /&gt;&lt;br /&gt;O.K. let's compare some recent cases of this prionpathy in other countries besides Gambetti's first 10 recently, that he claims is a spontaneous event, from a genetic disorder, that is not genetic, but sporadic, that is related to no animal TSE in North America, or the world. ...&lt;br /&gt;&lt;br /&gt;J Neurol Neurosurg Psychiatry doi:10.1136/jnnp.2009.175646&lt;br /&gt;&lt;br /&gt;Short report&lt;br /&gt;&lt;br /&gt;The first case of protease-sensitive prionopathy (PSPr) in The Netherlands: a patient with an unusual GSS-like clinical phenotype&lt;br /&gt;&lt;br /&gt;C Jansen1, M W Head2, W A van Gool3, F Baas4, H Yull2, J W Ironside2, A J M Rozemuller1,5 + Author Affiliations&lt;br /&gt;&lt;br /&gt;1Department of Pathology, Dutch Surveillance Centre for Prion Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands 2National Creutzfeldt-Jakob Disease Surveillance Unit, University of Edinburgh, Edinburgh, UK 3Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands 4Department of Neurogenetics, Academic Medical Centre, Amsterdam, The Netherlands 5Netherlands Brain Bank and Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands Correspondence to Dr C Jansen, Department of Pathology, Dutch Surveillance Centre for Prion Diseases, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands; c.jansen@umcutrecht.nl Received 16 February 2009 Revised 28 May 2009 Accepted 31 May 2009 Published Online First 14 June 2010&lt;br /&gt;&lt;br /&gt;Abstract&lt;br /&gt;&lt;br /&gt;An atypical case of prion disease is described in a 54-year-old Dutch man, homozygous for valine at codon 129 of the prion protein gene (PRNP). The clinical phenotype was characterised by progressive dementia, spastic paraplegia and sensorimotor polyneuropathy. The disease duration was 20 months. Genetic analysis of PRNP did not reveal any abnormalities. Neuropathologically, only mild spongiform change and a coarse granular immunohistochemical staining for the abnormal prion protein, PrPSc, was observed, with poorly formed plaques in the molecular layer of the cerebellar cortex. However, Western blotting showed low but detectable levels of proteinase K(PK)-resistant PrPSc occurring in an unusual ladder-like profile. These features define a phenotype that corresponds to the recently described protease-sensitive prionopathy (PSPr). Our report on the first Dutch patient with PSPr further expands the spectrum of prionopathies and exemplifies the need to re-evaluate cases of atypical prion disease.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://jnnp.bmj.com/content/early/2010/06/12/jnnp.2009.175646.abstract"&gt;http://jnnp.bmj.com/content/early/2010/06/12/jnnp.2009.175646.abstract&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;A case of protease sensitive prionopathy in a patient in the UK&lt;br /&gt;&lt;br /&gt;M. W. Head1, R. Knight1, M. Zeidler2, H. Yull1, A. Barlow3, J. W. Ironside1Article first published online: 7 AUG 2009&lt;br /&gt;&lt;br /&gt;DOI: 10.1111/j.1365-2990.2009.01040.x&lt;br /&gt;&lt;br /&gt;Scientific correspondence&lt;br /&gt;&lt;br /&gt;A case of protease sensitive prlonopathy in a patient in the UK&lt;br /&gt;&lt;br /&gt;In 2008 the USA National Prion Disease Pathology Surveillance Centre reported a novel human prion disease, whlch they termed protease sensitive prionopathy (PSPr), based on a cohort of 11 patients [I]. The clinical features Included behavioural and psychiatric presenting symptoms in addition to dementia and ataxia. The patients had a mean age at onset or 62 years and mean duruuon of illness of 20 months. Neuropathological assessment showed minimal spongiform change, minimal gliosis, microplaques in the cerebellum and abnormal prion protein accumulation in the form of coarse aggregates, granules and microplaques. The patients had no known risk factors for prion exposure: no mutations in the prton protein gene (PRNP) coding sequence were found. but each patient was homozygous for valine (VV) at codon 129 or PRNP, and a family history or dementia was reported in the majority or the patterns. The most striking and perhaps defining feature or the PSPr phenotype was the presence or abnormal prion protein (PrpSc) in a form that was markedly less protease-resistant than that found in other known human prion diseases, thus making it difficult to detect using conconventional western blot analysts for PrPSc, and resulting in a faint ladder or prion protein fragments extending from the low molecular weight range to the size of the N-terminally truncated PrP, characteristic of most forms of Creutzfeldt-Jakob disese (CJD) [2].&lt;br /&gt;&lt;br /&gt;Although the family history or dementia might be taken to suggest a genetic aetiology, an acquired or sporadic/spontaneous aetiology could NOT be ruled out. An International epidemiological evidence base is lacking for PSPr. In particular, it is important to determine the true prevalence or PSPr, whether It is a new disease or a newly described entity, and whether such cases have been referred to surveillance systems outside the USA [3]. Here we report a case of human prion disease referred to the UK National CJD Surveillance Unit that shares many features with PSPr.&lt;br /&gt;&lt;br /&gt;A 56-year woman presented with forgetfulness and unusual behaviour in January 2005. Four months later she became tearful, with odd speech patterns and diffi&amp;shy;culty finding her way around. She developed increasing difficulties in recognizing and using common objects and started to confusing fictional with real life. These difficulties progressed very rapidly, plateaued for a few weeks and then progressed again. Eight months after onset, she had features of a rapidly progressing dementia with frontal lobe features (Mini Mental State Examination 8, Addenbrooke's Cognitive Examination 29), but without any other specific neurological features. At 12 months she was significantly cognitively impaired. At 16 months, she was unable to name objects, was doubly incontinent, but mobile. Myoclonus was noted on two occaslons. At 25 months, she was nearly mute, but still able to eat; by 27 months, she was in an akinetic mute state, dying in June 2008, after a total illness duration or 42 months. In the early stages of the illness. she was tearful at times. prone to become agitated and exhibited some obsessional behaviour, but these were in the context of significant cognitive decline and no specifically psychiatric features were noted.&lt;br /&gt;&lt;br /&gt;Routine blood tests were normal (save for a positive anti-thyroid peroxidase). EEGs were undertaken on five occasions between 8 and 13 months and were normal, with nonspecific generalized slowing present at 23 months. Cerebral MRI was performed on three occasions showing generalized cerebral atrophy (8 and 10 months) and increased atrophy and periventricular white matter signal Change (23 months]. No basal ganglia or cortical changes typical of CJD were seen. A lumbar puncture per&amp;shy;formed at 10 months yielded acellular CSF with a weak positive 14-3-3 and an Sl00b of 0.65 ng/ml. A weak positive 14-3-3 result is not considered to be of diagnostic significance and as such is not included in our diagnostic criteria for sporadic CJD. Analysis of the PRNP gene showed no pathogenic mutations with valine homozygos&amp;shy;ity at codon 129. In life, she did not fullfill the current clinical diagnostic criteria for either probable or possible sporadic CJD. ...&lt;br /&gt;&lt;br /&gt;full text ;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2990.2009.01040.xlabstract"&gt;http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2990.2009.01040.xlabstract&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;let's go back to 1995-96 now and compare ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Lancet 1996; 347: 921- 25&lt;br /&gt;&lt;br /&gt;A new variant of Creutzfeldt-Jakob disease in the UK&lt;br /&gt;&lt;br /&gt;R G Will, J W Ironside, M Zeidler, S N Cousens, K Estibeiro, A Alperovitch, S Poser, M Pocchiari, A Hofman, P G Smith&lt;br /&gt;&lt;br /&gt;Summary&lt;br /&gt;&lt;br /&gt;Background Epidemiological surveillance of Creutzfeldt-Jakob disease (CJD) was reinstituted in the UK in 1990 to identify any changes in the occurrence of this disease after the epidemic of bovine spongiform encephalopathy (BSE) in cattle.&lt;br /&gt;&lt;br /&gt;Methods Case ascertainment of CJD was mostly by direct referral from neurologists and neuropathologists. Death certificates on which CJD was mentioned were also obtained. Clinical details were obtained for all referred cases, and information on potential risk factors for CJD was obtained by a standard questionnaire administered to patients' relatives. Neuropathological examination was carried out on approximately 70% of suspect cases. Epidemiological studies of CJD using similar methodology to the UK study have been carried out in France, Germany, Italy, and the Netherlands between 1993 and 1995.&lt;br /&gt;&lt;br /&gt;Findings Ten cases of CJD have been identified in the UK in recent months with a new neuropathological profile.&lt;br /&gt;&lt;br /&gt;Other consistent features that are unusual include the young age of the cases,&lt;br /&gt;&lt;br /&gt;clinical findings,&lt;br /&gt;&lt;br /&gt;and the absence of the electroencephalogram features typical for CJD.&lt;br /&gt;&lt;br /&gt;Similar cases have not been identified in other countries in the European surveillance system.&lt;br /&gt;&lt;br /&gt;Interpretatlon These cases appear to represent a new variant of CJD, which may be unique to the UK. This raises the possibility that they are causally linked to BSE. Although this may be the most plausible explanation for this cluster of cases, a link with BSE cannot be confirmed on the basis of this evidence alone. It is essential to obtain further information on the current and past clinical and neuropathological profiles of CJD in the UK and elsewhere.&lt;br /&gt;&lt;br /&gt;National CJD Surveillance Unit, Western General Hospital, Edinburgh EH4 2XU, UK (R G Will FRCP, J W lronside MRCPath, M Zeidler MRCP, K Estibeiro BSc); Department of Epidemiology and Population Science, London School of Hyglene and Tropical Medicine, London, UK (S N Cousens Dip Math Stat, Prof P G Smith DSC); INSEAM, Hopital de la Salpetrlere, Paris, France (A Alperovitch MD); Klinik und Poliklinik fur Neurologie, GeorgAugust- Universitat, Gottingen, Germany (S Poser MD); Laboratorio di Virologia, Istituto Superiore di Sanita, Rome, Italy (M Pocchiari MD); Erasmus University, Rotterdam, The Netherlands (Prof A Hofman MD) Correspondence to: Dr R G Will&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Table 1: Known cases of sporadic CJD* in the UK, **1970-96, dying aged less than 45 years&lt;br /&gt;&lt;br /&gt;These ten cases (four male) had disease onset from February, 1994, to October, 1995. One came to the attention of the CJD Surveillance Unit in March, 1995, and the other nine between October, 1995, and January, 1996. The ages at death of the eight patients who have died range from 19 to 41 years (median 29). Two patients remain alive at ages 18 and 31 years. Intervals between disease onsets and death range from 7.5 to 22.5 months (median 12). Surviving patients in March, 1996, have disease durations of 6 and 22 months. These patients are relatively young compared with most patients with CJD and their disease duration is relatively long. Among 185 cases of sporadic CJD identified since May, 1990, average age at onset was 65 years and median duration of disease four months; for half of these patients, duration was 2.5 to 6.5 months. Since May, 1990, only two other sporadic cases of CJD with age less than 45 years have been identified, both aged 44 years. These cases had disease onsets in 1993 and 1994; neither showed the neuropathological changes described.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Clinical course&lt;br /&gt;&lt;br /&gt;The clinical course of disease in the ten patients was distinct from that usually seen in sporadic CJD (table 2). Nine had behavioural changes as an early clinical feature and were referred to a psychiatrist. In four patients, an early symptom was dysaesthesiae and in another, pain in the feet persisted throughout the illness. Nine patients developed ataxia early in the course of the disease. While all patients developed progressive dementia, in only two was memory impairment part of initial clinical presentation. Seven of the patients developed myoclonus, often late in the course of the disease, and three had choreoathetosis. None of the cases had the electroencephalographic (EEG) features usually associated with CJD.&lt;br /&gt;&lt;br /&gt;With established diagnostic criteria for CJD[6] none of these cases would have been classified as "probable" cases of CJD on clinical grounds. At the time of initial referral to the CJD Surveillance Unit, two patients were classified as definite cases (after brain biopsy) and another as a possible case, while the remaining seven did not fulfil the criteria for even "possible" CJD.&lt;br /&gt;&lt;br /&gt;Information on PrP genotype is available for eight cases. All were methionine homozygotes at codon 129 of the PrP gene and none of the known mutations associated with the inherited forms of CJD was identified. In a study of codon 129 genotypes in sporadic CJD in the UK, 1990- 93, 83% of cases (n=111) were methionine homozygotes.&lt;br /&gt;&lt;br /&gt;Neuropathological features&lt;br /&gt;&lt;br /&gt;Neuropathological examination in all ten cases showed spongiform change and PrP plaques confirming the diagnosis of CJD[6]. In two cases investigated by cerebral biopsy and in the eight necropsy cases, neuropathological features were uniform, with spongiform change in a relatively sparse distribution throughout the cerebral cortex (although all areas were involved to a variable extent in each case who came to necropsy). Spongiform change, neuronal loss, and astrocytosis were most evident in the basal ganglia and thalamus, and were present focally in the cerebrum and cerebellum, most evidently in areas with confluent spongiform change.&lt;br /&gt;&lt;br /&gt;The most striking and consistent neuropathological abnormality in all cases was PrP plaques. In the eight necropsy cases, plaques were extensively distributed throughout the cerebrum and cerebellum, with smaller numbers in the basal ganglia, thalamus, and hypothalamus. Many of these plaques resembled kuru-type plaques with a dense eosinophilic centre and pale periphery and, unusually for this type of lesion, were surrounded by a zone of spongiform change (figures 1 and 2). This unusual feature was not seen in any of the other 175 sporadic CJD cases investigated. Similar lesions have, however, been described in scrapie, where they have been referred to as "florid" plaques[7]. Immunocytochemistry for PrP showed strong staining of these plaque-like lesions, but also showed many other smaller plaques, which appeared both as single and multicentric deposits. PrP deposition was also seen in a pericellular distribution in the cerebral cortex and in the molecular layer of the cerebellum, the pattern of which suggested deposition around small neurons (figure 3). Plaque and pericellular PrP deposits occurred throughout the cerebrum and cerebellum, and were clearly visible in the absence of confluent spongiform change in the surrounding neuropil. In the basal ganglia and thalamus, a perivacuolar pattern of PrP staining was also seen, with linear tract- like deposits within the grey matter. PrP plaques were also noted in these regions although there were fewer than in the cerebrum and cerebellum (figure 4).&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;PLEASE SEE FULL TEXT ;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cjd.ed.ac.uk/lancet.htm"&gt;http://www.cjd.ed.ac.uk/lancet.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;and now Gambetti's first 10, that seems to be growing ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Original Article&lt;br /&gt;&lt;br /&gt;Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein&lt;br /&gt;&lt;br /&gt;Wen-Quan Zou, MD, PhD 1 *, Gianfranco Puoti, MD, PhD 1, Xiangzhu Xiao, PhD 1, Jue Yuan, BA 1, Liuting Qing, PhD 1, Ignazio Cali, MSc 1, Miyuki Shimoji, PhD 1, Jan P.M. Langeveld, PhD 2, Rudy Castellani, MD 3, Silvio Notari, PhD 1, Barbara Crain, MD 4, Robert E. Schmidt, MD 5, Michael Geschwind, MD 6, Stephen J. DeArmond, MD, PhD 6, Nigel J. Cairns, MD 7, Dennis Dickson, MD 8, Lawrence Honig, MD 9, Juan Maria Torres, PhD 10, James Mastrianni, MD, PhD 11, Sabina Capellari, MD 12, Giorgio Giaccone, MD 13, Ermias D. Belay, MD 14, Lawrence B. Schonberger, MD, MPH 14, Mark Cohen, MD 1, George Perry, PhD 15, Qingzhong Kong, PhD 1, Piero Parchi, MD, PhD 12, Fabrizio Tagliavini, MD 13, Pierluigi Gambetti, MD 1 * 1Department of Pathology, National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH 2Central Veterinary Institute of Wageningen, Lelystad, the Netherlands 3Department of Neuropathology, University of Maryland Medical Center, Baltimore, MD 4Department of Neuropathology, Johns Hopkins University, Baltimore, MD 5Department of Neuropathology, Washington University, St. Louis, MO 6Department of Pathology, University of California at San Francisco, San Francisco, CA 7Departments of Neurology, Pathology, and Immunology, Washington University, St. Louis, MO 8Department of Neuropathology, Mayo Clinic-Jacksonville, Jacksonville, FL 9New York Presbyterian Hospital, Columbia University, New York, NY 10Centro de Investigación en Sanidad Animal, Madrid, Spain 11Department of Neurology, University of Chicago, Chicago, IL 12Department of Neurological Sciences, University of Bologna, Dipartimento di Scienze Neurologiche, Università di Bologna, Bologna, Italy 13IRCCS Foundation, National Neurological Institute, Instituto Nazionale Neurologico Carlo Besta, Milan, Italy 14Center of Investigation on Animal Health, Centers for Disease Control and Prevention, Atlanta, GA 15College of Science, University of Texas at San Antonio, San Antonio, TX&lt;br /&gt;&lt;br /&gt;email: Wen-Quan Zou (wenquan.zou@case.edu) Pierluigi Gambetti (pierluigi.gambetti@case.edu)&lt;br /&gt;&lt;br /&gt;*Correspondence to Wen-Quan Zou, Department of Pathology, National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH&lt;br /&gt;&lt;br /&gt;*Correspondence to Pierluigi Gambetti, Institute of Pathology, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106&lt;br /&gt;&lt;br /&gt;Potential Conflicts of Interest Nothing to report.&lt;br /&gt;&lt;br /&gt;Funded by: NIH; Grant Number: NIA AG14359, AG08702 NINDS; Grant Number: R01NS062787 Centers for Disease Control and Prevention; Grant Number: CCU 515004 Britton Fund CJD Foundation Alliance BioSecure University Center on Aging and Health with the support of the McGregor Foundation and President's Discretionary Fund (Case Western Reserve University) National Institute on Aging; Grant Number: AG05681&lt;br /&gt;&lt;br /&gt;Abstract&lt;br /&gt;&lt;br /&gt;Objective: The objective of the study is to report 2 new genotypic forms of protease-sensitive prionopathy (PSPr), a novel prion disease described in 2008, in 11 subjects all homozygous for valine at codon 129 of the prion protein (PrP) gene (129VV). The 2 new PSPr forms affect individuals who are either homozygous for methionine (129MM) or heterozygous for methionine/valine (129MV).&lt;br /&gt;&lt;br /&gt;Methods: Fifteen affected subjects with 129MM, 129MV, and 129VV underwent comparative evaluation at the National Prion Disease Pathology Surveillance Center for clinical, histopathologic, immunohistochemical, genotypical, and PrP characteristics.&lt;br /&gt;&lt;br /&gt;Results: Disease duration (between 22 and 45 months) was significantly different in the 129VV and 129MV subjects. Most other phenotypic features along with the PrP electrophoretic profile were similar but distinguishable in the 3 129 genotypes. A major difference laid in the sensitivity to protease digestion of the disease-associated PrP, which was high in 129VV but much lower, or altogether lacking, in 129MV and 129MM. This difference prompted the substitution of the original designation with variably protease-sensitive prionopathy (VPSPr). None of the subjects had mutations in the PrP gene coding region.&lt;br /&gt;&lt;br /&gt;Interpretation: Because all 3 129 genotypes are involved, and are associated with distinguishable phenotypes, VPSPr becomes the second sporadic prion protein disease with this feature after Creutzfeldt-Jakob disease, originally reported in 1920. However, the characteristics of the abnormal prion protein suggest that VPSPr is different from typical prion diseases, and perhaps more akin to subtypes of Gerstmann-Sträussler-Scheinker disease. ANN NEUROL 2010;68:162-172&lt;br /&gt;&lt;br /&gt;--------------------------------------------------------------------------------&lt;br /&gt;&lt;br /&gt;Received: 9 March 2010; Revised: 5 May 2010; Accepted: 19 May 2010&lt;br /&gt;&lt;br /&gt;Digital Object Identifier (DOI)&lt;br /&gt;&lt;br /&gt;10.1002/ana.22094 About DOI&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www3.interscience.wiley.com/journal/123598302/abstract?CRETRY=1&amp;amp;SRETRY=0"&gt;http://www3.interscience.wiley.com/journal/123598302/abstract?CRETRY=1&amp;amp;SRETRY=0&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; Because 8 out of 10 patients had a positive family history of dementia in the original study, a genetic cause was suspected. Although all cases were homozygous for valine at codon 129 of the PrP gene, NO mutations were detected. &lt;&lt;&lt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;NOW, does this all not look similar to you ? NOW, let's go back further and see some of the political issues ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2. The Collinge/Will dispute appears to rumble on. Dr. Collinge had told Dr. Tyrrell that Dr. Will's response to his criticism about sharing material had been ''quite unacceptable'' (in spite of it's apparently conciliatory tone). Apparently Professor Allen was now going to try and arrange a meeting to resolve the dispute. No action here for MAFF, although Mr. Murray may be interested.&lt;br /&gt;&lt;br /&gt;3. Dr. Tyrrell regretted that the Committee had not seen the article on BBD. However he felt that for the time being NO specific action was called for. The most important need was to consider the possibility that the condition might be transmissible. As we have discussed, I suggested that we might circulate a paper to the members of the committee giving our appreciation of this condition (and perhaps of other non-BSE neurological conditions that had been identified in negative cases) and of any necessary follow up action. IF any Committee member felt strongly about this, or if the issue CAME TO A HEAD, we would call an interim meeting. He was happy with this approach. I would be grateful if Mr. Maslin could, in discussion with CVL and veterinary colleagues draft such a note, which will presumably very largely follow what Mr. Bradley's briefing paper has already said, taking account of DOH comments, We can then clear a final version with DOH before circulating it to Committee members.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20030714222309/www.bseinquiry.gov.uk/files/yb/1992/10/29005001.pdf"&gt;http://web.archive.org/web/20030714222309/www.bseinquiry.gov.uk/files/yb/1992/10/29005001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;IN CONFIDENCE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;This is a highly competitive field and it really will be a pity if we allow many of the key findings to be published by overseas groups while we are unable to pursue our research findings because of this disagreement, which I hope we can make every effort to solve.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20030714222309/www.bseinquiry.gov.uk/files/yb/1992/10/26002001.pdf"&gt;http://web.archive.org/web/20030714222309/www.bseinquiry.gov.uk/files/yb/1992/10/26002001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;COLLINGE THREATENS TO GO TO MEDIA&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20030714222309/www.bseinquiry.gov.uk/files/yb/1992/12/16005001.pdf"&gt;http://web.archive.org/web/20030714222309/www.bseinquiry.gov.uk/files/yb/1992/12/16005001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, August 20, 2008&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Bovine Spongiform Encephalopathy Mad Cow Disease typical and atypical strains, was there a cover-up ? August 20, 2008&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2008/08/bovine-spongiform-encephalopathy-mad.html"&gt;http://bse-atypical.blogspot.com/2008/08/bovine-spongiform-encephalopathy-mad.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, July 08, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: results from a risk-based assessment of surgical interventions Public release date: 8-Jul-2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/07/nosocomial-transmission-of-sporadic.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/07/nosocomial-transmission-of-sporadic.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, July 08, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;GLOBAL CLUSTERS OF CREUTZFELDT JAKOB DISEASE - A REVIEW 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/07/global-clusters-of-creutzfeldt-jakob.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/07/global-clusters-of-creutzfeldt-jakob.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, July 17, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Variant Creutzfeldt-Jakob disease Ironside JW., Haemophilia. 2010 Jul;16 Suppl 5:175-80 REVIEW ARTICLE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://vcjdtransfusion.blogspot.com/2010/07/variant-creutzfeldtjakob-disease.html"&gt;http://vcjdtransfusion.blogspot.com/2010/07/variant-creutzfeldtjakob-disease.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, August 09, 2009&lt;br /&gt;&lt;br /&gt;CJD...Straight talk with...James Ironside...and...Terry Singeltary... 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2009/08/cjdstraight-talk-withjames.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2009/08/cjdstraight-talk-withjames.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, August 18, 2009&lt;br /&gt;&lt;br /&gt;BSE-The Untold Story - joe gibbs and singeltary 1999 - 2009&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowusda.blogspot.com/2009/08/bse-untold-story-joe-gibbs-and.html"&gt;http://madcowusda.blogspot.com/2009/08/bse-untold-story-joe-gibbs-and.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;****************PLEASE READ THE FOLLOWING CAREFULLY************&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;To date the OIE/WAHO assumes that the human and animal health standards set out in the BSE chapter for classical BSE (C-Type) applies to all forms of BSE which include the H-type and L-type atypical forms. This assumption is scientifically not completely justified and accumulating evidence suggests that this may in fact not be the case. Molecular characterization and the spatial distribution pattern of histopathologic lesions and immunohistochemistry (IHC) signals are used to identify and characterize atypical BSE. Both the L-type and H-type atypical cases display significant differences in the conformation and spatial accumulation of the disease associated prion protein (PrPSc) in brains of afflicted cattle. Transmission studies in bovine transgenic and wild type mouse models support that the atypical BSE types might be unique strains because they have different incubation times and lesion profiles when compared to C-type BSE. When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2"&gt;http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;14th International Congress on Infectious Diseases&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;H-type and L-type Atypical BSE January 2010 (special pre-congress edition) 18.173 page 189&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Experimental Challenge of Cattle with H-type and L-type Atypical BSE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;A. Buschmann1, U. Ziegler1, M. Keller1, R. Rogers2, B. Hills3, M.H. Groschup1. 1Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany, 2Health Canada, Bureau of Microbial Hazards, Health Products &amp;amp; Food Branch, Ottawa, Canada, 3Health Canada, Transmissible Spongiform Encephalopathy Secretariat, Ottawa, Canada&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Background: After the detection of two novel BSE forms designated H-type and L-type atypical BSE the question of the pathogenesis and the agent distribution of these two types in cattle was fully open. From initial studies of the brain pathology, it was already known that the anatomical distribution of L-type BSE differs from that of the classical type where the obex region in the brainstem always displays the highest PrPSc concentrations. In contrast in L-type BSE cases, the thalamus and frontal cortex regions showed the highest levels of the pathological prion protein, while the obex region was only weakly involved.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Methods:We performed intracranial inoculations of cattle (five and six per group) using 10%brainstemhomogenates of the two German H- and L-type atypical BSE isolates. The animals were inoculated under narcosis and then kept in a free-ranging stable under appropriate biosafety conditions.At least one animal per group was killed and sectioned in the preclinical stage and the remaining animals were kept until they developed clinical symptoms. The animals were examined for behavioural changes every four weeks throughout the experiment following a protocol that had been established during earlier BSE pathogenesis studies with classical BSE.&lt;br /&gt;&lt;br /&gt;Results and Discussion: All animals of both groups developed clinical symptoms and had to be euthanized within 16 months. The clinical picture differed from that of classical BSE, as the earliest signs of illness were loss of body weight and depression. However, the animals later developed hind limb ataxia and hyperesthesia predominantly and the head. Analysis of brain samples from these animals confirmed the BSE infection and the atypical Western blot profile was maintained in all animals. Samples from these animals are now being examined in order to be able to describe the pathogenesis and agent distribution for these novel BSE types.&lt;br /&gt;&lt;br /&gt;Conclusions: A pilot study using a commercially avaialble BSE rapid test ELISA revealed an essential restriction of PrPSc to the central nervous system for both atypical BSE forms. A much more detailed analysis for PrPSc and infectivity is still ongoing.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.isid.org/14th_icid/"&gt;http://www.isid.org/14th_icid/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ww2.isid.org/Downloads/IMED2009_AbstrAuth.pdf"&gt;http://ww2.isid.org/Downloads/IMED2009_AbstrAuth.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.isid.org/publications/ICID_Archive.shtml"&gt;http://www.isid.org/publications/ICID_Archive.shtml&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;14th ICID International Scientific Exchange Brochure - Final&lt;br /&gt;&lt;br /&gt;Abstract Number: ISE.114&lt;br /&gt;&lt;br /&gt;Session: International Scientific Exchange&lt;br /&gt;&lt;br /&gt;Transmissible Spongiform encephalopathy (TSE) animal and human TSE in North America update October 2009&lt;br /&gt;&lt;br /&gt;T. Singeltary Bacliff, TX, USA&lt;br /&gt;&lt;br /&gt;Background: An update on atypical BSE and other TSE in North America. Please remember, the typical U.K. c-BSE, the atypical l-BSE (BASE), and h-BSE have all been documented in North America, along with the typical scrapie's, and atypical Nor-98 Scrapie, and to date, 2 different strains of CWD, and also TME. All these TSE in different species have been rendered and fed to food producing animals for humans and animals in North America (TSE in cats and dogs ?), and that the trading of these TSEs via animals and products via the USA and Canada has been immense over the years, decades.&lt;br /&gt;&lt;br /&gt;Methods: 12 years independent research of available data&lt;br /&gt;&lt;br /&gt;Results: I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2009. With all the science to date refuting it, to continue to validate this old myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, medical i.e., surgical, blood, dental, endoscopy, optical, nutritional supplements, cosmetics etc.&lt;br /&gt;&lt;br /&gt;Conclusion: I would like to submit a review of past CJD surveillance in the USA, and the urgent need to make all human TSE in the USA a reportable disease, in every state, of every age group, and to make this mandatory immediately without further delay. The ramifications of not doing so will only allow this agent to spread further in the medical, dental, surgical arena's. Restricting the reporting of CJD and or any human TSE is NOT scientific. Iatrogenic CJD knows NO age group, TSE knows no boundaries. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Gajdusek, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Transmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;see page 114 ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf"&gt;http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;International Society for Infectious Diseases Web:&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.isid.org/"&gt;http://www.isid.org/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;I ask Professor Kong ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, December 04, 2008 3:37 PM&lt;br /&gt;&lt;br /&gt;Subject: RE: re--Chronic Wating Disease (CWD) and Bovine Spongiform Encephalopathies (BSE): Public Health Risk Assessment&lt;br /&gt;&lt;br /&gt;''IS the h-BSE more virulent than typical BSE as well, or the same as cBSE, or less virulent than cBSE? just curious.....''&lt;br /&gt;&lt;br /&gt;Professor Kong reply ;&lt;br /&gt;&lt;br /&gt;.....snip&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;''As to the H-BSE, we do not have sufficient data to say one way or another, but we have found that H-BSE can infect humans. I hope we could publish these data once the study is complete. Thanks for your interest.''&lt;br /&gt;&lt;br /&gt;Best regards,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Qingzhong Kong, PhD Associate Professor Department of Pathology Case Western Reserve University Cleveland, OH 44106 USA&lt;br /&gt;&lt;br /&gt;END...TSS&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P.4.23&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Transmission of atypical BSE in humanized mouse models&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Liuting Qing1, Wenquan Zou1, Cristina Casalone2, Martin Groschup3, Miroslaw Polak4, Maria Caramelli2, Pierluigi Gambetti1, Juergen Richt5, Qingzhong Kong1 1Case Western Reserve University, USA; 2Instituto Zooprofilattico Sperimentale, Italy; 3Friedrich-Loeffler-Institut, Germany; 4National Veterinary Research Institute, Poland; 5Kansas State University (Previously at USDA National Animal Disease Center), USA&lt;br /&gt;&lt;br /&gt;Background: Classical BSE is a world-wide prion disease in cattle, and the classical BSE strain (BSE-C) has led to over 200 cases of clinical human infection (variant CJD). Atypical BSE cases have been discovered in three continents since 2004; they include the L-type (also named BASE), the H-type, and the first reported case of naturally occurring BSE with mutated bovine PRNP (termed BSE-M). The public health risks posed by atypical BSE were largely undefined.&lt;br /&gt;&lt;br /&gt;Objectives: To investigate these atypical BSE types in terms of their transmissibility and phenotypes in humanized mice. Methods: Transgenic mice expressing human PrP were inoculated with several classical (C-type) and atypical (L-, H-, or Mtype) BSE isolates, and the transmission rate, incubation time, characteristics and distribution of PrPSc, symptoms, and histopathology were or will be examined and compared.&lt;br /&gt;&lt;br /&gt;Results: Sixty percent of BASE-inoculated humanized mice became infected with minimal spongiosis and an average incubation time of 20-22 months, whereas only one of the C-type BSE-inoculated mice developed prion disease after more than 2 years. Protease-resistant PrPSc in BASE-infected humanized Tg mouse brains was biochemically different from bovine BASE or sCJD. PrPSc was also detected in the spleen of 22% of BASE-infected humanized mice, but not in those infected with sCJD. Secondary transmission of BASE in the humanized mice led to a small reduction in incubation time. The atypical BSE-H strain is also transmissible with distinct phenotypes in the humanized mice, but no BSE-M transmission has been observed so far.&lt;br /&gt;&lt;br /&gt;Discussion: Our results demonstrate that BASE is more virulent than classical BSE, has a lymphotropic phenotype, and displays a modest transmission barrier in our humanized mice. BSE-H is also transmissible in our humanized Tg mice. The possibility of more than two atypical BSE strains will be discussed.&lt;br /&gt;&lt;br /&gt;Supported by NINDS NS052319, NIA AG14359, and NIH AI 77774.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf"&gt;http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P02.35&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Molecular Features of the Protease-resistant Prion Protein (PrPres) in H-type BSE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Biacabe, A-G1; Jacobs, JG2; Gavier-Widén, D3; Vulin, J1; Langeveld, JPM2; Baron, TGM1 1AFSSA, France; 2CIDC-Lelystad, Netherlands; 3SVA, Sweden&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Western blot analyses of PrPres accumulating in the brain of BSE-infected cattle have demonstrated 3 different molecular phenotypes regarding to the apparent molecular masses and glycoform ratios of PrPres bands. We initially described isolates (H-type BSE) essentially characterized by higher PrPres molecular mass and decreased levels of the diglycosylated PrPres band, in contrast to the classical type of BSE. This type is also distinct from another BSE phenotype named L-type BSE, or also BASE (for Bovine Amyloid Spongiform Encephalopathy), mainly characterized by a low representation of the diglycosylated PrPres band as well as a lower PrPres molecular mass. Retrospective molecular studies in France of all available BSE cases older than 8 years old and of part of the other cases identified since the beginning of the exhaustive surveillance of the disease in 20001 allowed to identify 7 H-type BSE cases, among 594 BSE cases that could be classified as classical, L- or H-type BSE. By Western blot analysis of H-type PrPres, we described a remarkable specific feature with antibodies raised against the C-terminal region of PrP that demonstrated the existence of a more C-terminal cleaved form of PrPres (named PrPres#2 ), in addition to the usual PrPres form (PrPres #1). In the unglycosylated form, PrPres #2 migrates at about 14 kDa, compared to 20 kDa for PrPres #1. The proportion of the PrPres#2 in cattle seems to by higher compared to the PrPres#1. Furthermore another PK–resistant fragment at about 7 kDa was detected by some more N-terminal antibodies and presumed to be the result of cleavages of both N- and C-terminal parts of PrP. These singular features were maintained after transmission of the disease to C57Bl/6 mice. The identification of these two additional PrPres fragments (PrPres #2 and 7kDa band) reminds features reported respectively in sporadic Creutzfeldt-Jakob disease and in Gerstmann-Sträussler-Scheinker (GSS) syndrome in humans.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neuroprion.com/pdf_docs/conferences/prion2007/abstract_book.pdf"&gt;http://www.neuroprion.com/pdf_docs/conferences/prion2007/abstract_book.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html"&gt;http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, June 24, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Accumulation of L-type Bovine Prions in Peripheral Nerve Tissues&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Volume 16, Number 7–July 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/06/accumulation-of-l-type-bovine-prions-in.html"&gt;http://bse-atypical.blogspot.com/2010/06/accumulation-of-l-type-bovine-prions-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;******$$$$$$******&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, June 12, 2010 PUBLICATION REQUEST AND FOIA REQUEST Project Number: 3625-32000-086-05 Study of Atypical Bse&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/06/publication-request-and-foia-request.html"&gt;http://bse-atypical.blogspot.com/2010/06/publication-request-and-foia-request.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;*******$$$$$$*********&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Archive Number 20100405.1091 Published Date 05-APR-2010 Subject PRO/AH/EDR&gt; Prion disease update 1010 (04)&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;[Terry S. Singeltary Sr. has added the following comment:&lt;br /&gt;&lt;br /&gt;"According to the World Health Organisation, the future public health threat of vCJD in the UK and Europe and potentially the rest of the world is of concern and currently unquantifiable. However, the possibility of a significant and geographically diverse vCJD epidemic occurring over the next few decades cannot be dismissed&lt;br /&gt;&lt;br /&gt;&lt;http:&gt;.&lt;br /&gt;&lt;br /&gt;The key word here is diverse. What does diverse mean? If USA scrapie transmitted to USA bovine does not produce pathology as the UK c-BSE, then why would CJD from there look like UK vCJD?"&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.promedmail.org/pls/apex/f?p=2400:1001:568933508083034::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,82101"&gt;http://www.promedmail.org/pls/apex/f?p=2400:1001:568933508083034::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,82101&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; Up until about 6 years ago, the pt worked at Tyson foods where she&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; worked on the assembly line, slaughtering cattle and preparing them for&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; packaging. She was exposed to brain and spinal cord matter when she&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; would euthanize the cattle.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8"&gt;http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html"&gt;http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, April 5, 2010&lt;br /&gt;&lt;br /&gt;UPDATE - CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/04/update-cjd-texas-38-year-old-female.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/04/update-cjd-texas-38-year-old-female.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;re-National Prion Disease Pathology Surveillance Center Cases Examined1 (July 31, 2010)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;i never saw this posted on the CJD Foundation site, or Gambetti's USA prion unit site ???&lt;br /&gt;&lt;br /&gt;please see video at _bottom_ of this link that i added this morning (turn it up).&lt;br /&gt;&lt;br /&gt;a damning and disturbing video.&lt;br /&gt;&lt;br /&gt;its an old video about Scjd, and the possibility of BSE being relating to sporadic CJD. Jeff Schwann and his Mother (Terry), is also in this video, and listen to Aguzzi and how he admits that sporadic CJD might very well be caused by BSE. then an Italian Scientist is talking about atypical BSE, and the fact that this atypical BSE is exactly like sporadic CJD. a shocking find. ...atypical BSE has the exact same pathological and molecular similarities as sporadic CJD. Dr. Aguzzi says the USA is not trying to find BSE. the USA, and North America, refused for many years to put any kind of surveillance for BSE, this is a huge problem, a disgrace, particularly cries to Heaven, USA HAD TO ADMIT A HOME GROWN CASE OF MAD COW IN TEXAS. sCJD under estimated, no mechanisim to find cases, we ARE missing lots of cases. ...WE WANT ANSWERS. ...(Thanks Terry Schwann !)&lt;br /&gt;&lt;br /&gt;National Prion Disease Pathology Surveillance Center Cases Examined1 (July 31, 2010)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TURN IT UP, and click on the video at the bottom of this link ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/08/national-prion-disease-pathology.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/08/national-prion-disease-pathology.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, June 1, 2010&lt;br /&gt;&lt;br /&gt;USA cases of dpCJD rising with 24 cases so far in 2010&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2010/06/usa-cases-of-dpcjd-rising-with-24-cases.html"&gt;http://cjdtexas.blogspot.com/2010/06/usa-cases-of-dpcjd-rising-with-24-cases.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, July 11, 2010&lt;br /&gt;&lt;br /&gt;CJD or prion disease 2 CASES McLennan County Texas population 230,213 both cases in their 40s&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/07/cjd-2-cases-mclennan-county-texas.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/07/cjd-2-cases-mclennan-county-texas.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, February 05, 2010&lt;br /&gt;&lt;br /&gt;New Variant Creutzfelt Jakob Disease case reports United States 2010 A Review&lt;br /&gt;&lt;br /&gt;&lt;a href="http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html"&gt;http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Manuscript Draft Manuscript Number: Title: HUMAN and ANIMAL TSE Classifications i.e. mad cow disease and the UKBSEnvCJD only theory Article Type: Personal View Corresponding Author: Mr. Terry S. Singeltary, Corresponding Author's Institution: na First Author: Terry S Singeltary, none Order of Authors: Terry S Singeltary, none; Terry S. Singeltary&lt;br /&gt;&lt;br /&gt;Abstract: TSEs have been rampant in the USA for decades in many species, and they all have been rendered and fed back to animals for human/animal consumption. I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2007.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.regulations.gov/fdmspublic/ContentViewer?objectId=090000648027c28e&amp;amp;disposition=attachment&amp;amp;contentType=pdf"&gt;http://www.regulations.gov/fdmspublic/ContentViewer?objectId=090000648027c28e&amp;amp;disposition=attachment&amp;amp;contentType=pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, June 13, 2009&lt;br /&gt;&lt;br /&gt;Monitoring the occurrence of emerging forms of Creutzfeldt-Jakob disease in the United States 2003 revisited 2009&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdusa.blogspot.com/2009/06/monitoring-occurrence-of-emerging-forms.html"&gt;http://cjdusa.blogspot.com/2009/06/monitoring-occurrence-of-emerging-forms.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, January 2, 2010&lt;br /&gt;&lt;br /&gt;Human Prion Diseases in the United States January 1, 2010 ***FINAL***&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;my comments to PLosone here ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd"&gt;http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;HOW many of you recieved a written CJD Questionnaire asking real questions pertaining to route and source (and there are many here in North America) ?&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;IS every case getting a cjd questionnaire asking real questions ???&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, November 30, 2007&lt;br /&gt;&lt;br /&gt;CJD QUESTIONNAIRE USA CWRU AND CJD FOUNDATION USA PRION UNIT&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdquestionnaire.blogspot.com/"&gt;http://cjdquestionnaire.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;nope, they cannot have there cake and eat it too. the big pond just does not change science that much. either Ironside was wrong, or Gambetti is wrong. i do NOT believe this mad cow cloaking devise the USA apparently has $$$&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, August 03, 2010&lt;br /&gt;&lt;br /&gt;Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;WHAT about the enfamous partial and voluntary mad cow feed ban in the USA of August 4, 1997, the one that was nothing more than ink on paper, and ramifications there from? what about all that mad cow feed in commerce in the USA to 2010 ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;10,000,000+ LBS. of PROHIBITED BANNED MAD COW FEED I.E. BLOOD LACED MBM IN COMMERCE USA 2007&lt;br /&gt;&lt;br /&gt;Date: March 21, 2007 at 2:27 pm PST&lt;br /&gt;&lt;br /&gt;RECALLS AND FIELD CORRECTIONS: VETERINARY MEDICINES -- CLASS II&lt;br /&gt;&lt;br /&gt;___________________________________&lt;br /&gt;&lt;br /&gt;PRODUCT&lt;br /&gt;&lt;br /&gt;Bulk cattle feed made with recalled Darling's 85% Blood Meal, Flash Dried, Recall # V-024-2007&lt;br /&gt;&lt;br /&gt;CODE&lt;br /&gt;&lt;br /&gt;Cattle feed delivered between 01/12/2007 and 01/26/2007&lt;br /&gt;&lt;br /&gt;RECALLING FIRM/MANUFACTURER&lt;br /&gt;&lt;br /&gt;Pfeiffer, Arno, Inc, Greenbush, WI. by conversation on February 5, 2007.&lt;br /&gt;&lt;br /&gt;Firm initiated recall is ongoing.&lt;br /&gt;&lt;br /&gt;REASON&lt;br /&gt;&lt;br /&gt;Blood meal used to make cattle feed was recalled because it was cross- contaminated with prohibited bovine meat and bone meal that had been manufactured on common equipment and labeling did not bear cautionary BSE statement.&lt;br /&gt;&lt;br /&gt;VOLUME OF PRODUCT IN COMMERCE&lt;br /&gt;&lt;br /&gt;42,090 lbs.&lt;br /&gt;&lt;br /&gt;DISTRIBUTION&lt;br /&gt;&lt;br /&gt;WI&lt;br /&gt;&lt;br /&gt;___________________________________&lt;br /&gt;&lt;br /&gt;PRODUCT&lt;br /&gt;&lt;br /&gt;Custom dairy premix products: MNM ALL PURPOSE Pellet, HILLSIDE/CDL Prot- Buffer Meal, LEE, M.-CLOSE UP PX Pellet, HIGH DESERT/ GHC LACT Meal, TATARKA, M CUST PROT Meal, SUNRIDGE/CDL PROTEIN Blend, LOURENZO, K PVM DAIRY Meal, DOUBLE B DAIRY/GHC LAC Mineral, WEST PIONT/GHC CLOSEUP Mineral, WEST POINT/GHC LACT Meal, JENKS, J/COMPASS PROTEIN Meal, COPPINI - 8# SPECIAL DAIRY Mix, GULICK, L-LACT Meal (Bulk), TRIPLE J - PROTEIN/LACTATION, ROCK CREEK/GHC MILK Mineral, BETTENCOURT/GHC S.SIDE MK-MN, BETTENCOURT #1/GHC MILK MINR, V&amp;amp;C DAIRY/GHC LACT Meal, VEENSTRA, F/GHC LACT Meal, SMUTNY, A- BYPASS ML W/SMARTA, Recall # V-025-2007&lt;br /&gt;&lt;br /&gt;CODE&lt;br /&gt;&lt;br /&gt;The firm does not utilize a code - only shipping documentation with commodity and weights identified.&lt;br /&gt;&lt;br /&gt;RECALLING FIRM/MANUFACTURER&lt;br /&gt;&lt;br /&gt;Rangen, Inc, Buhl, ID, by letters on February 13 and 14, 2007. Firm initiated recall is complete.&lt;br /&gt;&lt;br /&gt;REASON&lt;br /&gt;&lt;br /&gt;Products manufactured from bulk feed containing blood meal that was cross contaminated with prohibited meat and bone meal and the labeling did not bear cautionary BSE statement.&lt;br /&gt;&lt;br /&gt;VOLUME OF PRODUCT IN COMMERCE&lt;br /&gt;&lt;br /&gt;9,997,976 lbs.&lt;br /&gt;&lt;br /&gt;DISTRIBUTION&lt;br /&gt;&lt;br /&gt;ID and NV&lt;br /&gt;&lt;br /&gt;END OF ENFORCEMENT REPORT FOR MARCH 21, 2007&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.fda.gov/Safety/Recalls/EnforcementReports/2007/ucm120446.htm"&gt;http://www.fda.gov/Safety/Recalls/EnforcementReports/2007/ucm120446.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, March 2, 2010&lt;br /&gt;&lt;br /&gt;Animal Proteins Prohibited in Ruminant Feed/Adulterated/Misbranded Rangen Inc 2/11/10 USA&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/03/animal-proteins-prohibited-in-ruminant.html"&gt;http://madcowfeed.blogspot.com/2010/03/animal-proteins-prohibited-in-ruminant.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, March 1, 2010&lt;br /&gt;&lt;br /&gt;ANIMAL PROTEIN I.E. MAD COW FEED IN COMMERCE A REVIEW 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/03/animal-protien-ie-mad-cow-feed-in.html"&gt;http://madcowfeed.blogspot.com/2010/03/animal-protien-ie-mad-cow-feed-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr. (Submitted question): Monday, April 5, 2010&lt;br /&gt;&lt;br /&gt;Update on Feed Enforcement Activities to Limit the Spread of BSE April 5, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/04/update-on-feed-enforcement-activities.html"&gt;http://madcowfeed.blogspot.com/2010/04/update-on-feed-enforcement-activities.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, April 23, 2010&lt;br /&gt;&lt;br /&gt;Upcoming BSE Webinar on Thursday, April 22, 2010 a review&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bseusa.blogspot.com/2010/04/upcoming-bse-webinar-on-thursday-april.html"&gt;http://bseusa.blogspot.com/2010/04/upcoming-bse-webinar-on-thursday-april.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, January 17, 2010&lt;br /&gt;&lt;br /&gt;BSE USA feed inspection violations 01/01/2009 to 01/17/2010 FDA BSE/Ruminant Feed Inspections Firms Inventory Report&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/01/bse-usa-feed-inspection-violations.html"&gt;http://madcowfeed.blogspot.com/2010/01/bse-usa-feed-inspection-violations.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, January 15, 2010&lt;br /&gt;&lt;br /&gt;New York Firm Recalls Beef Carcass That Contains Prohibited Materials (BSE)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/01/new-york-firm-recalls-beef-carcass-that.html"&gt;http://bse-atypical.blogspot.com/2010/01/new-york-firm-recalls-beef-carcass-that.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, September 4, 2009&lt;br /&gt;&lt;br /&gt;FOIA REQUEST ON FEED RECALL PRODUCT 429,128 lbs. feed for ruminant animals may have been contaminated with prohibited material Recall # V-258-2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/09/foia-request-on-feed-recall-product.html"&gt;http://madcowfeed.blogspot.com/2009/09/foia-request-on-feed-recall-product.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, August 29, 2009&lt;br /&gt;&lt;br /&gt;FOIA REQUEST FEED RECALL 2009 Product may have contained prohibited materials Bulk Whole Barley, Recall # V-256-2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/08/foia-request-feed-recall-2009-product.html"&gt;http://madcowfeed.blogspot.com/2009/08/foia-request-feed-recall-2009-product.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;C O N F I R M E D&lt;br /&gt;&lt;br /&gt;----- Original Message -----&lt;br /&gt;From: "Terry S. Singeltary Sr."&lt;br /&gt;To:&lt;br /&gt;Sent: Thursday, November 05, 2009 9:25 PM&lt;br /&gt;Subject: [BSE-L] re-FOIA REQUEST ON FEED RECALL PRODUCT contaminated with prohibited material Recall # V-258-2009 and Recall # V-256-2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/11/re-foia-request-on-feed-recall-product.html"&gt;http://madcowfeed.blogspot.com/2009/11/re-foia-request-on-feed-recall-product.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, November 12, 2009&lt;br /&gt;&lt;br /&gt;BSE FEED RECALL Misbranding of product by partial label removal to hide original source of materials 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/11/bse-feed-recall-misbranding-of-product.html"&gt;http://madcowfeed.blogspot.com/2009/11/bse-feed-recall-misbranding-of-product.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, March 19, 2009&lt;br /&gt;&lt;br /&gt;MILLIONS AND MILLIONS OF POUNDS OF MAD COW FEED IN COMMERCE USA WITH ONGOING 12 YEARS OF DENIAL&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/03/millions-and-millions-of-pounds-of-mad.html"&gt;http://madcowfeed.blogspot.com/2009/03/millions-and-millions-of-pounds-of-mad.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CVM Annual Report Fiscal Year 2008: October 1, 2007-September 30, 2008&lt;br /&gt;&lt;br /&gt;PUTTING LIPSTICK ON A PIG AND TAKING HER TO A DANCE...TSS&lt;br /&gt;&lt;br /&gt;BSE Feed Rule Enforcement: A Decade of Success OFF TO A FAST START&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2008/06/texas-firm-recalls-cattle-heads-that.html"&gt;http://madcowfeed.blogspot.com/2008/06/texas-firm-recalls-cattle-heads-that.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, April 9, 2009&lt;br /&gt;&lt;br /&gt;Docket No. FDA2002N0031 (formerly Docket No. 2002N0273) RIN 0910AF46 Substances Prohibited From Use in Animal Food or Feed; Final Rule: Proposed&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/04/docket-no-fda2002n0031-formerly-docket.html"&gt;http://madcowfeed.blogspot.com/2009/04/docket-no-fda2002n0031-formerly-docket.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P03.137&lt;br /&gt;&lt;br /&gt;Transmission of BSE to Cynomolgus Macaque, a Non-human Primate; Development of Clinical Symptoms and Tissue Distribution of PrPSC&lt;br /&gt;&lt;br /&gt;Yamakawa, Y1; Ono, F2; Tase, N3; Terao, K3; Tannno, J3; Wada, N4; Tobiume, M5; Sato, Y5; Okemoto-Nakamura, Y1; Hagiwara, K1; Sata, T5 1National Institure of Infectious diseases, Cell biology and Biochemistry, Japan; 2Corporation for Production and Research Laboratory Primates., Japan; 3National Institure of Biomedical Innovation, Tsukuba Primate Reserch Center, Japan; 4Yamauchi Univ., Veterinary Medicine, Japan; 5National Institure of Infectious diseases, Pathology, Japan&lt;br /&gt;&lt;br /&gt;Two of three cynomolgus monkeys developed abnormal neuronal behavioral signs at 30-(#7) and 28-(#10) months after intracerebral inoculation of 200ul of 10% brain homogenates of BSE affected cattle (BSE/JP6). Around 30 months post inoculation (mpi), they developed sporadic anorexia and hyperekplexia with squeal against environmental stimulations such as light and sound. Tremor, myoclonic jerk and paralysis became conspicuous during 32 to 33-mpi, and symptoms become worsened according to the disease progression. Finally, one monkey (#7) fell into total paralysis at 36-mpi. This monkey was sacrificed at 10 days after intensive veterinary care including infusion and per oral supply of liquid food. The other monkey (#10) had to grasp the cage bars to keep an upright posture caused by the sever ataxia. This monkey was sacrificed at 35-mpi. EEG of both monkeys showed diffuse slowing. PSD characteristic for sporadic CJD was not observed in both monkeys. The result of forearm movement test showed the hypofunction that was observed at onset of clinical symptoms. Their cognitive function determined by finger maze test was maintained at the early stage of sideration. However, it was rapidly impaired followed by the disease progression. Their autopsied tissues were immunochemically investigated for the tissue distribution of PrPSc. Severe spongiform change in the brain together with heavy accumulation of PrPSc having the type 2B/4 glycoform profile confirmed successful transmission of BSE to Cynomolgus macaques. Granular and linear deposition of PrPSC was detected by IHC in the CNS of both monkeys. At cerebral cortex, PrPSC was prominently accumulated in the large plaques. Sparse accumulation of PrPSc was detected in several peripheral nerves of #7 but not in #10 monkey, upon the WB analysis. Neither #7 nor #10 monkey accumulated detectable amounts of PrPSc in their lymphatic organs such as tonsil, spleen, adrenal grands and thymus although PrPSc was barely detected in the submandibular lymph node of #7 monkey. Such confined tissue distribution of PrPSc after intracerebral infection with BSE agent is not compatible to that reported on the Cynomolgus macaques infected with BSE by oral or intra-venous (intra-peritoneal) routs, in which PrPSc was accumulated at not only CNS but also widely distributed lymphatic tissues.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P03.138&lt;br /&gt;&lt;br /&gt;Clustering of PrPres in Central Brain Regions of BSE-infected Macaques (M. Fascicularis)&lt;br /&gt;&lt;br /&gt;Motzkus, D1; Montag, J1; Hunsmann, G1; Schulz-Schaeffer, W2 1German Primate Center, Dept. Virology and Immunology, Germany; 2University of Göttingen, Dept. Neuropathology, Germany&lt;br /&gt;&lt;br /&gt;According to biochemical and epidemiological findings bovine spongiform encephalopathy (BSE) was transmitted to humans causing variant Creutzfeldt Jakob disease (vCJD). Previous studies have shown intracerebral (i.c.) transmission of BSE affected brain from cattle can cause TSEs in cynomolgus macaques (M. fascicularis). The lesion profile resembles that of vCJD. Recently, oral infection of M. fascicularis with macaque-adapted BSE material was reported. In cooperation with five European partners a quantitative study for the transmission of the BSE agent to M. fascicularis was initiated to assess the risk of vCJD infection in humans through contaminated food products (EU study QLK1-CT-2002-01096). Titration was performed orally and intracerebrally to determine the minimal infectious dose for cynomolgus monkeys. Here we report the outcome of the intracerebral infection with 50 mg BSE brain homogenate in six non-human primates. All animals showed clinical symptoms of TSE after an average of 1100 days. Using immunohistological and biochemical methods prion protein (PrP) deposits were confirmed in the brains of all animals. Using Western blot analysis the glycosylation pattern was compared to the inoculum and to the pattern of different CJD subtypes. Simian PrPres was detected with the monoclonal anti prion antibody 11C6, which revealed a higher sensitivity in comparison to 12F10 and 3F4. We found that the PrP glycopattern in BSE-infected cynomolgus macaques resembles human CJD type 2. We further analysed the distribution of PrPres by microdissection of seven different brain regions of all infected macaques. High concentrations of PrPres were detected in central brain regions, as gyrus cinguli, nucleus caudatus, vermis cerebelli and basis pontis. In contrast, in the peripheral regions gyrus frontalis, gyrus parietalis and gyrus occipitalis PrPres was hardly detectable.&lt;br /&gt;&lt;br /&gt;Thus, the incubation period related to the life expectancy, the PrPres glycosylation pattern as well as the distribution in certain brain regions resemble those in vCJD patients. The relative abundance of PrPres in macaques will be compared to that of orally infected animals.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P04.27&lt;br /&gt;&lt;br /&gt;Experimental BSE Infection of Non-human Primates: Efficacy of the Oral Route&lt;br /&gt;&lt;br /&gt;Holznagel, E1; Yutzy, B1; Deslys, J-P2; Lasmézas, C2; Pocchiari, M3; Ingrosso, L3; Bierke, P4; Schulz-Schaeffer, W5; Motzkus, D6; Hunsmann, G6; Löwer, J1 1Paul-Ehrlich-Institut, Germany; 2Commissariat à l´Energie Atomique, France; 3Instituto Superiore di Sanità, Italy; 4Swedish Institute for Infectious Disease control, Sweden; 5Georg August University, Germany; 6German Primate Center, Germany&lt;br /&gt;&lt;br /&gt;Background: In 2001, a study was initiated in primates to assess the risk for humans to contract BSE through contaminated food. For this purpose, BSE brain was titrated in cynomolgus monkeys.&lt;br /&gt;&lt;br /&gt;Aims: The primary objective is the determination of the minimal infectious dose (MID50) for oral exposure to BSE in a simian model, and, by in doing this, to assess the risk for humans. Secondly, we aimed at examining the course of the disease to identify possible biomarkers.&lt;br /&gt;&lt;br /&gt;Methods: Groups with six monkeys each were orally dosed with lowering amounts of BSE brain: 16g, 5g, 0.5g, 0.05g, and 0.005g. In a second titration study, animals were intracerebrally (i.c.) dosed (50, 5, 0.5, 0.05, and 0.005 mg).&lt;br /&gt;&lt;br /&gt;Results: In an ongoing study, a considerable number of high-dosed macaques already developed simian vCJD upon oral or intracerebral exposure or are at the onset of the clinical phase. However, there are differences in the clinical course between orally and intracerebrally infected animals that may influence the detection of biomarkers.&lt;br /&gt;&lt;br /&gt;Conclusions: Simian vCJD can be easily triggered in cynomolgus monkeys on the oral route using less than 5 g BSE brain homogenate. The difference in the incubation period between 5 g oral and 5 mg i.c. is only 1 year (5 years versus 4 years). However, there are rapid progressors among orally dosed monkeys that develop simian vCJD as fast as intracerebrally inoculated animals.&lt;br /&gt;&lt;br /&gt;The work referenced was performed in partial fulfilment of the study “BSE in primates“ supported by the EU (QLK1-2002-01096).&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neuroprion.org/resources/pdf_docs/conferences/prion2007/abstract_book.pdf"&gt;http://www.neuroprion.org/resources/pdf_docs/conferences/prion2007/abstract_book.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;PRION 2009 CONGRESS BOOK OF ABSTRACTS&lt;br /&gt;&lt;br /&gt;O.4.3&lt;br /&gt;&lt;br /&gt;Spread of BSE prions in cynomolgus monkeys (Macaca fascicularis) after oral transmission&lt;br /&gt;&lt;br /&gt;Edgar Holznagel1, Walter Schulz-Schaeffer2, Barbara Yutzy1, Gerhard Hunsmann3, Johannes Loewer1 1Paul-Ehrlich-Institut, Federal Institute for Sera and Vaccines, Germany; 2Department of Neuropathology, Georg-August University, Göttingen, Germany, 3Department of Virology and Immunology, German Primate Centre, Göttingen, Germany&lt;br /&gt;&lt;br /&gt;Background: BSE-infected cynomolgus monkeys represent a relevant animal model to study the pathogenesis of variant Creutzfeldt-Jacob disease (vCJD).&lt;br /&gt;&lt;br /&gt;Objectives: To study the spread of BSE prions during the asymptomatic phase of infection in a simian animal model.&lt;br /&gt;&lt;br /&gt;Methods: Orally BSE-dosed macaques (n=10) were sacrificed at defined time points during the incubation period and 7 orally BSE-dosed macaques were sacrificed after the onset of clinical signs. Neuronal and non-neuronal tissues were tested for the presence of proteinase-K-resistant prion protein (PrPres) by western immunoblot and by paraffin-embedded tissue (PET) blot technique.&lt;br /&gt;&lt;br /&gt;Results: In clinically diseased macaques (5 years p.i. + 6 mo.), PrPres deposits were widely spread in neuronal tissues (including the peripheral sympathetic and parasympathetic nervous system) and in lymphoid tissues including tonsils. In asymptomatic disease carriers, PrPres deposits could be detected in intestinal lymph nodes as early as 1 year p.i., but CNS tissues were negative until 3 – 4 years p.i. Lumbal/sacral segments of the spinal cord and medulla oblongata were PrPres positive as early as 4.1 years p.i., whereas sympathetic trunk and all thoracic/cervical segments of the spinal cord were still negative for PrPres. However, tonsil samples were negative in all asymptomatic cases.&lt;br /&gt;&lt;br /&gt;Discussion: There is evidence for an early spread of BSE to the CNS via autonomic fibres of the splanchnic and vagus nerves indicating that trans-synaptical spread may be a time-limiting factor for neuroinvasion. Tonsils were predominantly negative during the main part of the incubation period indicating that epidemiological vCJD screening results based on the detection of PrPres in tonsil biopsies may mostly tend to underestimate the prevalence of vCJD among humans.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;O.4.4&lt;br /&gt;&lt;br /&gt;PrPSc distribution pattern in cattle experimentally challenged with H-type and L-type atypical BSE&lt;br /&gt;&lt;br /&gt;Anne Buschmann1, Ute Ziegler1, Leila McIntyre2, Markus Keller1, Ron Rogers3, Bob Hills3, Martin H. Groschup1 1Friedrich-Loeffler-Institut, INEID, Germany; 2Faculty of Veterinary Medicine, University of Calgary, Canada; 3Health Canada, Ottawa, Canada&lt;br /&gt;&lt;br /&gt;Background: After the detection of two novel BSE forms designated H-type and L-type BSE, the question of the pathogenesis and the agent distribution in cattle affected with these forms was fully open. From initial studies, it was already known that the PrPSc distribution in L-type BSE affected cattle differed from that known for classical BSE (C-type) where the obex region always displays the highest PrPSc concentrations. In contrast in L-type BSE cases, the thalamus and frontal cortex regions showed the highest levels of the pathological prion protein, while the obex region was only weakly involved. No information was available on the distribution pattern in H-type BSE.&lt;br /&gt;&lt;br /&gt;Objectives: To analyse the PrPSc and infectivity distribution in cattle experimentally challenged with H-type and L-type BSE.&lt;br /&gt;&lt;br /&gt;Methods: We analysed CNS and peripheral tissue samples collected from cattle that were intracranially challenged with Htype (five animals) and L-type (six animals) using a commercial BSE rapid test (IDEXX HerdChek), immunohistochemistry (IHC) and a highly sensitive Western blot protocol including a phosphotungstic acid precipitation of PrPSc (PTA-WB). Samples collected during the preclinical and the clinical stages of the disease were examined. For the detection of BSE infectivity, selected samples were also inoculated into highly sensitive Tgbov XV mice overexpressing bovine prion protein (PrPC).&lt;br /&gt;&lt;br /&gt;Results: Analysis of a collection of fifty samples from the peripheral nervous, lymphoreticular, digestive, reproductive, respiratory and musculo-skeletal systems by PTA-WB, IDEXXHerdChek BSE EIA and IHC revealed a general restriction of the PrPSc accumulation to the central nervous system.&lt;br /&gt;&lt;br /&gt;Discussion: Our results on the PrPSc distribution in peripheral tissues of cattle affected with H-type and L-type BSE are generally in accordance with what has been known for C-type BSE. Bioassays are ongoing in highly sensitive transgenic mice in order to reveal infectivity.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;O.11.3&lt;br /&gt;&lt;br /&gt;Infectivity in skeletal muscle of BASE-infected cattle&lt;br /&gt;&lt;br /&gt;Silvia Suardi1, Chiara Vimercati1, Fabio Moda1, Ruggerone Margherita1, Ilaria Campagnani1, Guerino Lombardi2, Daniela Gelmetti2, Martin H. Groschup3, Anne Buschmann3, Cristina Casalone4, Maria Caramelli4, Salvatore Monaco5, Gianluigi Zanusso5, Fabrizio Tagliavini1 1Carlo Besta” Neurological Institute,Italy; 2IZS Brescia, Italy; 33FLI Insel Riems, D, Germany; 4CEA-IZS Torino, Italy; 5University of Verona, Italy&lt;br /&gt;&lt;br /&gt;Background: BASE is an atypical form of bovine spongiform encephalopathy caused by a prion strain distinct from that of BSE. Upon experimental transmission to cattle, BASE induces a previously unrecognized disease phenotype marked by mental dullness and progressive atrophy of hind limb musculature. Whether affected muscles contain infectivity is unknown. This is a critical issue since the BASE strain is readily transmissible to a variety of hosts including primates, suggesting that humans may be susceptible.&lt;br /&gt;&lt;br /&gt;Objectives: To investigate the distribution of infectivity in peripheral tissues of cattle experimentally infected with BASE. Methods: Groups of Tg mice expressing bovine PrP (Tgbov XV, n= 7-15/group) were inoculated both i.c. and i.p. with 10% homogenates of a variety of tissues including brain, spleen, cervical lymph node, kidney and skeletal muscle (m. longissimus dorsi) from cattle intracerebrally infected with BASE. No PrPres was detectable in the peripheral tissues used for inoculation either by immunohistochemistry or Western blot.&lt;br /&gt;&lt;br /&gt;Results: Mice inoculated with BASE-brain homogenates showed clinical signs of disease with incubation and survival times of 175±15 and 207±12 days. Five out of seven mice challenged with skeletal muscle developed a similar neurological disorder, with incubation and survival times of 380±11 and 410±12 days. At present (700 days after inoculation) mice challenged with the other peripheral tissues are still healthy. The neuropathological phenotype and PrPres type of the affected mice inoculated either with brain or muscle were indistinguishable and matched those of Tgbov XV mice infected with natural BASE.&lt;br /&gt;&lt;br /&gt;Discussion: Our data indicate that the skeletal muscle of cattle experimentally infected with BASE contains significant amount of infectivity, at variance with BSE-affected cattle, raising the issue of intraspecies transmission and the potential risk for humans. Experiments are in progress to assess the presence of infectivity in skeletal muscles of natural BASE.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P.5.3&lt;br /&gt;&lt;br /&gt;Differences in the expression levels of selected genes in the brain tissue of cattle naturally infected with classical and atypical BSE.&lt;br /&gt;&lt;br /&gt;Magdalena Larska1, Miroslaw P. Polak1, Jan F. Zmudzinski1, Juan M. Torres2 1National Veterinary Institute, Poland; 2CISA/INIA&lt;br /&gt;&lt;br /&gt;Background: Recently cases of BSE in older cattle named BSE type L and type H were distinguished on the basis of atypical glycoprofiles of PrPres. The nature of those strains is still not fully understood but it is suspected that the atypical BSE cases are sporadic. Hitherto most BSE cases were studied in respect to the features of PrPSc. Here we propose gene expression profiling as a method to characterize and distinguish BSE strains.&lt;br /&gt;&lt;br /&gt;Objectives: The aim of the study was to compare the activities of some factors which are known to play a role in TSE’s pathogenesis in order to distinguish the differences/similarities between all BSE types.&lt;br /&gt;&lt;br /&gt;Methods: 10 % homogenate of brain stem tissue collected from obex region of medulla oblongata from 20 naturally infected BSE cows (8 assigned as classical BSE, other 8 and 4 infected with atypical BSE L type and H type respectively) was used in the study. As negative control animals we’ve used 8 animals in the age between 2.5 and 13 years. The genes were relatively quantified using SYBR Green real time RT-PCR. Raw data of Ct values was transformed into normalized relative quantities using Qbase Plus®. Results and&lt;br /&gt;&lt;br /&gt;Discussion: In most of the tested genes significant differences in the expression levels between the brain stem of healthy cattle and animals infected with different BSE types were observed. In c-type BSE in comparison to healthy and atypical BSE the overexpression of the gene of bcl-2, caspase 3, 14-3-3 and tylosine kinase Fyn was significant.&lt;br /&gt;&lt;br /&gt;Simultaneously in atypical BSEs type-L and type-H the levels of prion protein, Bax and LPR gene was elevated in comparison to c-BSE. Additionally L-BSE was characterized by the overexpression of STI1 and SOD genes compared to the other of BSE types. The downregulation of the gene encoding NCAM1 was observed in all BSE types in comparison to healthy cows. Different gene expression profiles of bovine brains infected with classical and atypical BSE indicates possible different pathogenesis or source of the disease.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;O.10.1&lt;br /&gt;&lt;br /&gt;Transmission of uncommon forms of bovine prions to transgenic mice expressing human PrP: questions and progress&lt;br /&gt;&lt;br /&gt;Vincent Béringue, Hubert Laude INRA, UR 892, Virologie Immunologie Moléculaires, France&lt;br /&gt;&lt;br /&gt;The active, large-scale testing of livestock nervous tissues for the presence of protease-resistant prion protein (PrPres) has led to the recognition of 2 uncommon PrPres molecular signatures, termed H-type and L-type BSE. Their experimental transmission to various transgenic and inbred mouse lines unambiguously demonstrated the infectious nature of such cases and the existence of distinct prion strains in cattle. Like the classical BSE agent, H- and L-type (or BASE) prions can propagate in heterologous species. In addition L-type prions acquire molecular and neuropathologic phenotypic traits undistinguishable from BSE or BSE-related agents upon transmission to transgenic mice expressing ovine PrP (VRQ allele) or wild-type mice. An understanding of the transmission properties of these newly recognized prions when confronted with human PrP sequence was therefore needed. Toward this end, we inoculated mice expressing human PrP Met129 with several field isolates. Unlike classical BSE agent, L-type prions appeared to propagate in these mice with no obvious transmission barrier. In contrast, we repeatedly failed to infect them with Htype prions. Ongoing investigations aim to extend the knowledge on these uncommon strains: are these agents able to colonize lymphoid tissue, a potential key factor for successful transmission by peripheral route; is there any relationship between these assumedly sporadic forms of TSE in cattle and some sporadic forms of human CJD are among the issues that need to be addressed for a careful assessment of the risk for cattle-to-human transmission of H- and L-type prions.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P.4.23&lt;br /&gt;&lt;br /&gt;Transmission of atypical BSE in humanized mouse models&lt;br /&gt;&lt;br /&gt;Liuting Qing1, Wenquan Zou1, Cristina Casalone2, Martin Groschup3, Miroslaw Polak4, Maria Caramelli2, Pierluigi Gambetti1, Juergen Richt5, Qingzhong Kong1 1Case Western Reserve University, USA; 2Instituto Zooprofilattico Sperimentale, Italy; 3Friedrich-Loeffler-Institut, Germany; 4National Veterinary Research Institute, Poland; 5Kansas State University (Previously at USDA National Animal Disease Center), USA&lt;br /&gt;&lt;br /&gt;Background: Classical BSE is a world-wide prion disease in cattle, and the classical BSE strain (BSE-C) has led to over 200 cases of clinical human infection (variant CJD). Atypical BSE cases have been discovered in three continents since 2004; they include the L-type (also named BASE), the H-type, and the first reported case of naturally occurring BSE with mutated bovine PRNP (termed BSE-M). The public health risks posed by atypical BSE were largely undefined.&lt;br /&gt;&lt;br /&gt;Objectives: To investigate these atypical BSE types in terms of their transmissibility and phenotypes in humanized mice. Methods: Transgenic mice expressing human PrP were inoculated with several classical (C-type) and atypical (L-, H-, or Mtype) BSE isolates, and the transmission rate, incubation time, characteristics and distribution of PrPSc, symptoms, and histopathology were or will be examined and compared.&lt;br /&gt;&lt;br /&gt;Results: Sixty percent of BASE-inoculated humanized mice became infected with minimal spongiosis and an average incubation time of 20-22 months, whereas only one of the C-type BSE-inoculated mice developed prion disease after more than 2 years. Protease-resistant PrPSc in BASE-infected humanized Tg mouse brains was biochemically different from bovine BASE or sCJD. PrPSc was also detected in the spleen of 22% of BASE-infected humanized mice, but not in those infected with sCJD. Secondary transmission of BASE in the humanized mice led to a small reduction in incubation time. The atypical BSE-H strain is also transmissible with distinct phenotypes in the humanized mice, but no BSE-M transmission has been observed so far.&lt;br /&gt;&lt;br /&gt;Discussion: Our results demonstrate that BASE is more virulent than classical BSE, has a lymphotropic phenotype, and displays a modest transmission barrier in our humanized mice.&lt;br /&gt;&lt;br /&gt;BSE-H is also transmissible in our humanized Tg mice.&lt;br /&gt;&lt;br /&gt;The possibility of more than two atypical BSE strains will be discussed.&lt;br /&gt;&lt;br /&gt;Supported by NINDS NS052319, NIA AG14359, and NIH AI 77774.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf"&gt;http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Simian vCJD can be easily triggered in cynomolgus monkeys on the oral route using less than 5 g BSE brain homogenate.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prion2007.com/pdf/Prion%20Book%20of%20Abstracts.pdf"&gt;http://www.prion2007.com/pdf/Prion%20Book%20of%20Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;WE know now, and we knew decades ago, that 5.5 grams of suspect feed in TEXAS was enough to kill 100 cows.&lt;br /&gt;&lt;br /&gt;look at the table and you'll see that as little as 1 mg (or 0.001 gm) caused 7% (1 of 14) of the cows to come down with BSE;&lt;br /&gt;&lt;br /&gt;Risk of oral infection with bovine spongiform encephalopathy agent in primates&lt;br /&gt;&lt;br /&gt;Corinne Ida Lasmézas, Emmanuel Comoy, Stephen Hawkins, Christian Herzog, Franck Mouthon, Timm Konold, Frédéric Auvré, Evelyne Correia, Nathalie Lescoutra-Etchegaray, Nicole Salès, Gerald Wells, Paul Brown, Jean-Philippe Deslys Summary The uncertain extent of human exposure to bovine spongiform encephalopathy (BSE)--which can lead to variant Creutzfeldt-Jakob disease (vCJD)--is compounded by incomplete knowledge about the efficiency of oral infection and the magnitude of any bovine-to-human biological barrier to transmission. We therefore investigated oral transmission of BSE to non-human primates. We gave two macaques a 5 g oral dose of brain homogenate from a BSE-infected cow. One macaque developed vCJD-like neurological disease 60 months after exposure, whereas the other remained free of disease at 76 months. On the basis of these findings and data from other studies, we made a preliminary estimate of the food exposure risk for man, which provides additional assurance that existing public health measures can prevent transmission of BSE to man.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;BSE bovine brain inoculum&lt;br /&gt;&lt;br /&gt;100 g 10 g 5 g 1 g 100 mg 10 mg 1 mg 0·1 mg 0·01 mg&lt;br /&gt;&lt;br /&gt;Primate (oral route)* 1/2 (50%)&lt;br /&gt;&lt;br /&gt;Cattle (oral route)* 10/10 (100%) 7/9 (78%) 7/10 (70%) 3/15 (20%) 1/15 (7%) 1/15 (7%)&lt;br /&gt;&lt;br /&gt;RIII mice (ic ip route)* 17/18 (94%) 15/17 (88%) 1/14 (7%)&lt;br /&gt;&lt;br /&gt;PrPres biochemical detection&lt;br /&gt;&lt;br /&gt;The comparison is made on the basis of calibration of the bovine inoculum used in our study with primates against a bovine brain inoculum with a similar PrPres concentration that was inoculated into mice and cattle.8 *Data are number of animals positive/number of animals surviving at the time of clinical onset of disease in the first positive animal (%). The accuracy of bioassays is generally judged to be about plus or minus 1 log. ic ip=intracerebral and intraperitoneal.&lt;br /&gt;&lt;br /&gt;Table 1: Comparison of transmission rates in primates and cattle infected orally with similar BSE brain inocula&lt;br /&gt;&lt;br /&gt;Published online January 27, 2005&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.thelancet.com/journal/journal.isa"&gt;http://www.thelancet.com/journal/journal.isa&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;It is clear that the designing scientists must also have shared Mr Bradleys surprise at the results because all the dose levels right down to 1 gram triggered infection.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20040523230128/www.bseinquiry.gov.uk/files/ws/s145d.pdf"&gt;http://web.archive.org/web/20040523230128/www.bseinquiry.gov.uk/files/ws/s145d.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;it is clear that the designing scientists must have also shared Mr Bradleys surprise at the results because all the dose levels right down to 1 gram triggered infection.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20030526212610/http://www.bseinquiry.gov.uk/files/ws/s147f.pdf"&gt;http://web.archive.org/web/20030526212610/http://www.bseinquiry.gov.uk/files/ws/s147f.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;just food for thought here, but read and understand just what this sentence says here ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;IN CONFIDENCE&lt;br /&gt;&lt;br /&gt;AS implied in the Inset 25 we must not _ASSUME_ that transmission of BSE to other species will invariably present pathology typical of a scrapie-like disease.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://collections.europarchive.org/tna/20080102185948/http://www.bseinquiry.gov.uk/files/yb/1991/01/04004001.pdf"&gt;http://collections.europarchive.org/tna/20080102185948/http://www.bseinquiry.gov.uk/files/yb/1991/01/04004001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;and ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;In Confidence&lt;br /&gt;&lt;br /&gt;Perceptions of unconventional slow virus diseases of animals in the USA - APRIL-MAY 1989 - G A H Wells&lt;br /&gt;&lt;br /&gt;3. Prof. A Robertson gave a brief account of BSE. The US approach was to accord it a very low profile indeed. Dr. A Thiermann showed the picture in the ''Independent'' with cattle being incinerated and thought this was a fanatical incident to be avoided in the US at all costs. BSE was not reported in the USA.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://collections.europarchive.org/tna/20080102193705/http://www.bseinquiry.gov.uk/files/mb/m11b/tab01.pdf"&gt;http://collections.europarchive.org/tna/20080102193705/http://www.bseinquiry.gov.uk/files/mb/m11b/tab01.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;seems the USA PRION unit has been working hard to change the science since those atypical mad cow and human TSE cases started showing up around 2005-2006 ;&lt;br /&gt;&lt;br /&gt;Thursday, July 10, 2008&lt;br /&gt;&lt;br /&gt;A Novel Human Disease with Abnormal Prion Protein Sensitive to Protease update July 10, 2008 Friday, June 20, 2008&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdmadcowbaseoct2007.blogspot.com/2008/07/novel-human-disease-with-abnormal-prion.html"&gt;http://cjdmadcowbaseoct2007.blogspot.com/2008/07/novel-human-disease-with-abnormal-prion.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, July 10, 2008&lt;br /&gt;&lt;br /&gt;A New Prionopathy update July 10, 2008&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdmadcowbaseoct2007.blogspot.com/2008/07/new-prionopathy-update-july-10-2008.html"&gt;http://cjdmadcowbaseoct2007.blogspot.com/2008/07/new-prionopathy-update-july-10-2008.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Original Article&lt;br /&gt;&lt;br /&gt;Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www3.interscience.wiley.com/journal/123598302/abstract?CRETRY=1&amp;amp;SRETRY=0"&gt;http://www3.interscience.wiley.com/journal/123598302/abstract?CRETRY=1&amp;amp;SRETRY=0&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; Because 8 out of 10 patients had a positive family history of dementia in the original study, a genetic cause was suspected. Although all cases were homozygous for valine at codon 129 of the PrP gene, NO mutations were detected. &lt;&lt;&lt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;OR JUST MORE PRIONBALONEY $$$&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;anything but a home grown mad cow in the USA, and or a human case there from, it's all genetic, sporadic, spontaneous, with no genetic link to any human, just a genetic link to the mad cow in Alabama.&lt;br /&gt;&lt;br /&gt;i did not fall off a shrimp boat yesterday. ...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6604160603980694949-8698570306834045150?l=prionunitusaupdate2008.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://prionunitusaupdate2008.blogspot.com/feeds/8698570306834045150/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=6604160603980694949&amp;postID=8698570306834045150' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/8698570306834045150'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/8698570306834045150'/><link rel='alternate' type='text/html' href='http://prionunitusaupdate2008.blogspot.com/2010/08/variably-protease-sensitive-prionopathy.html' title='Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein or just more Prionbaloney ?'/><author><name>Terry S. Singeltary Sr.</name><uri>http://www.blogger.com/profile/06986622967539963260</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='22' src='http://bp2.blogger.com/_gwMAfd8g9xo/SHuerfBUR1I/AAAAAAAAAAM/nNI1xcLm_Z4/S220/scan0002.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6604160603980694949.post-1430870360933696482</id><published>2010-05-16T13:56:00.000-07:00</published><updated>2010-05-16T14:04:18.773-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='SCRAPIE'/><category scheme='http://www.blogger.com/atom/ns#' term='BSE'/><category scheme='http://www.blogger.com/atom/ns#' term='USA'/><category scheme='http://www.blogger.com/atom/ns#' term='PRION'/><category scheme='http://www.blogger.com/atom/ns#' term='CWD'/><category scheme='http://www.blogger.com/atom/ns#' term='CJD'/><category scheme='http://www.blogger.com/atom/ns#' term='TME'/><category scheme='http://www.blogger.com/atom/ns#' term='atypical BSE'/><title type='text'>The Final Report of the National Prion Research Program 2007 (updated 2010)</title><content type='html'>US Army Medical Research and Materiel Command&lt;br /&gt;&lt;br /&gt;Congressionally Directed Medical Research Programs&lt;br /&gt;&lt;br /&gt;National Prion Research Program&lt;br /&gt;&lt;br /&gt;Vision: eliminate the occurrence of human transmissible spongiform encephalopathies.&lt;br /&gt;&lt;br /&gt;Mission: develop a diagnostic test to detect the presence of prion disease.&lt;br /&gt;&lt;br /&gt;The Final Report of the National Prion Research Program&lt;br /&gt;&lt;br /&gt;1&lt;br /&gt;&lt;br /&gt;Introduction&lt;br /&gt;&lt;br /&gt;The Congressionally Directed Medical Research Programs (CDMRP) emerged from heightened public awareness, and increased interest in the community concerning various health issues. These efforts convinced Congress to direct the Department of Defense to manage programs that focus on specific diseases. A unique partnership, forged among the public, Congress, and the military, led to the establishment of CDMRP within the US Army Medical Research and Materiel Command (USAMRMC) in fiscal year 1993 (FY93) to manage these programs. CDMRP has grown to encompass multiple targeted programs and has received $4.36 billion in appropriations through FY07.&lt;br /&gt;&lt;br /&gt;During FY02, concerns over potential contamination of the food and blood supply prompted the U.S. Congress (Joint Appropriations Conference Committee Report No. 107-350) to provide the largest single appropriation in history for research on prion disease. The National Prion Research Program (NPRP) was established with $42.5 million from Congress. The FY02 Senate Appropriations Committee Report 107-109, pages 148-149, also stated that the “priority goal… is to rapidly develop a diagnostic test to detect the presence of prion disease.” The Congressional language recognized that there was “currently no test to confirm the presence of the disease” and that this disease “represents a significant threat to the U.S. population.” The direction from Congress was to create a coordinated effort with other Federal agencies in an attempt to develop complementary programs of research and avoid duplicative activities. This influx of funding provided the funds to support established investigators as well as those new to the field to collectively focus on understanding prion disease and developing the components of diagnostic tools. With this increased funding, there was hope of leveraging knowledge to answer the many questions associated with this disease.&lt;br /&gt;&lt;br /&gt;This Final Report of the NPRP examines the accomplishments of the NPRP with respect to the guidance set by Congress and in response to the recommendations made by the Institute of Medicine’s Committee on Transmissible Spongiform Encephalopathies: Assessment of Relevant Science. This report discusses the results of the October 2007 NPRP Summit that was convened by CDMRP to address ongoing critical knowledge gaps in the development of ante-mortem diagnostic tools for prion disease and to explore future courses of action for achieving the goal of having a diagnostic test for the detection of prion disease. The Final Report includes conclusions made by the Summit participants regarding the state of the science and recommendations to inform decision makers regarding future policy.&lt;br /&gt;&lt;br /&gt;Overview of Prion Diseases&lt;br /&gt;&lt;br /&gt;Transmissible spongiform encephalopathies (TSEs) are a group of related diseases including Creutzfeldt-Jacob disease (CJD) and its new variant (vCJD), kuru (all three affect humans), scrapie in sheep and goats, bovine spongiform encephalopathy (BSE; “mad cow disease”), and chronic wasting disease (CWD) in deer and elk. These diseases have long incubation periods of years or decades, cause progressive neurological degeneration, evoke no obvious inflammation or immune response, and are invariably fatal. The current disease theory attributes TSEs to prions, normal cell membrane proteins that can form atypical three-dimensional configurations. Upon infection, the incoming misfolded prion proteins (PrPSc) trigger a cascade converting&lt;br /&gt;&lt;br /&gt;The Final Report of the National Prion Research Program 2&lt;br /&gt;&lt;br /&gt;normal prion protein (PrPC) or a partially unfolded PrPC intermediate arising from normal conformational fluctuations to a misfolded form, PrPSc. The misfolded prion proteins aggregate in the central nervous system and lead to the symptoms of prion diseases. The initiation of the first prion protein misfolding is unknown, but one model proposes that the conformational change of PrPC to PrPSc is thermodynamically controlled with PrPC conformation favored at equilibrium. PrPSc is favored when it adds onto a seed or fibril-like aggregate of PrPSc proteins. This model predicts that fibril-like prion aggregates can replicate by fragmentation. Thus, transferring misfolded prion proteins to a new host by blood transfusion, tissue transplantation, contact with contaminated surgical instruments, or tissue ingestion can transmit the disease. In sporadic prion diseases, the origin of the prion protein misfolding is unknown. In familial prion diseases, several heritable mutations in the prion protein gene lead to accumulation of misfolded prion protein and subsequent disease manifestations. Scrapie, a prion disease of sheep, has been recognized for centuries, and it was his torically controlled by culling infected animals. When prion disease in cattle (BSE) was identified in the 1980s, it was also controlled by culling infected animals. Prion diseases in humans are relatively rare. Incidence of sporadic CJD (sCJD) in humans is about 1 in 1 million; about 10% of all human TSE cases are familial (i.e. about 1 in 10 million). In 2003, it was estimated that iatrogenic transmission through dura mater or corneal transplants, pituitary hormones, and instruments used in neurosurgery contaminated with prion-infected material had resulted in 250 cases of CJD worldwide. Modification of surgical procedures has eliminated or significantly limited this mode of transmission. Transmission of the human prion disease kuru by ingestion of brain tissue was recognized in the 1950s, and cessation of ritual cannibalism eliminated this mode of transmission. In all of the above examples, transmission is from human to human, or intraspecies transmission.&lt;br /&gt;&lt;br /&gt;The potential impact of prion diseases on human health was greatly magnified by the recognition that interspecies transfer of BSE to humans by beef ingestion resulted in vCJD. While changes in animal feed constituents and slaughter practices appear to have curtailed vCJD, there is concern that CWD of free-ranging deer and elk in the U.S. might also cross the species barrier. Thus, consuming venison could be a source of human prion disease. Whether BSE and CWD represent interspecies scrapie transfer or are newly arisen prion diseases is unknown. Therefore, the possibility of transmission of prion disease through other food animals cannot be ruled out. There is evidence that vCJD can be transmitted through blood transfusion. There is likely a pool of unknown size of asymptomatic individuals infected with vCJD, and there may be asymptomatic individuals infected with the CWD equivalent. These circumstances represent a potential threat to blood, blood products, and plasma supplies.&lt;br /&gt;&lt;br /&gt;These threats to the food and blood supplies are serious because the incubation time for prion diseases is so long and there is no reliable ante-mortem diagnostic test, i.e., a test that can be performed to detect the disease while the person or animal is alive. Definitive diagnosis can be only made by examining central nervous system tissue at autopsy. Prions do not elicit an obvious immune response, so detection by measuring an immune response in the host has not been possible. Developing a diagnostic test to detect prions in peripheral tissues is dependent on surmounting two major impediments: (1) PrPSc has exactly the same amino acid sequence as PrPC and (2) PrPSc represents only 0.001% of the total prion protein in an affected host.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Prevention (Workgroup 3)&lt;br /&gt;&lt;br /&gt;Dr. Bruno Oesch, Prionics, AG, Switzerland was the moderator for the Prevention Workgroup. Prevention is defined as any activity which reduces the burden of mortality or morbidity from disease. Defining the areas where we can try to prevent the spread of the disease in animals is the best focus. It is important to maintain and improve surveillance in the various species affected by prions: humans, cattle, sheep, deer, elk, and possibly mice and voles. Surveillance is needed on the entry of infectious material into animal feed and subsequently the food chain that may affect humans. Animal feed may consist of many different elements that may contain the&lt;br /&gt;&lt;br /&gt;The Final Report of the National Prion Research Program 13&lt;br /&gt;&lt;br /&gt;prion protein. Meat and bone meal (MBM) from some animal species is used for animal feed to other species. Also used for animal feed are “specified risk materials” (SRM), which includes the skull, brain, eyes, tonsils, spinal cord and the nerves of animals. SRM is considered high risk for its potential to contain prion proteins. Banning the use of SRM for both human and animal food was critical in halting the epidemic of BSE in the UK and Europe. The success of the ban illustrates the central importance of SRM spread of BSE and underscores the need to monitor and/or prevent the entry of SRM into the food chain.&lt;br /&gt;&lt;br /&gt;There is a concern that human infection could occur through prion contaminated blood transfusions, medical instruments, and tissue transplants. The research community needs to develop new methods for inactivation of prion proteins that are compatible with maintaining the viability of biological material for human use. The goal of prevention is to reduce the amount of prion contaminated material to which human may be exposed.&lt;br /&gt;&lt;br /&gt;The workgroup members suggested that the current surveillance methods need to be maintained and improved. Some group members expressed concern for the level of resources needed being too low to continue current levels of surveillance.&lt;br /&gt;&lt;br /&gt;Animal identification is the first step in surveillance. Traceback is a method by which an affected animal can be tracked back to its origin and the potential source of infection. Traceback is done through the National Animal Identification System (NAIS). The USDA representative suggested that traceback was important to reduce the spread of prion disease in livestock. Issues of the business cost for traceback are also a consideration.&lt;br /&gt;&lt;br /&gt;Recommendations from Workgroup 3&lt;br /&gt;&lt;br /&gt;• Develop policy on CWD surveillance. CWD occurs naturally in the wild among deer, elk, and moose. It poses a threat to hunters and others who consume meat from these animals. Deer meat (venison) is sometimes sent by hunters to commercial processors to be preserved as sausage and jerky (dried meat). If the venison is from a deer with CWD, it could contaminate processing machinery and spread the disease to previously uncontaminated meat products and then to unsuspecting consumers. Another threat is that deer are frequently raised on deer farms for hunting purposes and not monitored for CWD. Deer from farms can be sold and transported across state lines to other commercial farms, posing a significant risk of spreading CWD even further. A federal surveillance and monitoring program for CWD in wild and commercial herds is needed.&lt;br /&gt;&lt;br /&gt;• Conduct studies on surgical equipment contamination. The risk of asymptomatic prion contamination occurring in hospitals is not known. The risk of blood and tissue from patients with vCJD contaminating surgical rooms and equipment, as well as methods to inactivate the agent on surgical equipment need to be developed. The data need to be improved and based on today’s hospital environment, e.g., current heat, cleaning, inactivation steps should be reviewed. Prion researchers should initiate laboratory studies to assess the efficiency of hospital cleaning methods using human strains.&lt;br /&gt;&lt;br /&gt;The Final Report of the National Prion Research Program 14&lt;br /&gt;&lt;br /&gt;• Conduct studies on inactivation. A more systematic approach to studying inactivation of prion material is needed. Autoclaving of whole intact animals is not sufficient. It is unclear what combination of high temperature and pressure is needed to inactivate prions as residual infectivity can still be detectable. Further study needs to be done on the properties of prions as there appear to be a range of different forms, which may have distinct biological characteristics.&lt;br /&gt;&lt;br /&gt;• Review the use of MBM and SRM. MBM and SRM are valuable sources of protein in animal feed; they are also potential sources of infection. Surveillance of animals receiving MBM and SRM that are likely to become part of the human supply of food may reduce the risk of transmission.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Therapeutics and Surveillance (Workgroup 4)&lt;br /&gt;&lt;br /&gt;Dr. Phil Minor, National Institute for Biological Standards and Control, Potters Bar, UK was the moderator for the Therapeutics and Surveillance workgroup session.&lt;br /&gt;&lt;br /&gt;With the lack of an effective vCJD treatment, surveillance is essential to control transmission. Surveillance studies are a high priority and remain critical to tracking the disease. The workgroup had an active discussion on BSE surveillance. It was suggested that they should treat the US and Canada in the same way by using a high level of surveillance in both countries. BSE is currently classified as a select agent. The U.S. Departments of Health and Human Services (HHS) and Agriculture (USDA) published final rules for the possession, use, and transfer of select agents and toxins (42 C.F.R. Part 73, 7 C.F.R. Part 331, and 9 C.F.R. Part 121) in the Federal Register on March 18, 2005. BSE was listed by the USDA as one of several select agents and toxins that could be used during acts of terrorism. Other examples include avian influenza and foot-and-mouth disease viruses. The issues surrounding select agents were discussed and lead to suggestions for a containment policy.&lt;br /&gt;&lt;br /&gt;Tracking of human TSE through autopsies has increased due to support and education of physicians and family members of the deceased. Hopefully, the autopsied tissues will lead to a better understanding of pathological pathways and contribute to the development of diagnostics. Surveillance for prion disease through autopsies is a problem due to difficulty obtaining consent, and not being able to control the risk of infection from autopsied materials. Government agencies could address those issues by increasing support and allocating resources to educate family members, physicians and medical examiners on the need for more autopsies, as well as continuing support for research on decontaminating autopsy laboratories.&lt;br /&gt;&lt;br /&gt;Better diagnostics are key to successful treatments in the future. One issue that will need clarification is who should receive prophylactic measures. Should it be assumed any blood donor could be potentially infectious with prion disease? Do all blood product recipients have the same risk of incurring infection? Without better diagnostics to determine the nature and extent of prion disease, it is difficult to focus on prophylactic therapeutics.&lt;br /&gt;&lt;br /&gt;In terms of clinical trials, the researchers need to establish a consensus on a standard clinical trial design for general use and there is a need to coordinate the clinical trials. If clinical trial&lt;br /&gt;&lt;br /&gt;The Final Report of the National Prion Research Program 15&lt;br /&gt;&lt;br /&gt;designs are coordinated in advance among the researchers, results that support surveillance and treatment guidelines will be reached sooner.&lt;br /&gt;&lt;br /&gt;In terms of vaccines, the workgroup said vaccines were an important consideration. Studying the immune response during infection is of interest. If the Government had a vaccine or other alternate intervention to stop CWD transmission, this would be of great importance. In relation to CWD and hunters, Government regulators such as State Fish and Wildlife or Game officers need to better promote the requirement to turn in deer heads to determine the real prevalence of the disease. If ante mortem tests were available, State Fish and Wildlife offices could offer them to hunters before they slaughter deer for consumption. However, the repercussions for testing include the socio-economic effects of finding increased prevalence of CWD on the hunting industry.&lt;br /&gt;&lt;br /&gt;Recommendations from Workgroup 4&lt;br /&gt;&lt;br /&gt;• Reconsider the research safety restrictions related to BSE. The administrative requirements to track every sample, criminal penalties, and inspections associated with the select agent status of BSE make research on it very difficult. The select agent status and Biological Safety Lab (BSL) level required should be based on the type of material being studied and the stage of the experiment, rather than indiscriminately applied to all materials and experiment components. Cattle with BSE should be managed under BSL-2 requirements, not the more restrictive BSL-3 requirements. If management standards are reduced to reflect the nature of the disease, BSE research will be easier and less expensive to perform, while continuing to be safe.&lt;br /&gt;&lt;br /&gt;• Improve containment measure standard. Regulators need to revisit containment measures for BSE and scrapie following the most up to date scientific principles. The regulators need to establish a high level committee to devise a standard that is for unique TSE diseases.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Stanley B. Prusiner&lt;br /&gt;&lt;br /&gt;Institute for Neurodegenerative Diseases University of California, San Francisco, CA&lt;br /&gt;&lt;br /&gt;Award: DAMD17-03-1-0425&lt;br /&gt;&lt;br /&gt;Antemortem Prion Diagnostics&lt;br /&gt;&lt;br /&gt;Prions cause bovine spongiform encephalopathy (BSE) of cattle, Creutzfeldt-Jakob disease (CJD) of humans, scrapie of sheep, and chronic wasting disease (CWD) of deer and elk. Four new concepts have emerged from studies of prions. First, prions are infectious proteins that are devoid of nucleic acid. Second, prion diseases may be manifest as infectious, genetic, and sporadic disorders. Third, prion diseases result from the accumulation of PrPSc, the conformation of which differs substantially from that of its precursor PrPC. Fourth, PrPSc can exist in a variety of different conformations, each of which seems to specify a particular disease phenotype. That the mammalian prion contains only PrPSc, thus supporting the hypothesis that prions are infectious proteins, has recently been demonstrated by using recombinant (rec) PrP produced in E. coli (Legname, Nguyen et al. 2005). Late in the course of disease, both humans and animals develop signs and symptoms of CNS dysfunction. At this advanced stage, PrPSc is generally detectable in the CNS when sensitive tests, such as the conformation-dependent immunoassay (CDI), are used (Safar, Geschwind et al. 2005). Towards developing a sensitive and specific presymptomatic diagnostic test for prion disease, we have made advances in understanding the biology of disease progression, elucidating chemical conditions for prion protein (PrP) precipitation, and establishing diagnostic protocols. Using SELDI-TOF MS and a ProteinChip platform in mouse models of prion disease, protein profiles of fractionated brain homogenates were produced from symptomatic CD-1 mice infected with RML prions and compared to controls; 24 protein biomarkers were identified. Additionally, we established a FACS protocol for fractionating human white blood cells (WBCs) from CJD patients. PrPSc in human WBCs will be measured using the CDI. In parallel work aimed to increase the sensitivity of the CDI by precipitation of prions, Keggin-type polyoxometalate (POM) complexes demonstrated superior ability to precipitate selectively disease-causing PrPSc. We propose that prion aggregation may involve multivalent electrostatic interactions between the POM anions and positively charged cleft sites of PrPSc. Using POMs, we are continuing to adapt the CDI to human plasma using samples from healthy controls and patients dying of sporadic CJD. From these studies, we conclude that a protease-sensitive (s) form of PrPSc is present at low concentrations in the plasma of patients with sporadic CJD. Whether or not there is sufficient sPrPSc present in the plasma of CJD patients so that it can be used as a diagnostic marker remains to be established.&lt;br /&gt;&lt;br /&gt;References cited&lt;br /&gt;&lt;br /&gt;Stanley B. Prusiner1,2,3, Jiri G. Safar1,2, In Su Lee1,5, Laura Moriarty1, Edward Choi1, Giuseppe Legname1,2, Michael D. Geschwind1,2, Stephen J. DeArmond1,2,4, Bruce L. Miller1,2 and Jeffrey R. Long5 1Institute for Neurodegenerative Diseases, Departments of 2Neurology, 3Biochemistry and Biophysics, and 4Pathology, University of California, San Francisco, CA; 5Department of Chemistry, University of California, Berkeley, CA.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Robert G. Rohwer&lt;br /&gt;&lt;br /&gt;VA Maryland Healthcare System, Baltimore, MD&lt;br /&gt;&lt;br /&gt;Award: DAMD17-03-1-0756&lt;br /&gt;&lt;br /&gt;Development of a Diagnostic for the Detection of PrPres in Blood and Urine&lt;br /&gt;&lt;br /&gt;We have developed a sensitive assay based on the ORIGEN electrochemiluminescence technology that is capable of detecting 5 pg/ml prion protein at twice background levels in the presence of plasma. Comparison with other published assay formats indicates that all of the most sensitive assays have similar twice background sensitivities in the presence of plasma. We therefore propose twice background sensitivity as a standard point of comparison between assays. From our infectivity measurements in blood, we deduce that we will need at least 50 fold greater sensitivity to detect endogenous infection-specific prion protein in blood. This can be achieved either by increasing the sensitivity of the assay or concentrating the prion protein before assay.&lt;br /&gt;&lt;br /&gt;Our assay development efforts have utilized our laboratory’s quantitative model for blood-borne TSE infectivity in hamsters as well as naturally infected blood from scrapie infected sheep. Infected sheep blood can be obtained in 500 ml quantities equal to those in a human blood donation. This has enabled us to explore several methods of concentrating the prion protein from human scale blood collections prior to assay including precipitants, immuno-affinity, and synthetic ligand-affinity capture methods.&lt;br /&gt;&lt;br /&gt;A blood-based diagnostic must also be capable of discriminating infection-specific prion protein from a &gt;10,000 fold excess of native prion protein. We have been exploiting the ORIGEN assay to characterize and optimized protease digestion conditions, differential separation methods, and a novel immunological method.&lt;br /&gt;&lt;br /&gt;Urine would be an ideal substrate for TSE diagnosis but initial reports of infection-specific prion protein in urine have proved to be an artifact. However, it is now claimed that urine contains TSE infectivity. We are attempting to verify this claim by applying the same highly sensitive and precise methods that we have developed for assaying TSE infectivity in blood to urine.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;please see full report 90 pages with abstracts here ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cdmrp.army.mil/nprp/NPRP08_Summit_Final_Report_7_2_08.pdf"&gt;http://cdmrp.army.mil/nprp/NPRP08_Summit_Final_Report_7_2_08.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The National Prion Research Program (NPRP) Congressionally Directed Medical Research Programs&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Prion disease in sheep, known as scrapie, has been recognized for centuries and controlled by removing infected animals from herds (culling). When BSE was identified in cattle in the 1980s, it was also controlled by culling infected animals. Prion diseases in humans are relatively rare. The incidence of CJD in humans is about 1 in 1 million; about 10% of such cases are inherited. However, the potential impact of prion diseases on human health was greatly magnified by the recognition that the transfer of BSE in cows to humans by beef ingestion resulted in vCJD. Changes in animal feed constituents and slaughter practices appear to have curtailed vCJD, but there is concern that CWD of free-ranging deer in the United States might be transferred from deer to humans through venison consumption. Whether BSE and CWD represent a transfer of scrapie in sheep to cows and deer or are newly arisen prion diseases is unknown. The possible transmission of prion disease through other food animals also cannot be ruled out. There is evidence that vCJD can be transmitted through blood transfusion. It is possible that an unknown number of asymptomatic individuals are infected with vCJD from BSE, CWD, or scrapie. This potential threat to blood and plasma supplies is of great concern to both civilian and military health professionals.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cdmrp.army.mil/pubs/pips/nppip.pdf"&gt;http://cdmrp.army.mil/pubs/pips/nppip.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES TERRORISM AND OTHER PUBLIC HEALTH EMERGENCIES&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.swt.usace.army.mil/library/Terrorism%20and%20Other%20Health%20Emergencies/HHSMedisReferenceGuideFinal.pdf"&gt;http://www.swt.usace.army.mil/library/Terrorism%20and%20Other%20Health%20Emergencies/HHSMedisReferenceGuideFinal.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Headquarters Department of the Army Washington, DC 6 May 2009 Safety Safety Standards for Microbiological and Biomedical Laboratories *Department of the Army Pamphlet 385–69&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.army.mil/usapa/epubs/pdf/p385_69.pdf"&gt;http://www.army.mil/usapa/epubs/pdf/p385_69.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;USAF GUIDELINES FOR INFECTION CONTROL IN DENTISTRY APRIL 2010&lt;br /&gt;&lt;br /&gt;&lt;a href="http://airforcemedicine.afms.mil/idc/groups/public/documents/afms/ctb_109794.pdf"&gt;http://airforcemedicine.afms.mil/idc/groups/public/documents/afms/ctb_109794.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; Up until about 6 years ago, the pt worked at Tyson foods where she worked on the assembly line, slaughtering cattle and preparing them for packaging. She was exposed to brain and spinal cord matter when she would euthanize the cattle. &lt;&lt;&lt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010 in Mesquite Texas&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010 in Mesquite Texas.She left 6 Kids and a Husband.The Purpose of this web is to give information in Spanish to the Hispanic community, and to all the community who want's information about this terrible disease.-&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Physician Discharge Summary, Parkland Hospital, Dallas Texas Admit Date: 12/29/2009&lt;br /&gt;&lt;br /&gt;Discharge Date: 1/20/2010&lt;br /&gt;&lt;br /&gt;Attending Provider: Greenberg, Benjamin Morris;&lt;br /&gt;&lt;br /&gt;General Neurology Team:&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;General Neurology Team Linda was a Hispanic female with no past medical history presents with 14 months of incresing/progressive altered mental status, generalized weakness, inability to walk, loss of appetite, inability to speak, tremor and bowel/blader incontinence.She was, in her usual state of health up until February, 2009, when her husbans notes that she began forgetting things like names and short term memories. He also noticed mild/vague personality changes such as increased aggression. In March, she was involved in a hit and run MVA,although she was not injured. The police tracked her down and ticketed her. At that time, her son deployed to Iraq with the Army and her husband assumed her mentation changes were due to stress over these two events. Also in March, she began to have weakness in her legs, making it difficult to walk. Over the next few months, her mentation and personality changes worsened, getting to a point where she could no longer recognized her children. She was eating less and less. She was losing more weight. In the last 2-3 months, she reached the point where she could not walk without an assist, then 1 month ago, she stopped talking, only making grunting/aggressive sounds when anyone came near her. She also became both bowel and bladder incontinent, having to wear diapers. Her '"tremor'" and body jerks worsened and her hands assumed a sort of permanent grip position, leading her family to put tennis balls in her hands to protect her fingers. The husband says that they have lived in Nebraska for the past 21 years. They had seen a doctor there during the summer time who prescribed her Seroquel and Lexapro, Thinking these were sx of a mood disorder. However, the medications did not help and she continued to deteriorate clinically. Up until about 6 years ago, the pt worked at Tyson foods where she worked on the assembly line, slaughtering cattle and preparing them for packaging. She was exposed to brain and spinal cord matter when she would euthanize the cattle. The husband says that he does not know any fellow workers with a similar illness. He also says that she did not have any preceeding illness or travel.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8"&gt;http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; Up until about 6 years ago, the pt worked at Tyson foods where she worked on the assembly line, slaughtering cattle and preparing them for packaging. She was exposed to brain and spinal cord matter when she would euthanize the cattle. &lt;&lt;&lt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please see full text ; Monday, March 29, 2010 Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010 in Mesquite Texas&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/03/irma-linda-andablo-cjd-victim-she-died.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/03/irma-linda-andablo-cjd-victim-she-died.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html"&gt;http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Archive Number 20100405.1091 Published Date 05-APR-2010 Subject PRO/AH/EDR&gt; Prion disease update 1010 (04)&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;[Terry S. Singeltary Sr. has added the following comment:&lt;br /&gt;&lt;br /&gt;"According to the World Health Organisation, the future public health threat of vCJD in the UK and Europe and potentially the rest of the world is of concern and currently unquantifiable. However, the possibility of a significant and geographically diverse vCJD epidemic occurring over the next few decades cannot be dismissed.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The key word here is diverse. What does diverse mean? If USA scrapie transmitted to USA bovine does not produce pathology as the UK c-BSE, then why would CJD from there look like UK vCJD?"&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.promedmail.org/pls/apex/f?p=2400:1001:568933508083034::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,82101"&gt;http://www.promedmail.org/pls/apex/f?p=2400:1001:568933508083034::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,82101&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;14th International Congress on Infectious Diseases H-type and L-type Atypical BSE January 2010 (special pre-congress edition)&lt;br /&gt;&lt;br /&gt;18.173 page 189&lt;br /&gt;&lt;br /&gt;Experimental Challenge of Cattle with H-type and L-type Atypical BSE&lt;br /&gt;&lt;br /&gt;A. Buschmann1, U. Ziegler1, M. Keller1, R. Rogers2, B. Hills3, M.H. Groschup1. 1Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany, 2Health Canada, Bureau of Microbial Hazards, Health Products &amp;amp; Food Branch, Ottawa, Canada, 3Health Canada, Transmissible Spongiform Encephalopathy Secretariat, Ottawa, Canada&lt;br /&gt;&lt;br /&gt;Background: After the detection of two novel BSE forms designated H-type and L-type atypical BSE the question of the pathogenesis and the agent distribution of these two types in cattle was fully open. From initial studies of the brain pathology, it was already known that the anatomical distribution of L-type BSE differs from that of the classical type where the obex region in the brainstem always displays the highest PrPSc concentrations. In contrast in L-type BSE cases, the thalamus and frontal cortex regions showed the highest levels of the pathological prion protein, while the obex region was only weakly involved.&lt;br /&gt;&lt;br /&gt;Methods:We performed intracranial inoculations of cattle (five and six per group) using 10%brainstemhomogenates of the two German H- and L-type atypical BSE isolates. The animals were inoculated under narcosis and then kept in a free-ranging stable under appropriate biosafety conditions.At least one animal per group was killed and sectioned in the preclinical stage and the remaining animals were kept until they developed clinical symptoms. The animals were examined for behavioural changes every four weeks throughout the experiment following a protocol that had been established during earlier BSE pathogenesis studies with classical BSE.&lt;br /&gt;&lt;br /&gt;Results and Discussion: All animals of both groups developed clinical symptoms and had to be euthanized within 16 months. The clinical picture differed from that of classical BSE, as the earliest signs of illness were loss of body weight and depression. However, the animals later developed hind limb ataxia and hyperesthesia predominantly and the head. Analysis of brain samples from these animals confirmed the BSE infection and the atypical Western blot profile was maintained in all animals. Samples from these animals are now being examined in order to be able to describe the pathogenesis and agent distribution for these novel BSE types. Conclusions: A pilot study using a commercially avaialble BSE rapid test ELISA revealed an essential restriction of PrPSc to the central nervous system for both atypical BSE forms. A much more detailed analysis for PrPSc and infectivity is still ongoing.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.isid.org/14th_icid/"&gt;http://www.isid.org/14th_icid/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ww2.isid.org/Downloads/IMED2009_AbstrAuth.pdf"&gt;http://ww2.isid.org/Downloads/IMED2009_AbstrAuth.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.isid.org/publications/ICID_Archive.shtml"&gt;http://www.isid.org/publications/ICID_Archive.shtml&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;14th ICID International Scientific Exchange Brochure -&lt;br /&gt;&lt;br /&gt;Final Abstract Number: ISE.114&lt;br /&gt;&lt;br /&gt;Session: International Scientific Exchange&lt;br /&gt;&lt;br /&gt;Transmissible Spongiform encephalopathy (TSE) animal and human TSE in North America&lt;br /&gt;&lt;br /&gt;update October 2009&lt;br /&gt;&lt;br /&gt;T. Singeltary&lt;br /&gt;&lt;br /&gt;Bacliff, TX, USA&lt;br /&gt;&lt;br /&gt;Background:&lt;br /&gt;&lt;br /&gt;An update on atypical BSE and other TSE in North America. Please remember, the typical U.K. c-BSE, the atypical l-BSE (BASE), and h-BSE have all been documented in North America, along with the typical scrapie's, and atypical Nor-98 Scrapie, and to date, 2 different strains of CWD, and also TME. All these TSE in different species have been rendered and fed to food producing animals for humans and animals in North America (TSE in cats and dogs ?), and that the trading of these TSEs via animals and products via the USA and Canada has been immense over the years, decades.&lt;br /&gt;&lt;br /&gt;Methods:&lt;br /&gt;&lt;br /&gt;12 years independent research of available data&lt;br /&gt;&lt;br /&gt;Results:&lt;br /&gt;&lt;br /&gt;I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2009. With all the science to date refuting it, to continue to validate this old myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, medical i.e., surgical, blood, dental, endoscopy, optical, nutritional supplements, cosmetics etc.&lt;br /&gt;&lt;br /&gt;Conclusion:&lt;br /&gt;&lt;br /&gt;I would like to submit a review of past CJD surveillance in the USA, and the urgent need to make all human TSE in the USA a reportable disease, in every state, of every age group, and to make this mandatory immediately without further delay. The ramifications of not doing so will only allow this agent to spread further in the medical, dental, surgical arena's. Restricting the reporting of CJD and or any human TSE is NOT scientific. Iatrogenic CJD knows NO age group, TSE knows no boundaries. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Gajdusek, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Transmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf"&gt;http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;International Society for Infectious Diseases Web: &lt;a href="http://www.isid.org/"&gt;http://www.isid.org&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/01/14th-international-congress-on.html"&gt;http://bse-atypical.blogspot.com/2010/01/14th-international-congress-on.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, February 14, 2010&lt;br /&gt;&lt;br /&gt;[Docket No. FSIS-2006-0011] FSIS Harvard Risk Assessment of Bovine Spongiform Encephalopathy (BSE)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bseusa.blogspot.com/2010/02/docket-no-fsis-2006-0011-fsis-harvard.html"&gt;http://bseusa.blogspot.com/2010/02/docket-no-fsis-2006-0011-fsis-harvard.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2010/02/transmissible-spongiform-encephalopathy.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2010/02/transmissible-spongiform-encephalopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TSE&lt;br /&gt;&lt;br /&gt;please read Senate 'Down Under' link at bottom of the following url ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;To date the OIE/WAHO assumes that the human and animal health standards set out in the BSE chapter for classical BSE (C-Type) applies to all forms of BSE which include the H-type and L-type atypical forms. This assumption is scientifically not completely justified and accumulating evidence suggests that this may in fact not be the case. Molecular characterization and the spatial distribution pattern of histopathologic lesions and immunohistochemistry (IHC) signals are used to identify and characterize atypical BSE. Both the L-type and H-type atypical cases display significant differences in the conformation and spatial accumulation of the disease associated prion protein (PrPSc) in brains of afflicted cattle. Transmission studies in bovine transgenic and wild type mouse models support that the atypical BSE types might be unique strains because they have different incubation times and lesion profiles when compared to C-type BSE. When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2"&gt;http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please see full text ;&lt;br /&gt;&lt;br /&gt;Monday, April 5, 2010&lt;br /&gt;&lt;br /&gt;UPDATE - CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/04/update-cjd-texas-38-year-old-female.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/04/update-cjd-texas-38-year-old-female.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html"&gt;http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, March 28, 2010&lt;br /&gt;&lt;br /&gt;Nor-98 atypical Scrapie, atypical BSE, spontaneous TSE, trade policy, sound science ?&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-atypical-bse.html"&gt;http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-atypical-bse.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;*****URGENT NOTE HERE ABOUT OIE AND THEIR JUNK SCIENCE ABOUT ATYPICAL BSE*****&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html"&gt;http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD SURVEILLANCE TEXAS&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2007/12/creutzfeldt-jakob-disease-surveillance.html"&gt;http://cjdtexas.blogspot.com/2007/12/creutzfeldt-jakob-disease-surveillance.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2009 UPDATE ON ALABAMA AND TEXAS MAD COWS 2005 and 2006&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html"&gt;http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, May 14, 2010&lt;br /&gt;&lt;br /&gt;Prion Strain Mutation Determined by Prion Protein Conformational Compatibility and Primary Structure&lt;br /&gt;&lt;br /&gt;Published Online May 13, 2010 Science DOI: 10.1126/science.1187107 Science Express Index&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2010/05/prion-strain-mutation-determined-by.html"&gt;http://chronic-wasting-disease.blogspot.com/2010/05/prion-strain-mutation-determined-by.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, April 12, 2009&lt;br /&gt;&lt;br /&gt;CWD UPDATE Infection Studies in Two Species of Non-Human Primates and one Environmental reservoir infectivity study and evidence of two strains&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2009/04/cwd-update-infection-studies-in-two.html"&gt;http://chronic-wasting-disease.blogspot.com/2009/04/cwd-update-infection-studies-in-two.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Epidemiology of Chronic Wasting Disease: PrPres Detection, Shedding, and Environmental Contamination&lt;br /&gt;&lt;br /&gt;1. REPORT DATE 1 August 2009&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;EXECUTIVE SUMMARY&lt;br /&gt;&lt;br /&gt;Obviously the most important goal is to develop an extremely sensitive assay for the infective prion protein. We have made substantial progress since the start of the grant period but are still short of the goal. In a continuation of the proteomics work initiated last year we identified several candidate proteins that are found in urine of infected deer but not in uninfected controls. For some of these we were able to find antibodies and have confirmed the presence of three of these proteins over time using the samples that have been collected for deer over the infection period. Preliminary results indicate that the levels of the proteins increase during the infection period. We have started optimizing the assays on several of the proteins.&lt;br /&gt;&lt;br /&gt;As this is a final report I will not reiterate the details presented in the past five years of the grant. However, I will summarize the results and total the publications etc. We are also in the process of filing a patent disclosure on the biomarker proteins we have identified.&lt;br /&gt;&lt;br /&gt;INTRODUCTION&lt;br /&gt;&lt;br /&gt;Chronic wasting disease (CWD) of deer (Odocoileus spp.) and elk (Cervus elaphus) is unique among the transmissible spongiform encephalopathies (TSEs) in that it occurs in free-ranging as well as captive wild ruminants and environmental contamination appears to play a significant role in maintenance of the disease. The precise modes of transmission of CWD are not known although we have shown that horizontal transmission and environmental contamination associated with excreta and carcasses may occur (Miller et al., 2004). But maternal transmission does not appear to play a significant role (Miller and Williams, 2003) in maintenance of CWD in cervid populations. Our long-term goal is to better understand the epidemiology of CWD and apply that information to development of strategies for management and control. To that end we are investigating the dynamics and modes of CWD agent shedding from infected mule deer, white-tailed deer, and elk. The approach includes experimentally infecting cervids, serial collections of a variety of biological samples, and assay of these materials by various means to attempt to detect protease resistant prion protein (PrPres). In addition, because of the concern about environmental contamination associated with excreta, we will be collecting and assaying a variety of environmental specimens collected from areas of presumed high, moderate, and low contamination in CWD endemic facilities.&lt;br /&gt;&lt;br /&gt;BODY&lt;br /&gt;&lt;br /&gt;Aim 1: Develop analytical tools to detect PrPCWD in excreta, blood, and environmental samples.&lt;br /&gt;&lt;br /&gt;Biomarker Discovery for Chronic Wasting Disease&lt;br /&gt;&lt;br /&gt;Initial Identification of Biomarkers&lt;br /&gt;&lt;br /&gt;We have accomplished an extensive analysis of urine from CWD-positive animals. The analysis has identified 11 potential biomarkers, as represented in Table 1. Urine is an ideal source for biomarkers (Aguzzi A, 2004) and we feel strongly that markers found in the urine will also be present in the serum and other tissues of infected animals and our preliminary results are confirming this. The potential protein markers were identified based on their similarity to known proteins from other mammals, since the deer genome sequence has not been characterized. As such, it is imperative that we accurately identify these proteins. We present them here as CWD-1 thru 11 because we are not completely sure of the proteins identity (except where noted) even though we are seeing antibody crossreactivity as will be demonstrated in the following pages. Additionally, several of the proteins have a number of isoforms and we are unsure of which isoform we have identified that we are now seeing in blood and urine samples. Research contained within this proposal will appropriately identify the proteins.&lt;br /&gt;&lt;br /&gt;Table 1: The identified potential biomarkers of Chronic Wasting Disease.&lt;br /&gt;&lt;br /&gt;Biomarker Possible Physiological Role Summary&lt;br /&gt;&lt;br /&gt;CWD-1 Required for a specialized brain endocytosis responsible for generating the synaptic vesicles that store and then release neurotransmitters. Also implicated in Alzheimer’s and early loss of cognitive ability.&lt;br /&gt;&lt;br /&gt;CWD-2 Reported roles in cell function, clotting, memory and necrosis. Implicated in Alzheimer’s and its role in cleaving CWD-1 (see above) and is hypothesized to be partly responsible for early loss of cognitive ability.&lt;br /&gt;&lt;br /&gt;CWD-3 Molecular chaperone in the eukaryotic cytosol assisting in protein folding.&lt;br /&gt;&lt;br /&gt;CWD-4 A protein truncated in some forms of schizophrenia.&lt;br /&gt;&lt;br /&gt;CWD-5 Found in Alexander’s disease, a progressive neurological disorder, associated with the destruction of white matter.&lt;br /&gt;&lt;br /&gt;CWD-6 Indicator of multi-drug resistance in lung cancer.&lt;br /&gt;&lt;br /&gt;CWD-7 A protein scaffold that is involved throughout the cell cycle.&lt;br /&gt;&lt;br /&gt;CWD-8 A serine threonine protein kinase involved in mitosis.&lt;br /&gt;&lt;br /&gt;CWD-9 Transmembrane protein that plays a critical role in cell adhesion.&lt;br /&gt;&lt;br /&gt;CWD-10 Light chain IgG (Serban A, 2004)&lt;br /&gt;&lt;br /&gt;CWD-11 An unknown protein that is visibly increased throughout the progression of the disease. Plans for its identification are underway.&lt;br /&gt;&lt;br /&gt;Preliminary screening of samples with biomarker antibodies Initially to determine which of the proteins have merit as biomarkers for CWD, we purchased commercially available antibodies against the human or mouse forms of the protein, when available. This predisposes the interpretations to be overly cautious. However, the fact that those proteins for which we were able to obtain antibodies are showing up-regulation, or higher expression, in response to the diseased state strongly suggests we are on the right track. We have not tested some of the biomarkers as commercially available antibodies do not exist for them and we&lt;br /&gt;&lt;br /&gt;currently do not have funding to generate those antibodies. So we have 6 markers (CWD 1,2,3,4, 10 and 11) that we have positive preliminary data on and that merit further validation. Given that we developed these protein biomarkers from urine, our initial screens of available proteins focused on urine from both positive and negative animals. Figure 2 shows the potential that these biomarkers hold. Using an off-the-shelf antibody to another species we obtained positive results. Further, we obtained results that show a tendency of the proteins to be increasingly abundant as the disease progresses. Urine is an ideal source of biomarker material in humans, but may prove less than ideal when trying to test for CWD. However, urine has been identified as an acceptable medium for the development of diagnostic tools (Aguzzi A, 2004).&lt;br /&gt;&lt;br /&gt;Densitometry on the western blot of CWD-1 tested in urine shows a significant trend for the biomarker to be quantifiably higher as the disease progresses (Figure 3A). Figure 3B illustrates that there are still potential biomarkers to be discovered. Although it is beyond the scope of this grant to identify this potential marker, their existence helps to define the potential that protein biomarkers have in diagnosing CWD. All western blot results shown were performed on 10X concentrated urine. Recent analysis indicates that we can indeed detect the markers in unconcentrated urine (Figure 4). Further, the biomarkers can be observed and demonstrate a quantifiable difference throughout the disease state.&lt;br /&gt;&lt;br /&gt;Testing in feces was undertaken as another means by which to indicate disease. Some preliminary successes were accomplished (data not shown). However, fecal samples have proved very difficult to analyze. Given that CWD is the only one of the TSE diseases that lends itself to being monitored through feces, we have not chosen to continue this line of research. Serum and urine are far more useful when applied to human TSE’s and the TSE’s that are known to affect humans, which CWD does not.&lt;br /&gt;&lt;br /&gt;Further diversification of the medium of detection to serum broadens the capability of the biomarkers. We have met with limited success in this endeavor largely due to the non specific nature of the antibodies. One clear success on this front is CWD-4 (which according to literature should be represented by a 100kDa and 75kDa band), which is visible at appropriate molecular weights (Figure 5) in the infected animal and clearly less prevalent in the non-infected animals.&lt;br /&gt;&lt;br /&gt;We are basing our premise that these will be good biomarkers for the disease on the fact that even with the imperfect antibodies and conditions, we are seeing the protein(s) in the infected animals at well above background levels as the disease progresses in the urine, serum and feces. Perhaps most importantly, we see signal above background very early in the infection.&lt;br /&gt;&lt;br /&gt;Preliminary Results Summary&lt;br /&gt;&lt;br /&gt;Results obtained thus far are very promising but underscore the need to develop species specific antibodies. The different and complex mediums in which we are testing require specific antibodies if these biomarkers are ever to be used to develop a quick, ante mortem test.&lt;br /&gt;&lt;br /&gt;The different TSE diseases lend themselves to detection via biomarkers in different mediums. It is not very efficient to collect urine from wild animals within wild populations such is the case in CWD. As well, blood and serum work well for BSE in the feedlot or slaughter house but urine would seem to be the easiest medium of detection in CJD or vCJD. In both of these mediums we have had success in detecting the markers. The limiting factor is non-specificity to the species. Having multiple biomarkers would allow a testing format that would not rely on a single marker, thus reducing the possibility of getting false positive or negative results. A multiple marker format would also alleviate the argument raised against the use of ESM as an indicator of TSE disease, which is that different individuals have varying levels of transcript (Glock B, 2003) As with all biomarkers there is the potential that the markers may be abundant in other states than the disease of interest. However, a multiple marker format would alleviate that concern. In our proposed system only having one marker indicate positive would not be a positive result. It would require more than one of the markers to indicate the presence of the disease with certainty. Further, our proposed method of utilizing the known light chain IgG (CWD-10) as a fail-safe control alleviates that concern that one marker is insufficient to diagnose the diseased state. With specific antibodies we can determine not only which of the biomarkers are amenable to detection but if they are preferentially detected in one medium and not another.&lt;br /&gt;&lt;br /&gt;Given that our laboratory has an extensive library of CWD infected tissues in addition to the facilities and equipment required, we are proposing to develop the biomarkers further using CWD as our TSE of choice. We do expect to be able to test the relevance of our biomarkers in other TSE diseases, but that is beyond the scope of this grant. It is our goal to establish which of the biomarkers, when specific antibodies are used for detection, are useful for confirming the disease. As well, we will establish which biomarkers are useful when applied to urine or serum. With that information we can then develop a test format that will quickly and accurately diagnose the presence of CWD.&lt;br /&gt;&lt;br /&gt;KEY RESEARCH ACCOMPLISHMENTS&lt;br /&gt;&lt;br /&gt;Determined that high sensitivity detection of the prion protein cannot be accomplished with out sacrificing both false negative and positive results. Confirmed difficulties reported by others with all of the amplification methods, particularly the false positives, which obviate their standard use for detection. Identified several proteins that can serve as biomarkers for detection of CWD in live animals from both urine and serum. Aim 2. Evaluate multiple biological samples collected from experimentally infected mule deer, white-tailed deer, and elk throughout the CWD incubation period.&lt;br /&gt;&lt;br /&gt;KEY RESEARCH ACCOMPLISHMENTS&lt;br /&gt;&lt;br /&gt;• CWD infections established, confirmed, and monitored to terminus in mule deer and white-tailed deer and elk. • Serial samples of excreta collected from throughout the disease course from both mule deer and white-tailed deer and elk are available for analysis of prion shedding patterns. • Genetic influences on disease course in infected white-tailed deer and elk demonstrated, affording opportunities to evaluate the influence of genotype on agent shedding. • Archived materials shared with other laboratories to advance overall progress on developing sensitive assays for prion detection in blood and excreta, investigating potential routes of prion shedding in deer and elk, and exploring patterns of prion shedding during the disease course. Aim 3. The goal of this Aim is to determine if PrPres can be detected in samples collected from facilities contaminated with the CWD agent.&lt;br /&gt;&lt;br /&gt;KEY RESEARCH ACCOMPLISHMENTS&lt;br /&gt;&lt;br /&gt;• CWD infections established and confirmed in mule deer and white-tailed deer. • PrPCWD demonstrated in tonsil and rectal mucosa biopsies from infected mule deer and white-tailed deer.&lt;br /&gt;&lt;br /&gt;• Clinical CWD demonstrated in experimentally infected mule deer and white-tailed deer. • Archived materials shared with other laboratories to advance overall progress on developing sensitive assays for prion detection in blood.&lt;br /&gt;&lt;br /&gt;PUBLICATIONS ARISING FROM GRANT WORK&lt;br /&gt;&lt;br /&gt;(2007) Chang, B., X. Cheng, S. Yin, T. Pan, H. Zhang, P. Wong, S.-C. Kang, F. Xiao, H. Yan, C. Li, L. L. Wolfe, M. W. Miller, T. Wisniewski, M. I. Greene, and M.-S. Sy.. Test for detection of disease-associated prion aggregate in the blood of infected but asymptomatic animals. Clinical and Vaccine Immunology 14:36-43.&lt;br /&gt;&lt;br /&gt;(2007) Wolfe, L. L., T. R. Spraker, L. González, M. P. Dagleish, T. M. Sirochman, J. C. Brown, M. Jeffrey, &amp;amp; M. W. Miller. PrPCWD in rectal lymphoid tissue of deer (Odocoileus spp.). Journal of General Virology 88: 2078-2082.&lt;br /&gt;&lt;br /&gt;(2008) Benjamin D. Brooks, Amy E. Albertson, Justin A. Jones, Jonathan O. Speare, Randolph V. Lewis, Efficient screening of high-signal and low-background antibody pairs in the bio-bar code assay using prion protein as the target, Analytical Biochemistry 382: 60-62.&lt;br /&gt;&lt;br /&gt;(2009) Brooks, Benjamin and Lewis, Randolph V. Identification of Problems Developing an Ultrasensitive Immunoassay for the Ante Mortem Detection of the Infectious Isoform of the CWD-Associated Prion Protein, Journal of Immunoassay and Immunochemistry, 30: 135– 139.&lt;br /&gt;&lt;br /&gt;OTHER COLLABORATIONS ARISING FROM GRANT WORK&lt;br /&gt;&lt;br /&gt;Surplus samples collected in the course of investigations supported by this grant have been shared with at least three other collaborating institutions (Rocky Mountain Laboratories, NIHNIAID; Case Western Reserve University; Institute for Neurodegenerative Diseases, University of California, San Francisco) in the hopes of advancing scientific understanding of CWD in particular and prion diseases in general. Other similar collaborative endeavors will be supported as feasible using materials arising from our work.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.dtic.mil/cgi-bin/GetTRDoc?AD=ADA511155&amp;amp;Location=U2&amp;amp;doc=GetTRDoc.pdf"&gt;http://www.dtic.mil/cgi-bin/GetTRDoc?AD=ADA511155&amp;amp;Location=U2&amp;amp;doc=GetTRDoc.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, April 03, 2008&lt;br /&gt;&lt;br /&gt;A prion disease of cervids: Chronic wasting disease&lt;br /&gt;&lt;br /&gt;2008 1: Vet Res. 2008 Apr 3;39(4):41&lt;br /&gt;&lt;br /&gt;A prion disease of cervids: Chronic wasting disease&lt;br /&gt;&lt;br /&gt;Sigurdson CJ.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;*** twenty-seven CJD patients who regularly consumed venison were reported to the Surveillance Center***,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;full text ;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2008/04/prion-disease-of-cervids-chronic.html"&gt;http://chronic-wasting-disease.blogspot.com/2008/04/prion-disease-of-cervids-chronic.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;From: TSS (216-119-163-189.ipset45.wt.net)&lt;br /&gt;&lt;br /&gt;Subject: CWD aka MAD DEER/ELK TO HUMANS ???&lt;br /&gt;&lt;br /&gt;Date: September 30, 2002 at 7:06 am PST&lt;br /&gt;&lt;br /&gt;From: "Belay, Ermias"&lt;br /&gt;&lt;br /&gt;To:&lt;br /&gt;&lt;br /&gt;Cc: "Race, Richard (NIH)" ; ; "Belay,&lt;br /&gt;&lt;br /&gt;Ermias"&lt;br /&gt;&lt;br /&gt;Sent: Monday, September 30, 2002 9:22 AM&lt;br /&gt;&lt;br /&gt;Subject: RE: TO CDC AND NIH - PUB MED- 3 MORE DEATHS - CWD - YOUNG HUNTERS&lt;br /&gt;&lt;br /&gt;Dear Sir/Madam,&lt;br /&gt;&lt;br /&gt;In the Archives of Neurology you quoted (the abstract of which was&lt;br /&gt;&lt;br /&gt;attached to your email), we did not say CWD in humans will present like&lt;br /&gt;&lt;br /&gt;variant CJD.&lt;br /&gt;&lt;br /&gt;That assumption would be wrong. I encourage you to read the whole&lt;br /&gt;&lt;br /&gt;article and call me if you have questions or need more clarification&lt;br /&gt;&lt;br /&gt;(phone: 404-639-3091). Also, we do not claim that "no-one has ever been&lt;br /&gt;&lt;br /&gt;infected with prion disease from eating venison." Our conclusion stating&lt;br /&gt;&lt;br /&gt;that we found no strong evidence of CWD transmission to humans in the&lt;br /&gt;&lt;br /&gt;article you quoted or in any other forum is limited to the patients we&lt;br /&gt;&lt;br /&gt;investigated.&lt;br /&gt;&lt;br /&gt;Ermias Belay, M.D.&lt;br /&gt;&lt;br /&gt;Centers for Disease Control and Prevention&lt;br /&gt;&lt;br /&gt;-----Original Message-----&lt;br /&gt;&lt;br /&gt;From:&lt;br /&gt;&lt;br /&gt;Sent: Sunday, September 29, 2002 10:15 AM&lt;br /&gt;&lt;br /&gt;To: rr26k@nih.gov; rrace@niaid.nih.gov; ebb8@CDC.GOV&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Subject: TO CDC AND NIH - PUB MED- 3 MORE DEATHS - CWD - YOUNG&lt;br /&gt;&lt;br /&gt;HUNTERS&lt;br /&gt;&lt;br /&gt;Sunday, November 10, 2002 6:26 PM ......snip........end..............TSS&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;SEE also ;&lt;br /&gt;&lt;br /&gt;A. Aguzzi - Chronic Wasting Disease (CWD) also needs to be addressed. Most&lt;br /&gt;&lt;br /&gt;serious because of rapid horizontal spread and higher prevalence than BSE in&lt;br /&gt;&lt;br /&gt;UK, up to 15% in some populations. Also may be a risk to humans - evidence&lt;br /&gt;&lt;br /&gt;that it is not dangerous to humans is thin.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;http://www.tseandfoodsafety.org/activities/bse_conference_basel_april_02/2summar&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;SNIP...END...TSS&lt;br /&gt;&lt;br /&gt;Chronic Wasting Disease and Potential Transmission to Humans&lt;br /&gt;&lt;br /&gt;Ermias D. Belay,* Ryan A. Maddox,* Elizabeth S. Williams,? Michael W. Miller,? Pierluigi Gambetti,§ and Lawrence B. Schonberger*&lt;br /&gt;&lt;br /&gt;*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ?University of Wyoming, Laramie, Wyoming, USA; ?Colorado Division of Wildlife, Fort Collins, Colorado, USA; and §Case Western Reserve University, Cleveland, Ohio, USA&lt;br /&gt;&lt;br /&gt;Suggested citation for this article: Belay ED, Maddox RA, Williams ES, Miller MW, Gambetti P, Schonberger LB. Chronic wasting disease and potential transmission to humans. Emerg Infect Dis [serial on the Internet]. 2004 Jun [date cited]. Available from:&lt;br /&gt;&lt;br /&gt;http://www.cdc.gov/ncidod/EID/vol10no6/03-1082.htm&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;----------------------------------------------------------&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Chronic wasting disease (CWD) of deer and elk is endemic in a tri-corner area of Colorado, Wyoming, and Nebraska, and new foci of CWD have been detected in other parts of the United States. Although detection in some areas may be related to increased surveillance, introduction of CWD due to translocation or natural migration of animals may account for some new foci of infection. Increasing spread of CWD has raised concerns about the potential for increasing human exposure to the CWD agent. The foodborne transmission of bovine spongiform encephalopathy to humans indicates that the species barrier may not completely protect humans from animal prion diseases. Conversion of human prion protein by CWD-associated prions has been demonstrated in an in vitro cell-free experiment, but limited investigations have not identified strong evidence for CWD transmission to humans. More epidemiologic and laboratory studies are needed to monitor the possibility of such transmissions.&lt;br /&gt;&lt;br /&gt;snip...full text ;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cdc.gov/ncidod/EID/vol10no6/03-1082.htm"&gt;http://www.cdc.gov/ncidod/EID/vol10no6/03-1082.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Volume 12, Number 10-October 2006&lt;br /&gt;&lt;br /&gt;Research&lt;br /&gt;&lt;br /&gt;Human Prion Disease and Relative Risk Associated with Chronic Wasting Disease&lt;br /&gt;&lt;br /&gt;Samantha MaWhinney,* W. John Pape,? Jeri E. Forster,* C. Alan Anderson,?§ Patrick Bosque,?¶ and Michael W. Miller#&lt;br /&gt;&lt;br /&gt;*University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA; ?Colorado Department of Public Health and Environment, Denver, Colorado, USA; ?University of Colorado School of Medicine, Denver, Colorado, USA; §Denver Veteran's Affairs Medical Center, Denver, Colorado, USA; ¶Denver Health Medical Center, Denver, Colorado, USA; and #Colorado Division of Wildlife, Fort Collins, Colorado, USA&lt;br /&gt;&lt;br /&gt;Suggested citation for this article&lt;br /&gt;&lt;br /&gt;The transmission of the prion disease bovine spongiform encephalopathy (BSE) to humans raises concern about chronic wasting disease (CWD), a prion disease of deer and elk. In 7 Colorado counties with high CWD prevalence, 75% of state hunting licenses are issued locally, which suggests that residents consume most regionally harvested game. We used Colorado death certificate data from 1979 through 2001 to evaluate rates of death from the human prion disease Creutzfeldt-Jakob disease (CJD). The relative risk (RR) of CJD for CWD-endemic county residents was not significantly increased (RR 0.81, 95% confidence interval [CI] 0.40-1.63), and the rate of CJD did not increase over time (5-year RR 0.92, 95% CI 0.73-1.16). In Colorado, human prion disease resulting from CWD exposure is rare or nonexistent. However, given uncertainties about the incubation period, exposure, and clinical presentation, the possibility that the CWD agent might cause human disease cannot be eliminated.&lt;br /&gt;&lt;br /&gt;snip... full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://0-www.cdc.gov.mill1.sjlibrary.org/ncidod/EID/vol12no10/06-0019.htm"&gt;http://0-www.cdc.gov.mill1.sjlibrary.org/ncidod/EID/vol12no10/06-0019.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2006_12_01_archive.html"&gt;http://chronic-wasting-disease.blogspot.com/2006_12_01_archive.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CHRONIC WASTING DISEASE BLOG&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/"&gt;http://chronic-wasting-disease.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Subject: BSE: TIME TO TAKE H.B. PARRY SERIOUSLY&lt;br /&gt;&lt;br /&gt;If the scrapie agent is generated from ovine DNA and thence causes disedase in other species, then perhaps, bearing in mind the possible role of scrpaie in CJD of humans (Davinpour et al, 1985), scrapie and not BSE should be the notifiable disease. ...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://collections.europarchive.org/tna/20090505194948/http://bseinquiry.gov.uk/files/yb/1988/06/08004001.pdf"&gt;http://collections.europarchive.org/tna/20090505194948/http://bseinquiry.gov.uk/files/yb/1988/06/08004001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://scrapie-usa.blogspot.com/2007/12/scrapie-hb-parry-seriously-yb886841.html"&gt;http://scrapie-usa.blogspot.com/2007/12/scrapie-hb-parry-seriously-yb886841.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1: J Infect Dis 1980 Aug;142(2):205-8&lt;br /&gt;&lt;br /&gt;Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to nonhuman primates.&lt;br /&gt;&lt;br /&gt;Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC.&lt;br /&gt;&lt;br /&gt;Kuru and Creutzfeldt-Jakob disease of humans and scrapie disease of sheep and goats were transmitted to squirrel monkeys (Saimiri sciureus) that were exposed to the infectious agents only by their nonforced consumption of known infectious tissues. The asymptomatic incubation period in the one monkey exposed to the virus of kuru was 36 months; that in the two monkeys exposed to the virus of Creutzfeldt-Jakob disease was 23 and 27 months, respectively; and that in the two monkeys exposed to the virus of scrapie was 25 and 32 months, respectively. Careful physical examination of the buccal cavities of all of the monkeys failed to reveal signs or oral lesions. One additional monkey similarly exposed to kuru has remained asymptomatic during the 39 months that it has been under observation.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;The successful transmission of kuru, Creutzfeldt-Jakob disease, and scrapie by natural feeding to squirrel monkeys that we have reported provides further grounds for concern that scrapie-infected meat may occasionally give rise in humans to Creutzfeldt-Jakob disease.&lt;br /&gt;&lt;br /&gt;PMID: 6997404&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=6997404&amp;amp;dopt=Abstract"&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=6997404&amp;amp;dopt=Abstract&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Recently the question has again been brought up as to whether scrapie is transmissible to man. This has followed reports that the disease has been transmitted to primates. One particularly lurid speculation (Gajdusek 1977) conjectures that the agents of scrapie, kuru, Creutzfeldt-Jakob disease and transmissible encephalopathy of mink are varieties of a single "virus". The U.S. Department of Agriculture concluded that it could "no longer justify or permit scrapie-blood line and scrapie-exposed sheep and goats to be processed for human or animal food at slaughter or rendering plants" (ARC 84/77)" The problem is emphasised by the finding that some strains of scrapie produce lesions identical to the once which characterise the human dementias"&lt;br /&gt;&lt;br /&gt;Whether true or not. the hypothesis that these agents might be transmissible to man raises two considerations. First, the safety of laboratory personnel requires prompt attention. Second, action such as the "scorched meat" policy of USDA makes the solution of the acrapie problem urgent if the sheep industry is not to suffer grievously.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;76/10.12/4.6&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20010305223125/www.bseinquiry.gov.uk/files/yb/1976/10/12004001.pdf"&gt;http://web.archive.org/web/20010305223125/www.bseinquiry.gov.uk/files/yb/1976/10/12004001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Nature. 1972 Mar 10;236(5341):73-4.&lt;br /&gt;&lt;br /&gt;Transmission of scrapie to the cynomolgus monkey (Macaca fascicularis). Gibbs CJ Jr, Gajdusek DC.&lt;br /&gt;&lt;br /&gt;Nature 236, 73 - 74 (10 March 1972); doi:10.1038/236073a0&lt;br /&gt;&lt;br /&gt;Transmission of Scrapie to the Cynomolgus Monkey (Macaca fascicularis)&lt;br /&gt;&lt;br /&gt;C. J. GIBBS jun. &amp;amp; D. C. GAJDUSEK&lt;br /&gt;&lt;br /&gt;National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland&lt;br /&gt;&lt;br /&gt;SCRAPIE has been transmitted to the cynomolgus, or crab-eating, monkey (Macaca fascicularis) with an incubation period of more than 5 yr from the time of intracerebral inoculation of scrapie-infected mouse brain. The animal developed a chronic central nervous system degeneration, with ataxia, tremor and myoclonus with associated severe scrapie-like pathology of intensive astroglial hypertrophy and proliferation, neuronal vacuolation and status spongiosus of grey matter. The strain of scrapie virus used was the eighth passage in Swiss mice (NIH) of a Compton strain of scrapie obtained as ninth intracerebral passage of the agent in goat brain, from Dr R. L. Chandler (ARC, Compton, Berkshire).&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nature.com/nature/journal/v236/n5341/abs/236073a0.html"&gt;http://www.nature.com/nature/journal/v236/n5341/abs/236073a0.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;EMBO reports 4, 5, 530–533 (2003) doi:10.1038/sj.embor.embor827 AOP Published online: 11 April 2003&lt;br /&gt;&lt;br /&gt;Widespread PrPSc accumulation in muscles of hamsters orally infected with scrapie&lt;br /&gt;&lt;br /&gt;Achim Thomzig, Christine Kratzel, Gudrun Lenz, Dominique Krüger &amp;amp; Michael Beekes&lt;br /&gt;&lt;br /&gt;Robert Koch-Institut, P26, Nordufer 20, D-13353 Berlin, Germany&lt;br /&gt;&lt;br /&gt;To whom correspondence should be addressed Michael Beekes Tel: +49 30 4547 2396; Fax: +49 30 4547 2609; BeekesM@rki.de&lt;br /&gt;&lt;br /&gt;Received 13 February 2003; Accepted 13 March 2003; Published online 11 April 2003.&lt;br /&gt;&lt;br /&gt;Abstract&lt;br /&gt;&lt;br /&gt;Scrapie, bovine spongiform encephalopathy and chronic wasting disease are orally communicable, transmissible spongiform encephalopathies (TSEs). As zoonotic transmissions of TSE agents may pose a risk to human health, the identification of reservoirs for infectivity in animal tissues and their exclusion from human consumption has become a matter of great importance for consumer protection. In this study, a variety of muscles from hamsters that were orally challenged with scrapie was screened for the presence of a molecular marker for TSE infection, PrPSc (the pathological isoform of the prion protein PrP). Sensitive western blotting revealed consistent PrPSc accumulation in skeletal muscles from forelimb and hindlimb, head, back and shoulder, and in tongue. Previously, our animal model has provided substantial baseline information about the peripheral routing of infection in naturally occurring and orally acquired ruminant TSEs. Therefore, the findings described here highlight further the necessity to investigate thoroughly whether muscles of TSE-infected sheep, cattle, elk and deer contain infectious agents.&lt;br /&gt;&lt;br /&gt;EMBO reports 4, 5, 530–533 (2003) doi:10.1038/sj.embor.embor827 AOP Published online: 11 April 2003&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nature.com/embor/journal/v4/n5/full/embor827.html"&gt;http://www.nature.com/embor/journal/v4/n5/full/embor827.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Greetings,&lt;br /&gt;&lt;br /&gt;Unusual event if you consider the officials hypothisis that Nor-98 atypical scrapie is a spontaneous event. seems there was a great deal of spontaneous mutations for the this time period ;-)...TSS&lt;br /&gt;&lt;br /&gt;Atypical Nor-98 states in this report for January 2010 include ; Maine, Pennsylvania, Ohio, and Oregon&lt;br /&gt;&lt;br /&gt;kind regards, terry&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, December 14, 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Similarities between Forms of Sheep Scrapie and Creutzfeldt-Jakob Disease Are Encoded by Distinct Prion Types&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;hmmm, this is getting interesting now...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sporadic CJD type 1 and atypical/ Nor98 scrapie are characterized by fine (reticular) deposits,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;see also ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;All of the Heidenhain variants were of the methionine/ methionine type 1 molecular subtype.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdusa.blogspot.com/2009/09/co-existence-of-scrapie-prion-protein.html"&gt;http://cjdusa.blogspot.com/2009/09/co-existence-of-scrapie-prion-protein.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;see full text ;&lt;br /&gt;&lt;br /&gt;Monday, December 14, 2009&lt;br /&gt;&lt;br /&gt;Similarities between Forms of Sheep Scrapie and Creutzfeldt-Jakob Disease Are Encoded by Distinct Prion Types&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2009/12/similarities-between-forms-of-sheep.html"&gt;http://nor-98.blogspot.com/2009/12/similarities-between-forms-of-sheep.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sent: Friday, April 16, 2010 11:38 AM Subject: PRO-MED ATYPICAL SCRAPIE&lt;br /&gt;&lt;br /&gt;Background ----------- "Retrospective studies have identified cases predating the initial identification of this form of scrapie, and epidemiological studies have indicated that it does not conform to the behaviour of an infectious disease, giving rise to the hypothesis that it represents spontaneous disease. However, atypical scrapie isolates have been shown to be infectious experimentally, through intracerebral inoculation in transgenic mice and sheep. [Many of the neurological diseases can be transmitted by intracerebral inoculation, which causes this moderator to approach intracerebral studies as a tool for study, but not necessarily as a direct indication of transmissibility of natural diseases. - Mod.TG]&lt;br /&gt;&lt;br /&gt;"The 1st successful challenge of a sheep with 'field' atypical scrapie from an homologous donor sheep was reported in 2007.&lt;br /&gt;&lt;br /&gt;"Results -------- "This study demonstrates that atypical scrapie has distinct clinical, pathological, and biochemical characteristics which are maintained on transmission and sub-passage, and which are distinct from other strains of transmissible spongiform encephalopathies in the same host genotype.&lt;br /&gt;&lt;br /&gt;"Conclusions ------------ Atypical scrapie is consistently transmissible within AHQ homozygous sheep, and the disease phenotype is preserved on sub-passage."&lt;br /&gt;&lt;br /&gt;Lastly, this moderator wishes to thank Terry Singletary for some of his behind the scenes work of providing citations and references for this posting. - Mod.TG]&lt;br /&gt;&lt;br /&gt;The HealthMap/ProMED-mail interactive map of Australia is available at &lt;http:&gt;. - Sr.Tech.Ed.MJ]&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.promedmail.org/pls/otn/f?p=2400:1001:962575216785367::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,81729"&gt;http://www.promedmail.org/pls/otn/f?p=2400:1001:962575216785367::NO::F2400_P1001_BACK_PAGE,F2400_P1001_PUB_MAIL_ID:1000,81729&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please see full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, April 18, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;SCRAPIE AND ATYPICAL SCRAPIE TRANSMISSION STUDIES A REVIEW 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://scrapie-usa.blogspot.com/2010/04/scrapie-and-atypical-scrapie.html"&gt;http://scrapie-usa.blogspot.com/2010/04/scrapie-and-atypical-scrapie.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;NOW WHAT ABOUT THE INFAMOUS AUGUST 4, 1997 PARTIAL AND VOLUNTARY MAD COW FEED BAN ???&lt;br /&gt;&lt;br /&gt;nothing but ink on paper $$$&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, April 5, 2010&lt;br /&gt;&lt;br /&gt;Update on Feed Enforcement Activities to Limit the Spread of BSE April 5, 2010&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/04/update-on-feed-enforcement-activities.html"&gt;http://madcowfeed.blogspot.com/2010/04/update-on-feed-enforcement-activities.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr. (Submitted question): Monday, March 1, 2010&lt;br /&gt;&lt;br /&gt;ANIMAL PROTEIN I.E. MAD COW FEED IN COMMERCE A REVIEW 2010&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/03/animal-protien-ie-mad-cow-feed-in.html"&gt;http://madcowfeed.blogspot.com/2010/03/animal-protien-ie-mad-cow-feed-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;10,000,000+ LBS. of PROHIBITED BANNED MAD COW FEED I.E. BLOOD LACED MBM IN COMMERCE USA 2007&lt;br /&gt;&lt;br /&gt;Date: March 21, 2007 at 2:27 pm PST RECALLS AND FIELD CORRECTIONS: VETERINARY MEDICINES -- CLASS II&lt;br /&gt;&lt;br /&gt;___________________________________&lt;br /&gt;&lt;br /&gt;PRODUCT Bulk cattle feed made with recalled Darling's 85% Blood Meal, Flash Dried, Recall # V-024-2007 CODE Cattle feed delivered between 01/12/2007 and 01/26/2007 RECALLING FIRM/MANUFACTURER Pfeiffer, Arno, Inc, Greenbush, WI. by conversation on February 5, 2007. Firm initiated recall is ongoing. REASON Blood meal used to make cattle feed was recalled because it was cross- contaminated with prohibited bovine meat and bone meal that had been manufactured on common equipment and labeling did not bear cautionary BSE statement.&lt;br /&gt;&lt;br /&gt;VOLUME OF PRODUCT IN COMMERCE 42,090 lbs.&lt;br /&gt;&lt;br /&gt;DISTRIBUTION WI&lt;br /&gt;&lt;br /&gt;___________________________________&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr. (Submitted question):&lt;br /&gt;&lt;br /&gt;PRODUCT Custom dairy premix products: MNM ALL PURPOSE Pellet, HILLSIDE/CDL Prot- Buffer Meal, LEE, M.-CLOSE UP PX Pellet, HIGH DESERT/ GHC LACT Meal, TATARKA, M CUST PROT Meal, SUNRIDGE/CDL PROTEIN Blend, LOURENZO, K PVM DAIRY Meal, DOUBLE B DAIRY/GHC LAC Mineral, WEST PIONT/GHC CLOSEUP Mineral, WEST POINT/GHC LACT Meal, JENKS, J/COMPASS PROTEIN Meal, COPPINI - 8# SPECIAL DAIRY Mix, GULICK, L-LACT Meal (Bulk), TRIPLE J - PROTEIN/LACTATION, ROCK CREEK/GHC MILK Mineral, BETTENCOURT/GHC S.SIDE MK-MN, BETTENCOURT #1/GHC MILK MINR, V&amp;amp;C DAIRY/GHC LACT Meal, VEENSTRA, F/GHC LACT Meal, SMUTNY, A- BYPASS ML W/SMARTA, Recall # V-025-2007 CODE The firm does not utilize a code - only shipping documentation with commodity and weights identified. RECALLING FIRM/MANUFACTURER Rangen, Inc, Buhl, ID, by letters on February 13 and 14, 2007. Firm initiated recall is complete. REASON Products manufactured from bulk feed containing blood meal that was cross contaminated with prohibited meat and bone meal and the labeling did not b Terry S. Singeltary Sr. (Submitted question): Products manufactured from bulk feed containing blood meal that was cross contaminated with prohibited meat and bone meal and the labeling did not bear cautionary BSE statement.&lt;br /&gt;&lt;br /&gt;VOLUME OF PRODUCT IN COMMERCE&lt;br /&gt;&lt;br /&gt;9,997,976 lbs.&lt;br /&gt;&lt;br /&gt;DISTRIBUTION&lt;br /&gt;&lt;br /&gt;ID and NV&lt;br /&gt;&lt;br /&gt;END OF ENFORCEMENT REPORT FOR MARCH 21, 2007&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;http://www.fda.gov/bbs/topics/enforce/2007/ENF00996.html&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;NEW URL&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.fda.gov/Safety/Recalls/EnforcementReports/2007/ucm120446.htm"&gt;http://www.fda.gov/Safety/Recalls/EnforcementReports/2007/ucm120446.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr. (Submitted question): Monday, March 8, 2010&lt;br /&gt;&lt;br /&gt;UPDATE 429,128 lbs. feed for ruminant animals may have been contaminated with prohibited material Recall # V-258-2009&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/03/update-429128-lbs-feed-for-ruminant.html"&gt;http://madcowfeed.blogspot.com/2010/03/update-429128-lbs-feed-for-ruminant.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;see canine spongiform encephalopathysee full text, and be sure to read the BSE Inquiry documents toward the bottom ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://caninespongiformencephalopathy.blogspot.com/2010/03/canine-spongiform-encephalopathy-aka.html"&gt;http://caninespongiformencephalopathy.blogspot.com/2010/03/canine-spongiform-encephalopathy-aka.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://caninespongiformencephalopathy.blogspot.com/"&gt;http://caninespongiformencephalopathy.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, March 19, 2009&lt;br /&gt;&lt;br /&gt;MILLIONS AND MILLIONS OF POUNDS OF MAD COW FEED IN COMMERCE USA WITH ONGOING 12 YEARS OF DENIAL&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/03/millions-and-millions-of-pounds-of-mad.html"&gt;http://madcowfeed.blogspot.com/2009/03/millions-and-millions-of-pounds-of-mad.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, April 23, 2010&lt;br /&gt;&lt;br /&gt;Upcoming BSE Webinar on Thursday, April 22, 2010 a review&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bseusa.blogspot.com/2010/04/upcoming-bse-webinar-on-thursday-april.html"&gt;http://bseusa.blogspot.com/2010/04/upcoming-bse-webinar-on-thursday-april.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD USA RISING, with UNKNOWN PHENOTYPE ;&lt;br /&gt;&lt;br /&gt;5 Includes 41 cases in which the diagnosis is pending, and 17 inconclusive cases; 6 Includes 46 cases with type determination pending in which the diagnosis of vCJD has been excluded.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cjdsurveillance.com/pdf/case-table.pdf"&gt;http://www.cjdsurveillance.com/pdf/case-table.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, January 2, 2010&lt;br /&gt;&lt;br /&gt;Human Prion Diseases in the United States January 1, 2010 ***FINAL***&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;my comments to PLosone here ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd"&gt;http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, February 05, 2010&lt;br /&gt;&lt;br /&gt;New Variant Creutzfelt Jakob Disease case reports United States 2010 A Review&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html"&gt;http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;WHY does the O.I.E. recognize the U.S.A. and all of North America as a BSE controled risk, even though the G.A.O. and the O.I.G repeatedly reported of the failures and flaws of not only the BSE surveillance program in the USA, also the ruminant feed ban of August 4, 1997, where it still fails today in 2010 ?&lt;br /&gt;&lt;br /&gt;Wednesday, April 28, 2010&lt;br /&gt;&lt;br /&gt;BSE, Scrapie, CWD, REPORT OF THE MEETING OF THE OIE TERRESTRIAL ANIMAL HEALTH STANDARDS COMMISSION Paris, 8-12 February 2010&lt;br /&gt;&lt;br /&gt;REPORT OF THE MEETING OF THE OIE TERRESTRIAL ANIMAL&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://usdameatexport.blogspot.com/2010/04/bse-scrapie-cwd-report-of-meeting-of.html"&gt;http://usdameatexport.blogspot.com/2010/04/bse-scrapie-cwd-report-of-meeting-of.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, May 11, 2010&lt;br /&gt;&lt;br /&gt;Current risk of iatrogenic Creutzfeld-Jakob disease in the UK: efficacy of available cleaning chemistries and reusability of neurosurgical instruments&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/05/current-risk-of-iatrogenic.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/05/current-risk-of-iatrogenic.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, May 06, 2010&lt;br /&gt;&lt;br /&gt;Sporadic Creutzfeldt-Jakob disease mimicking nonconvulsive status epilepticus&lt;br /&gt;&lt;br /&gt;Published online before print May 5, 2010 (Neurology 2010, doi:10.1212/WNL.0b013e3181e39703)&lt;br /&gt;&lt;br /&gt;Received November 10, 2009 Accepted March 9, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/05/sporadic-creutzfeldt-jakob-disease.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/05/sporadic-creutzfeldt-jakob-disease.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;WHO WILL WATCH THE CHILDREN FOR CJD OVER THE NEXT 5 + DECADES ???&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;For 4+ years, dead stock downer cows, the most high risk cattle for mad cow type disease, and other deadly pathogens, were fed to our kids, via the NSLP and the USDA all across our Nation.&lt;br /&gt;&lt;br /&gt;Do you actually believe that the USDA et al jumped in on the law suit against Westland/Hallmark, at the time the largest beef recall in USA history, just because a few animals were abused on a video, or to cover their ass, for letting our children, from school district to school district, from state to state, be fed dead stock downer cows.&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; In the papers, the government alleges the meatpacking plant slaughtered and processed downer cows for nearly four years - from January 2004 to September 2007 - at the average rate of one every six weeks... &lt;&lt;&lt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://downercattle.blogspot.com/2009/09/suit-meatpacker-used-downer-cows-for-4.html"&gt;http://downercattle.blogspot.com/2009/09/suit-meatpacker-used-downer-cows-for-4.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Do you actually believe all these schools recalled this meat because of a few cattle being abused, see list ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;FNS All Regions Affected School Food Authorities By State United States Department of Agriculture Food and Nutrition Service National School Lunch Program March 24, 2008 School Food Authorities Affected by Hallmark/Westland Meat Packing Co. Beef Recall February 2006 - February 2008&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.fns.usda.gov/fns/safety/Hallmark-Westland_byState.pdf"&gt;http://www.fns.usda.gov/fns/safety/Hallmark-Westland_byState.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;IF url does not work above, go to this link to find out if any of your children and their school were part of this recall ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;go to this site ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.fns.usda.gov/fns/"&gt;http://www.fns.usda.gov/fns/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;left hand corner search ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Hallmark/Westland Meat Packing Co. Beef Recall your should get this ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://65.216.150.153/texis/search?pr=FNS"&gt;http://65.216.150.153/texis/search?pr=FNS&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1 through 1 of 1 matching documents, best matches first. sort by date 1: Hallmark - Westland SFA Reporting by State - 3-24-2008.xls Lunch Program March 24, 2008 School Food Authorities Affected by Hallmark/Westland Meat Packing Co. Beef Recall February 2006 - February 2008 The U.S. Department of Agriculture ...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.fns.usda.gov/...ety/Hallmark-Westland_byState.pdf"&gt;http://www.fns.usda.gov/...ety/Hallmark-Westland_byState.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;PLEASE SEE ALSO ; Members of The HSUS are also concerned about the meat products provided to their children through the National School Lunch Program. More than 31 million school children receive lunches through the program each school day. To assist states in providing healthful, low-cost or free meals, USDA provides states with various commodities including ground beef. As evidenced by the HallmarkNVestland investigation and recall, the potential for downed animals to make their way into the National School Lunch Program is neither speculative nor hypothetical.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://biotech.law.lsu.edu/cases/FDA/hsus-v-schafer-usda-complaint.pdf"&gt;http://biotech.law.lsu.edu/cases/FDA/hsus-v-schafer-usda-complaint.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;some history on dead stock downers in the USA ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Over the next 8-10 weeks, approximately 40% of all the adult mink on the farm died from TME.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The rancher was a ''dead stock'' feeder using mostly (&gt;95%) downer or dead dairy cattle...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20030516051623/http://www.bseinquiry.gov.uk/files/mb/m09/tab05.pdf"&gt;http://web.archive.org/web/20030516051623/http://www.bseinquiry.gov.uk/files/mb/m09/tab05.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TME&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissible-mink-encephalopathy.blogspot.com/2009/07/transmissible-mink-encephalopathy.html"&gt;http://transmissible-mink-encephalopathy.blogspot.com/2009/07/transmissible-mink-encephalopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissible-mink-encephalopathy.blogspot.com/2007/12/phenotypic-similarity-of-transmissible.html"&gt;http://transmissible-mink-encephalopathy.blogspot.com/2007/12/phenotypic-similarity-of-transmissible.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissible-mink-encephalopathy.blogspot.com/"&gt;http://transmissible-mink-encephalopathy.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, April 12, 2010&lt;br /&gt;&lt;br /&gt;Senator Kay Bailey Hutchison says NO to safer food and S. 510 FDA Food Safety Modernization Act of 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://fdafailedus.blogspot.com/2010/04/senator-kay-bailey-hutchison-says-no-to.html"&gt;http://fdafailedus.blogspot.com/2010/04/senator-kay-bailey-hutchison-says-no-to.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr. P.O. Box 42 Bacliff, Texas USA 77518&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6604160603980694949-1430870360933696482?l=prionunitusaupdate2008.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://prionunitusaupdate2008.blogspot.com/feeds/1430870360933696482/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=6604160603980694949&amp;postID=1430870360933696482' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/1430870360933696482'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/1430870360933696482'/><link rel='alternate' type='text/html' href='http://prionunitusaupdate2008.blogspot.com/2010/05/final-report-of-national-prion-research.html' title='The Final Report of the National Prion Research Program 2007 (updated 2010)'/><author><name>Terry S. Singeltary Sr.</name><uri>http://www.blogger.com/profile/06986622967539963260</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='22' src='http://bp2.blogger.com/_gwMAfd8g9xo/SHuerfBUR1I/AAAAAAAAAAM/nNI1xcLm_Z4/S220/scan0002.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6604160603980694949.post-3478169181392281947</id><published>2010-04-05T11:43:00.000-07:00</published><updated>2010-04-05T11:49:30.338-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='Prion Unit CWRU'/><category scheme='http://www.blogger.com/atom/ns#' term='Texas'/><category scheme='http://www.blogger.com/atom/ns#' term='CJD'/><category scheme='http://www.blogger.com/atom/ns#' term='38 year old'/><title type='text'>UPDATE - CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER</title><content type='html'>----- Original Message -----&lt;br /&gt;&lt;br /&gt;From: Katie Glisic&lt;br /&gt;To: Terry S. Singeltary Sr.&lt;br /&gt;Sent: Monday, April 05, 2010 7:39 AM&lt;br /&gt;Subject: Re: [cjdsurv] CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Dear Mr. Singelteary,&lt;br /&gt;&lt;br /&gt;Thank you for contacting the Center. We are aware of Ms. Andablo's case and are in the process of testing, however thank you very much for the enclosed information. As you are aware, there have been no confirmed cases of vCJD (Mad Cow) contracting in the United States. The Center has been testing and diagnosing cases of CJD for over 10 years and reporting our findings to the Centers for Disease Control and Prevention. Of the two cases we have documented, neither was contracting in the US. One was contracted in the UK where cases of Mad Cow are known and one was contracted in Saudi Arabia.&lt;br /&gt;&lt;br /&gt;Please note, we also performed the testing on Ms. Vinson and her family is well informed of the diagnosis provided by the Center. The United States government as well as the USDA go to great lengths to ensure that the US beef consumed by our country is both safe and continually tested to prevent outbreaks of food born illnesses such as Mad Cow. Please rest assured that Dr. Gambetti and the rest of the Center's researchers work tirelessly to provide accurate diagnosis to families with loved ones suffering from CJD.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;On Fri, Apr 2, 2010 at 12:38 PM, Terry S. Singeltary Sr. &lt;flounder9@verizon.net&gt;wrote:&lt;br /&gt;&lt;br /&gt;Greetings Professor Gambetti Sir,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;A kind greetings from sunny Bacliff, Texas !&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sadly, i thought i should pass this data to you. You are probably much aware of this, but it seems odd that no media has commented? also, the last suspect nvCJD case i remember here in the USA, it was the USDA that the so called 'confidentiality agreements between family', and came out officially first and over ruled the nvCJD and called in sporadic CJD, well, i don't think they ever even officially called it that, but Aretha N. Vinson family knows what she had, and PD Notebook won in the end ;&lt;br /&gt;&lt;br /&gt;Portsmouth woman did not die of mad cow-related condition, ___USDA___ says&lt;br /&gt;&lt;br /&gt;By Nancy Young The Virginian-Pilot © May 7, 2008&lt;br /&gt;&lt;br /&gt;(towards the end of this blog...tss)&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-atypical-bse.html"&gt;http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-atypical-bse.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Professor Gambetti Sir, Thank You for your continued work on TSE and all. ....&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Kindest Regard and very Respectfully,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr.&lt;br /&gt;P.O. Box 42&lt;br /&gt;Bacliff, Texas USA 77518&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; Up until about 6 years ago, the pt worked at Tyson foods where she worked on the assembly line, slaughtering cattle and preparing them for packaging. She was exposed to brain and spinal cord matter when she would euthanize the cattle. &lt;&lt;&lt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010 in Mesquite Texas&lt;br /&gt;&lt;br /&gt;Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010 in Mesquite Texas. She left 6 Kids and a Husband.The Purpose of this web is to give information in Spanish to the Hispanic community, and to all the community who want's information about this terrible disease.- Physician Discharge Summary, Parkland Hospital, Dallas Texas Admit Date: 12/29/2009 Discharge Date: 1/20/2010 Attending Provider: Greenberg, Benjamin Morris; General Neurology Team: General Neurology Team Linda was a Hispanic female with no past medical history presents with 14 months of incresing/progressive altered mental status, generalized weakness, inability to walk, loss of appetite, inability to speak, tremor and bowel/blader incontinence.She was, in her usual state of health up until February, 2009, when her husbans notes that she began forgetting things like names and short term memories. He also noticed mild/vague personality changes such as increased aggression. In March, she was involved in a hit and run MVA,although she was not injured. The police tracked her down and ticketed her. At that time, her son deployed to Iraq with the Army and her husband assumed her mentation changes were due to stress over these two events. Also in March, she began to have weakness in her legs, making it difficult to walk. Over the next few months, her mentation and personality changes worsened, getting to a point where she could no longer recognized her children. She was eating less and less. She was losing more weight. In the last 2-3 months, she reached the point where she could not walk without an assist, then 1 month ago, she stopped talking, only making grunting/aggressive sounds when anyone came near her. She also became both bowel and bladder incontinent, having to wear diapers. Her '"tremor'" and body jerks worsened and her hands assumed a sort of permanent grip position, leading her family to put tennis balls in her hands to protect her fingers. The husband says that they have lived in Nebraska for the past 21 years. They had seen a doctor there during the summer time who prescribed her Seroquel and Lexapro, Thinking these were sx of a mood disorder. However, the medications did not help and she continued to deteriorate clinically. Up until about 6 years ago, the pt worked at Tyson foods where she worked on the assembly line, slaughtering cattle and preparing them for packaging. She was exposed to brain and spinal cord matter when she would euthanize the cattle. The husband says that he does not know any fellow workers with a similar illness. He also says that she did not have any preceeding illness or travel.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8"&gt;http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; Up until about 6 years ago, the pt worked at Tyson foods where she worked on the assembly line, slaughtering cattle and preparing them for packaging. She was exposed to brain and spinal cord matter when she would euthanize the cattle. &lt;&lt;&lt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Irma Linda Andablo, victima de CJD&lt;br /&gt;&lt;br /&gt;"...padeció durante un año de CJD Esporádico, Falleció a la edad de 38 años en la ciudad de Mesquite Texas un 6 de Febrero del año 2010" Irma Linda Martinez nació en el pueblo de Batesville Texas un 17 de mayo de 1971, padeció durante un año de CJD Esporádico (mal de la vaca loca conocido en español) Falleció a la edad de 38 años en la ciudad de Mesquite Texas un 6 de Febrero del año 2010. A continuación describiremos datos de su padecimiento: Se casó a la edad de 16 años con Everardo Andablo (Lalo) ella residió en Lexington Nebraska, desde ese entonces, trabajó aproximadamente 11 años en una compañia de matanza de vacas y procesadora de carne (Tyson) ella trabajaba en el rastro o el área de matanza, para el 2008 ella trabajaba como agente de seguridad para esta misma compañia, para ese entonces ella empezó a presentar cambios en su vida, su próximo trabajo fue en Subway dentro de una tienda comercial, donde los cambios de salud empezaron a ser muy notorios pues empezó a perder mucho peso, de 237 L de su peso normal empezó perdiendo 24 L en menos de un mes, esto era sorprendente!!! fué entonces cuando dejó el trabajo en febrero del 2009, de repente empezó a olvidar datos importantes. La siguiente información es una traducción pertenece al comunicado que el equipo de neurologia del hospital Parkland en la ciudad de Dallas Texas liberó a su salida, después de haber estado internada del 29 de diciembre del 2009 a enero 20 del 2010, en este comunicado se encuentra el historial tanto médico como de sintomas presentados en Linda: Physician Discharge Summary : (traducido y adaptado) "...Mujer de 38 años presento 10 meses de una estado mental progresivo y alterado, con debilidad general, temblor, inhabilidad para caminar, para hablar, con pérdida de apetito e incontinencia de esfínteres, ella empezó a mostrar debilidad en las piernas, durante los siguientes meses su estado mental se agravó al tanto que ella no conoció más a sus propios hijos" "El 29 de Diciembre del 2009 Fué admitida en el Hospital Parkland de Dallas por demencia de acuerdo a los síntomas de presentaba, Mujer de 38 años presentó 14 meses de una estado mental progresivo y alterado, con debilidad general, temblor, inhabilidad para caminar, para hablar, con pérdida de apetito e incontinencia de esfinteres. Ella empezó a olvidar los nombres de las personas que la rodeaban, datos importantes personales, también presentó algunos cambios de personalidad como incremento de agresión.Para el mes de Marzo del 2008 ella empezó a mostrar debilidad en las piernas, durante los siguientes meses su estado mental se agravó al tanto que ella no conoció más a sus propios hijos (6 hijos), ella cada vez comia menos, cada vez perdia más peso.Para el tiempo que ella arrivo a Dallas para la navidad del 2009 ella no caminaba en lo absoluto, no hablaba solo hacia sonidos agresivos cuando alguien se acercaba a ella, el temblor en sus manos empezó a ser más fuerte, sus manos solo tenian posición de sostener algo fuerte, ella siempre... Read more...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.recordandoalinda.com/"&gt;http://www.recordandoalinda.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;"...padeció durante un año de CJD Esporádico, Falleció a la edad de 38 años en la ciudad de Mesquite Texas un 6 de Febrero del año 2010"&lt;br /&gt;&lt;br /&gt;Irma Linda Martinez nació en el pueblo de Batesville Texas un 17 de mayo de 1971, padeció durante un año de CJD Esporádico (mal de la vaca loca conocido en español) Falleció a la edad de 38 años en la ciudad de Mesquite Texas un 6 de Febrero del año 2010.&lt;br /&gt;&lt;br /&gt;A continuación describiremos datos de su padecimiento:&lt;br /&gt;&lt;br /&gt;Se casó a la edad de 16 años con Everardo Andablo (Lalo) ella residió en Lexington Nebraska, desde ese entonces, trabajó aproximadamente 11 años en una compañia de matanza de vacas y procesadora de carne (Tyson) ella trabajaba en el rastro o el área de matanza, para el 2008 ella trabajaba como agente de seguridad para esta misma compañia, para ese entonces ella empezó a presentar cambios en su vida, su próximo trabajo fue en Subway dentro de una tienda comercial, donde los cambios de salud empezaron a ser muy notorios pues empezó a perder mucho peso, de 237 L de su peso normal empezó perdiendo 24 L en menos de un mes, esto era sorprendente!!! fué entonces cuando dejó el trabajo en febrero del 2009, de repente empezó a olvidar datos importantes.&lt;br /&gt;&lt;br /&gt;La siguiente información es una traducción pertenece al comunicado que el equipo de neurologia del hospital Parkland en la ciudad de Dallas Texas liberó a su salida, después de haber estado internada del 29 de diciembre del 2009 a enero 20 del 2010, en este comunicado se encuentra el historial tanto médico como de sintomas presentados en Linda:&lt;br /&gt;&lt;br /&gt;Physician Discharge Summary : (traducido y adaptado)&lt;br /&gt;&lt;br /&gt;"...Mujer de 38 años presento 10 meses de una estado mental progresivo y alterado, con debilidad general, temblor, inhabilidad para caminar, para hablar, con pérdida de apetito e incontinencia de esfínteres, ella empezó a mostrar debilidad en las piernas, durante los siguientes meses su estado mental se agravó al tanto que ella no conoció más a sus propios hijos"&lt;br /&gt;&lt;br /&gt;"El 29 de Diciembre del 2009 Fué admitida en el Hospital Parkland de Dallas por demencia de acuerdo a los síntomas de presentaba, Mujer de 38 años presentó 14 meses de una estado mental progresivo y alterado, con debilidad general, temblor, inhabilidad para caminar, para hablar, con pérdida de apetito e incontinencia de esfinteres. Ella empezó a olvidar los nombres de las personas que la rodeaban, datos importantes personales, también presentó algunos cambios de personalidad como incremento de agresión.Para el mes de Marzo del 2008 ella empezó a mostrar debilidad en las piernas, durante los siguientes meses su estado mental se agravó al tanto que ella no conoció más a sus propios hijos (6 hijos), ella cada vez comia menos, cada vez perdia más peso.Para el tiempo que ella arrivo a Dallas para la navidad del 2009 ella no caminaba en lo absoluto, no hablaba solo hacia sonidos agresivos cuando alguien se acercaba a ella, el temblor en sus manos empezó a ser más fuerte, sus manos solo tenian posición de sostener algo fuerte, ella siempre portaba pelotas pequeñas para que no se lastimara con sus propias uñas"&lt;br /&gt;&lt;br /&gt;En terminos Médicos ella prensento un desorden mental con ansiedad y pérdida del habla y contracciones en los musculos que la inmobilizaba. Esto llevo a los médicos a predecir el diagnostico de CJD esporádico o variante, después de reuniones familiares se llego al acuerdo de no proseguir con los exámenes indicados como una biopsia cerebral debido al estado de debilidad y gravedad de ella, pues peligraba su vida y por consiguiente peligraban los médicos que le aplicarian el exámen ya que es demasiado contagioso.&lt;br /&gt;&lt;br /&gt;Ella fué dada de alta con el diagnostico de CJD Esporádico, sin medicamento y con pocas esperanzas y semanas de vida.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=2:frontpage&amp;amp;catid=1:frontpage"&gt;http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=2:frontpage&amp;amp;catid=1:frontpage&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please see full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, March 29, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010 in Mesquite Texas&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/03/irma-linda-andablo-cjd-victim-she-died.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/03/irma-linda-andablo-cjd-victim-she-died.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html"&gt;http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;YOU can be assured they are squirming behind closed doors, and that they are doing there best to squirm right out of this one. they will come up with something, international travel long ago, or some strange PRNP mutation that they might say like sporadic ffi ??? or a case of atypical case of inherited Creutzfeldt-Jakob disease (CJD) ??? they will make up something. but it will be anything but BSE related here in the USA, in my opinion. sporadic FFI, or sporadic GSS, or sporadic inherited CJD is an oxymoron. it's either familial or not. or even this new novel human disease known as Protease-Sensitive Prionopathy (PSPr), they might come up with that. if they cannot do this, it will be an occupational TSE infection, whether they want to admit it or not. and they don't admit those to often, they cover them up. just like that Spanish Doctor that handled cjd infected tissue. but we never heard nothing about that one either ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Investigator succumbs to CJD THE head of Pathological Anatomy at Principe de Asturias hospital in Alcala de Henares, Dr Antonio Ruiz Villaescusa, has died from Creutzfeldt-Jakob's disease. It is believed that Dr Ruiz, a specialist in CJD, contracted the disease after exposure to tissue from infected patients.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.euroweeklynews.com/news_spanish_press.html"&gt;http://www.euroweeklynews.com/news_spanish_press.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://74.125.47.132/search?q=cache:MfWnPKrMDEwJ:www.euroweeklynews.com/news_spanish_press.html+Principe+de+Asturias+in+Alcala+de+Henares+cjd&amp;amp;cd=5&amp;amp;hl=en&amp;amp;ct=clnk&amp;amp;gl=us"&gt;http://74.125.47.132/search?q=cache:MfWnPKrMDEwJ:www.euroweeklynews.com/news_spanish_press.html+Principe+de+Asturias+in+Alcala+de+Henares+cjd&amp;amp;cd=5&amp;amp;hl=en&amp;amp;ct=clnk&amp;amp;gl=us&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;14th ICID International Scientific Exchange Brochure -&lt;br /&gt;&lt;br /&gt;Final Abstract Number: ISE.114&lt;br /&gt;&lt;br /&gt;Session: International Scientific Exchange&lt;br /&gt;&lt;br /&gt;Transmissible Spongiform encephalopathy (TSE) animal and human TSE in North America&lt;br /&gt;&lt;br /&gt;update October 2009&lt;br /&gt;&lt;br /&gt;T. Singeltary&lt;br /&gt;&lt;br /&gt;Bacliff, TX, USA&lt;br /&gt;&lt;br /&gt;Background:&lt;br /&gt;&lt;br /&gt;An update on atypical BSE and other TSE in North America. Please remember, the typical U.K. c-BSE, the atypical l-BSE (BASE), and h-BSE have all been documented in North America, along with the typical scrapie's, and atypical Nor-98 Scrapie, and to date, 2 different strains of CWD, and also TME. All these TSE in different species have been rendered and fed to food producing animals for humans and animals in North America (TSE in cats and dogs ?), and that the trading of these TSEs via animals and products via the USA and Canada has been immense over the years, decades.&lt;br /&gt;&lt;br /&gt;Methods:&lt;br /&gt;&lt;br /&gt;12 years independent research of available data&lt;br /&gt;&lt;br /&gt;Results:&lt;br /&gt;&lt;br /&gt;I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2009. With all the science to date refuting it, to continue to validate this old myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, medical i.e., surgical, blood, dental, endoscopy, optical, nutritional supplements, cosmetics etc.&lt;br /&gt;&lt;br /&gt;Conclusion:&lt;br /&gt;&lt;br /&gt;I would like to submit a review of past CJD surveillance in the USA, and the urgent need to make all human TSE in the USA a reportable disease, in every state, of every age group, and to make this mandatory immediately without further delay. The ramifications of not doing so will only allow this agent to spread further in the medical, dental, surgical arena's. Restricting the reporting of CJD and or any human TSE is NOT scientific. Iatrogenic CJD knows NO age group, TSE knows no boundaries. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Gajdusek, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Transmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf"&gt;http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;International Society for Infectious Diseases Web: &lt;a href="http://www.isid.org/"&gt;http://www.isid.org&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, January 2, 2010&lt;br /&gt;&lt;br /&gt;Human Prion Diseases in the United States January 1, 2010 ***FINAL***&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;my comments to PLosone here ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd"&gt;http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, February 05, 2010&lt;br /&gt;&lt;br /&gt;New Variant Creutzfelt Jakob Disease case reports United States 2010 A Review&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html"&gt;http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, February 14, 2010&lt;br /&gt;&lt;br /&gt;[Docket No. FSIS-2006-0011] FSIS Harvard Risk Assessment of Bovine Spongiform Encephalopathy (BSE)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bseusa.blogspot.com/2010/02/docket-no-fsis-2006-0011-fsis-harvard.html"&gt;http://bseusa.blogspot.com/2010/02/docket-no-fsis-2006-0011-fsis-harvard.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2010/02/transmissible-spongiform-encephalopathy.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2010/02/transmissible-spongiform-encephalopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TSE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please read Senate 'Down Under' link at bottom of the following url ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;To date the OIE/WAHO assumes that the human and animal health standards set out in the BSE chapter for classical BSE (C-Type) applies to all forms of BSE which include the H-type and L-type atypical forms. This assumption is scientifically not completely justified and accumulating evidence suggests that this may in fact not be the case. Molecular characterization and the spatial distribution pattern of histopathologic lesions and immunohistochemistry (IHC) signals are used to identify and characterize atypical BSE. Both the L-type and H-type atypical cases display significant differences in the conformation and spatial accumulation of the disease associated prion protein (PrPSc) in brains of afflicted cattle. Transmission studies in bovine transgenic and wild type mouse models support that the atypical BSE types might be unique strains because they have different incubation times and lesion profiles when compared to C-type BSE. When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2"&gt;http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please see full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html"&gt;http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, March 28, 2010&lt;br /&gt;&lt;br /&gt;Nor-98 atypical Scrapie, atypical BSE, spontaneous TSE, trade policy, sound science ?&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-atypical-bse.html"&gt;http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-atypical-bse.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;*****URGENT NOTE HERE ABOUT OIE AND THEIR JUNK SCIENCE ABOUT ATYPICAL BSE*****&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html"&gt;http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD SURVEILLANCE TEXAS&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2007/12/creutzfeldt-jakob-disease-surveillance.html"&gt;http://cjdtexas.blogspot.com/2007/12/creutzfeldt-jakob-disease-surveillance.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2009 UPDATE ON ALABAMA AND TEXAS MAD COWS 2005 and 2006&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html"&gt;http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD USA RISING, with UNKNOWN PHENOTYPE ;&lt;br /&gt;&lt;br /&gt;5 Includes 41 cases in which the diagnosis is pending, and 17 inconclusive cases; 6 Includes 46 cases with type determination pending in which the diagnosis of vCJD has been excluded.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cjdsurveillance.com/pdf/case-table.pdf"&gt;http://www.cjdsurveillance.com/pdf/case-table.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, January 2, 2010&lt;br /&gt;&lt;br /&gt;Human Prion Diseases in the United States January 1, 2010 ***FINAL***&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, March 12, 2010&lt;br /&gt;&lt;br /&gt;CJD 2010 and the CJD Foundation Family Conference&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/03/cjd-2010-and-cjd-foundation-family.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/03/cjd-2010-and-cjd-foundation-family.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr.&lt;br /&gt;P.O. Box 42&lt;br /&gt;Bacliff, Texas USA 77518&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;--&lt;br /&gt;Katie Glisic&lt;br /&gt;Executive Assistant to Pierluigi Gambetti, MD&lt;br /&gt;Professor and Director&lt;br /&gt;National Prion Disease Pathology Surveillance Center&lt;br /&gt;Case Western Reserve University&lt;br /&gt;Phone: 216-368-0587&lt;br /&gt;Fax: 216-368-2546&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;=============END...TSS==========&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, April 5, 2010&lt;br /&gt;&lt;br /&gt;Update on Feed Enforcement Activities to Limit the Spread of BSE April 5, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/04/update-on-feed-enforcement-activities.html"&gt;http://madcowfeed.blogspot.com/2010/04/update-on-feed-enforcement-activities.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TSS&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6604160603980694949-3478169181392281947?l=prionunitusaupdate2008.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://prionunitusaupdate2008.blogspot.com/feeds/3478169181392281947/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=6604160603980694949&amp;postID=3478169181392281947' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/3478169181392281947'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/3478169181392281947'/><link rel='alternate' type='text/html' href='http://prionunitusaupdate2008.blogspot.com/2010/04/update-cjd-texas-38-year-old-female.html' title='UPDATE - CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER'/><author><name>Terry S. Singeltary Sr.</name><uri>http://www.blogger.com/profile/06986622967539963260</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='22' src='http://bp2.blogger.com/_gwMAfd8g9xo/SHuerfBUR1I/AAAAAAAAAAM/nNI1xcLm_Z4/S220/scan0002.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6604160603980694949.post-6341999936178136086</id><published>2010-03-12T15:13:00.000-08:00</published><updated>2010-04-02T08:41:13.222-07:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='sporadic CJD'/><category scheme='http://www.blogger.com/atom/ns#' term='atypical CWD'/><category scheme='http://www.blogger.com/atom/ns#' term='atypical Nor-98 Scrapie'/><category scheme='http://www.blogger.com/atom/ns#' term='atypical BSE'/><category scheme='http://www.blogger.com/atom/ns#' term='2010 CJD Foundation Family Conference'/><title type='text'>CJD 2010 and the CJD Foundation Family Conference</title><content type='html'>CJD 2010 and the CJD Foundation Family Conference&lt;br /&gt;&lt;br /&gt;Tentative Schedule&lt;br /&gt;&lt;br /&gt;Friday, July 16&lt;br /&gt;&lt;br /&gt;8:30 – 7:30 Registration&lt;br /&gt;&lt;br /&gt;12:30 – 2:30 Familial Prion Disease Meeting *This meeting is only for families affected by a familial prion disease Deana Simpson, RN - Chairman Macomb, Michigan Corporate Director of Clinical Transformation, Detroit Medical Center; Founder and Director, CJD Insight; Member, CJD Foundation Board of Directors&lt;br /&gt;&lt;br /&gt;Pierluigi Gambetti, MD Cleveland, Ohio Professor and Director, Division of Neuropathology, Case Western Reserve University School of Medicine and University Hospitals of Cleveland; Director, The National Prion Disease Pathology Surveillance Center; Medical Director, CJD Foundation Thomas Wisniewski, MD New York, New York Professor, Departments of Neurology, Pathology and Psychiatry, New York University School Medicine&lt;br /&gt;&lt;br /&gt;3:00 - 5:00 Bereavement Workshop Brian Appleby, MD - Chairman Baltimore, Maryland Co-Director, The Frontotemporal Dementia and Young-Onset Dementias Clinic, The Johns Hopkins Hospital; Assistant Professor, Psychiatry and Behavioral Sciences, Johns Hopkins University Deana Simpson, RN Katrina Hallmark, PsyD San Antonio, Texas Neuropsychologist, Southwest Mental Health Center 6:00 – 7:30 Welcome Reception 1 2 Saturday, July 17&lt;br /&gt;&lt;br /&gt;Co-Chairmen: Pierluigi Gambetti, MD Neil Cashman, MD, FRCP(C), FCAHS&lt;br /&gt;&lt;br /&gt;7:30 Conference Registration&lt;br /&gt;&lt;br /&gt;7:30 – 8:30 Continental Breakfast&lt;br /&gt;&lt;br /&gt;8:00 – 8:15 Conference Welcome&lt;br /&gt;&lt;br /&gt;Florence Kranitz Akron, Ohio President, The CJD Foundation; Co-Chairman, The CJD International Support Alliance 8:15 – 8:40 Memorial Service&lt;br /&gt;&lt;br /&gt;Overviews&lt;br /&gt;&lt;br /&gt;8:40 – 9:05 The Future of Prion Disease Research and Treatments John Collinge, MD, FRCP, FRS London, United Kingdom Professor and Head, Department of Neurodegenerative Disease, Institute of Neurology, University College London; Director, UK Medical Research Council's Prion Unit; Director, UK National Prion Clinic, National Hospital for Neurology and Neurosurgery&lt;br /&gt;&lt;br /&gt;9:05 – 9:15 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;9:15 – 9:40 CJD World Overview and Difficulties in Making A CJD Diagnosis Robert Will, MD, FRCP(E) Edinburgh, United Kingdom Professor of Neurology, Personal Chair in Clinical Neurology, University of Edinburgh; Consultant Neurologist, Western General Hospital; Former Director and Founder, National CJD Surveillance Unit&lt;br /&gt;&lt;br /&gt;9:40 – 9:50 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;9:50 - 10:05 Coffee Break&lt;br /&gt;&lt;br /&gt;Diagnosis and Treatment&lt;br /&gt;&lt;br /&gt;10:05 – 10:25 The Current State of Prion Disease Diagnostics Jiri Safar, MD Cleveland, Ohio Co-Director, The National Prion Disease Pathology Surveillance Center&lt;br /&gt;&lt;br /&gt;10:25 – 10:30 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;10:30 – 10:50 The Future of Prion Disease Diagnostics David Wishart, PhD Alberta, Canada Professor, Departments of Computer Science and Biological Science, University of Alberta; Principal Investigator, Nano Life Sciences, National Institute for Nanotechnology, National Research Council&lt;br /&gt;&lt;br /&gt;10:50 - 10:55 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;3&lt;br /&gt;&lt;br /&gt;10:55 - 11:15 Human Prion Disease Vaccine Thomas Wisniewski, MD&lt;br /&gt;&lt;br /&gt;11:15 - 11:20 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;11:20 - 11:40 Doxycycline Clinical Trial Update Fabrizio Tagliavini, MD Milan, Italy Director, Divisions of Neuropathology and Neurology Fondazione IRCCS Istituto Neurologico Carlo Besta&lt;br /&gt;&lt;br /&gt;11:40 - 11:45 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;11:45 - 1:00 Lunch&lt;br /&gt;&lt;br /&gt;1:00 - 1:20 The National Prion Monitoring Cohort Study Simon Mead, PhD London, United Kingdom Head, Human Genetics Program, MRC Prion Unit; Lead Clinician, National Prion Clinic&lt;br /&gt;&lt;br /&gt;1:20 - 1:25 Q&amp;amp;A Surveillance&lt;br /&gt;&lt;br /&gt;1:25 – 1:40 Prion Disease Surveillance in the United States Pierluigi Gambetti, MD&lt;br /&gt;&lt;br /&gt;1:40 – 1:55 Prion Disease Surveillance in Canada Gerard Jansen, MD, FRCP(C) Ottawa, Canada Neuropathologist, Head of Anatomical Pathology, Principal Investigator, CJD Neuropathology, Ottawa Hospital; Medical Specialist, Prion Diagnostics, Public Health Agency of Canada&lt;br /&gt;&lt;br /&gt;1:55 - 2:10 Prion Disease Surveillance in the United Kingdom Richard Knight, MD, FRCP(E) Edinburgh, United Kingdom Deputy Director, UK National CJD Surveillance Unit; Professor and Personal Chair, Clinical Neurology, University of Edinburgh; Honorary Consultant, Clinical Neurology, Department of Clinical Neurosciences, Western General Hospital&lt;br /&gt;&lt;br /&gt;2:10 – 2:25 Prion Disease Surveillance in China Xiao-Ping Dong, PhD Beijing, China Director, Division of Science and Technology, Chinese Center for Disease Control and Prevention&lt;br /&gt;&lt;br /&gt;2:25 - 2:40 Prion Disease Surveillance in France Jean-Philippe Brandel, MD Paris, France Cellulle Nationale de référence des maladies de Creutzfeldt-Jakob Groupe Hospitalier Pitié-Salpêtrière&lt;br /&gt;&lt;br /&gt;2:40 – 3:00 Surveillance Q&amp;amp;A Panel&lt;br /&gt;&lt;br /&gt;4&lt;br /&gt;&lt;br /&gt;3:00 - 3:15 Coffee and Cookie Break&lt;br /&gt;&lt;br /&gt;3:15 - 5:00 Moving Round Tables&lt;br /&gt;&lt;br /&gt;7:00 – 7:30 Reception&lt;br /&gt;&lt;br /&gt;7:30 Banquet&lt;br /&gt;&lt;br /&gt;Sunday, July 18 Co-Chairmen: Florence Kranitz Marisa Boarman&lt;br /&gt;&lt;br /&gt;7:30 – 9:00 Continental Breakfast&lt;br /&gt;&lt;br /&gt;9:00 - 9:15 CJDF Update&lt;br /&gt;&lt;br /&gt;Mark Goldfarb Akron, Ohio Chairman, Board of Directors, The CJD Foundation Ruthie George Akron, Ohio Treasurer, Board of Directors, The CJD Foundation&lt;br /&gt;&lt;br /&gt;9:15 - 9:30 CJDF Questionnaire Report&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;=========&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdquestionnaire.blogspot.com/2007/11/cjd-questionnaire.html"&gt;http://cjdquestionnaire.blogspot.com/2007/11/cjd-questionnaire.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdquestionnaire.blogspot.com/2009/09/multi-state-study-of-creutzfeldt-jakob.html"&gt;http://cjdquestionnaire.blogspot.com/2009/09/multi-state-study-of-creutzfeldt-jakob.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdquestionnaire.blogspot.com/"&gt;http://cjdquestionnaire.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TSS&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;================&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;9:30 - 9:35 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;9:35 - 9:50 The Centers for Disease Control and Prevention Report Ryan Maddox, MPH Atlanta, Georgia Epidemiologist, Prion Disease Office, Office of the Director, Division of Viral and Rickettsial Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention&lt;br /&gt;&lt;br /&gt;9:50 - 9:55 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;9:55 - 10:10 Pentosan Sulphate: A Friendly Delivery System for Therapy in Prion Diseases&lt;br /&gt;&lt;br /&gt;2009 CJD Foundation Human Prion Disease Grant Recipient Maurizio Pocchiari, MD Research Director and Head, Clinical, Diagnosis and Therapy of Neurodegenerative Disorders Unit, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita&lt;br /&gt;&lt;br /&gt;10:10 - 10:15 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;10:15 - 10:30 Searching for Custom Dominant Negative PrPs by In Vitro Prion Replication Studies&lt;br /&gt;&lt;br /&gt;2009 CJD Foundation Human Prion Disease Grant Recipient Joaquin Castilla, PhD Bizkaia, Spain Principal Investigator, Prion Lab, Proteomic Unit, CIC bioGUNE&lt;br /&gt;&lt;br /&gt;10:30 - 10:35 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;5&lt;br /&gt;&lt;br /&gt;10:35 - 10:50 Analyses of the Protein Tau to Help Determine Whether the Newly Discovered Protease-Sensitive Prionopathy is the Sporadic Form of Gerstmann-Sträussler-Scheinker Disease (GSS) 2010 Patrick Yobs GSS Memorial Fund Grant Recipient Gianfranco Puoti, MD, PhD Cleveland, Ohio Neurologist and Reserach Associate, The National Prion Disease Pathology Surveillance Center&lt;br /&gt;&lt;br /&gt;10:50 - 10:55 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;10:55 - 11:10 Coffee Break&lt;br /&gt;&lt;br /&gt;11:10 - 11:25 Etiology of Sporadic CJD: Somatic Mutations of the Human Prion Protein Gene in Brain Cells 2010 CJD Foundation Human Prion Disease Grant Recipient Qingzhong Kong, PhD Cleveland, Ohio Associate Professor, Division of Pathology, Case Western Reserve University; Researcher, The National Prion Disease Pathology Surveillance Center&lt;br /&gt;&lt;br /&gt;11:25 - 11:30 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;11:30 - 11:45 Adult Neurogenesis in Prion Diseases: A New Lead for Therapeutics?&lt;br /&gt;&lt;br /&gt;2010 CJD Foundation Human Prion Disease Grant Recipient #2 Sylvain Lehmann, MD, PhD &amp;amp; Carole Crozet, PhD Montpellier, France Research Group Leader, Department of Molecular and Cellular Pathologies, Institut de Génétique Humaine&lt;br /&gt;&lt;br /&gt;11:45 - 11:50 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;11:50 - 12:05 2010 CJD Foundation Human Prion Disease Grant Recipient MEK-inhibitors clear prion-infected cells from PrPSc Elin Allard, PhD Stockholm, Sweden Researcher, Department of Neuroscience, Karolinska Institutet&lt;br /&gt;&lt;br /&gt;12:05 - 12:10 Q&amp;amp;A&lt;br /&gt;&lt;br /&gt;12:10 - 12:20 Alberta Prion Research Institute (APRI) Kevin Keough, PhD, FCAHS Alberta, Canada Executive Director, The Alberta Prion Research Institute 1 2:20 – 1:30 Lunch Support Organization Reports&lt;br /&gt;&lt;br /&gt;1:30 – 1:45 CJD Support Group Network, Australia Suzanne Solvyns Glenhaven NSW, Australia National Coordinator, CJD Support Group Network&lt;br /&gt;&lt;br /&gt;6&lt;br /&gt;&lt;br /&gt;1:45 – 2:00 Maladie de Creutzfeldt-Jakob par Hormone de Croissance Contaminée (MCJ-HCC), France JB Mathieu Paris, France President, MCJ-HCC&lt;br /&gt;&lt;br /&gt;2:00 - 2:15 CJD Foundation, Israel Alice Anane Israel President, CJD Foundation, Israel&lt;br /&gt;&lt;br /&gt;2:15 - 2:30 Associazione Italiana Encefalopatie da Prioni (A.I.En.P.), Italy Roberto Borgis Torino, Italy President, A.I.En.P. Raffaella Robello Genova, Italy Vice President, A.I.En.P.&lt;br /&gt;&lt;br /&gt;2:30 – 2:45 CJD Support Network, Japan Minae Askawa Japan Counselor, CJD Support Network, Japan&lt;br /&gt;&lt;br /&gt;2:45 – 3:00 CJD Support Network, United Kingdom&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cjdfoundation.org/pdfs/2010conference.pdf"&gt;http://www.cjdfoundation.org/pdfs/2010conference.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD 2010 and the CJD Foundation Family Conference&lt;br /&gt;will be held July 16 – 18, 2010 at the&lt;br /&gt;Washington Court Hotel in Washington,&lt;br /&gt;D.C. Advocacy Day on Capitol Hill will&lt;br /&gt;be on Monday, July 19th for interested&lt;br /&gt;families.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P.O. Box 5312, Akron, Ohio 44334&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;􀃌 330.665.5590&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;􀃌 HelpLine 1.800.659.1991&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="mailto:help@cjdfoundation.org"&gt;help@cjdfoundation.org&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cjdfoundation.org/"&gt;http://www.cjdfoundation.org/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TSS&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;14th ICID International Scientific Exchange Brochure -&lt;br /&gt;&lt;br /&gt;Final Abstract Number: ISE.114&lt;br /&gt;&lt;br /&gt;Session: International Scientific Exchange&lt;br /&gt;&lt;br /&gt;Transmissible Spongiform encephalopathy (TSE) animal and human TSE in North America&lt;br /&gt;&lt;br /&gt;update October 2009&lt;br /&gt;&lt;br /&gt;T. Singeltary&lt;br /&gt;&lt;br /&gt;Bacliff, TX, USA&lt;br /&gt;&lt;br /&gt;Background:&lt;br /&gt;&lt;br /&gt;An update on atypical BSE and other TSE in North America. Please remember, the typical U.K. c-BSE, the atypical l-BSE (BASE), and h-BSE have all been documented in North America, along with the typical scrapie's, and atypical Nor-98 Scrapie, and to date, 2 different strains of CWD, and also TME. All these TSE in different species have been rendered and fed to food producing animals for humans and animals in North America (TSE in cats and dogs ?), and that the trading of these TSEs via animals and products via the USA and Canada has been immense over the years, decades.&lt;br /&gt;&lt;br /&gt;Methods:&lt;br /&gt;&lt;br /&gt;12 years independent research of available data&lt;br /&gt;&lt;br /&gt;Results:&lt;br /&gt;&lt;br /&gt;I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2009. With all the science to date refuting it, to continue to validate this old myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, medical i.e., surgical, blood, dental, endoscopy, optical, nutritional supplements, cosmetics etc.&lt;br /&gt;&lt;br /&gt;Conclusion:&lt;br /&gt;&lt;br /&gt;I would like to submit a review of past CJD surveillance in the USA, and the urgent need to make all human TSE in the USA a reportable disease, in every state, of every age group, and to make this mandatory immediately without further delay. The ramifications of not doing so will only allow this agent to spread further in the medical, dental, surgical arena's. Restricting the reporting of CJD and or any human TSE is NOT scientific. Iatrogenic CJD knows NO age group, TSE knows no boundaries. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Gajdusek, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Transmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;see page 114 ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf"&gt;http://ww2.isid.org/Downloads/14th_ICID_ISE_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, February 24, 2010&lt;br /&gt;&lt;br /&gt;Transmissible Spongiform encephalopathy (TSE) animal and human TSE in North America 14th&lt;br /&gt;&lt;br /&gt;ICID International Scientific Exchange Brochure -&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/2010/02/transmissible-spongiform-encephalopathy.html"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/2010/02/transmissible-spongiform-encephalopathy.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;TSE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;International Society for Infectious Diseases Web: http://www.isid.org&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, October 19, 2009&lt;br /&gt;&lt;br /&gt;Atypical BSE, BSE, and other human and animal TSE in North America Update October 19, 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2009/10/atypical-bse-bse-and-other-human-and.html"&gt;http://bse-atypical.blogspot.com/2009/10/atypical-bse-bse-and-other-human-and.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, February 14, 2010&lt;br /&gt;&lt;br /&gt;[Docket No. FSIS-2006-0011] FSIS Harvard Risk Assessment of Bovine Spongiform Encephalopathy (BSE)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bseusa.blogspot.com/2010/02/docket-no-fsis-2006-0011-fsis-harvard.html"&gt;http://bseusa.blogspot.com/2010/02/docket-no-fsis-2006-0011-fsis-harvard.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010 in Mesquite Texas&lt;br /&gt;&lt;br /&gt;Irma Linda Andablo CJD Victim, she died at 38 years old on February 6, 2010 in Mesquite Texas.She left 6 Kids and a Husband.The Purpose of this web is to give information in Spanish to the Hispanic community, and to all the community who want's information about this terrible disease.-&lt;br /&gt;&lt;br /&gt;Physician Discharge Summary, Parkland Hospital, Dallas Texas&lt;br /&gt;&lt;br /&gt;Admit Date: 12/29/2009 Discharge Date: 1/20/2010 Attending Provider: Greenberg, Benjamin Morris; General Neurology Team: General Neurology Team&lt;br /&gt;&lt;br /&gt;Linda was a Hispanic female with no past medical history presents with 14 months of incresing/progressive altered mental status, generalized weakness, inability to walk, loss of appetite, inability to speak, tremor and bowel/blader incontinence.She was, in her usual state of health up until February, 2009, when her husbans notes that she began forgetting things like names and short term memories. He also noticed mild/vague personality changes such as increased aggression. In March, she was involved in a hit and run MVA,although she was not injured. The police tracked her down and ticketed her. At that time, her son deployed to Iraq with the Army and her husband assumed her mentation changes were due to stress over these two events. Also in March, she began to have weakness in her legs, making it difficult to walk. Over the next few months, her mentation and personality changes worsened, getting to a point where she could no longer recognized her children. She was eating less and less. She was losing more weight. In the last 2-3 months, she reached the point where she could not walk without an assist, then 1 month ago, she stopped talking, only making grunting/aggressive sounds when anyone came near her. She also became both bowel and bladder incontinent, having to wear diapers. Her '"tremor'" and body jerks worsened and her hands assumed a sort of permanent grip position, leading her family to put tennis balls in her hands to protect her fingers.&lt;br /&gt;&lt;br /&gt;The husband says that they have lived in Nebraska for the past 21 years. They had seen a doctor there during the summer time who prescribed her Seroquel and Lexapro, Thinking these were sx of a mood disorder. However, the medications did not help and she continued to deteriorate clinically. Up until about 6 years ago, the pt worked at Tyson foods where she worked on the assembly line, slaughtering cattle and preparing them for packaging. She was exposed to brain and spinal cord matter when she would euthanize the cattle. The husband says that he does not know any fellow workers with a similar illness. He also says that she did not have any preceeding illness or travel.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8"&gt;http://www.recordandoalinda.com/index.php?option=com_content&amp;amp;view=article&amp;amp;id=19:cjd-english-info&amp;amp;catid=9:cjd-ingles&amp;amp;Itemid=8&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt;&gt;&gt; Up until about 6 years ago, the pt worked at Tyson foods where she worked on the assembly line, slaughtering cattle and preparing them for packaging. She was exposed to brain and spinal cord matter when she would euthanize the cattle. &lt;&lt;&lt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2010/03/irma-linda-andablo-cjd-victim-she-died.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2010/03/irma-linda-andablo-cjd-victim-she-died.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD TEXAS 38 YEAR OLD FEMALE WORKED SLAUGHTERING CATTLE EXPOSED TO BRAIN AND SPINAL CORD MATTER&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html"&gt;http://cjdtexas.blogspot.com/2010/03/cjd-texas-38-year-old-female-worked.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;YOU can be assured they are squirming behind closed doors, and that they are doing there best to squirm right out of this one. they will come up with something, international travel long ago, or some strange PRNP mutation that they might say like sporadic ffi ??? or a case of atypical case of inherited Creutzfeldt-Jakob disease (CJD) ??? they will make up something. but it will be anything but BSE related here in the USA, in my opinion. sporadic FFI, or sporadic GSS, or sporadic inherited CJD is an oxymoron. it's either familial or not. or even this new novel human disease known as Protease-Sensitive Prionopathy (PSPr), they might come up with that. if they cannot do this, it will be an occupational TSE infection, whether they want to admit it or not. and they don't admit those to often, they cover them up. just like that Spanish Doctor that handled cjd infected tissue. but we never heard nothing about that one either ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Investigator succumbs to CJD THE head of Pathological Anatomy at Principe de Asturias hospital in Alcala de Henares, Dr Antonio Ruiz Villaescusa, has died from Creutzfeldt-Jakob's disease. It is believed that Dr Ruiz, a specialist in CJD, contracted the disease after exposure to tissue from infected patients.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.euroweeklynews.com/news_spanish_press.html"&gt;http://www.euroweeklynews.com/news_spanish_press.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://74.125.47.132/search?q=cache:MfWnPKrMDEwJ:www.euroweeklynews.com/news_spanish_press.html+Principe+de+Asturias+in+Alcala+de+Henares+cjd&amp;amp;cd=5&amp;amp;hl=en&amp;amp;ct=clnk&amp;amp;gl=us"&gt;http://74.125.47.132/search?q=cache:MfWnPKrMDEwJ:www.euroweeklynews.com/news_spanish_press.html+Principe+de+Asturias+in+Alcala+de+Henares+cjd&amp;amp;cd=5&amp;amp;hl=en&amp;amp;ct=clnk&amp;amp;gl=us&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please read Senate 'Down Under' link at bottom of the following url ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://transmissiblespongiformencephalopathy.blogspot.com/"&gt;http://transmissiblespongiformencephalopathy.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle / position: Post Doctoral Fellow&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;To date the OIE/WAHO assumes that the human and animal health standards set out in the BSE chapter for classical BSE (C-Type) applies to all forms of BSE which include the H-type and L-type atypical forms. This assumption is scientifically not completely justified and accumulating evidence suggests that this may in fact not be the case. Molecular characterization and the spatial distribution pattern of histopathologic lesions and immunohistochemistry (IHC) signals are used to identify and characterize atypical BSE. Both the L-type and H-type atypical cases display significant differences in the conformation and spatial accumulation of the disease associated prion protein (PrPSc) in brains of afflicted cattle. Transmission studies in bovine transgenic and wild type mouse models support that the atypical BSE types might be unique strains because they have different incubation times and lesion profiles when compared to C-type BSE. When L-type BSE was inoculated into ovine transgenic mice and Syrian hamster the resulting molecular fingerprint had changed, either in the first or a subsequent passage, from L-type into C-type BSE. In addition, non-human primates are specifically susceptible for atypical BSE as demonstrated by an approximately 50% shortened incubation time for L-type BSE as compared to C-type. Considering the current scientific information available, it cannot be assumed that these different BSE types pose the same human health risks as C-type BSE or that these risks are mitigated by the same protective measures. &lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2"&gt;http://www.prionetcanada.ca/detail.aspx?menu=5&amp;amp;dt=293380&amp;amp;app=93&amp;amp;cat1=387&amp;amp;tp=20&amp;amp;lk=no&amp;amp;cat2&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;please see full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html"&gt;http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, March 28, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Nor-98 atypical Scrapie, atypical BSE, spontaneous TSE, trade policy, sound science ?&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-atypical-bse.html"&gt;http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-atypical-bse.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;*****URGENT NOTE HERE ABOUT OIE AND THEIR JUNK SCIENCE ABOUT ATYPICAL BSE*****&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 31, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Atypical BSE in Cattle&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html"&gt;http://bse-atypical.blogspot.com/2010/03/atypical-bse-in-cattle-position-post.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2009 UPDATE ON ALABAMA AND TEXAS MAD COWS 2005 and 2006&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html"&gt;http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 3, 2010&lt;br /&gt;&lt;br /&gt;NOR-98 ATYPICAL SCRAPIE USA 4 CASES DETECTED JANUARY 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-usa-4-cases.html"&gt;http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-usa-4-cases.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Canada - Case of BSE (Mad cow disease) in 6 year old cow 17th domestic case&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bseusa.blogspot.com/2010/03/canada-case-of-bse-mad-cow-disease-in-6.html"&gt;http://bseusa.blogspot.com/2010/03/canada-case-of-bse-mad-cow-disease-in-6.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, March 11, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CANADA TYPICAL AND ATYPICAL SCRAPIE REPORT TO MARCH 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2010/03/canada-typical-and-atypical-scrapie.html"&gt;http://nor-98.blogspot.com/2010/03/canada-typical-and-atypical-scrapie.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, February 09, 2010&lt;br /&gt;&lt;br /&gt;Chronic Wasting Disease: Surveillance Update: February 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2010/02/chronic-wasting-disease-surveillance.html"&gt;http://chronic-wasting-disease.blogspot.com/2010/02/chronic-wasting-disease-surveillance.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Saturday, January 2, 2010&lt;br /&gt;&lt;br /&gt;Human Prion Diseases in the United States January 1, 2010 ***FINAL***&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html"&gt;http://prionunitusaupdate2008.blogspot.com/2010/01/human-prion-diseases-in-united-states.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;my comments to PLosone here ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd"&gt;http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, February 05, 2010&lt;br /&gt;&lt;br /&gt;New Variant Creutzfelt Jakob Disease case reports United States 2010 A Review&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html"&gt;http://vcjd.blogspot.com/2010/02/new-variant-creutzfelt-jakob-disease.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Prion data suggest BSE link to sporadic CJD Declan Butler&lt;br /&gt;&lt;br /&gt;Predicting the number of cases of Creutzfeldt-Jakob disease (CJD) in people as a result of transmission of bovine spongiform encephalopathy (BSE) has just got more difficult.Whereas it was thought that BSE only caused a new form of the disease called variant CJD (vCJD), a study in mice from a team led by John Collinge at University College London suggests that it may also cause a disease indistinguishable from the commonest form of classical, or 'sporadic', CJD (E.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nature.com/nature/journal/v420/n6915/full/420450a.html"&gt;http://www.nature.com/nature/journal/v420/n6915/full/420450a.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Mouse model sheds new light on human prion disease&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Professor John Collinge said We are not saying that all or even most cases of sporadic CJD are as a result of BSE exposure, but some more recent cases may be the incidence of sporadic CJD has shown an upward trend in the UK over the last decade. While most of this apparent increase may be because doctors are now more aware of CJD and better at diagnosing it, serious consideration should be given to a proportion of this rise being BSE-related. Switzerland, which has had a substantial BSE epidemic, has noted a sharp recent increase in sporadic CJD.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.mrc.ac.uk/txt/index/public-interest/public-news-4/public-news_archive/public-news-archive_nov_dec_02/public-bse_and_sporadic_cjd.htm"&gt;http://www.mrc.ac.uk/txt/index/public-interest/public-news-4/public-news_archive/public-news-archive_nov_dec_02/public-bse_and_sporadic_cjd.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein&lt;br /&gt;&lt;br /&gt;Emmanuel A. Asante, Jacqueline M. Linehan, Melanie Desbruslais, Susan Joiner, Ian Gowland, Andrew L. Wood, Julie Welch, Andrew F. Hill, Sarah E. Lloyd, Jonathan D.F. Wadsworth, and John Collinge1 MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College, Queen Square, London WC1N 3BG, UK 1Corresponding author e-mail: j.collinge@prion.ucl.ac.ukReceived August 1, 2002; Revised September 24, 2002; Accepted October 17, 2002.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC136957/?tool=pubmed"&gt;http://www.ncbi.nlm.nih.gov/pmc/articles/PMC136957/?tool=pubmed&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nature.com/emboj/journal/v21/n23/full/7594869a.html"&gt;http://www.nature.com/emboj/journal/v21/n23/full/7594869a.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, March 2, 2010&lt;br /&gt;&lt;br /&gt;Animal Proteins Prohibited in Ruminant Feed/Adulterated/Misbranded Rangen Inc 2/11/10 USA&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/03/animal-proteins-prohibited-in-ruminant.html"&gt;http://madcowfeed.blogspot.com/2010/03/animal-proteins-prohibited-in-ruminant.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, March 1, 2010&lt;br /&gt;&lt;br /&gt;ANIMAL PROTEIN I.E. MAD COW FEED IN COMMERCE A REVIEW 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2010/03/animal-protien-ie-mad-cow-feed-in.html"&gt;http://madcowfeed.blogspot.com/2010/03/animal-protien-ie-mad-cow-feed-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The most recent assessments (and reassessments) were published in June 2005 (Table I; 18), and included the categorisation of Canada, the USA, and Mexico as GBR III. Although only Canada and the USA have reported cases, the historically open system of trade in North America suggests that it is likely that BSE is present also in Mexico.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.oie.int/boutique/extrait/06heim937950.pdf"&gt;http://www.oie.int/boutique/extrait/06heim937950.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;----- Original Message -----&lt;br /&gt;&lt;br /&gt;From: "Terry S. Singeltary Sr." &lt;flounder9@verizon.net&gt;&lt;br /&gt;To: &lt;bse-l@lists.aegee.org&gt;&lt;br /&gt;Sent: Sunday, March 07, 2010 5:41 PM&lt;br /&gt;Subject: Re: [BSE-L] FOIA REQUEST ON FEED RECALL PRODUCT 429,128 lbs. feed for ruminant animals may have been contaminated with prohibited material Recall # V-258-2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;see full text, and be sure to read the BSE Inquiry documents toward the bottom ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://caninespongiformencephalopathy.blogspot.com/2010/03/canine-spongiform-encephalopathy-aka.html"&gt;http://caninespongiformencephalopathy.blogspot.com/2010/03/canine-spongiform-encephalopathy-aka.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Wednesday, March 3, 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;NOR-98 ATYPICAL SCRAPIE USA 4 CASES DETECTED JANUARY 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-usa-4-cases.html"&gt;http://nor-98.blogspot.com/2010/03/nor-98-atypical-scrapie-usa-4-cases.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, August 04, 2009&lt;br /&gt;&lt;br /&gt;Susceptibilities of Nonhuman Primates to Chronic Wasting Disease&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;From: TSS (216-119-163-189.ipset45.wt.net)&lt;br /&gt;&lt;br /&gt;Subject: CWD aka MAD DEER/ELK TO HUMANS ???&lt;br /&gt;&lt;br /&gt;Date: September 30, 2002 at 7:06 am PST&lt;br /&gt;&lt;br /&gt;From: "Belay, Ermias"&lt;br /&gt;&lt;br /&gt;To:&lt;br /&gt;&lt;br /&gt;Cc: "Race, Richard (NIH)" ; ; "Belay,&lt;br /&gt;&lt;br /&gt;Ermias"&lt;br /&gt;&lt;br /&gt;Sent: Monday, September 30, 2002 9:22 AM&lt;br /&gt;&lt;br /&gt;Subject: RE: TO CDC AND NIH - PUB MED- 3 MORE DEATHS - CWD - YOUNG HUNTERS&lt;br /&gt;&lt;br /&gt;Dear Sir/Madam,&lt;br /&gt;&lt;br /&gt;In the Archives of Neurology you quoted (the abstract of which was attached to your email), we did not say CWD in humans will present like variant CJD.&lt;br /&gt;&lt;br /&gt;That assumption would be wrong. I encourage you to read the whole article and call me if you have questions or need more clarification (phone: 404-639-3091). Also, we do not claim that "no-one has ever been infected with prion disease from eating venison." Our conclusion stating that we found no strong evidence of CWD transmission to humans in the article you quoted or in any other forum is limited to the patients we investigated.&lt;br /&gt;&lt;br /&gt;Ermias Belay, M.D.&lt;br /&gt;&lt;br /&gt;Centers for Disease Control and Prevention&lt;br /&gt;&lt;br /&gt;-----Original Message-----&lt;br /&gt;&lt;br /&gt;From:&lt;br /&gt;&lt;br /&gt;Sent: Sunday, September 29, 2002 10:15 AM&lt;br /&gt;&lt;br /&gt;To: rr26k@nih.gov; rrace@niaid.nih.gov; ebb8@CDC.GOV&lt;br /&gt;&lt;br /&gt;Subject: TO CDC AND NIH - PUB MED- 3 MORE DEATHS - CWD - YOUNG&lt;br /&gt;&lt;br /&gt;HUNTERS&lt;br /&gt;&lt;br /&gt;Sunday, November 10, 2002 6:26 PM ......snip........end..............TSS&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2009/08/susceptibilities-of-nonhuman-primates.html"&gt;http://chronic-wasting-disease.blogspot.com/2009/08/susceptibilities-of-nonhuman-primates.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Thursday, December 10, 2009&lt;br /&gt;&lt;br /&gt;Chronic Wasting Disease (CWD) Susceptibility of Several North American Rodents That Are Sympatric with Cervid CWD Epidemics&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/2009/12/chronic-wasting-disease-cwd.html"&gt;http://chronic-wasting-disease.blogspot.com/2009/12/chronic-wasting-disease-cwd.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CHRONIC WASTING DISEASE (CWD)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://chronic-wasting-disease.blogspot.com/"&gt;http://chronic-wasting-disease.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;What about CJD in the USA ?&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;USA sporadic CJD cases rising ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;There is a growing number of human CJD cases, and they were presented last week in San Francisco by Luigi Gambatti(?) from his CJD surveillance collection.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;He estimates that it may be up to 14 or 15 persons which display selectively SPRPSC and practically no detected RPRPSC proteins.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.fda.gov/ohrms/dockets/ac/06/transcripts/1006-4240t1.htm"&gt;http://www.fda.gov/ohrms/dockets/ac/06/transcripts/1006-4240t1.htm&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4240t1.pdf"&gt;http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4240t1.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD USA RISING, with UNKNOWN PHENOTYPE ;&lt;br /&gt;&lt;br /&gt;5 Includes 41 cases in which the diagnosis is pending, and 17 inconclusive cases; 6 Includes 46 cases with type determination pending in which the diagnosis of vCJD has been excluded.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.cjdsurveillance.com/pdf/case-table.pdf"&gt;http://www.cjdsurveillance.com/pdf/case-table.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;JOURNAL OF NEUROLOGY&lt;br /&gt;&lt;br /&gt;MARCH 26, 2003&lt;br /&gt;&lt;br /&gt;Send Post-Publication Peer Review to journal:&lt;br /&gt;&lt;br /&gt;Re: RE-Monitoring the occurrence of emerging forms of Creutzfeldt-Jakob&lt;br /&gt;&lt;br /&gt;disease in the United States&lt;br /&gt;&lt;br /&gt;Email Terry S. Singeltary:&lt;br /&gt;&lt;br /&gt;flounder@wt.net&lt;br /&gt;&lt;br /&gt;I lost my mother to hvCJD (Heidenhain Variant CJD). I would like to comment on the CDC's attempts to monitor the occurrence of emerging forms of CJD. Asante, Collinge et al [1] have reported that BSE transmission to the 129-methionine genotype can lead to an alternate phenotype that is indistinguishable from type 2 PrPSc, the commonest sporadic CJD. However, CJD and all human TSEs are not reportable nationally. CJD and all human TSEs must be made reportable in every state and internationally. I hope that the CDC does not continue to expect us to still believe that the 85%+ of all CJD cases which are sporadic are all spontaneous, without route/source. We have many TSEs in the USA in both animal and man. CWD in deer/elk is spreading rapidly and CWD does transmit to mink, ferret, cattle, and squirrel monkey by intracerebral inoculation. With the known incubation periods in other TSEs, oral transmission studies of CWD may take much longer. Every victim/family of CJD/TSEs should be asked about route and source of this agent. To prolong this will only spread the agent and needlessly expose others. In light of the findings of Asante and Collinge et al, there should be drastic measures to safeguard the medical and surgical arena from sporadic CJDs and all human TSEs. I only ponder how many sporadic CJDs in the USA are type 2 PrPSc?&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.neurology.org/cgi/eletters/60/2/176#535"&gt;http://www.neurology.org/cgi/eletters/60/2/176#535&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Newsdesk The Lancet Infectious Diseases, Volume 3, Issue 8, Page 463, August 2003 doi:10.1016/S1473-3099(03)00715-1Cite or Link Using DOI&lt;br /&gt;&lt;br /&gt;Tracking spongiform encephalopathies in North America&lt;br /&gt;&lt;br /&gt;Xavier Bosch&lt;br /&gt;&lt;br /&gt;"My name is Terry S Singeltary Sr, and I live in Bacliff, Texas. I lost my mom to hvCJD (Heidenhain variant CJD) and have been searching for answers ever since. What I have found is that we have not been told the truth. CWD in deer and elk is a small portion of a much bigger problem." 49-year-old Singeltary is one of a number of people who have remained largely unsatisfied after being told that a close relative died from a rapidly progressive dementia compatible with spontaneous Creutzfeldt-Jakob disease (CJD). So he decided to gather hundreds of documents on transmissible spongiform encephalopathies (TSE) and realised that if Britons could get variant CJD from bovine spongiform encephalopathy (BSE), Americans might get a similar disorder from chronic wasting disease (CWD)-the relative of mad cow disease seen among deer and elk in the USA. Although his feverish.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://linkinghub.elsevier.com/retrieve/pii/S1473309903007151"&gt;http://linkinghub.elsevier.com/retrieve/pii/S1473309903007151&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(03)00715-1/fulltext"&gt;http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(03)00715-1/fulltext&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.mdconsult.com/das/article/body/180784492-2/jorg=journal&amp;amp;source=&amp;amp;sp=13979213&amp;amp;sid=0/N/368742/1.html?issn=14733099"&gt;http://www.mdconsult.com/das/article/body/180784492-2/jorg=journal&amp;amp;source=&amp;amp;sp=13979213&amp;amp;sid=0/N/368742/1.html?issn=14733099&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Diagnosis and Reporting of Creutzfeldt-Jakob Disease&lt;br /&gt;&lt;br /&gt;Singeltary, Sr et al. JAMA.2001; 285: 733-734. Vol. 285 No. 6, February 14, 2001 JAMA&lt;br /&gt;&lt;br /&gt;Diagnosis and Reporting of Creutzfeldt-Jakob Disease&lt;br /&gt;&lt;br /&gt;To the Editor: In their Research Letter, Dr Gibbons and colleagues1 reported that the annual US death rate due to Creutzfeldt-Jakob disease (CJD) has been stable since 1985. These estimates, however, are based only on reported cases, and do not include misdiagnosed or preclinical cases. It seems to me that misdiagnosis alone would drastically change these figures. An unknown number of persons with a diagnosis of Alzheimer disease in fact may have CJD, although only a small number of these patients receive the postmortem examination necessary to make this diagnosis. Furthermore, only a few states have made CJD reportable. Human and animal transmissible spongiform encephalopathies should be reportable nationwide and internationally.&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary, Sr Bacliff, Tex&lt;br /&gt;&lt;br /&gt;1. Gibbons RV, Holman RC, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States: 1979-1998. JAMA. 2000;284:2322-2323. FREE FULL TEXT&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://jama.ama-assn.org/cgi/content/extract/285/6/733?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=singeltary&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;resourcetype=HWCIT"&gt;http://jama.ama-assn.org/cgi/content/extract/285/6/733?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=singeltary&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;resourcetype=HWCIT&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://jama.ama-assn.org/cgi/content/full/285/6/733?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=singeltary&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;resourcetype=HWCIT"&gt;http://jama.ama-assn.org/cgi/content/full/285/6/733?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=singeltary&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;resourcetype=HWCIT&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;DER SPIEGEL (9/2001) - 24.02.2001 (9397 Zeichen) USA: Loch in der Mauer Die BSE-Angst erreicht Amerika: Trotz strikter Auflagen gelangte in Texas verbotenes Tiermehl ins Rinderfutter - die Kontrollen der Aufsichtsbehördensind lax.Link auf diesen Artikel im Archiv:&lt;br /&gt;&lt;br /&gt;&lt;a href="http://service.spiegel.de/digas/find?DID=18578755"&gt;http://service.spiegel.de/digas/find?DID=18578755&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;"Löcher wie in einem Schweizer Käse" hat auch Terry Singeltary im Regelwerk der FDA ausgemacht. Der Texaner kam auf einem tragischen Umweg zu dem Thema: Nachdem seine Mutter 1997 binnen weniger Wochen an der Creutzfeldt-Jakob-Krankheit gestorben war, versuchte er, die Ursachen der Infektion aufzuspüren. Er klagte auf die Herausgabe von Regierungsdokumenten und arbeitete sich durch Fachliteratur; heute ist er überzeugt, dass seine Mutter durch die stetige Einnahme von angeblich kräftigenden Mitteln erkrankte, in denen - völlig legal - Anteile aus Rinderprodukten enthalten sind.&lt;br /&gt;&lt;br /&gt;Von der Fachwelt wurde Singeltary lange als versponnener Außenseiter belächelt. Doch mittlerweile sorgen sich auch Experten, dass ausgerechnet diese verschreibungsfreien Wundercocktails zur Stärkung von Intelligenz, Immunsystem oder Libido von den Importbeschränkungen ausgenommen sind. Dabei enthalten die Pillen und Ampullen, die in Supermärkten verkauft werden, exotische Mixturen aus Rinderaugen; dazu Extrakte von Hypophyse oder Kälberföten, Prostata, Lymphknoten und gefriergetrocknetem Schweinemagen. In die USA hereingelassen werden auch Blut, Fett, Gelatine und Samen. Diese Stoffe tauchen noch immer in US-Produkten auf, inklusive Medizin und Kosmetika. Selbst in Impfstoffen waren möglicherweise gefährliche Rinderprodukte enthalten. Zwar fordert die FDA schon seit acht Jahren die US-Pharmaindustrie auf, keine Stoffe aus Ländern zu benutzen, in denen die Gefahr einer BSE-Infizierung besteht. Aber erst kürzlich verpflichteten sich fünf Unternehmen, darunter Branchenführer wie GlaxoSmithKline, Aventis und American Home Products, ihre Seren nur noch aus unverdächtigem Material herzustellen.&lt;br /&gt;&lt;br /&gt;"Its as full of holes as Swiss Cheese" says Terry Singeltary of the FDA regulations. ...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.spiegel.de/spiegel/print/d-18578755.html"&gt;http://www.spiegel.de/spiegel/print/d-18578755.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://wissen.spiegel.de/wissen/image/show.html?did=18578755&amp;amp;aref=image024/E0108/SCSP200100901440145.pdf&amp;amp;thumb=false"&gt;http://wissen.spiegel.de/wissen/image/show.html?did=18578755&amp;amp;aref=image024/E0108/SCSP200100901440145.pdf&amp;amp;thumb=false&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://service.spiegel.de/digas/servlet/find/DID=18578755"&gt;http://service.spiegel.de/digas/servlet/find/DID=18578755&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Suspect symptoms&lt;br /&gt;&lt;br /&gt;What if you can catch old-fashioned CJD by eating meat from a sheep infected with scrapie?&lt;br /&gt;&lt;br /&gt;28 Mar 01&lt;br /&gt;&lt;br /&gt;Like lambs to the slaughter 31 March 2001 by Debora MacKenzie Magazine issue 2284. Subscribe and get 4 free issues. FOUR years ago, Terry Singeltary watched his mother die horribly from a degenerative brain disease. Doctors told him it was Alzheimer's, but Singeltary was suspicious. The diagnosis didn't fit her violent symptoms, and he demanded an autopsy. It showed she had died of sporadic Creutzfeldt-Jakob disease.&lt;br /&gt;&lt;br /&gt;Most doctors believe that sCJD is caused by a prion protein deforming by chance into a killer. But Singeltary thinks otherwise. He is one of a number of campaigners who say that some sCJD, like the variant CJD related to BSE, is caused by eating meat from infected animals. Their suspicions have focused on sheep carrying scrapie, a BSE-like disease that is widespread in flocks across Europe and North America.&lt;br /&gt;&lt;br /&gt;Now scientists in France have stumbled across new evidence that adds weight to the campaigners' fears. To their complete surprise, the researchers found that one strain of scrapie causes the same brain damage in mice as sCJD.&lt;br /&gt;&lt;br /&gt;"This means we cannot rule out that at least some sCJD may be caused by some strains of scrapie," says team member Jean-Philippe Deslys of the French Atomic Energy Commission's medical research laboratory in Fontenay-aux-Roses, south-west of Paris. Hans Kretschmar of the University of Göttingen, who coordinates CJD surveillance in Germany, is so concerned by the findings that he now wants to trawl back through past sCJD cases to see if any might have been caused by eating infected mutton or lamb.&lt;br /&gt;&lt;br /&gt;Scrapie has been around for centuries and until now there has been no evidence that it poses a risk to human health. But if the French finding means that scrapie can cause sCJD in people, countries around the world may have overlooked a CJD crisis to rival that caused by BSE.&lt;br /&gt;&lt;br /&gt;Deslys and colleagues were originally studying vCJD, not sCJD. They injected the brains of macaque monkeys with brain from BSE cattle, and from French and British vCJD patients. The brain damage and clinical symptoms in the monkeys were the same for all three. Mice injected with the original sets of brain tissue or with infected monkey brain also developed the same symptoms.&lt;br /&gt;&lt;br /&gt;As a control experiment, the team also injected mice with brain tissue from people and animals with other prion diseases: a French case of sCJD; a French patient who caught sCJD from human-derived growth hormone; sheep with a French strain of scrapie; and mice carrying a prion derived from an American scrapie strain. As expected, they all affected the brain in a different way from BSE and vCJD. But while the American strain of scrapie caused different damage from sCJD, the French strain produced exactly the same pathology.&lt;br /&gt;&lt;br /&gt;"The main evidence that scrapie does not affect humans has been epidemiology," says Moira Bruce of the neuropathogenesis unit of the Institute for Animal Health in Edinburgh, who was a member of the same team as Deslys. "You see about the same incidence of the disease everywhere, whether or not there are many sheep, and in countries such as New Zealand with no scrapie." In the only previous comparisons of sCJD and scrapie in mice, Bruce found they were dissimilar.&lt;br /&gt;&lt;br /&gt;But there are more than 20 strains of scrapie, and six of sCJD. "You would not necessarily see a relationship between the two with epidemiology if only some strains affect only some people," says Deslys. Bruce is cautious about the mouse results, but agrees they require further investigation. Other trials of scrapie and sCJD in mice, she says, are in progress.&lt;br /&gt;&lt;br /&gt;People can have three different genetic variations of the human prion protein, and each type of protein can fold up two different ways. Kretschmar has found that these six combinations correspond to six clinical types of sCJD: each type of normal prion produces a particular pathology when it spontaneously deforms to produce sCJD.&lt;br /&gt;&lt;br /&gt;But if these proteins deform because of infection with a disease-causing prion, the relationship between pathology and prion type should be different, as it is in vCJD. "If we look at brain samples from sporadic CJD cases and find some that do not fit the pattern," says Kretschmar, "that could mean they were caused by infection."&lt;br /&gt;&lt;br /&gt;There are 250 deaths per year from sCJD in the US, and a similar incidence elsewhere. Singeltary and other US activists think that some of these people died after eating contaminated meat or "nutritional" pills containing dried animal brain. Governments will have a hard time facing activists like Singeltary if it turns out that some sCJD isn't as spontaneous as doctors have insisted.&lt;br /&gt;&lt;br /&gt;Deslys's work on macaques also provides further proof that the human disease vCJD is caused by BSE. And the experiments showed that vCJD is much more virulent to primates than BSE, even when injected into the bloodstream rather than the brain. This, says Deslys, means that there is an even bigger risk than we thought that vCJD can be passed from one patient to another through contaminated blood transfusions and surgical instruments.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.newscientist.com/article/mg16922840.300-like-lambs-to-the-slaughter.html"&gt;http://www.newscientist.com/article/mg16922840.300-like-lambs-to-the-slaughter.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;UPDATE 2010&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;hmmm, this is getting interesting now...&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; Sporadic CJD type 1 and atypical/ Nor98 scrapie are characterized by fine (reticular) deposits,&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;see also ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&gt; All of the Heidenhain variants were of the methionine/ methionine type 1 molecular subtype.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdusa.blogspot.com/2009/09/co-existence-of-scrapie-prion-protein.html"&gt;http://cjdusa.blogspot.com/2009/09/co-existence-of-scrapie-prion-protein.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;(American Journal of Pathology. 2009;175:2566-2573.) © 2009 American Society for Investigative Pathology DOI: 10.2353/ajpath.2009.090623&lt;br /&gt;&lt;br /&gt;Similarities between Forms of Sheep Scrapie and Creutzfeldt-Jakob Disease Are Encoded by Distinct Prion Types&lt;br /&gt;&lt;br /&gt;Wiebke M. Wemheuer*, Sylvie L. Benestad, Arne Wrede*, Ulf Schulze-Sturm*, Wilhelm E. Wemheuer, Uwe Hahmann*, Joanna Gawinecka, Ekkehard Schütz, Inga Zerr, Bertram Brenig, Bjørn Bratberg, Olivier Andréoletti¶ and Walter J. Schulz-Schaeffer* From the Prion and Dementia Research Unit,* Department of Neuropathology, and the National Transmissible Spongiform Encephalopathies Reference Center, Department of Neurology, University Medical Center Goettingen, Goettingen, Germany; the Department of Pathology, National Veterinary Institute, Oslo, Norway; the Institute of Veterinary Medicine, Faculty for Agricultural Sciences, University of Goettingen, Goettingen, Germany; and Animal Health,¶ Interactions Hôte Agent Pathogène, Ecole Nationale Vétérinaire de Toulouse, Toulouse, France&lt;br /&gt;&lt;br /&gt;Transmissible spongiform encephalopathies such as scrapie in sheep, Creutzfeldt-Jakob disease (CJD) in humans, and bovine sporadic encephalopathy in cattle are characterized by the accumulation of a misfolded protein: the pathological prion protein. Ever since bovine sporadic encephalopathy was discovered as the likely cause of the new variant of CJD in humans, parallels between human and animal transmissible spongiform encephalopathies must be viewed under the aspect of a disease risk for humans. In our study we have compared prion characteristics of different forms of sheep scrapie with those of different phenotypes of sporadic CJD. The disease characteristics of sporadic CJD depend considerably on the prion type 1 or 2. Our results show that there are obvious parallels between sporadic CJD type 1 and the so-called atypical/Nor98 scrapie. These parelleles apply to the deposition form of pathological prion protein in the brain, detected by the paraffin-embedded-tissue blot and the prion aggregate stability with regard to denaturation by the chaotropic salt guanidine hydrochloride. The same applies to sporadic CJD type 2 and classical scrapie. The observed parallels between types of sporadic CJD and types of sheep scrapie demonstrate that distinct groups of prion disease exist in different species. This should be taken into consideration when discussing interspecies transmission.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ajp.amjpathol.org/cgi/content/abstract/175/6/2566"&gt;http://ajp.amjpathol.org/cgi/content/abstract/175/6/2566&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;P.5.21&lt;br /&gt;&lt;br /&gt;Parallels between different forms of sheep scrapie and types of Creutzfeldt-Jakob disease (CJD)&lt;br /&gt;&lt;br /&gt;Wiebke M. Wemheuer1, Sylvie L. Benestad2, Arne Wrede1, Wilhelm E. Wemheuer3, Tatjana Pfander1, Bjørn Bratberg2, Bertram Brenig3,Walter J. Schulz-Schaeffer1 1University Medical Center Goettingen, Germany; 2Institute of Veterinary Medicine Oslo, Norway; 3Institute of Veterinary Medicine Goettingen, Germany&lt;br /&gt;&lt;br /&gt;Background: Scrapie in sheep and goats is often regarded as the archetype of prion diseases. In 1998, a new form of scrapie - atypical/Nor98 scrapie - was described that differed from classical scrapie in terms of epidemiology, Western blot profile, the distribution of pathological prion protein (PrPSc) in the body and its stability against proteinase K. In a similar way, distinct disease types exist in sporadic Creutzfeldt-Jakob disease (CJD). They differ with regard to their clinical outcome, Western blot profile and PrPSc deposition pattern in the central nervous system (CNS).&lt;br /&gt;&lt;br /&gt;Objectives: The comparison of PrPSc deposits in sheep scrapie and human sporadic CJD.&lt;br /&gt;&lt;br /&gt;Methods: Tissues of the CNS of sheep with classical scrapie, sheep with atypical/Nor98 scrapie and 20 patients with sporadic CJD were examined using the sensitive Paraffin Embedded Tissue (PET) blot method. The results were compared with those obtained by immunohistochemistry. With the objective of gaining information on the protein conformation, the PrPSc of classical and atypical/Nor98 sheep scrapie and sporadic CJD was tested for its stability against denaturation with guanidine hydrochloride (GdnHCl) using a Membrane Adsorption Assay.&lt;br /&gt;&lt;br /&gt;Results: The PrPSc of atypical/Nor98 scrapie cases and of CJD prion type 1 patients exhibits a mainly reticular/synaptic deposition pattern in the brain and is relatively sensitive to denaturation with GdnHCl. In contrast classical scrapie cases and CJD prion type 2 patients have a more complex PrPSc deposition pattern in common that consists of larger PrPSc aggregates and the PrPSc itself is comparatively stable against denaturation.&lt;br /&gt;&lt;br /&gt;Discussion: The similarity between CJD types and scrapie types indicates that at least two comparable forms of the misfolded prion protein exist beyond species barriers and can elicit prion diseases. It seems therefore reasonable to classify classical and atypical/Nor98 scrapie - in analogy to the existing CJD types - as different scrapie types.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf"&gt;http://www.prion2009.com/sites/default/files/Prion2009_Book_of_Abstracts.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, November 30, 2009&lt;br /&gt;&lt;br /&gt;USDA AND OIE COLLABORATE TO EXCLUDE ATYPICAL SCRAPIE NOR-98 ANIMAL HEALTH CODE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2009/11/usda-and-oie-collaborate-to-exclude.html"&gt;http://nor-98.blogspot.com/2009/11/usda-and-oie-collaborate-to-exclude.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, December 1, 2008&lt;br /&gt;&lt;br /&gt;When Atypical Scrapie cross species barriers&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2008/12/when-atypical-scrapie-cross-species.html"&gt;http://nor-98.blogspot.com/2008/12/when-atypical-scrapie-cross-species.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;EVIDENCE OF SCRAPIE IN SHEEP AS A RESULT OF FOOD BORNE EXPOSURE&lt;br /&gt;&lt;br /&gt;This is provided by the statistically significant increase in the incidence of sheep scrape from 1985, as determined from analyses of the submissions made to VI Centres, and from individual case and flock incident studies. ........&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20010305222246/www.bseinquiry.gov.uk/files/yb/1994/02/07002001.pdf"&gt;http://web.archive.org/web/20010305222246/www.bseinquiry.gov.uk/files/yb/1994/02/07002001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;1: J Infect Dis 1980 Aug;142(2):205-8&lt;br /&gt;&lt;br /&gt;Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to nonhuman primates.&lt;br /&gt;&lt;br /&gt;Gibbs CJ Jr, Amyx HL, Bacote A, Masters CL, Gajdusek DC.&lt;br /&gt;&lt;br /&gt;Kuru and Creutzfeldt-Jakob disease of humans and scrapie disease of sheep and goats were transmitted to squirrel monkeys (Saimiri sciureus) that were exposed to the infectious agents only by their nonforced consumption of known infectious tissues. The asymptomatic incubation period in the one monkey exposed to the virus of kuru was 36 months; that in the two monkeys exposed to the virus of Creutzfeldt-Jakob disease was 23 and 27 months, respectively; and that in the two monkeys exposed to the virus of scrapie was 25 and 32 months, respectively. Careful physical examination of the buccal cavities of all of the monkeys failed to reveal signs or oral lesions. One additional monkey similarly exposed to kuru has remained asymptomatic during the 39 months that it has been under observation.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;The successful transmission of kuru, Creutzfeldt-Jakob disease, and scrapie by natural feeding to squirrel monkeys that we have reported provides further grounds for concern that scrapie-infected meat may occasionally give rise in humans to Creutzfeldt-Jakob disease.&lt;br /&gt;&lt;br /&gt;PMID: 6997404&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=6997404&amp;amp;dopt=Abstract"&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=6997404&amp;amp;dopt=Abstract&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;12/10/76 AGRICULTURAL RESEARCH COUNCIL REPORT OF THE ADVISORY COMMITTE ON SCRAPIE Office Note CHAIRMAN: PROFESSOR PETER WILDY&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;A The Present Position with respect to Scrapie A] The Problem&lt;br /&gt;&lt;br /&gt;Scrapie is a natural disease of sheep and goats. It is a slow and inexorably progressive degenerative disorder of the nervous system and it ia fatal. It is enzootic in the United Kingdom but not in all countries.&lt;br /&gt;&lt;br /&gt;The field problem has been reviewed by a MAFF working group (ARC 35/77). It is difficult to assess the incidence in Britain for a variety of reasons but the disease causes serious financial loss; it is estimated that it cost Swaledale breeders alone $l.7 M during the five years 1971-1975. A further inestimable loss arises from the closure of certain export markets, in particular those of the United States, to British sheep.&lt;br /&gt;&lt;br /&gt;It is clear that scrapie in sheep is important commercially and for that reason alone effective measures to control it should be devised as quickly as possible.&lt;br /&gt;&lt;br /&gt;Recently the question has again been brought up as to whether scrapie is transmissible to man. This has followed reports that the disease has been transmitted to primates. One particularly lurid speculation (Gajdusek 1977) conjectures that the agents of scrapie, kuru, Creutzfeldt-Jakob disease and transmissible encephalopathy of mink are varieties of a single "virus". The U.S. Department of Agriculture concluded that it could "no longer justify or permit scrapie-blood line and scrapie-exposed sheep and goats to be processed for human or animal food at slaughter or rendering plants" (ARC 84/77)" The problem is emphasised by the finding that some strains of scrapie produce lesions identical to the once which characterise the human dementias"&lt;br /&gt;&lt;br /&gt;Whether true or not. the hypothesis that these agents might be transmissible to man raises two considerations. First, the safety of laboratory personnel requires prompt attention. Second, action such as the "scorched meat" policy of USDA makes the solution of the acrapie problem urgent if the sheep industry is not to suffer grievously.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;76/10.12/4.6&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20010305223125/www.bseinquiry.gov.uk/files/yb/1976/10/12004001.pdf"&gt;http://web.archive.org/web/20010305223125/www.bseinquiry.gov.uk/files/yb/1976/10/12004001.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Nature. 1972 Mar 10;236(5341):73-4.&lt;br /&gt;&lt;br /&gt;Transmission of scrapie to the cynomolgus monkey (Macaca fascicularis). Gibbs CJ Jr, Gajdusek DC.&lt;br /&gt;&lt;br /&gt;Nature 236, 73 - 74 (10 March 1972); doi:10.1038/236073a0&lt;br /&gt;&lt;br /&gt;Transmission of Scrapie to the Cynomolgus Monkey (Macaca fascicularis)&lt;br /&gt;&lt;br /&gt;C. J. GIBBS jun. &amp;amp; D. C. GAJDUSEK&lt;br /&gt;&lt;br /&gt;National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland&lt;br /&gt;&lt;br /&gt;SCRAPIE has been transmitted to the cynomolgus, or crab-eating, monkey (Macaca fascicularis) with an incubation period of more than 5 yr from the time of intracerebral inoculation of scrapie-infected mouse brain. The animal developed a chronic central nervous system degeneration, with ataxia, tremor and myoclonus with associated severe scrapie-like pathology of intensive astroglial hypertrophy and proliferation, neuronal vacuolation and status spongiosus of grey matter. The strain of scrapie virus used was the eighth passage in Swiss mice (NIH) of a Compton strain of scrapie obtained as ninth intracerebral passage of the agent in goat brain, from Dr R. L. Chandler (ARC, Compton, Berkshire).&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.nature.com/nature/journal/v236/n5341/abs/236073a0.html"&gt;http://www.nature.com/nature/journal/v236/n5341/abs/236073a0.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Epidemiology of Scrapie in the United States 1977&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;http://www.bseinquiry.gov.uk/files/mb/m08b/tab64.pdf&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;NEW URL ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://web.archive.org/web/20030513212324/http://www.bseinquiry.gov.uk/files/mb/m08b/tab64.pdf"&gt;http://web.archive.org/web/20030513212324/http://www.bseinquiry.gov.uk/files/mb/m08b/tab64.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, April 28, 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Nor98-like Scrapie in the United States of America&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://nor-98.blogspot.com/2009/04/nor98-like-scrapie-in-united-states-of.html"&gt;http://nor-98.blogspot.com/2009/04/nor98-like-scrapie-in-united-states-of.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Scrapie USA&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://scrapie-usa.blogspot.com/"&gt;http://scrapie-usa.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2 January 2000&lt;br /&gt;&lt;br /&gt;British Medical Journal&lt;br /&gt;&lt;br /&gt;U.S. Scientist should be concerned with a CJD epidemic in the U.S., as well&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.bmj.com/cgi/eletters/320/7226/8/b#6117"&gt;http://www.bmj.com/cgi/eletters/320/7226/8/b#6117&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;15 November 1999&lt;br /&gt;&lt;br /&gt;British Medical Journal&lt;br /&gt;&lt;br /&gt;vCJD in the USA * BSE in U.S.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.bmj.com/cgi/eletters/319/7220/1312/b#5406"&gt;http://www.bmj.com/cgi/eletters/319/7220/1312/b#5406&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, August 10, 2008&lt;br /&gt;&lt;br /&gt;A New Prionopathy OR more of the same old BSe and sporadic CJD&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2008/08/new-prionopathy-or-more-of-same-old-bse.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2008/08/new-prionopathy-or-more-of-same-old-bse.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;THE PATHOLOGICAL PROTEIN&lt;br /&gt;&lt;br /&gt;BY Philip Yam&lt;br /&gt;&lt;br /&gt;Yam Philip Yam News Editor Scientific American www.sciam.com&lt;br /&gt;&lt;br /&gt;Answering critics like Terry Singeltary, who feels that the U.S. under- counts CJD, Schonberger conceded that the current surveillance system has errors but stated that most of the errors will be confined to the older population.&lt;br /&gt;&lt;br /&gt;CHAPTER 14&lt;br /&gt;&lt;br /&gt;Laying Odds&lt;br /&gt;&lt;br /&gt;Are prion diseases more prevalent than we thought?&lt;br /&gt;&lt;br /&gt;Researchers and government officials badly underestimated the threat that mad cow disease posed when it first appeared in Britain. They didn't think bovine spongiform encephalopathy was a zoonosis-an animal disease that can sicken people. The 1996 news that BSE could infect humans with a new form of Creutzfeldt-Jakob disease stunned the world. It also got some biomedical researchers wondering whether sporadic CJD may really be a manifestation of a zoonotic sickness. Might it be caused by the ingestion of prions, as variant CJD is?&lt;br /&gt;&lt;br /&gt;Revisiting Sporadic CJD&lt;br /&gt;&lt;br /&gt;It's not hard to get Terry Singeltary going. "I have my conspiracy theories," admitted the 49-year-old Texan.1 Singeltary is probably the nation's most relentless consumer advocate when it comes to issues in prion diseases. He has helped families learn about the sickness and coordinated efforts with support groups such as CJD Voice and the CJD Foundation. He has also connected with others who are critical of the American way of handling the threat of prion diseases. Such critics include Consumers Union's Michael Hansen, journalist John Stauber, and Thomas Pringle, who used to run the voluminous www.madcow. org Web site. These three lend their expertise to newspaper and magazine stories about prion diseases, and they usually argue that prions represent more of a threat than people realize, and that the government has responded poorly to the dangers because it is more concerned about protecting the beef industry than people's health.&lt;br /&gt;&lt;br /&gt;Singeltary has similar inclinations. ...&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;THE PATHOLOGICAL PROTEIN&lt;br /&gt;&lt;br /&gt;Hardcover, 304 pages plus photos and illustrations. ISBN 0-387-95508-9&lt;br /&gt;&lt;br /&gt;June 2003&lt;br /&gt;&lt;br /&gt;BY Philip Yam&lt;br /&gt;&lt;br /&gt;CHAPTER 14 LAYING ODDS&lt;br /&gt;&lt;br /&gt;Answering critics like Terry Singeltary, who feels that the U.S. under- counts CJD, Schonberger conceded that the current surveillance system has errors but stated that most of the errors will be confined to the older population.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.thepathologicalprotein.com/"&gt;http://www.thepathologicalprotein.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://books.google.com/books?id=ePbrQNFrHtoC&amp;amp;pg=PA223&amp;amp;lpg=PA223&amp;amp;dq=the+pathological+protein+laying+odds+It%E2%80%99s+not+hard+to+get+Terry+Singeltary+going&amp;amp;source=bl&amp;amp;ots=um0PFAZSZD&amp;amp;sig=JWaGR7M7-1WeAr2qAXq8D6J_jak&amp;amp;hl=en&amp;amp;ei=MhtjS8jMJM2ztgeFoa2iBg&amp;amp;sa=X&amp;amp;oi=book_result&amp;amp;ct=result&amp;amp;resnum=1&amp;amp;ved=0CAcQ6AEwAA#v=onepage&amp;amp;q=&amp;amp;f=false"&gt;http://books.google.com/books?id=ePbrQNFrHtoC&amp;amp;pg=PA223&amp;amp;lpg=PA223&amp;amp;dq=the+pathological+protein+laying+odds+It%E2%80%99s+not+hard+to+get+Terry+Singeltary+going&amp;amp;source=bl&amp;amp;ots=um0PFAZSZD&amp;amp;sig=JWaGR7M7-1WeAr2qAXq8D6J_jak&amp;amp;hl=en&amp;amp;ei=MhtjS8jMJM2ztgeFoa2iBg&amp;amp;sa=X&amp;amp;oi=book_result&amp;amp;ct=result&amp;amp;resnum=1&amp;amp;ved=0CAcQ6AEwAA#v=onepage&amp;amp;q=&amp;amp;f=false&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.springerlink.com/content/r2k2622661473336/fulltext.pdf?page=1"&gt;http://www.springerlink.com/content/r2k2622661473336/fulltext.pdf?page=1&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.thepathologicalprotein.com/"&gt;http://www.thepathologicalprotein.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://prionunitusaupdate2008.blogspot.com/2009/04/national-prion-disease-pathology.html"&gt;http://prionunitusaupdate2008.blogspot.com/2009/04/national-prion-disease-pathology.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;HUMAN and ANIMAL TSE Classifications i.e. mad cow disease and the UKBSEnvCJD&lt;br /&gt;only theory JUNE 2008&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdmadcowbaseoct2007.blogspot.com/2008/06/human-and-animal-tse-classifications-ie.html"&gt;http://cjdmadcowbaseoct2007.blogspot.com/2008/06/human-and-animal-tse-classifications-ie.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CJD QUESTIONNAIRE&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdquestionnaire.blogspot.com/2007/11/cjd-questionnaire.html"&gt;http://cjdquestionnaire.blogspot.com/2007/11/cjd-questionnaire.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdquestionnaire.blogspot.com/"&gt;http://cjdquestionnaire.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, January 29, 2010&lt;br /&gt;&lt;br /&gt;14th International Congress on Infectious Diseases H-type and L-type Atypical BSE January 2010 (special pre-congress edition)&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2010/01/14th-international-congress-on.html"&gt;http://bse-atypical.blogspot.com/2010/01/14th-international-congress-on.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, August 11, 2009&lt;br /&gt;&lt;br /&gt;Characteristics of Established and Proposed Sporadic Creutzfeldt-Jakob Disease Variants&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2009/08/characteristics-of-established-and.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2009/08/characteristics-of-established-and.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, July 27, 2009&lt;br /&gt;&lt;br /&gt;U.S.A. HIDING MAD COW DISEASE VICTIMS AS SPORADIC CJD ?&lt;br /&gt;&lt;br /&gt;WHY DID THIS VIDEO NOT SHOW ON EVERY NEWS CHANNEL IN THE U.S.A. $$$&lt;br /&gt;&lt;br /&gt;IT IS A DAMNING VIDEO !!!&lt;br /&gt;&lt;br /&gt;I WATCHED THIS RECENTLY, and had never seen it. i was so mad, i was spitting nails out faster than a framing gun.&lt;br /&gt;&lt;br /&gt;WHY DID THE CANADIAN MEDIA ONLY PRESENT THIS TO THE U.S.A. PUBLIC (thank you very much though), and why has the U.S.A. MEDIA FAILED US ???&lt;br /&gt;&lt;br /&gt;SNIP...&lt;br /&gt;&lt;br /&gt;SEE DAMNING VIDEO AT BOTTOM OF BLOG HERE ;&lt;br /&gt;&lt;br /&gt;Monday, July 27, 2009&lt;br /&gt;&lt;br /&gt;U.S.A. HIDING MAD COW DISEASE VICTIMS AS SPORADIC CJD ?&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2009/07/usa-hiding-mad-cow-disease-victims-as.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2009/07/usa-hiding-mad-cow-disease-victims-as.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;NOW, AFTER SEEING THAT VIDEO, (first watch the video) lets go back in mad cow time here in the USA, shall we.&lt;br /&gt;&lt;br /&gt;THERE must be an independent review of this cover-up, and the infamous ENHANCED BSE SURVEILLANCE AND TESTING OF 2004, that was nothing but a cover-up, and blundered at that, and plus a REDO of the testing of no less than 1 million head of cattle tested each year, for five years, with scientist from the EU overseeing the testing protocols, surveillance, and confirmation of all cases.&lt;br /&gt;&lt;br /&gt;this video states the 'USA had to _admit_ a home grown case of mad cow in TEXAS." fact was, they did not finally admit anything, IT TOOK AN ACT OF CONGRESS, THE HONORABLE PHYLISS FONG AND THE O.I.G., TO MAKE THEM RETEST AND CONFIRM! that my friend is fact. and only after Prof. Aguzzi, Dr. Jean-Philippe Deslys, Dr. Collinge et al slammed them over the testing of that animal. and then we had the mad cow in Texas that they just refused to test, and was sent to a pet food rendering plant. NO TEST AT ALL. you must realize, when other officials, doctors, and such from other country's confront issues about things in the USA, they must walk on ice when doing so. read inbetween the lines here ;&lt;br /&gt;&lt;br /&gt;i wrote all these scientist and doctors and the OIG about that damn texas cow, gave them the evidence i had from TAHC. so did others, but finally fong et al did something.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, July 28, 2009&lt;br /&gt;&lt;br /&gt;MAD COW COVER-UP USA MASKED AS SPORADIC CJD&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowtesting.blogspot.com/2009/07/mad-cow-cover-up-usa-masked-as-sporadic.html"&gt;http://madcowtesting.blogspot.com/2009/07/mad-cow-cover-up-usa-masked-as-sporadic.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;The most recent assessments (and reassessments) were published in June 2005 (Table I; 18), and included the categorisation of Canada, the USA, and Mexico as GBR III. Although only Canada and the USA have reported cases, the historically open system of trade in North America suggests that it is likely that BSE is present also in Mexico.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.oie.int/boutique/extrait/06heim937950.pdf"&gt;http://www.oie.int/boutique/extrait/06heim937950.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, July 14, 2009&lt;br /&gt;&lt;br /&gt;U.S. Emergency Bovine Spongiform Encephalopathy Response Plan Summary and BSE Red Book Date: February 14, 2000 at 8:56 am PST&lt;br /&gt;&lt;br /&gt;WHERE did we go wrong $$$&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowtesting.blogspot.com/2009/07/us-emergency-bovine-spongiform.html"&gt;http://madcowtesting.blogspot.com/2009/07/us-emergency-bovine-spongiform.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, August 09, 2009&lt;br /&gt;&lt;br /&gt;CJD...Straight talk with...James Ironside...and...Terry Singeltary... 2009&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2009/08/cjdstraight-talk-withjames.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2009/08/cjdstraight-talk-withjames.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Tuesday, August 18, 2009&lt;br /&gt;&lt;br /&gt;BSE-The Untold Story - joe gibbs and singeltary 1999 - 2009&lt;br /&gt;&lt;br /&gt;...snip&lt;br /&gt;&lt;br /&gt;Tuesday, August 18, 2009&lt;br /&gt;&lt;br /&gt;BSE-The Untold Story - joe gibbs and singeltary 1999 - 2009&lt;br /&gt;&lt;br /&gt;Wed, 29 Nov 2000 14:14:18 -0500&lt;br /&gt;&lt;br /&gt;a private email from the late Dr. Gibbs, a true pioneer in the research of human/animal TSEs and one that never wavered on helping the families and victims of this horrible disease, and one that helped me many times in trying to seek out the truth;&lt;br /&gt;&lt;br /&gt;Subject: Re: Hello Dr. Gibbs...........&lt;br /&gt;Date: Wed, 29 Nov 2000 14:14:18 -0500&lt;br /&gt;From: "Clarence J. Gibbs, Jr., Ph.D."&lt;br /&gt;To: "Terry S. Singeltary Sr." References: &lt;3a254430.9fb97284@wt.net&gt;&lt;br /&gt;&lt;br /&gt;Hi Terry:&lt;br /&gt;&lt;br /&gt;326 E Stret N.E., Washington, D. C. 20002.&lt;br /&gt;&lt;br /&gt;Better shrimp and oysters than cards!!!!&lt;br /&gt;&lt;br /&gt;Have a happy holiday and thanks for all the information you bring to the screen.&lt;br /&gt;&lt;br /&gt;Joe Gibbs ==========&lt;br /&gt;&lt;br /&gt;please see full text ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowusda.blogspot.com/2009/08/bse-untold-story-joe-gibbs-and.html"&gt;http://madcowusda.blogspot.com/2009/08/bse-untold-story-joe-gibbs-and.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, October 12, 2009&lt;br /&gt;&lt;br /&gt;SEAC Science and Technology Committee's investigation of research funding priorities on behalf of the Advisory Committee on Dangerous Pathogens TSE&lt;br /&gt;&lt;br /&gt;• Are some commoner types of neurodegenerative disease (including Alzheimer's disease and Parkinson's disease) also transmissible? Some recent scientific research has suggested this possibility&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.seac.gov.uk/pdf/hol-response091008.pdf"&gt;http://www.seac.gov.uk/pdf/hol-response091008.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2009/10/seac-science-and-technology-committees.html"&gt;http://bse-atypical.blogspot.com/2009/10/seac-science-and-technology-committees.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, January 4, 2010&lt;br /&gt;&lt;br /&gt;Rising Tide: The Impact of Dementia in Canada Huge wave of dementia cases coming, warns report&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://betaamyloidcjd.blogspot.com/2010/01/rising-tide-impact-of-dementia-in.html"&gt;http://betaamyloidcjd.blogspot.com/2010/01/rising-tide-impact-of-dementia-in.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Terry S. Singeltary Sr.&lt;br /&gt;P.O. Box 42&lt;br /&gt;Bacliff, Texas USA 77518&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/6604160603980694949-6341999936178136086?l=prionunitusaupdate2008.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://prionunitusaupdate2008.blogspot.com/feeds/6341999936178136086/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment.g?blogID=6604160603980694949&amp;postID=6341999936178136086' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/6341999936178136086'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6604160603980694949/posts/default/6341999936178136086'/><link rel='alternate' type='text/html' href='http://prionunitusaupdate2008.blogspot.com/2010/03/cjd-2010-and-cjd-foundation-family.html' title='CJD 2010 and the CJD Foundation Family Conference'/><author><name>Terry S. Singeltary Sr.</name><uri>http://www.blogger.com/profile/06986622967539963260</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='32' height='22' src='http://bp2.blogger.com/_gwMAfd8g9xo/SHuerfBUR1I/AAAAAAAAAAM/nNI1xcLm_Z4/S220/scan0002.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6604160603980694949.post-7874149579347232058</id><published>2010-01-02T12:30:00.000-08:00</published><updated>2010-01-02T12:59:17.459-08:00</updated><category scheme='http://www.blogger.com/atom/ns#' term='TSE'/><category scheme='http://www.blogger.com/atom/ns#' term='GSS'/><category scheme='http://www.blogger.com/atom/ns#' term='nvCJD'/><category scheme='http://www.blogger.com/atom/ns#' term='atypical CWD'/><category scheme='http://www.blogger.com/atom/ns#' term='PRION'/><category scheme='http://www.blogger.com/atom/ns#' term='CJD'/><category scheme='http://www.blogger.com/atom/ns#' term='TME'/><category scheme='http://www.blogger.com/atom/ns#' term='atypical BSE'/><category scheme='http://www.blogger.com/atom/ns#' term='atypical Nor-98 Scrapie'/><category scheme='http://www.blogger.com/atom/ns#' term='BSE'/><category scheme='http://www.blogger.com/atom/ns#' term='SCRAPIE'/><category scheme='http://www.blogger.com/atom/ns#' term='FFI'/><category scheme='http://www.blogger.com/atom/ns#' term='UNKNOWN CJD'/><category scheme='http://www.blogger.com/atom/ns#' term='CWD'/><title type='text'>Human Prion Diseases in the United States January 1, 2010</title><content type='html'>----- Original Message -----&lt;br /&gt;From: "Terry S. Singeltary Sr."&lt;br /&gt;To:&lt;br /&gt;Sent: Friday, January 01, 2010 11:39 AM&lt;br /&gt;Subject: [BSE-L] Human Prion Diseases in the United States&lt;br /&gt;&lt;br /&gt;-------------------- BSE-L@LISTS.AEGEE.ORG --------------------&lt;br /&gt;&lt;br /&gt;Human Prion Diseases in the United States&lt;br /&gt;&lt;br /&gt;Robert C. Holman1*, Ermias D. Belay1, Krista Y. Christensen1, Ryan A. Maddox1, Arialdi M. Minino2, Arianne M. Folkema1, Dana L. Haberling1, Teresa A. Hammett1, Kenneth D. Kochanek2, James J. Sejvar1, Lawrence B. Schonberger1&lt;br /&gt;&lt;br /&gt;1 Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-borne and Enteric Diseases, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services (USDHHS), Atlanta, Georgia, United States of America, 2 Division of Vital Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services (USDHHS), Hyattsville, Maryland, United States of America&lt;br /&gt;&lt;br /&gt;Abstract Top Background Prion diseases are a family of rare, progressive, neurodegenerative disorders that affect humans and animals. The most common form of human prion disease, Creutzfeldt-Jakob disease (CJD), occurs worldwide. Variant CJD (vCJD), a recently emerged human prion disease, is a zoonotic foodborne disorder that occurs almost exclusively in countries with outbreaks of bovine spongiform encephalopathy.&lt;br /&gt;&lt;br /&gt;This study describes the occurrence and epidemiology of CJD and vCJD in the United States.&lt;br /&gt;&lt;br /&gt;Methodology/Principal Findings Analysis of CJD and vCJD deaths using death certificates of US residents for 1979-2006, and those identified through other surveillance mechanisms during 1996-2008. Since CJD is invariably fatal and illness duration is usually less than one year, the CJD incidence is estimated as the death rate. During 1979 through 2006, an estimated 6,917 deaths with CJD as a cause of death were reported in the United States, an annual average of approximately 247 deaths (range 172-304 deaths). The average annual age-adjusted incidence for CJD was 0.97 per 1,000,000 persons. Most (61.8%) of the CJD deaths occurred among persons =65 years of age for an average annual incidence of 4.8 per 1,000,000 persons in this population. Most deaths were among whites (94.6%); the age-adjusted incidence for whites was 2.7 times higher than that for blacks (1.04 and 0.40, respectively). Three patients who died since 2004 were reported with vCJD; epidemiologic evidence indicated that their infection was acquired outside of the United States.&lt;br /&gt;&lt;br /&gt;Conclusion/Significance Surveillance continues to show an annual CJD incidence rate of about 1 case per 1,000,000 persons and marked differences in CJD rates by age and race in the United States. Ongoing surveillance remains important for monitoring the stability of the CJD incidence rates, and detecting occurrences of vCJD and possibly other novel prion diseases in the United States.&lt;br /&gt;&lt;br /&gt;Citation: Holman RC, Belay ED, Christensen KY, Maddox RA, Minino AM, et al. (2010) Human Prion Diseases in the United States. PLoS ONE 5(1): e8521. doi:10.1371/journal.pone.0008521&lt;br /&gt;&lt;br /&gt;Editor: Mick F. Tuite, University of Kent, United Kingdom&lt;br /&gt;&lt;br /&gt;Received: July 21, 2009; Accepted: October 30, 2009; Published: January 1, 2010&lt;br /&gt;&lt;br /&gt;Holman et al. This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.&lt;br /&gt;&lt;br /&gt;Funding: The authors have no support or funding to report.&lt;br /&gt;&lt;br /&gt;Competing interests: The authors have declared that no competing interests exist.&lt;br /&gt;&lt;br /&gt;* E-mail: rholman@cdc.gov&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Discussion Top The US incidence of CJD during 1979 through 2006 remained relatively stable at approximately 1 case per 1,000,000 persons; this incidence is similar to that reported in many other countries [23], [32]-[34]. In the present study, the large number of cases identified in ongoing US surveillance provides insights into the incidence of CJD by sex. These data demonstrate a majority (52.6%) of cases in females largely because of the higher number of women compared to men in the older age populations that experienced the highest CJD incidence rates. Incidence rates of CJD by sex were almost the same among persons &lt;60 years of age and were higher among males relative to females as the age of the population groups increased. These findings are consistent with other studies that indicate a relative excess of cases among females [33], [35]-[38] but a higher incidence of CJD among the male population [35], [39]. The CJD incidence rates varied regionally, with the highest rate in the Northeast region and the lowest rates in the South and West regions. The low rate in the West is of particular interest due to the longstanding presence of chronic wasting disease (CWD) among cervids in parts of the region, particularly in Colorado and Wyoming.&lt;br /&gt;&lt;br /&gt;Ongoing US surveillance data continue to demonstrate marked differences in CJD incidence by race and age. Similar to previous US reports [23], [35], [40], the age-adjusted incidence remains more than 2.5 times higher for whites than for blacks. Although the reasons for this disparity are unknown, it is possible that genetic differences and/or under-diagnosis among non-white patients could contribute. These continuing differences in incidence by race in the United States raise the possibility that the CJD incidence in countries where black populations predominate might be significantly lower than in countries where white populations predominate, an issue that deserves future study.&lt;br /&gt;&lt;br /&gt;The incidence of CJD by age continues to show a pattern that is strikingly different from that reported for vCJD. Almost all vCJD cases, including all three US resident cases, died before 55 years of age. The US surveillance analysis illustrates that only about 11 percent of the CJD cases occurred in this younger US population. This relatively low proportion, and incidence rate, of CJD cases in this younger age group occurred despite an increased focus in US surveillance efforts on suspected cases in this age group since 1996 [12]. Cases of CJD &lt;30 years of age in the United States remain extremely rare, with most of these cases being attributable to iatrogenic exposure or a genetic mutation.&lt;br /&gt;&lt;br /&gt;The incidence of CJD dramatically increased with increasing age until it peaked in the 70-79 year age group. An explanation for the subsequent drop in incidence of CJD among those 80 years of age and older, a phenomenon consistently observed in earlier surveillance studies of CJD [40], remains uncertain. The rarity of CJD, however, in postmortem studies of possibly clinically unrecognized cases of CJD in the elderly has led to the suggestion that the decline in incidence among the elderly is real and unlikely an artifact of a varying sensitivity, by age group, of surveillance [41].&lt;br /&gt;&lt;br /&gt;Since vCJD was initially recognized in the United Kingdom in 1996, CDC received reports of three subsequently confirmed cases of vCJD among US residents. The epidemiological data indicated that each of these cases was most likely infected in the United Kingdom (2 cases) and in Saudi Arabia (1 case) [13], [30].&lt;br /&gt;&lt;br /&gt;Through mid-2009, twenty cases of BSE were identified among cattle in North America, including three that were identified in the United States [42]. In comparison, the United Kingdom reported more than 184,000 BSE cases as of September 30, 2008 and 168 cases of vCJD as of March 2, 2009 [16], [43], [44]. These BSE/vCJD data suggest that the greatest risk of vCJD in US residents will continue to be among persons who as a child or young adult consumed UK beef products during 1980-1996, the years when such products were most subject to BSE contamination [12], [30]. Such US residents would include those who were born and raised either in the United Kingdom or in another country where potentially BSE contaminated UK beef products were available for consumption. These persons would also include those who consumed such UK beef products as a child or young adult during visits abroad. The United States historically has imported few or no live cattle, beef products, or livestock nutritional supplements from the United Kingdom, and throughout the 1990s had banned the import of live ruminants and most ruminant products from known BSE countries [16]. Because indigenous BSE cases in North America were initially documented in 2003 and have continued to occur through 2008, albeit in relatively low numbers [42], the results of ongoing US vCJD surveillance receives considerable attention, particularly among those concerned about the emergence of indigenous vCJD cases in the United States.&lt;br /&gt;&lt;br /&gt;Limitations of using the US national multiple cause-of-death data include possible coding and reporting discrepancies, and misdiagnosis of CJD as a cause of death. However, the use of national death certificate data has been found to be a reasonably sensitive (=80%) method compared to more active methods of CJD case ascertainment [45], [46]. Furthermore, the US prion disease surveillance includes activities carried out by the NPDPSC. The NPDPSC, established by CDC in collaboration with the American Association of Neuropathologists, makes prion disease testing available free-of-charge to US physicians that can help to improve the accuracy of prion disease diagnoses [2], [47]. This center can confirm or refute the presence of vCJD, and also detect other unusual or new prion diseases [48]. The prion surveillance efforts further utilizes the laboratory test results in the investigation and identification of CJD among persons &lt;55 years of age. Finally, the use of the SuperMICAR procedure beginning in 1999 (fully in 2003) enables detection of deaths with prion disease even if cause of death on the death certificate is miscoded (e.g., an inappropriate coding rule, a misinterpretation or a misreading of the certificate) [22].&lt;br /&gt;&lt;br /&gt;The occurrence of CJD and vCJD continues to be an international and national concern. Ongoing CJD and vCJD surveillance in many countries of the world, including the United States, remains critical for determining the extent to which the agents of classic and possibly atypical BSE may cause disease in humans [49]. Physicians and health care workers in the United States are encouraged to indicate CJD, as appropriate, on death certificates for all their patients who die with CJD or vCJD. In addition, health care workers who provide care to patients with suspected or clinically diagnosed CJD or vCJD should discuss possible options for autopsy with their local and state health department and the NPDPSC. Brain tissue specimens obtained by autopsy from these patients may be submitted to the NPDPSC for further analysis and confirmation of the CJD diagnosis. The ongoing prion disease surveillance and diagnostic testing is important for monitoring the stability of the CJD incidence rates, and detecting possible occurrences of vCJD and other new prion diseases in the United States.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0008521?utm_source=feedburner&amp;amp;utm_medium=feed&amp;amp;utm_campaign=Feed%3A+plosone%2FPLoSONE+%28PLoS+ONE+Alerts%3A+New+Articles%29"&gt;http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0008521?utm_source=feedburner&amp;amp;utm_medium=feed&amp;amp;utm_campaign=Feed%3A+plosone%2FPLoSONE+%28PLoS+ONE+Alerts%3A+New+Articles%29&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0008521&amp;amp;representation=PDF"&gt;http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0008521&amp;amp;representation=PDF&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;my comments to PLosone here, additional comments below ;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd"&gt;http://www.plosone.org/annotation/listThread.action?inReplyTo=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&amp;amp;root=info%3Adoi%2F10.1371%2Fannotation%2F04ce2b24-613d-46e6-9802-4131e2bfa6fd&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Friday, January 01, 2010&lt;br /&gt;&lt;br /&gt;Human Prion Diseases in the United States&lt;br /&gt;&lt;br /&gt;re-Human Prion Diseases in the United States Posted by flounder on 01 Jan 2010 at 18:11 GMT I kindly disagree with your synopsis for the following reasons ;&lt;br /&gt;&lt;br /&gt;Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification&lt;br /&gt;&lt;br /&gt;Piero Parchi Æ Rosaria Strammiello Æ Silvio Notari Æ Armin Giese Æ Jan P. M. Langeveld Æ Anna Ladogana Æ Inga Zerr Æ Federico Roncaroli Æ Patrich Cras Æ Bernardino Ghetti Æ Maurizio Pocchiari Æ Hans Kretzschmar Æ Sabina Capellari&lt;br /&gt;&lt;br /&gt;Received: 30 June 2009 / Revised: 16 August 2009 / Accepted: 17 August 2009 / Published online: 29 August 2009&lt;br /&gt;&lt;br /&gt; The Author(s) 2009. This article is published with open access at Springerlink.com&lt;br /&gt;&lt;br /&gt;Abstract&lt;br /&gt;&lt;br /&gt;Six subtypes of sporadic Creutzfeldt-Jakob disease with distinctive clinico-pathological features have been identified largely based on two types of the abnormal prion protein, PrPSc, and the methionine (M)/valine (V) polymorphic codon 129 of the prion protein. The existence of affected subjects showing mixed phenotypic features and concurrent PrPSc types has been reported but with inconsistencies among studies in both results and their interpretation. The issue currently complicates diagnosis and classification of cases and also has implications for disease pathogenesis. To explore the issue in depth, we carried out a systematic regional study in a large series of 225 cases. PrPSc types 1 and 2 concurrence was detected in 35% of cases and was higher in MM than in MV or VV subjects. The deposition of either type 1 or 2, when concurrent, was not random and always characterized by the coexistence of phenotypic features previously described in the pure subtypes. PrPSc type 1 accumulation and related pathology predominated in MM and MV cases, while the type 2 phenotype prevailed in VVs. Neuropathological examination best identified the mixed types 1 and 2 features in MMs and most MVs, and also uniquely revealed the cooccurrence of pathological variants sharing PrPSc type 2. In contrast, molecular typing best detected the concurrent PrPSc types in VV subjects and MV cases with kuru plaques. The present data provide an updated disease classification and are of importance for future epidemiologic and transmission studies aimed to identify etiology and extent of strain variation in sporadic Creutzfeldt-Jakob disease.&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;Discussion&lt;br /&gt;&lt;br /&gt;Previous studies have addressed the issue of PrPSc types 1 and 2 co-occurrence in sCJD. Most of them raised the question of the influence of the number of cases and brain areas analyzed and emphasized the possibility that the cooccurrence of PrPSc types 1 and 2 is underestimated [13, 18, 20, 30, 37, 40, 43]. On the other hand, the use of a novel, potentially very sensitive approach, later shown to have pitfalls related to the detection of unspecific bands generated by partially digested PrPSc fragments [25], likely led other investigators to overestimate the incidence of the concurrent PrPSc types [35, 45]. Thus, the overall results on the phenomenon of the coexistence of molecular and clinico-pathological sCJD subtypes are at present inconclusive with respect to incidence, effect on disease phenotype and criteria for disease classification. To contribute to the full understanding of these issues, in the present study, we combined a systematic analysis of several brain regions in a large series of case including all codon 129 genotypes and the rarest phenotypes with the use of a refined methodology for the detection of the PrPSc type concurrence, which provides good sensitivity combined with high specificity [25].&lt;br /&gt;&lt;br /&gt;After screening about 4,200 samples from a largely consecutive series of 200 cases, we estimated that PrPSc types 1 and 2 coexist in about 35% of sCJD cases, which is overall consistent with figures from some of the previous studies [13, 37, 43] in which the number of cases and areas analyzed were significantly lower. This finding supports the idea that PrPSc types co-occurrence involves a relevant but limited group of sCJD subjects and indicates that the incidence of the phenomenon had not been significantly underestimated.&lt;br /&gt;&lt;br /&gt;As far as the characteristics of the CJD population with mixed phenotypes are concerned, our data show that the PrPSc types 1 and 2 co-occur more frequently in the MM than in the MV and VV genotypes. More specifically, the large majority of sCJD cases with concurrent PrPSc types combines features of the MM and MM 2C sCJD subtypes, in variable proportions. Most commonly, in such cases, the MM1 phenotype is predominant over the MM 2C phenotype, but the opposite situation also rarely occurs. The latter results significantly differ from those obtained in most previous studies. Indeed, Head et al. [13] mainly found a focal type 1 co-occurrence in MM and MV subjects with dominant type 2, Schoch et al. [40] detected the mixed protein types mostly in MV2 cases showing the type 1 only focally in subcortical areas, and Uro-Coste et al. [43] mainly detected a random co-occurrence of type 1 in MV or VV cases with dominant type 2. Given that only our study was based on a large series of consecutive cases, we attribute such heterogeneity of previous results to case selection biases, although methodological differences may also have contributed [43].&lt;br /&gt;&lt;br /&gt;Since subjects with mixed PrPSc types represent a significant proportion of the sCJD population, show distinctive phenotypic features, and potentially represent a distinct subtype in terms of biological relevance, it is important that they are properly identified and are added as new subtypes in the current sCJD classification (Table 6). Despite the emphasis on molecular features of current sCJD classification, it has become increasingly clear that PrPSc typing alone, when limited to a single or even a few brain samples, fails to provide an accurate classification in a significant proportion of cases. This is mainly related to the focal nature of the ''mixed features'' in many sCJD cases with PrPSc types 1 and 2 concurrence. Indeed, we would have misclassified the disease subtype in about 27.5% (using 3F4) of cases with MM or MV genotype, if we had analyzed PrPSc only in the frontal cortex, the area more commonly used for typing worldwide. For the same reason, discrepancies may arise when PrPSc-typing and PrP immunohistochemistry are performed from individual samples taken from opposite hemispheres or even adjacent cortical gyri. However, our study shows that the regional deposition of either type 1 or type 2 when concurrent is not random and that a relatively limited number of critical brain structures must be assessed to reach an accurate classification. Furthermore, our results further underline the importance of applying both molecular and neuropathological assessment for sCJD subtype classification. In this regard, the lack of detection of PrPSc type 2 in a minority of MM subjects, despite the presence of a mixed synaptic and perivacuolar pattern of PrP deposition, indicates that when type 2 is very focal or limited in amount, histopathologic examination is more sensitive in identifying such cases than PrPSc typing, at least when only the 3F4 antibody is used. Given the very strong correlation in MM subjects between PrPSc type 2 detection and the large ''grape-like'' vacuoles and the perivacuolar pattern of PrP deposition on histopathologic examination, which is in line with results previously obtained in other studies [18, 37], we propose that these cases are classified as MM 1?2C or MV 1?2C even without the final proof of type 2 detection by western blot. Alternatively, PrPSc typing using the antibody 1E4 was in our hand as sensitive as the histopathologic examination in the detection of cases with very focal type 2. In the light of the present results, the most important regions to be assessed pathologically include the cerebral cortex from each of the 4 lobes, the striatum, hippocampus, thalamus and cerebellum. The cerebellum, in particular, is critical for the recognition of the synaptic pattern of PrP deposition as marker of PrPSc type 1 concurrence in the cases with dominant type 2.&lt;br /&gt;&lt;br /&gt;Taken together, our data indicate that a protocol including the neuropathologic assessment of the eight brain regions mentioned above and PrPSc typing in four critical regions such as the temporal, parietal and occipital neocortices, and medial thalamus is strongly recommended for a reliable sCJD group classification addressing the issue of mixed phenotypes. Indeed, by applying this protocol instead of examining all 21 brain regions, we would have reached the same classification of cases in the present series.&lt;br /&gt;&lt;br /&gt;We also wish to underline the importance of identifying correctly the sCJD cases with mixed features for transmission purposes. Indeed, the question of whether the concurrence of PrPSc types 1 and 2 in CJD reflects a coinfection by two prion strains related to specific undiscovered human genotypes, or determined by epigenetic factors remains unanswered and will largely rely on transmission studies in which the careful selection of samples will be of critical importance. Concerning this critical question, we find intriguing that the large, confluent vacuoles and the perivacuolar pattern of PrPSc deposition, we originally linked to sCJD MM 2C are also found in a subgroup of MV 2K subjects in addition to MM/MV 1?2C. In addition, we have described here the same morphological features in one case of fatal insomnia (i.e. the MM2-thalamic subtype or MM 2T) which adds to two previously reported cases [19, 30, 31]. Thus, it seems that large confluent vacuoles and the perivacuolar pattern of PrPSc deposition may be found in sCJD associated with all phenotypes linked to MM or MV at codon 129. Although this observation remains difficult to interpret at present, it appears relevant for our future understanding of the molecular basis and the extent of strain variation in sCJD. In any case, our observation strongly suggests that the phenomenon of mixed phenotypes in sCJD goes beyond PrPSc types 1 and 2 coexistence and also involves subtypes which shares the same PrPSc type. This, in turn, further underlines the importance of combining histopathological assessment and biochemical PrPSc typing for sCJD subtype characterization.&lt;br /&gt;&lt;br /&gt;The present data also show that the association of two PrP27-30 fragments, which does not represent a bona-fide type 1 and 2 concurrence, may also be a feature of some sCJD cases. Thus, the PrP27-30 profile in VV2 cases in the cerebellum, thalamus and midbrain is sometime characterized by a doublet comprising a 18.5 kDa in addition to the typical 19 kDa band, while the western blot profile of PrP27-30 in the MV 2K cases appears almost invariably characterized by the association of two PrPSc core fragments including a classic 19 kDa type 2 band and a slower migrating band of about 20 kDa. Although these profiles truly represent concurrent PrPSc fragments, and the 20 and 18.5 kDa fragments likely reflect specific PK cleavage sites, the 20 and 18.5 kDa bands are distinguished from the type 1 and type 2 fragments because, at least to date, they were never detected independently from types 1 and 2, and are not markers of specific clinico-pathological phenotypes. Knowledge of these regional variations is nonetheless important to avoid misinterpreting a PrPSc profile as novel when only one brain region is analyzed [21].&lt;br /&gt;&lt;br /&gt;Finally, the results obtained from the analyses of lesion profiles and clinical features in the subgroups of sCJD cases with mixed features deserve further comment. By showing that the relative ''load'' of each of the two PrPSc types significantly correlates with disease duration, the relative frequency of certain symptoms, and the ratio between cortical and cerebellar pathology, our study provides further strong evidence for the PrPSc type being a major biological determinant in human prion disease. In conclusion, the present data add to our knowledge of the prevalence and phenotypic spectrum of the sCJD variants with mixed molecular and pathological features, provide an updated molecular classification of the disease subtypes and will serve for future epidemiologic and transmission studies aimed at disclosing the etiology and extent of strain variation in sCJD.&lt;br /&gt;&lt;br /&gt;Acknowledgments We wish to thank Barbara Polischi and Sabrina Boninsegna for her technical assistance. We also thank all the physicians who provided clinical data and helped in the collection of tissues and all family members who consented to the use of tissue for research. This study was funded in the frame of the bilateral Italy (ISS)-USA (NIH, Office for Rare Diseases) agreement on joint research on rare diseases, by the European Commission (FOOD-CT- 2004-506579), the Italian Ministry of University, Research and Technology (FIRB-2003-RBNE03FMCJ_006), the Federal Ministry of Health (ZV2-1369-340): grant PHS P30 AG010133, and the Gino Galletti Foundation.&lt;br /&gt;&lt;br /&gt;Keywords Prion protein  Brain mapping  Molecular typing  Neurodegeneration  Classification&lt;br /&gt;&lt;br /&gt;P. Parchi  R. Strammiello  S. Notari  S. Capellari Dipartimento di Scienze Neurologiche, Universita` di Bologna, Bologna, Italy A. Giese  H. Kretzschmar Institut fu¨r Neuropathologie, Ludwig-Maximilians-Universita¨t Mu¨nchen, Munich, Germany J. P. M. Langeveld Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands A. Ladogana  M. Pocchiari Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita`, Rome, Italy I. Zerr Department of Neurology, National Reference Center for TSE Surveillance, Georg-August University, Go¨ttingen, Germany F. Roncaroli Division of Neuroscience and Mental Health, Department of Clinical Neuroscience, Imperial College, London, UK P. Cras Born-Bunge Institute (BBI), University of Antwerp (UA), Antwerp, Belgium B. Ghetti Department of Pathology, Indiana University, Indianapolis, IN, USA P. Parchi (&amp;amp;) Department of Neurological Sciences, Universtity of Bologna, Via Foscolo 7, 40123 Bologna, Italy e-mail: piero.parchi@unibo.it&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.springerlink.com/content/21552482u6761291/fulltext.pdf"&gt;http://www.springerlink.com/content/21552482u6761291/fulltext.pdf&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;MANY, MANY THANKS TO Parchi et al for this study, AND for the public access to full text. ...TSS&lt;br /&gt;&lt;br /&gt;Tuesday, August 11, 2009&lt;br /&gt;&lt;br /&gt;Characteristics of Established and Proposed Sporadic Creutzfeldt-Jakob Disease Variants&lt;br /&gt;&lt;br /&gt;Brian S. Appleby, MD; Kristin K. Appleby, MD; Barbara J. Crain, MD, PhD; Chiadi U. Onyike, MD, MHS; Mitchell T. Wallin, MD, MPH; Peter V. Rabins, MD, MPH&lt;br /&gt;&lt;br /&gt;Background: The classic Creutzfeldt-Jakob disease (CJD), Heidenhain, and Oppenheimer-Brownell variants are sporadic CJD (sCJD) phenotypes frequently described in the literature, but many cases present with neuropsychiatric symptoms, suggesting that there may be additional sCJD phenotypes.&lt;br /&gt;&lt;br /&gt;Objective: To characterize clinical, diagnostic, and molecular features of 5 sCJD variants.&lt;br /&gt;&lt;br /&gt;Design: Retrospective analysis.&lt;br /&gt;&lt;br /&gt;Setting: The Johns Hopkins and Veterans Administration health care systems.&lt;br /&gt;&lt;br /&gt;Participants: Eighty-eight patients with definite or probable sCJD.&lt;br /&gt;&lt;br /&gt;Main Outcome Measures: Differences in age at onset, illness progression, diagnostic test results, and molecular subtype.&lt;br /&gt;&lt;br /&gt;Results: The age at onset differed among sCJD variants (P=.03); the affective variant had the youngest mean age at onset (59.7 years). Survival time (P.001) and the time to clinical presentation (P=.003) differed among groups. Patients with the classic CJD phenotype had the shortest median survival time from symptom onset (66 days) and those who met criteria for the affective sCJD variant had the longest (421 days) and presented to clinicians significantly later (median time from onset to presentation, 92 days; P=.004). Cerebrospinal fluid analyses were positive for 14-3-3 protein in all of the affective variants, regardless of illness duration. Periodic sharp-wave complexes were not detected on any of the electroencephalography tracings in the Oppenheimer-Brownell group; basal ganglia hyperintensity was not detected on brain magnetic resonance imaging in this group either. All of the Heidenhain variants were of the methionine/ methionine type 1 molecular subtype.&lt;br /&gt;&lt;br /&gt;Conclusions: The classic CJD phenotype and the Heidenhain, Oppenheimer-Brownell, cognitive, and affective sCJD variants differ by age at disease onset, survival time, and diagnostic test results. Characteristics of these 5 phenotypes are provided to facilitate further clinicopathologic investigation that may lead to more reliable and timely diagnoses of sCJD.&lt;br /&gt;&lt;br /&gt;Arch Neurol. 2009;66(2):208-215&lt;br /&gt;&lt;br /&gt;snip...&lt;br /&gt;&lt;br /&gt;COMMENT&lt;br /&gt;&lt;br /&gt;snip...see full text ;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2009/08/characteristics-of-established-and.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2009/08/characteristics-of-established-and.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monitoring the occurrence of emerging forms of Creutzfeldt-Jakob disease in the United States 2003 revisited 2009&lt;br /&gt;&lt;br /&gt;August 10, 2009&lt;br /&gt;&lt;br /&gt;Greetings,&lt;br /&gt;&lt;br /&gt;I would like to submit a review of past CJD surveillance in the USA, and the urgent need to make all human TSE in the USA a reportable disease, in every state, of every age group, and to make this mandatory immediately without further delay. The ramifications of not doing so will only allow this agent to spread further in the medical, dental, surgical arena's. North America seems to have the most species with documented Transmissible Spongiform Encephalopathy's, most all of which have been rendered and fed back to food producing animals and to humans for years. If you look at the statistics, sporadic CJD seems to be rising in the USA, and has been, with atypical cases of the sCJD. I find deeply disturbing in the year of 2009, that Human Transmissible Spongiform Encephalopathy of any strain and or phenotype, of all age groups, and I stress all age groups, because human TSE's do not know age, and they do not know borders. someone 56 years old, that has a human TSE, that has surgery, can pass this TSE agent on i.e. friendly fire, and or passing it forward, and there have been documented nvCJD in a 74 year old. Remembering also that only sporadic CJD has been documented to transmit via iatrogenic routes, until recently with the 4 cases of blood related transmission, of which the origin is thought to be nvCJD donors. However most Iatrogenic CJD cases are nothing more than sporadic CJD, until the source is proven, then it becomes Iatrogenic. An oxymoron of sorts, because all sporadic CJD is, are multiple forms, or strains, or phenotypes of Creutzfeldt Jakob Disease, that the route and source and species have not been confirmed and or documented. When will the myth of the UKBSEnvCJD only theory be put to bed for good. This theory in my opinion, and the following there from, as the GOLD STANDARD, has done nothing more than help spread this agent around the globe. Politics and money have caused the terrible consequences to date, and the fact that TSEs are a slow incubating death, but a death that is 100% certain for those that are exposed and live long enough to go clinical. once clinical, there is no recourse, to date. But, while sub-clinical, how many can one exposed human infect? Can humans exposed to CWD and scrapie strains pass it forward as some form of sporadic CJD in the surgical and medical arenas? why must we wait decades and decades to prove this point, only to expose millions needlessly, only for the sake of the industries involved? would it not have been prudent from the beginning to just include all TSE's, and rule them out from there with transmission studies and change policies there from, as opposed to doing just the opposite? The science of TSE's have been nothing more than a political circus since the beginning, and for anyone to still believe in this one strain, one group of bovines, in one geographical location, with only one age group of human TSE i.e. nvCJD myth, for anyone to believe this today only enhances to spreading of these human and animal TSE's. This is exactly why we have been in this quagmire.&lt;br /&gt;&lt;br /&gt;The ones that believe that there is a spontaneous CJD in 85%+ of all cases of human TSE, and the ones that do not believe that cattle can have this same phenomenon, are two of the same, the industry, and so goes the political science aspect of this tobacco and or asbestos scenario i.e. follow the money. I could go into all angles of this man made nightmare, the real facts and science, for instance, the continuing rendering technology and slow cooking with low temps that brewed this stew up, and the fact that THE USA HAD THIS TECHNOLOGY FIRST AND SHIPPED IT TO THE U.K. SOME 5 YEARS BEFORE THE U.S. STARTED USING THE SAME TECHNOLOGY, to save on fuel cost. This is what supposedly amplified the TSE agent via sheep scrapie, and spread via feed in the U.K. bovine, and other countries exporting the tainted product. BUT most everyone ignores this fact, and the fact that the U.S. has been recycling more TSE, from more species with TSEs, than any other country documented, but yet, it's all spontaneous, and the rise in sporadic CJD in the U.S. is a happenstance of bad luck ??? I respectfully disagree. To top that all off, the infamous BSE-FIREWALL that the USDA always brags about was nothing more than ink on paper, and I can prove this. YOU can ignore it, but this is FACT (see source, as late as 2007, in one recall alone, some 10,000,000 MILLION POUNDS OF BANNED MAD COW FEED WENT OUT INTO COMMERCE TO BE FED OUT, and most was never recovered. This was banned blood laced, meat and bone meal. 2006 was a banner year for banned mad cow protein going into commerce in the U.S. (see source of FDA feed ban warning letter below). I stress that the August 4, 1997 USA mad cow feed ban and this infamous BSE firewall, was nothing more than ink on paper, it was never enforceable.&lt;br /&gt;&lt;br /&gt;I propose that the current diagnostic criteria for human TSEs only enhances and helps the spreading of human TSE from the continued belief of the UKBSEnvCJD only theory in 2009. With all the science to date refuting it, to continue to validate this old myth, will only spread this TSE agent through a multitude of potential routes and sources i.e. consumption, medical i.e., surgical, blood, dental, endoscopy, optical, nutritional supplements, cosmetics etc. I propose as with Aguzzi, Asante, Collinge, Caughey, Deslys, Dormont, Gibbs, Gajdusek, Ironside, Manuelidis, Marsh, et al and many more, that the world of TSE Transmissible Spongiform Encephalopathy is far from an exact science, but there is enough proven science to date that this myth should be put to rest once and for all, and that we move forward with a new classification for human and animal TSE that would properly identify the infected species, the source species, and then the route. This would further have to be broken down to strain of species and then the route of transmission would further have to be broken down. Accumulation and Transmission are key to the threshold from sub- clinical to clinical disease, and key to all this, is to stop the amplification and transmission of this agent, the spreading of, no matter what strain. In my opinion, to continue with this myth that the U.K. strain of BSE one strain TSE in cows, and the nv/v CJD one strain TSE humans, and the one geographical location source i.e. U.K., and that all the rest of human TSE are just one single strain i.e. sporadic CJD, a happenstance of bad luck that just happens due to a twisted protein that just twisted the wrong way, IN 85%+ OF ALL HUMAN TSEs, when to date there are 6 different phenotypes of sCJD, and growing per Gambetti et al, and that no other animal TSE transmits to humans ??? With all due respect to all Scientist that believe this, I beg to differ. To continue with this masquerade will only continue to spread, expose, and kill, who knows how many more in the years and decades to come. ONE was enough for me, My Mom, hvCJD i.e. Heidenhain Variant CJD, DOD 12/14/97 confirmed, which is nothing more than another mans name added to CJD, like CJD itself, Jakob and Creutzfeldt, or Gerstmann-Straussler-Scheinker syndrome, just another CJD or human TSE, named after another human. WE are only kidding ourselves with the current diagnostic criteria for human and animal TSE, especially differentiating between the nvCJD vs the sporadic CJD strains and then the GSS strains and also the FFI fatal familial insomnia strains or the ones that mimics one or the other of those TSE? Tissue infectivity and strain typing of the many variants of the human and animal TSEs are paramount in all variants of all TSE. There must be a proper classification that will differentiate between all these human TSE in order to do this. With the CDI and other more sensitive testing coming about, I only hope that my proposal will some day be taken seriously. ...&lt;br /&gt;&lt;br /&gt;please see history, and the ever evolving TSE science to date ;&lt;br /&gt;&lt;br /&gt;Saturday, June 13, 2009&lt;br /&gt;&lt;br /&gt;Monitoring the occurrence of emerging forms of Creutzfeldt-Jakob disease in the United States 2003 revisited 2009&lt;br /&gt;&lt;br /&gt;&lt;a href="http://cjdusa.blogspot.com/2009/06/monitoring-occurrence-of-emerging-forms.html"&gt;http://cjdusa.blogspot.com/2009/06/monitoring-occurrence-of-emerging-forms.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;WHO WILL WATCH THE CHILDREN for CJD over the next 5 decades ?&lt;br /&gt;&lt;br /&gt;SCHOOL LUNCH PROGRAM FROM DOWNER CATTLE UPDATE&lt;br /&gt;&lt;br /&gt;&lt;a href="http://downercattle.blogspot.com/2009/05/who-will-watch-children.html"&gt;http://downercattle.blogspot.com/2009/05/who-will-watch-children.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://downercattle.blogspot.com/"&gt;http://downercattle.blogspot.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Monday, October 19, 2009&lt;br /&gt;&lt;br /&gt;Atypical BSE, BSE, and other human and animal TSE in North America Update October 19, 2009&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2009/10/atypical-bse-bse-and-other-human-and.html"&gt;http://bse-atypical.blogspot.com/2009/10/atypical-bse-bse-and-other-human-and.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sunday, September 6, 2009&lt;br /&gt;&lt;br /&gt;MAD COW USA 1997 SECRET VIDEO&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowusda.blogspot.com/2009/09/mad-cow-usa-1997-video.html"&gt;http://madcowusda.blogspot.com/2009/09/mad-cow-usa-1997-video.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;U.S.A. HIDING MAD COW DISEASE VICTIMS AS SPORADIC CJD ? see video at bottom&lt;br /&gt;&lt;br /&gt;&lt;a href="http://creutzfeldt-jakob-disease.blogspot.com/2009/07/usa-hiding-mad-cow-disease-victims-as.html"&gt;http://creutzfeldt-jakob-disease.blogspot.com/2009/07/usa-hiding-mad-cow-disease-victims-as.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;DAMNING TESTIMONY FROM STANLEY PRUSINER THE NOBEL PEACE PRIZE WINNER ON PRIONS SPEAKING ABOUT ANN VENEMAN see video&lt;br /&gt;&lt;br /&gt;&lt;a href="http://maddeer.org/video/embedded/prusinerclip.html"&gt;http://maddeer.org/video/embedded/prusinerclip.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;CVM Annual Report Fiscal Year 2008: October 1, 2007-September 30, 2008&lt;br /&gt;&lt;br /&gt;PUTTING LIPSTICK ON A PIG AND TAKING HER TO A DANCE...TSS&lt;br /&gt;&lt;br /&gt;BSE Feed Rule Enforcement: A Decade of Success OFF TO A FAST START&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2008/06/texas-firm-recalls-cattle-heads-that.html"&gt;http://madcowfeed.blogspot.com/2008/06/texas-firm-recalls-cattle-heads-that.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;2009 UPDATE ON ALABAMA AND TEXAS MAD COWS 2005 and 2006&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html"&gt;http://bse-atypical.blogspot.com/2006/08/bse-atypical-texas-and-alabama-update.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Sent: Tuesday, November 03, 2009 9:07 PM&lt;br /&gt;&lt;br /&gt;Subject: [BSE-L] re-FOIA REQUEST ON FEED RECALL PRODUCT contaminated with prohibited material Recall # V-258-2009 and Recall # V-256-2009 (CONFIRMED BSE RELATED, BOTH INCIDENCES)&lt;br /&gt;&lt;br /&gt;&lt;a href="http://madcowfeed.blogspot.com/2009/11/re-foia-request-on-feed-recall-product.html"&gt;http://madcowfeed.blogspot.com/2009/11/re-foia-r
